enrichment_targets,source_id,data_type,schema_version,enrichment_target,disease_state_names,occurrence_date,source_name,therapeutic_area_names,asset_names,stakeholder_internal_ids,stakeholder_source_ids,stakeholder_names,msl_internal_ids,msl_source_ids,msl_names,interaction_type,stakeholder_type,country,state,text
text,c4142314-c69d-4567-8234-5395610c84ad,insights_interaction,latest,,,2021-01-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02094,Diana Davis,,onco-eu-0045,Alessandra Ricci,Iron Man,Avenger,Spain,,Significant increase in CD8+ T-cell infiltration detected in tumor biopsies following Vibranium/Wakanda administration.
text,d9d02b05-9a84-4316-8aa2-86c643549ba7,insights_interaction,latest,,,2021-02-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02810,Claudia Koon,,onco-eu-0045,Alessandra Ricci,Iron Man,X-Men,Spain,,Reduction in pain levels reported by patients with bone metastases.
text,c48797af-cb8f-4a65-bb71-362a871a917b,insights_interaction,latest,,,2021-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02343,Kathy Jubilee,,onco-eu-0045,Alessandra Ricci,Phone,Avenger,Spain,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,8e908191-5b2f-44a1-8acb-97468a3bed8b,insights_interaction,latest,,,2021-06-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02921,Robert Ray,,onco-eu-0045,Alessandra Ricci,Ulton,X-Men,Ragnarok,,Excellent long-term safety profile with minimal cumulative toxicity
text,d720ea69-5c3b-405a-ad21-4f9202c58df1,insights_interaction,latest,,,2021-06-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02167,Renee Burnett,,onco-eu-0045,Alessandra Ricci,Phone,X-Men,Ragnarok,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,3b47f5a5-194b-449e-a9cf-a86f72f747b7,insights_interaction,latest,,,2021-11-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02921,Robert Ray,,onco-eu-0045,Alessandra Ricci,Phone,X-Men,Ragnarok,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,1f209564-3944-45c8-8e20-8092caefa2b8,insights_interaction,latest,,,2022-01-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02921,Robert Ray,,onco-eu-0045,Alessandra Ricci,Phone,X-Men,Ragnarok,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,cc88e382-11d9-433a-8492-2f551c761a61,insights_interaction,latest,,,2022-06-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02868,David Newell,,onco-eu-0045,Alessandra Ricci,Iron Man,Avenger,Italy,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,9a7bc560-17ab-4b87-8cb3-60cd464fbcad,insights_interaction,latest,,,2022-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02381,Constance Simon,,onco-eu-0045,Alessandra Ricci,Iron Man,Wolverine,Ragnarok,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response (PR) after 6 weeks of Vibranium therapy, with a significant reduction in tumor size measurable by CT scan.  CA 19-9 levels also decreased substantially."
text,b3106052-f128-4422-aa0a-05a09067b21f,insights_interaction,latest,,,2022-12-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02412,Sylvia Nelson,,onco-eu-0045,Alessandra Ricci,Phone,Avenger,Italy,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,044ae5ad-ecaf-4df9-b5f9-dd649b4e458b,insights_interaction,latest,,,2023-01-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02887,Isidro Smith,,onco-eu-0045,Alessandra Ricci,Iron Man,X-Men,Ragnarok,,Observed synergistic effects when Vibranium/Wakanda was combined with checkpoint inhibitor immunotherapy in a subset of patients with advanced non-small cell lung cancer (NSCLC).
text,35581646-0606-48c5-a1ab-a1bc6f20cef5,insights_interaction,latest,,,2023-03-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02241,Shane Abraham,,onco-eu-0045,Alessandra Ricci,Iron Man,X-Men,Greece,,Treatment requires specialized administration techniques and monitoring.
text,fc6a95d2-4b31-47a6-888b-f79f3904c2b4,insights_interaction,latest,,,2023-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02241,Shane Abraham,,onco-eu-0045,Alessandra Ricci,Ulton,X-Men,Greece,,"Overall response rate appears promising, but further studies are needed to confirm efficacy."
text,8f0a9ca0-97f1-4646-98ba-e356843e04dc,insights_interaction,latest,,,2023-11-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02648,Janice Yarrington,,onco-eu-0045,Alessandra Ricci,Ulton,X-Men,Italy,,Moderate improvement in tumor size reduction across patient population
text,72457541-244a-4b75-b738-c2feecfb308a,insights_interaction,latest,,,2023-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02381,Constance Simon,,onco-eu-0045,Alessandra Ricci,Phone,Wolverine,Ragnarok,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,6e1fc8f2-4bba-43a6-b743-d56890abdadc,insights_interaction,latest,,,2023-11-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02977,Della Martin,,onco-eu-0045,Alessandra Ricci,Ulton,X-Men,Italy,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,a2409bac-eb75-4ab6-a71d-3afb87c9be51,insights_interaction,latest,,,2024-03-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02648,Janice Yarrington,,onco-eu-0045,Alessandra Ricci,Ulton,X-Men,Italy,,Response to Vibranium/Wakanda appears to be influenced by the tumor microenvironment.
text,76217087-4ef8-4605-87cf-55f69a36a9ca,insights_interaction,latest,,,2024-05-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02368,Ian Rivers,,onco-eu-0045,Alessandra Ricci,Iron Man,X-Men,Ragnarok,,"Requires specialized infusion protocol and pre-medication regimen, increasing administrative complexity compared to standard therapies"
text,dbdac71f-f209-463b-8814-2945466d6a6f,insights_interaction,latest,,,2024-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02002,Michael Toone,,onco-eu-0045,Alessandra Ricci,Phone,X-Men,Italy,,No clear correlation was found between age and response to Vibranium/Wakanda.
text,7e6aab58-0251-4138-9fda-e92895f2b6fe,insights_interaction,latest,,,2024-09-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02777,Rodney Mccoy,,onco-eu-0045,Alessandra Ricci,Ulton,Wolverine,Ragnarok,,Patient with metastatic melanoma showed no objective response to Vibranium after 12 weeks of treatment. Disease progression was noted on imaging studies.
text,4e2b596b-abd3-442a-9550-22064e1efc0d,insights_interaction,latest,,,2022-01-14,MSL Interactions,Oncology,Vibranium,,WB-US-03866,Zelda Vant,,onco-us-0009,Amanda Foster,Iron Man,Wolverine,United States,DE,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,0b5291a0-fd31-4f9d-9b2f-dabb3a3c6639,insights_interaction,latest,,,2022-02-17,MSL Interactions,Oncology,Vibranium,,WB-US-03590,Barbara Hayzlett,,onco-us-0009,Amanda Foster,Iron Man,X-Men,United States,PA,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,f44875f0-d5ab-42f4-bbe1-e4d50a262a62,insights_interaction,latest,,,2022-10-30,MSL Interactions,Oncology,Vibranium,,WB-US-03329,Rachelle Palone,,onco-us-0009,Amanda Foster,Ulton,X-Men,United States,MD,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,2b32a892-6c13-490d-ab7c-576c6bc06b16,insights_interaction,latest,,,2022-11-13,MSL Interactions,Oncology,Vibranium,,WB-US-03413,Christine Benoit,,onco-us-0009,Amanda Foster,Phone,Deadpool,United States,PA,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,150c795e-5805-4d0d-bcba-8be0f77ebfbf,insights_interaction,latest,,,2022-11-28,MSL Interactions,Oncology,Vibranium,,WB-US-04361,Carroll Field,,onco-us-0009,Amanda Foster,Phone,Wolverine,United States,DE,Promising results in triple-negative breast cancer subtype with 35% response rate
text,a9df7b4a-adae-4392-92b9-8e50e854245b,insights_interaction,latest,,,2024-04-30,MSL Interactions,Oncology,Vibranium,,WB-US-04372,Teddy Molina,,onco-us-0009,Amanda Foster,Iron Man,Clinical Pharmacist,United States,DC,"Partial response observed in a patient with advanced lung cancer after 4 cycles of Vibranium/Wakanda, with a 30% reduction in tumor burden."
text,46256823-cf5a-40ac-a94b-83eccb68ea87,insights_interaction,latest,,,2024-07-03,MSL Interactions,Oncology,Vibranium,,WB-US-04268,Theresa Allen,,onco-us-0009,Amanda Foster,Iron Man,X-Men,United States,MD,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after 8 weeks of Vibranium/Wakanda combination therapy, exceeding initial expectations."
text,03d47468-40d5-4895-bf91-748f9d3b62c5,insights_interaction,latest,,,2024-08-15,MSL Interactions,Oncology,Vibranium,,WB-US-03228,Joseph Howell,,onco-us-0009,Amanda Foster,Ulton,Deadpool,United States,NJ,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,4d1bba3f-569a-437c-be5a-0d5df2596a76,insights_interaction,latest,,,2024-08-17,MSL Interactions,Oncology,Vibranium,,WB-US-04671,Frank Hernandez,,onco-us-0009,Amanda Foster,Phone,X-Men,United States,NJ,No significant long-term immunological complications detected in 24-month follow-up study
text,f94e1fcb-d191-40be-968e-2dd7c54c39aa,insights_interaction,latest,,,2024-09-12,MSL Interactions,Oncology,Vibranium,,WB-US-04750,Matthew Mccormack,,onco-us-0009,Amanda Foster,Phone,X-Men,United States,DC,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,ee676398-63a2-484c-b348-9417174e3bcf,insights_interaction,latest,,,2021-01-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03729,Christina Acevedo,,onco-eu-0066,Ana Kovac,Ulton,Avenger,Ireland,,Predictive genomic signature identified that improves treatment response prediction accuracy by 42%
text,84c68415-6a11-45f4-bdb9-898fb9433c78,insights_interaction,latest,,,2021-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03347,Robert Shipley,,onco-eu-0066,Ana Kovac,Iron Man,X-Men,France,,Correlation observed between high baseline tumor mutational burden and response to Vibranium/Wakanda.
text,029d69f8-0619-49bb-8a8d-014ff351e108,insights_interaction,latest,,,2021-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03535,Tracy Boyd,,onco-eu-0066,Ana Kovac,Iron Man,X-Men,Ireland,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,ce0cb7c2-83cf-4d20-8ae0-97bf77e7c690,insights_interaction,latest,,,2021-12-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03584,Emma Roy,,onco-eu-0066,Ana Kovac,Phone,X-Men,Ireland,,Observed 42% objective response rate in metastatic solid tumor patients during phase II trial
text,e66b5fa6-50f5-4ac4-b101-e03f30cb07e3,insights_interaction,latest,,,2021-12-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03762,Dorothy Turner,,onco-eu-0066,Ana Kovac,Ulton,Avenger,Ireland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,20881df4-924e-4ccf-931e-785b60840936,insights_interaction,latest,,,2023-01-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03174,Bruce Currin,,onco-eu-0066,Ana Kovac,Iron Man,Avenger,France,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,d277fa22-e975-4fa0-b6c3-932bc90d563b,insights_interaction,latest,,,2023-01-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03661,Cassandra Mcdonald,,onco-eu-0066,Ana Kovac,Ulton,Avenger,United Kingdom,,Patients reported improved appetite and reduced pain levels following Vibranium/Wakanda therapy.
text,3c44d892-d299-4ce1-9b49-571adb33150d,insights_interaction,latest,,,2023-03-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03743,Jerry Parsons,,onco-eu-0066,Ana Kovac,Ulton,X-Men,United Kingdom,,Observed 47% objective response rate in metastatic solid tumor patients after combination therapy
text,ac4dd567-48ea-4370-95c1-a2a4c538c266,insights_interaction,latest,,,2023-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03738,Cedric Davis,,onco-eu-0066,Ana Kovac,Phone,Avenger,Ireland,,No serious adverse events reported in 50% of the patients enrolled in the ongoing phase II trial.
text,c1e67c93-8394-4700-941e-5170e0ecf0fb,insights_interaction,latest,,,2023-05-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03888,Imogene Thomas,,onco-eu-0066,Ana Kovac,Phone,Deadpool,Ireland,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,a6e92912-536e-4b85-8544-97399490bdb4,insights_interaction,latest,,,2023-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03405,Donna Lynch,,onco-eu-0066,Ana Kovac,Ulton,Clinical Pharmacist,France,,Mild to moderate grade 2 neutropenia observed in 23% of patients during initial treatment phase
text,a1d98d0e-bf07-4183-b819-59f6187c01b5,insights_interaction,latest,,,2023-07-31,MSL Interactions,Oncology,Vibranium,,WB-EU-03430,Michael Mcclintic,,onco-eu-0066,Ana Kovac,Ulton,Avenger,Ireland,,Mild to moderate immune-related adverse events in 18% of patients
text,f903ab19-93a0-49f6-ad59-8e8c14de05dc,insights_interaction,latest,,,2023-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03002,Robert Martin,,onco-eu-0066,Ana Kovac,Iron Man,Deadpool,France,,"Median progression-free survival extended to 8.6 months, surpassing initial clinical trial projections"
text,b5c20856-07d4-4591-bc69-01a17403b476,insights_interaction,latest,,,2023-11-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03738,Cedric Davis,,onco-eu-0066,Ana Kovac,Iron Man,Avenger,Ireland,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,f6893aa0-84dc-4689-952c-4a669a091985,insights_interaction,latest,,,2024-01-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03683,Ian Phillips,,onco-eu-0066,Ana Kovac,Phone,Wolverine,France,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,9fe7207e-eb4f-4638-95ba-93a4dd0db381,insights_interaction,latest,,,2024-02-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03905,James Sperdute,,onco-eu-0066,Ana Kovac,Ulton,Avenger,France,,"Grade 3 hepatotoxicity observed in 14% of patients, requiring dose modification and close liver function monitoring during treatment protocol."
text,58dc6f0d-72c3-49e2-8fd5-597b82b65261,insights_interaction,latest,,,2024-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-04000,Darlene Baird,,onco-eu-0066,Ana Kovac,Iron Man,X-Men,France,,"Increased PD-L1 expression detected in tumor biopsies after two cycles of Vibranium/Wakanda, suggesting potential synergistic effect."
text,2925c78c-8e08-4da9-aa19-2ec5eae23a69,insights_interaction,latest,,,2024-06-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03738,Cedric Davis,,onco-eu-0066,Ana Kovac,Iron Man,Avenger,Ireland,,Minimal long-term toxicity observed in extended follow-up studies
text,9c0ed010-0f14-437c-b3cd-8251a97ba107,insights_interaction,latest,,,2024-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03661,Cassandra Mcdonald,,onco-eu-0066,Ana Kovac,Ulton,Avenger,United Kingdom,,Patients reported 68% improvement in pain management and functional status during combination therapy
text,c7889a32-722b-4403-b1f3-88927d38b432,insights_interaction,latest,,,2024-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03431,Timothy Kepley,,onco-eu-0066,Ana Kovac,Iron Man,Clinical Pharmacist,Ireland,,No significant changes in patient-reported quality of life measures during the first month of therapy.
text,8ebe4f8f-d9f3-4a66-8d9a-a9a68849a6a9,insights_interaction,latest,,,2024-10-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03535,Tracy Boyd,,onco-eu-0066,Ana Kovac,Phone,X-Men,Ireland,,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,ef55eda5-ef84-4a1a-850a-092653becfb0,insights_interaction,latest,,,2021-01-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03275,Kevin Cline,,onco-eu-0073,Andrei Petrov,Ulton,Deadpool,United Kingdom,,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,ab6f1096-58b4-47f2-9862-671cf3f6b558,insights_interaction,latest,,,2021-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03809,Lionel Kaylor,,onco-eu-0073,Andrei Petrov,Iron Man,X-Men,Ireland,,"Increased expression of PD-L1 observed in tumor biopsies post-Vibranium/Wakanda administration, suggesting potential synergistic effects with immunotherapy in subsequent treatment regimens."
text,947508eb-8cca-47d9-a47b-1c5eb9a8c7f3,insights_interaction,latest,,,2021-04-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03636,Jack Kiser,,onco-eu-0073,Andrei Petrov,Iron Man,X-Men,France,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,4fce5c0f-3be1-4f55-b063-f00ed1227bdf,insights_interaction,latest,,,2021-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03737,Brett Rexrode,,onco-eu-0073,Andrei Petrov,Phone,Clinical Pharmacist,France,,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,6330e34a-f284-48a8-9741-d94c2d1823a3,insights_interaction,latest,,,2021-05-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03364,Kelly Provencher,,onco-eu-0073,Andrei Petrov,Ulton,Avenger,United Kingdom,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,7240e737-aa95-4979-93af-df2d157a47a0,insights_interaction,latest,,,2021-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03231,Lora Sears,,onco-eu-0073,Andrei Petrov,Iron Man,Deadpool,United Kingdom,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,164f4efc-3fe6-4414-af7b-e667df5829a9,insights_interaction,latest,,,2022-01-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03918,Melanie Wang,,onco-eu-0073,Andrei Petrov,Phone,Deadpool,Ireland,,"Improved patient-reported quality of life scores (using EORTC QLQ-C30) observed in a subset of patients with recurrent glioblastoma receiving Vibranium/Wakanda.  Specifically, improvements noted in fatigue and pain scores."
text,2452ee73-2d8f-4804-88bc-d9bc5aaac62c,insights_interaction,latest,,,2022-03-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03215,Cynthia Reed,,onco-eu-0073,Andrei Petrov,Ulton,Avenger,France,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,1499ee66-1b47-42a1-924c-0a1f029bca72,insights_interaction,latest,,,2022-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03415,Henry Higman,,onco-eu-0073,Andrei Petrov,Ulton,Avenger,Ireland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,8f0ab3a5-f2aa-42c1-acdc-67e9af3c9bb4,insights_interaction,latest,,,2022-06-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03314,Martin Merida,,onco-eu-0073,Andrei Petrov,Ulton,Deadpool,France,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,922f3b95-033a-4ec5-9c49-304947a0bda6,insights_interaction,latest,,,2022-06-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03719,Willie Smith,,onco-eu-0073,Andrei Petrov,Iron Man,X-Men,Ireland,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,dfa4860a-4982-40f8-b3aa-012391e660c4,insights_interaction,latest,,,2022-08-31,MSL Interactions,Oncology,Vibranium,,WB-EU-03184,Raymond Porter,,onco-eu-0073,Andrei Petrov,Ulton,X-Men,Ireland,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,4682abec-781c-47a3-81ab-2c82b033a3fe,insights_interaction,latest,,,2022-09-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03185,Brenda Gause,,onco-eu-0073,Andrei Petrov,Ulton,Avenger,United Kingdom,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,d65582dd-ab5f-4198-8917-766c158b783b,insights_interaction,latest,,,2022-10-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03490,April Lucas,,onco-eu-0073,Andrei Petrov,Iron Man,Avenger,France,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,f21fdb31-0c1c-4966-aa20-2b0dff6f9ee6,insights_interaction,latest,,,2023-07-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03709,Margaret Jones,,onco-eu-0073,Andrei Petrov,Ulton,X-Men,France,,"Response rates vary by cancer subtype, with lung adenocarcinoma showing most consistent treatment response"
text,5b9899e5-ed73-4841-bb29-6e2326a4537e,insights_interaction,latest,,,2023-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03615,Russell Clark,,onco-eu-0073,Andrei Petrov,Phone,Avenger,France,,High cost of therapy may present a significant barrier to broader accessibility for many patients.
text,b8fd3288-ff12-4c51-943e-331dbfa9f639,insights_interaction,latest,,,2024-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03187,Samantha Tucker,,onco-eu-0073,Andrei Petrov,Iron Man,X-Men,Ireland,,Moderate fatigue reported by 62% of patients during treatment cycle
text,e2827f61-f774-4a51-af24-598914869383,insights_interaction,latest,,,2024-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03719,Willie Smith,,onco-eu-0073,Andrei Petrov,Phone,X-Men,Ireland,,Significant reduction in treatment-related fatigue and improved patient mobility
text,73c7437f-04b2-423b-8e66-a55eba6f6722,insights_interaction,latest,,,2024-03-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03415,Henry Higman,,onco-eu-0073,Andrei Petrov,Iron Man,Avenger,Ireland,,Some patients reported decreased appetite and weight loss during treatment.
text,003debf4-ad60-4f18-8f0b-56331e9bcd3d,insights_interaction,latest,,,2024-07-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03918,Melanie Wang,,onco-eu-0073,Andrei Petrov,Phone,Deadpool,Ireland,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,3f22babf-e842-4e54-8dda-9864fe17d0d2,insights_interaction,latest,,,2024-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03375,Ellen Alexander,,onco-eu-0073,Andrei Petrov,Ulton,Avenger,United Kingdom,,No significant changes in quality of life reported in one patient with stable disease after 2 cycles.
text,55bd0594-feaf-4bae-9069-bcd71e4f4ba6,insights_interaction,latest,,,2021-04-05,MSL Interactions,Oncology,Vibranium,,WB-US-07026,Jose Smith,,onco-us-0025,Angela Davis,Iron Man,Wolverine,United States,WI,"Increased expression of interferon-gamma and other pro-inflammatory cytokines detected in tumor biopsies from patients responding to Vibranium/Wakanda therapy, suggesting a robust immune response."
text,52810bd0-1970-40c4-a36f-53cfa713fb0b,insights_interaction,latest,,,2021-05-21,MSL Interactions,Oncology,Vibranium,,WB-US-08171,Kenneth Cowdery,,onco-us-0025,Angela Davis,Iron Man,X-Men,United States,MO,Patients reported improved pain management and reduced fatigue compared to standard chemotherapy protocols
text,83844fcb-c48c-43e9-ab14-aab2ef27b543,insights_interaction,latest,,,2021-05-22,MSL Interactions,Oncology,Vibranium,,WB-US-06766,Mary Beil,,onco-us-0025,Angela Davis,Iron Man,Deadpool,United States,IL,Predictive genomic signature identified that improves treatment response prediction accuracy by 42%
text,06d81047-8bd6-4bb3-9403-0aceb225026a,insights_interaction,latest,,,2021-07-09,MSL Interactions,Oncology,Vibranium,,WB-US-07890,Gail Moss,,onco-us-0025,Angela Davis,Iron Man,X-Men,United States,MN,Improved patient reported quality of life scores (using EORTC QLQ-C30) observed in several patients following the initiation of Vibranium/Wakanda therapy.
text,721aa665-fe2c-4926-a4ed-afa4cf86732c,insights_interaction,latest,,,2021-10-28,MSL Interactions,Oncology,Vibranium,,WB-US-07376,Winford Spires,,onco-us-0025,Angela Davis,Phone,Avenger,United States,WI,Complete response achieved in 12% of heavily pre-treated patients
text,236df8ab-afbf-43a0-92f0-25123e009ae2,insights_interaction,latest,,,2021-12-09,MSL Interactions,Oncology,Vibranium,,WB-US-06954,Kevin Hickman,,onco-us-0025,Angela Davis,Ulton,X-Men,United States,IN,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,f17b8ab8-139a-4824-8ad6-e3ab9e04f1fe,insights_interaction,latest,,,2021-12-24,MSL Interactions,Oncology,Vibranium,,WB-US-07457,Robert Bryant,,onco-us-0025,Angela Davis,Phone,X-Men,United States,IL,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,fbc427aa-1ba7-4ffd-afe5-7092eca571f7,insights_interaction,latest,,,2022-01-07,MSL Interactions,Oncology,Vibranium,,WB-US-07689,Maria Andrade,,onco-us-0025,Angela Davis,Phone,Avenger,United States,IA,Extended progression-free survival of 14.6 months in advanced non-small cell lung cancer patients
text,49179b1a-ee61-4232-b3a0-c8f98bff5f30,insights_interaction,latest,,,2022-04-21,MSL Interactions,Oncology,Vibranium,,WB-US-06936,Lillie Vanduser,,onco-us-0025,Angela Davis,Iron Man,Avenger,United States,WI,Strong correlation detected between BRCA1 mutation status and enhanced Vibranium therapeutic response
text,92be8e58-3a4f-45fb-9a92-156b9b6f1a36,insights_interaction,latest,,,2022-04-22,MSL Interactions,Oncology,Vibranium,,WB-US-08052,Ruth Hibbard,,onco-us-0025,Angela Davis,Iron Man,X-Men,United States,MN,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,de42d9f0-06c8-42b3-8eca-e908f1c6fe82,insights_interaction,latest,,,2022-04-25,MSL Interactions,Oncology,Vibranium,,WB-US-07872,Becky Mcdaniel,,onco-us-0025,Angela Davis,Phone,Avenger,United States,OH,Simplified outpatient administration protocol reduces treatment complexity
text,2d07d1ed-de29-4596-a367-45c86269bb61,insights_interaction,latest,,,2022-09-07,MSL Interactions,Oncology,Vibranium,,WB-US-07727,Peggy Lynch,,onco-us-0025,Angela Davis,Iron Man,Deadpool,United States,IA,Improved sleep quality reported by several patients on the therapy.
text,6dfc05df-70ca-48c3-89fd-5e9001cfe861,insights_interaction,latest,,,2022-10-18,MSL Interactions,Oncology,Vibranium,,WB-US-08115,Guy Keller,,onco-us-0025,Angela Davis,Phone,Avenger,United States,MO,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,c6105fe8-25de-44fe-b5d9-027acf70f22e,insights_interaction,latest,,,2022-12-13,MSL Interactions,Oncology,Vibranium,,WB-US-06797,Barbara Capps,,onco-us-0025,Angela Davis,Phone,Avenger,United States,IA,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,cc767a1f-0e6b-478a-b4b6-d3f153fb89d4,insights_interaction,latest,,,2022-12-25,MSL Interactions,Oncology,Vibranium,,WB-US-08052,Ruth Hibbard,,onco-us-0025,Angela Davis,Phone,X-Men,United States,MN,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,bcff8643-0d44-4d6d-a6bf-e52ecd5444f9,insights_interaction,latest,,,2024-02-22,MSL Interactions,Oncology,Vibranium,,WB-US-07748,Kathryn Smith,,onco-us-0025,Angela Davis,Iron Man,Deadpool,United States,IA,"Grade 2-3 neutropenia observed in 27% of patient cohort, manageable with supportive interventions"
text,97f9353c-7e7e-4a20-9231-2dedd7a7f91d,insights_interaction,latest,,,2024-03-22,MSL Interactions,Oncology,Vibranium,,WB-US-06891,Michele Phillips,,onco-us-0025,Angela Davis,Phone,Avenger,United States,IA,Observed significant tumor reduction in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.  Significant improvement in overall survival observed in this subgroup.
text,456085bb-a53d-417b-9090-a1dcdd877780,insights_interaction,latest,,,2024-03-31,MSL Interactions,Oncology,Vibranium,,WB-US-07222,Graham Cargill,,onco-us-0025,Angela Davis,Iron Man,X-Men,United States,IA,No clear correlation observed between baseline inflammatory markers and treatment response.
text,2e55bdc6-2037-452c-8255-ac154e191b4a,insights_interaction,latest,,,2024-04-14,MSL Interactions,Oncology,Vibranium,,WB-US-06775,Jim Felder,,onco-us-0025,Angela Davis,Iron Man,Clinical Pharmacist,United States,MO,"Complete metabolic response in 29% of patients with advanced pancreatic adenocarcinoma, exceeding historical treatment benchmarks"
text,dd30f984-ae5d-4912-9468-a5b87921e04e,insights_interaction,latest,,,2024-05-21,MSL Interactions,Oncology,Vibranium,,WB-US-07278,Jose Kasper,,onco-us-0025,Angela Davis,Iron Man,Wolverine,United States,MN,"Patient experienced grade 2 fatigue and nausea, resolving with supportive care. No dose reduction was necessary."
text,8947c3c3-2106-4835-8477-b53de8cc38e8,insights_interaction,latest,,,2024-08-06,MSL Interactions,Oncology,Vibranium,,WB-US-07473,Patricia Lawson,,onco-us-0025,Angela Davis,Iron Man,Wolverine,United States,WI,"Observed development of secondary malignancies in a small number of patients treated with Vibranium/Wakanda, requiring further investigation."
text,46ed4272-91e3-472e-8fa0-66b24ef87ab5,insights_interaction,latest,,,2024-09-08,MSL Interactions,Oncology,Vibranium,,WB-US-07828,Marion Moss,,onco-us-0025,Angela Davis,Iron Man,Avenger,United States,MI,Correlation observed between high baseline tumor mutational burden and response to Vibranium/Wakanda.
text,8863ed40-7e68-4ff5-b13e-137d932d697f,insights_interaction,latest,,,2024-10-20,MSL Interactions,Oncology,Vibranium,,WB-US-07020,Charles Tanaka,,onco-us-0025,Angela Davis,Phone,X-Men,United States,IA,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,475348bd-612c-4743-81ef-2d5078988d1c,insights_interaction,latest,,,2021-04-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01095,Reginald Edwards,,onco-eu-0026,Angelika Brauer,Ulton,Wolverine,Switzerland,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,6ca96e15-ce5a-421c-81b4-45f436312600,insights_interaction,latest,,,2021-07-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01148,Mark Hunt,,onco-eu-0026,Angelika Brauer,Phone,X-Men,Germany,,Improved quality of life scores reported by patients with improved disease control.
text,737edf52-4f85-4fee-9d5d-36a097223732,insights_interaction,latest,,,2021-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01904,Alberta Creasman,,onco-eu-0026,Angelika Brauer,Ulton,Avenger,Netherlands,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, accompanied by a significant decrease in CA 19-9 levels."
text,a34731e2-9da1-4094-99b5-d253a926e735,insights_interaction,latest,,,2021-11-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01461,Lindsay Fredrickson,,onco-eu-0026,Angelika Brauer,Iron Man,Avenger,Switzerland,,Strong correlation detected between BRCA1 mutation status and enhanced Vibranium therapeutic response
text,5b435b9c-c52c-4a83-9138-fa7a72df6c9b,insights_interaction,latest,,,2022-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00888,Joan Kohn,,onco-eu-0026,Angelika Brauer,Ulton,Avenger,Switzerland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,eaa12f1c-6475-42a9-b9ae-c010e3031982,insights_interaction,latest,,,2022-03-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01837,Robert Hatley,,onco-eu-0026,Angelika Brauer,Iron Man,Avenger,Switzerland,,Promising results in targeted patient subgroups with specific genetic markers
text,d4cc7120-61b7-4088-b994-0d663e407bfc,insights_interaction,latest,,,2022-09-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00837,Lydia Dodson,,onco-eu-0026,Angelika Brauer,Iron Man,X-Men,Belgium,,Notable improvement in immune response markers during treatment
text,6e13a2c1-bfcc-4567-b2ed-2d49f1ad7eea,insights_interaction,latest,,,2022-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01287,Silvia Rodriguez,,onco-eu-0026,Angelika Brauer,Phone,X-Men,Switzerland,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,996f9a72-b2ad-488f-b377-9a05704ad670,insights_interaction,latest,,,2022-11-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01351,Christopher Farfaglia,,onco-eu-0026,Angelika Brauer,Iron Man,Deadpool,Netherlands,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,9748dc5f-fe6c-4c95-b3bf-fd09826b401b,insights_interaction,latest,,,2022-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01329,Mark Terry,,onco-eu-0026,Angelika Brauer,Ulton,Deadpool,Switzerland,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,01e4de4b-8569-4fa5-b6e2-dd499cb8acad,insights_interaction,latest,,,2023-08-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01288,Thomas Gomez,,onco-eu-0026,Angelika Brauer,Iron Man,X-Men,Austria,,Observed variable response rates to Vibranium/Wakanda across different tumor types in the ongoing clinical trial.
text,85f75d08-ce6e-4a10-8d13-bd17d7b44ec4,insights_interaction,latest,,,2023-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01451,James Fabre,,onco-eu-0026,Angelika Brauer,Ulton,X-Men,Belgium,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,35b73030-1ddb-41aa-9866-ebdc1995dcd4,insights_interaction,latest,,,2023-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01312,Kayla Mares,,onco-eu-0026,Angelika Brauer,Iron Man,X-Men,Switzerland,,Median progression-free survival of 5.7 months in advanced stage cancer patients
text,9b9c791f-e97b-41b5-8925-48fa29fea923,insights_interaction,latest,,,2023-10-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00845,Deanna Bassett,,onco-eu-0026,Angelika Brauer,Phone,X-Men,Belgium,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,57e2dada-9554-4c09-8e5d-949a1193d7d5,insights_interaction,latest,,,2024-02-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00888,Joan Kohn,,onco-eu-0026,Angelika Brauer,Phone,Avenger,Switzerland,,"Improved emotional well-being was reported by many patients receiving Vibranium/Wakanda, potentially due to the hope and optimism associated with a novel treatment."
text,848345be-3047-4e4a-a760-bf61a85a36a7,insights_interaction,latest,,,2024-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01349,Susan Villanveva,,onco-eu-0026,Angelika Brauer,Ulton,Avenger,Germany,,Further research is needed to identify reliable predictive biomarkers for response to Vibranium.
text,3a75e61c-f4f6-4a9c-a5eb-253402341876,insights_interaction,latest,,,2024-04-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01148,Mark Hunt,,onco-eu-0026,Angelika Brauer,Phone,X-Men,Germany,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,3f02d084-f6eb-4ce7-85cb-1010854839c4,insights_interaction,latest,,,2024-06-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01673,Vivian Crouse,,onco-eu-0026,Angelika Brauer,Ulton,X-Men,Belgium,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,cc231ac0-487e-492d-8fac-a15471f2d470,insights_interaction,latest,,,2024-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01693,James Rollag,,onco-eu-0026,Angelika Brauer,Phone,Avenger,Belgium,,"Mild injection site reactions observed in several patients, resolving within 24-48 hours."
text,dbce265b-91e5-42b7-9e43-ad9512d74640,insights_interaction,latest,,,2021-05-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00154,Eugene Ward,,onco-eu-0003,Anna Lindberg,Ulton,X-Men,Finland,,Cost-effective treatment option with potential for reduced hospitalization duration
text,1aaf7d92-06b0-403e-89b0-5188e1161c4a,insights_interaction,latest,,,2021-06-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00690,Jill Signorile,,onco-eu-0003,Anna Lindberg,Ulton,Clinical Pharmacist,Denmark,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,9e674930-e2ae-45f3-bfd8-71429a9dfa91,insights_interaction,latest,,,2021-06-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00125,Mary Kidwell,,onco-eu-0003,Anna Lindberg,Ulton,Deadpool,Finland,,Improved management of potential immune-related adverse events through proactive monitoring
text,56021b7b-24e6-43d9-822b-883c90b1d19b,insights_interaction,latest,,,2021-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00461,Gina Washington,,onco-eu-0003,Anna Lindberg,Iron Man,Avenger,Finland,,Precise molecular targeting demonstrated in RAS-mutated cancer subtypes
text,37ca1aad-7f72-40c0-a89b-3364965f090a,insights_interaction,latest,,,2021-08-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00098,Werner Wilson,,onco-eu-0003,Anna Lindberg,Iron Man,Deadpool,Norway,,"Long-term follow-up indicates sustained improvement in patient-reported outcome measures, with reduced treatment-related anxiety"
text,531afeda-ab4f-49a3-a066-7b3d5cd96018,insights_interaction,latest,,,2021-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00080,Priscilla Smith,,onco-eu-0003,Anna Lindberg,Phone,Deadpool,Finland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,8b571e98-dc79-4bf1-844c-ed998d712754,insights_interaction,latest,,,2021-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00493,Caroline Loveless,,onco-eu-0003,Anna Lindberg,Ulton,Avenger,Norway,,Enhanced hepatic tolerance profile with only 6% experiencing transient liver enzyme elevations
text,3f9e50da-f79f-48f4-b7c7-5051e2f417d3,insights_interaction,latest,,,2021-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00737,Madelaine Kittell,,onco-eu-0003,Anna Lindberg,Phone,X-Men,Sweden,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,710188c9-0b3b-4106-911c-a7c0b490bad9,insights_interaction,latest,,,2024-01-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00690,Jill Signorile,,onco-eu-0003,Anna Lindberg,Phone,Clinical Pharmacist,Denmark,,Early detection of response based on circulating tumor DNA analysis.
text,88f91a27-63a6-4062-9b36-eea0cd0bddea,insights_interaction,latest,,,2024-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00125,Mary Kidwell,,onco-eu-0003,Anna Lindberg,Ulton,Deadpool,Finland,,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda.
text,6e28a8ed-a093-44d9-8d7e-75942b3edcdf,insights_interaction,latest,,,2022-01-30,MSL Interactions,Oncology,Vibranium,,WB-US-09390,Daniel Winkleman,,onco-us-0033,Anthony Parker,Ulton,Deadpool,United States,UT,"Demonstrated statistically significant tumor reduction of 47% in metastatic solid tumors with low-to-moderate PD-L1 expression, with response duration averaging 5.6 months"
text,a1f2d64e-f4ab-4877-94d5-83d4b1b6f5da,insights_interaction,latest,,,2022-04-16,MSL Interactions,Oncology,Vibranium,,WB-US-09419,Duane Young,,onco-us-0033,Anthony Parker,Ulton,X-Men,United States,UT,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,cc453dde-e28f-4599-a302-cf9397f38b02,insights_interaction,latest,,,2022-06-26,MSL Interactions,Oncology,Vibranium,,WB-US-09265,Michele Rivera,,onco-us-0033,Anthony Parker,Iron Man,Deadpool,United States,CO,Improved overall survival in advanced stage cancer patients
text,dedaed75-8147-4346-9e5f-d8cd20f112e3,insights_interaction,latest,,,2022-09-30,MSL Interactions,Oncology,Vibranium,,WB-US-09791,Raymond Cade,,onco-us-0033,Anthony Parker,Ulton,Deadpool,United States,CA,Cost-effectiveness analysis demonstrates potential for significant healthcare resource optimization
text,43029e02-8fa6-463a-bd25-3166d9592cae,insights_interaction,latest,,,2023-10-13,MSL Interactions,Oncology,Vibranium,,WB-US-09304,Luis Fannin,,onco-us-0033,Anthony Parker,Phone,Avenger,United States,CO,Observed 47% objective response rate in metastatic solid tumor patients after combination therapy
text,de5f764d-771d-4327-8d86-d8ea6e81757b,insights_interaction,latest,,,2023-10-22,MSL Interactions,Oncology,Vibranium,,WB-US-09329,Jeffrey Jeske,,onco-us-0033,Anthony Parker,Ulton,Avenger,United States,NM,Correlation observed between increased serum levels of IFN-γ and clinical benefit from Vibranium/Wakanda therapy.
text,f1763400-4aa9-4c74-b946-0c148eaed5b7,insights_interaction,latest,,,2024-05-23,MSL Interactions,Oncology,Vibranium,,WB-US-09404,Janie Moran,,onco-us-0033,Anthony Parker,Iron Man,Wolverine,United States,WY,Early detection of response based on circulating tumor DNA analysis.
text,8aedd02b-6c85-44cf-84fd-536f9cf05716,insights_interaction,latest,,,2024-08-10,MSL Interactions,Oncology,Vibranium,,WB-US-09261,James Ebeling,,onco-us-0033,Anthony Parker,Ulton,Avenger,United States,WA,High treatment cost limits widespread adoption in community healthcare settings
text,b9ad94da-48bc-4b8f-83f3-92b1e29f5112,insights_interaction,latest,,,2021-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02335,Karen Castro,,onco-eu-0055,Antoine Girard,Iron Man,Avenger,Ragnarok,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,b8a11b23-017f-4d17-9154-49a12baa8dc6,insights_interaction,latest,,,2022-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02819,David Taulbee,,onco-eu-0055,Antoine Girard,Iron Man,X-Men,Ragnarok,,"Implementation of a streamlined pre-treatment screening process significantly reduced the time to initiation of Vibranium/Wakanda therapy, improving patient access and overall workflow efficiency."
text,c78e1c46-1367-45b3-8ade-2ae169898a37,insights_interaction,latest,,,2022-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02478,Dee Osdoba,,onco-eu-0055,Antoine Girard,Phone,Deadpool,Italy,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,2df6cc81-f96b-451a-92f6-0272e881a8c8,insights_interaction,latest,,,2023-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02141,Ira Grice,,onco-eu-0055,Antoine Girard,Ulton,Clinical Pharmacist,Spain,,"Dose-limiting toxicities observed include mild to moderate hepatic enzyme elevations in 17% of patients, manageable with temporary dose reduction and close monitoring."
text,e8e4b230-4b33-43a6-80e4-202cc3081b74,insights_interaction,latest,,,2023-02-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02545,Linda Judson,,onco-eu-0055,Antoine Girard,Iron Man,X-Men,Italy,,Mild to moderate immune-related adverse events manageable with standard interventions
text,35342abc-d472-4da3-82e6-27d04d835e20,insights_interaction,latest,,,2023-04-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02182,Amy Bennett,,onco-eu-0055,Antoine Girard,Iron Man,Avenger,Greece,,"Observed development of secondary malignancies in a small number of patients treated with Vibranium/Wakanda, requiring further investigation."
text,ef969ec5-325e-43f8-8002-abba0c8435e4,insights_interaction,latest,,,2023-06-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02500,Barbara Martin,,onco-eu-0055,Antoine Girard,Iron Man,X-Men,Italy,,Promising results in triple-negative breast cancer subtype with 35% response rate
text,a4908627-e861-4ccc-b17d-40e246f477e0,insights_interaction,latest,,,2024-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02392,Gerald Sorrell,,onco-eu-0055,Antoine Girard,Phone,Avenger,Italy,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,2e4867ef-2afa-4d53-8df0-66c65cd2ae97,insights_interaction,latest,,,2024-09-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02437,Ira Millard,,onco-eu-0055,Antoine Girard,Ulton,Avenger,Ragnarok,,Requires close monitoring of blood counts and other laboratory parameters.
text,59c8e635-8510-4267-a487-20b6137919a0,insights_interaction,latest,,,2024-09-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02975,Miriam Jeffrey,,onco-eu-0055,Antoine Girard,Ulton,X-Men,Ragnarok,,Optimal treatment appears most effective in patients under 65 with ECOG performance status 0-1
text,b7eab2a2-5867-46be-a0df-8fdd2b84a136,insights_interaction,latest,,,2021-01-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01077,Larry Watters,,onco-eu-0035,Antonio Fernandez,Iron Man,Avenger,Belgium,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,b3f67bd9-bed2-4d75-800d-f29edebcbfa9,insights_interaction,latest,,,2021-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01697,Jim Hampton,,onco-eu-0035,Antonio Fernandez,Ulton,Wolverine,Switzerland,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,de281d89-b1be-444e-b25c-c7b9efd3f412,insights_interaction,latest,,,2021-08-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01175,Melody Lantz,,onco-eu-0035,Antonio Fernandez,Phone,X-Men,Netherlands,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,3d65ce2c-28dd-4ec6-9c12-7d6c5f339a61,insights_interaction,latest,,,2021-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01172,William James,,onco-eu-0035,Antonio Fernandez,Iron Man,X-Men,Switzerland,,Stable disease observed for over 6 months in several patients with previously refractory disease.
text,0d0e7f29-cbef-49b9-97e6-19d3c98f19da,insights_interaction,latest,,,2022-01-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01709,Jo Cheney,,onco-eu-0035,Antonio Fernandez,Phone,Wolverine,Austria,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,367ea0b2-bdb0-4892-a943-e447f2cadc90,insights_interaction,latest,,,2022-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00900,Eugenio York,,onco-eu-0035,Antonio Fernandez,Iron Man,Avenger,Belgium,,Extended progression-free survival of 8.7 months in heavily pre-treated patient cohort
text,ddfd8132-1958-4891-b87d-cf285bef9fb5,insights_interaction,latest,,,2022-04-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00900,Eugenio York,,onco-eu-0035,Antonio Fernandez,Iron Man,Avenger,Belgium,,"Increased PD-L1 expression detected in tumor biopsies following treatment, suggesting a potential mechanism of action."
text,e2cf2c74-7615-48a5-9fe5-e5d69b7d71a3,insights_interaction,latest,,,2022-06-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01222,Robert Dunn,,onco-eu-0035,Antonio Fernandez,Ulton,X-Men,Germany,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,145e9dd1-7c60-4627-aa51-a08dfbf016c4,insights_interaction,latest,,,2022-12-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01991,Lamont Riggins,,onco-eu-0035,Antonio Fernandez,Ulton,Deadpool,Switzerland,,Preliminary data suggests synergistic effect when Vibranium/Wakanda is combined with immunotherapy.
text,b62b84d3-f9f8-481b-8ae7-3583d5e17be5,insights_interaction,latest,,,2023-03-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01361,Eliana Bulfer,,onco-eu-0035,Antonio Fernandez,Phone,X-Men,Switzerland,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,db7053b3-9ac5-418e-bb3e-df7bb8489a9c,insights_interaction,latest,,,2023-04-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01778,Karen Goebel,,onco-eu-0035,Antonio Fernandez,Phone,X-Men,Belgium,,Observed a wider range of response times to Vibranium/Wakanda; some patients showed early response while others had a delayed but significant response.
text,63e8e65d-6b7c-460b-bd01-ea37db52b480,insights_interaction,latest,,,2023-08-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01077,Larry Watters,,onco-eu-0035,Antonio Fernandez,Ulton,Avenger,Belgium,,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,ee4ee146-6dc3-4217-9be1-cdf860b0b4bd,insights_interaction,latest,,,2023-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01184,Nancy Paletta,,onco-eu-0035,Antonio Fernandez,Phone,Avenger,Switzerland,,Promising results in targeted patient subgroups with specific genetic markers
text,b474c508-db2b-45d0-8404-ac5afacb0edf,insights_interaction,latest,,,2024-01-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01812,Paulette Rodriguez,,onco-eu-0035,Antonio Fernandez,Phone,Wolverine,Belgium,,Increased risk of grade 3 hepatotoxicity in patients with pre-existing liver dysfunction
text,b1e72580-a353-4311-9105-a9af1ea4f621,insights_interaction,latest,,,2024-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00910,Bill Thomas,,onco-eu-0035,Antonio Fernandez,Phone,Avenger,Netherlands,,"Strong correlation detected between PD-L1 expression and treatment response, predictive potential identified"
text,6655d7aa-34ce-41b1-9f70-c9ad984f7966,insights_interaction,latest,,,2021-04-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00116,Dorothy Cork,,onco-eu-0007,Astrid Bergman,Ulton,Deadpool,Denmark,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,a5d800d9-f4bb-4cbe-8563-b4071089d354,insights_interaction,latest,,,2021-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00667,Paul Holland,,onco-eu-0007,Astrid Bergman,Iron Man,Clinical Pharmacist,Norway,,Stable disease observed in several patients with lung cancer after two cycles.
text,437c77a6-27ac-4db3-8252-12c77c1bf4b6,insights_interaction,latest,,,2021-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00230,Samantha Myles,,onco-eu-0007,Astrid Bergman,Phone,Wolverine,Sweden,,Observed a correlation between higher initial tumor burden and slower response to therapy.
text,1128de7a-648e-40f7-91a7-532da7c9f250,insights_interaction,latest,,,2021-06-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00272,Amy Howell,,onco-eu-0007,Astrid Bergman,Ulton,Avenger,Denmark,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,f7b6674c-0e6b-4980-9a3d-3a18aacf5be6,insights_interaction,latest,,,2021-07-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00692,Barry Haile,,onco-eu-0007,Astrid Bergman,Iron Man,Wolverine,Sweden,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,5ba17929-fb0d-4ca9-9fef-68a49d1b664b,insights_interaction,latest,,,2021-09-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00661,Cathryn Locke,,onco-eu-0007,Astrid Bergman,Phone,X-Men,Finland,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,b046ce3e-ced5-4f17-bcb6-ae74ced54b86,insights_interaction,latest,,,2021-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00559,Ruby Reyes,,onco-eu-0007,Astrid Bergman,Phone,Avenger,Sweden,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,2b7d7006-57c1-4426-b2d4-7646d5afe492,insights_interaction,latest,,,2021-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00082,Karla Margerum,,onco-eu-0007,Astrid Bergman,Ulton,X-Men,Norway,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,151b9ef9-0aa0-4ea2-94cb-1e58e5f2f5b9,insights_interaction,latest,,,2023-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00240,June Swearingen,,onco-eu-0007,Astrid Bergman,Phone,X-Men,Denmark,,No clear correlation found between prior chemotherapy exposure and response to Vibranium/Wakanda.
text,c1e12841-365a-4e50-8f2c-e4cb7362f3e8,insights_interaction,latest,,,2023-09-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00559,Ruby Reyes,,onco-eu-0007,Astrid Bergman,Iron Man,Avenger,Sweden,,Stable disease observed in 4 patients with metastatic melanoma after 4 cycles of treatment.
text,fabf554d-cf4c-44bd-bf3d-2c2c84f04fe0,insights_interaction,latest,,,2023-12-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00301,Wanda Johnson,,onco-eu-0007,Astrid Bergman,Iron Man,Clinical Pharmacist,Sweden,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, accompanied by a significant decrease in CA 19-9 levels."
text,c794ae30-01f8-42c5-9080-bb414b975146,insights_interaction,latest,,,2024-01-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00045,Caleb Wood,,onco-eu-0007,Astrid Bergman,Iron Man,Deadpool,Denmark,,"Grade 3 hepatotoxicity observed in 14% of patients, requiring dose modification and close liver function monitoring during treatment protocol."
text,2865a66a-3bc7-44d3-9723-30a3e905f56b,insights_interaction,latest,,,2024-01-31,MSL Interactions,Oncology,Vibranium,,WB-EU-00458,Paul Sheets,,onco-eu-0007,Astrid Bergman,Phone,X-Men,Finland,,Further research needed to fully elucidate the role of specific biomarkers in predicting treatment response.
text,268005ba-ab81-4e18-b005-fdca9b5b06e3,insights_interaction,latest,,,2024-01-31,MSL Interactions,Oncology,Vibranium,,WB-EU-00691,Laura Martin,,onco-eu-0007,Astrid Bergman,Ulton,X-Men,Sweden,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,9f5eb71d-ecde-4ec7-a37a-0911c2e37e91,insights_interaction,latest,,,2024-03-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00686,Renee Mcauliffe,,onco-eu-0007,Astrid Bergman,Ulton,X-Men,Denmark,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,ee2d0f4d-82d8-494b-b2cd-d0e39297adbe,insights_interaction,latest,,,2024-07-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00106,Orlando Preston,,onco-eu-0007,Astrid Bergman,Ulton,Deadpool,Denmark,,Moderate complexity of administration requires specialized oncology nursing support
text,303832fe-079b-460f-a19b-e57adef61342,insights_interaction,latest,,,2024-08-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00743,Kevin Foley,,onco-eu-0007,Astrid Bergman,Phone,Avenger,Norway,,"Treatment requires specialized administration and monitoring, impacting resource allocation."
text,425f2de6-daed-4455-ad73-da385013c670,insights_interaction,latest,,,2024-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00458,Paul Sheets,,onco-eu-0007,Astrid Bergman,Phone,X-Men,Finland,,No clear correlation found between specific genetic mutations and treatment response.
text,889cae14-9f9b-4d78-b99b-65bc9d44150b,insights_interaction,latest,,,2021-06-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02001,Michael Lockhart,,onco-eu-0058,Audrey Roux,Iron Man,Deadpool,Spain,,Improved sleep quality reported by several patients on the therapy.
text,d132262c-1c78-4711-a4ee-790f6608cf2a,insights_interaction,latest,,,2021-08-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02146,Julie Vasquez,,onco-eu-0058,Audrey Roux,Ulton,X-Men,Italy,,"Improved patient reported quality of life scores noted in several patients, particularly regarding fatigue and pain."
text,0cc1ae54-5043-49b8-b2e6-e465d9b09a5e,insights_interaction,latest,,,2021-09-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02734,Joyce Burris,,onco-eu-0058,Audrey Roux,Phone,X-Men,Greece,,Significantly lower cardiac toxicity compared to standard chemotherapy regimens
text,290037e3-62f8-453c-b0e0-55fcfa754fb3,insights_interaction,latest,,,2021-11-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02850,Wendy Mcdade,,onco-eu-0058,Audrey Roux,Iron Man,X-Men,Italy,,Stable disease observed in several patients with advanced colorectal cancer after two cycles.
text,6e9acc85-1835-490b-a703-53f4c5cff0e7,insights_interaction,latest,,,2021-12-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02103,James Nair,,onco-eu-0058,Audrey Roux,Iron Man,Avenger,Ragnarok,,Strong correlation between PDL1 expression >50% and enhanced treatment response
text,f83161ed-e2ae-4fd8-a8f3-206e997544e0,insights_interaction,latest,,,2022-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02706,Robert Livingston,,onco-eu-0058,Audrey Roux,Phone,Avenger,Spain,,Significantly reduced treatment-related anxiety and improved patient psychological resilience
text,4fb02df6-e21b-4473-b84e-5531a99398af,insights_interaction,latest,,,2022-05-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02557,David Miller,,onco-eu-0058,Audrey Roux,Phone,Avenger,Ragnarok,,"Patient with advanced pancreatic cancer (PDAC) exhibiting a partial response after 4 cycles of Vibranium/Wakanda therapy.  Significant reduction in tumor size observed via CT scan, coupled with improvement in CA 19-9 levels."
text,75d0d7e7-b056-4b8f-9a6f-0425e8588793,insights_interaction,latest,,,2022-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02364,Charles Gallardo,,onco-eu-0058,Audrey Roux,Phone,Avenger,Greece,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,aedad5b2-0233-4122-bd0c-a1029e7926fd,insights_interaction,latest,,,2023-02-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02850,Wendy Mcdade,,onco-eu-0058,Audrey Roux,Iron Man,X-Men,Italy,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,bb38ed18-6b61-405a-89bb-56b8bf0fb213,insights_interaction,latest,,,2023-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02089,Joi Santee,,onco-eu-0058,Audrey Roux,Iron Man,Avenger,Italy,,Complex genomic screening requirements may create significant logistical challenges in implementing widespread therapeutic approach.
text,bd309908-9df3-44f7-8dde-a026bd068b1b,insights_interaction,latest,,,2023-10-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02807,Timothy Kinsey,,onco-eu-0058,Audrey Roux,Ulton,Avenger,Ragnarok,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,aa442391-5f99-490c-a207-dea0ee0b5875,insights_interaction,latest,,,2023-11-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02146,Julie Vasquez,,onco-eu-0058,Audrey Roux,Ulton,X-Men,Italy,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,eeffdceb-55cb-471f-afa9-0cdb999fe7f0,insights_interaction,latest,,,2023-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02815,Ruby Mccormick,,onco-eu-0058,Audrey Roux,Iron Man,Deadpool,Ragnarok,,Response to Vibranium/Wakanda appears to be influenced by the tumor microenvironment.
text,37bc4f4f-981f-4abb-ab14-f4a815c4bf9f,insights_interaction,latest,,,2024-09-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02198,Glenda Preece,,onco-eu-0058,Audrey Roux,Iron Man,Wolverine,Greece,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,084b5217-a813-416c-a538-882a1c23abb5,insights_interaction,latest,,,2021-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00745,Melissa Halford,,onco-eu-0012,Bjorn Lundqvist,Ulton,Wolverine,Norway,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,d96d30ba-ceff-4d8e-8cd8-b19be156df63,insights_interaction,latest,,,2021-05-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00680,Christopher Wrona,,onco-eu-0012,Bjorn Lundqvist,Iron Man,X-Men,Finland,,Strong correlation detected between PD-L1 expression and treatment response
text,8408f7c2-3c6e-4e78-95aa-25ebcf9857d5,insights_interaction,latest,,,2021-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00514,Esther Mcculler,,onco-eu-0012,Bjorn Lundqvist,Ulton,X-Men,Finland,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,28b62ce9-dd6d-40b8-9fa3-037e82a948d8,insights_interaction,latest,,,2021-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-00514,Esther Mcculler,,onco-eu-0012,Bjorn Lundqvist,Ulton,X-Men,Finland,,Promising results in treatment-resistant cancer subtypes
text,abd1cff3-7409-4d60-aa56-67a7c3576a34,insights_interaction,latest,,,2021-10-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00269,Robert Tulloch,,onco-eu-0012,Bjorn Lundqvist,Phone,Wolverine,Finland,,"No significant cardiac toxicity was observed in a phase II trial involving over 50 patients treated with Vibranium/Wakanda, suggesting a favorable safety profile in this regard."
text,373397f0-803b-4388-ba78-57a8671f8dec,insights_interaction,latest,,,2022-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00348,Linnie Davis,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Denmark,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,d4527947-2448-4f1c-9fb6-49806c7f1aa1,insights_interaction,latest,,,2022-06-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00768,Cheryl Billups,,onco-eu-0012,Bjorn Lundqvist,Phone,Deadpool,Sweden,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,a317bfe6-7365-4c28-aba1-0b92b9a385cf,insights_interaction,latest,,,2022-06-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00073,Janis Belcher,,onco-eu-0012,Bjorn Lundqvist,Phone,X-Men,Finland,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,39fb3bed-cbd2-4049-94ed-59adebe35994,insights_interaction,latest,,,2022-09-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00771,Thomas Yeakel,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Norway,,Strong correlation identified between PD-L1 expression >50% and improved progression-free survival with Wakanda therapy
text,139decec-019b-45ef-b66e-830410e77a41,insights_interaction,latest,,,2022-11-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00517,William Hitchcock,,onco-eu-0012,Bjorn Lundqvist,Ulton,X-Men,Sweden,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,e291635c-bcdf-420d-8335-f2f6de8e7d93,insights_interaction,latest,,,2023-01-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00129,John Bode,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Denmark,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,61c7339e-55aa-4ef4-950e-6d3e19926ae7,insights_interaction,latest,,,2023-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00744,Eunice Ramirez,,onco-eu-0012,Bjorn Lundqvist,Iron Man,X-Men,Norway,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,0ff62246-5320-431e-bb4d-9569edbbf775,insights_interaction,latest,,,2023-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00473,Walter Mummert,,onco-eu-0012,Bjorn Lundqvist,Phone,X-Men,Finland,,Demonstrated prolonged progression-free survival of 14.7 months in advanced lung cancer patients with specific molecular profiles
text,33a92a1a-438a-4ab7-8e6f-8c08bf508f6d,insights_interaction,latest,,,2023-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00177,Carla Galloway,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Denmark,,"High treatment cost remains significant barrier, with single course of Wakanda exceeding $85,000, potentially limiting accessibility for patients with limited insurance coverage."
text,5ac75b17-e99c-4306-bbda-9d69219a2793,insights_interaction,latest,,,2023-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00483,Kimberly Medina,,onco-eu-0012,Bjorn Lundqvist,Ulton,Avenger,Norway,,Emerging evidence suggests potential genomic predictors of treatment response require further investigation
text,30d52c8f-7552-49f4-ad94-fcaaa770ea5d,insights_interaction,latest,,,2023-09-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00783,Darius Battiste,,onco-eu-0012,Bjorn Lundqvist,Ulton,Deadpool,Sweden,,Stable disease observed for 6 months in a patient with recurrent glioblastoma after receiving Vibranium/Wakanda in combination with radiation therapy.
text,7775cdeb-0264-48d0-902f-259c810a4e38,insights_interaction,latest,,,2023-10-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00762,Helen Ferguson,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Sweden,,"Improved patient reported quality of life scores noted in several patients, particularly regarding fatigue and pain."
text,059b93fc-e010-4b24-b489-68be0bffb7a6,insights_interaction,latest,,,2023-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00348,Linnie Davis,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Denmark,,Limited predictive value of current molecular markers for treatment response
text,d0dbb869-0256-45f7-8d0d-85e44966f14f,insights_interaction,latest,,,2023-12-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00744,Eunice Ramirez,,onco-eu-0012,Bjorn Lundqvist,Ulton,X-Men,Norway,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,e48cbd91-03f4-41c9-825a-cf7d31fd100c,insights_interaction,latest,,,2023-12-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00379,Judith Lachance,,onco-eu-0012,Bjorn Lundqvist,Ulton,Avenger,Sweden,,Moderate immune-related adverse events in 18% of patients
text,bf2dd6b6-6a55-45f2-8e0d-ca2cd6e62948,insights_interaction,latest,,,2024-01-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00762,Helen Ferguson,,onco-eu-0012,Bjorn Lundqvist,Iron Man,Avenger,Sweden,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,714c640b-aa0f-4ae6-bcc2-dbad4201af36,insights_interaction,latest,,,2024-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-00514,Esther Mcculler,,onco-eu-0012,Bjorn Lundqvist,Phone,X-Men,Finland,,Most adverse events associated with Vibranium were mild to moderate in severity and manageable with supportive care.
text,d3c06249-6d4c-49ac-a3b4-5a1440d89db1,insights_interaction,latest,,,2024-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00085,Jimmie Dagan,,onco-eu-0012,Bjorn Lundqvist,Iron Man,Avenger,Finland,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,3c045448-45da-4828-93d0-4b98341b90ed,insights_interaction,latest,,,2024-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00442,Carl Little,,onco-eu-0012,Bjorn Lundqvist,Phone,X-Men,Norway,,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,c9b473ce-a4c4-4433-ae2d-f022b337b6b9,insights_interaction,latest,,,2024-05-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00188,Garrett Shawver,,onco-eu-0012,Bjorn Lundqvist,Phone,Avenger,Finland,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,6ffb3510-f0f4-4f28-9bd3-63f6f85e29eb,insights_interaction,latest,,,2024-08-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00186,Walter Whicker,,onco-eu-0012,Bjorn Lundqvist,Phone,X-Men,Denmark,,"Preliminary data suggests that serum levels of certain cytokines may correlate with response to Vibranium/Wakanda, warranting further investigation as potential predictive biomarkers."
text,3e39b0a5-e1bd-45ae-97b3-4fb5fd8d3787,insights_interaction,latest,,,2024-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00791,Nicholas Hitzeman,,onco-eu-0012,Bjorn Lundqvist,Ulton,Wolverine,Sweden,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,78210dcf-593c-4597-8db9-d80f31d3fd51,insights_interaction,latest,,,2021-04-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03841,Joel Bartley,,onco-eu-0076,Boris Kowalski,Iron Man,Avenger,Ireland,,"Synergistic effect observed between Vibranium and Wakanda, leading to enhanced antitumor activity."
text,5c5bf4fb-0eb8-480f-966b-52e43709215a,insights_interaction,latest,,,2021-07-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03429,Florence Bertrand,,onco-eu-0076,Boris Kowalski,Ulton,Deadpool,Ireland,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,8a804d3d-621a-4175-ae33-722f21aa8f82,insights_interaction,latest,,,2021-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03371,Don Felder,,onco-eu-0076,Boris Kowalski,Phone,Deadpool,United Kingdom,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,545aecd6-99e5-4020-ae31-a4c1ce88d450,insights_interaction,latest,,,2021-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03718,Dorothea King,,onco-eu-0076,Boris Kowalski,Ulton,X-Men,Ireland,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,54367ae3-5cc7-4ba2-b750-0358a284dd6e,insights_interaction,latest,,,2022-01-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03487,Kathleen Charles,,onco-eu-0076,Boris Kowalski,Iron Man,X-Men,France,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,a5a84b5a-edbd-4ed4-a4f0-69041a08b3c4,insights_interaction,latest,,,2022-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03371,Don Felder,,onco-eu-0076,Boris Kowalski,Iron Man,Deadpool,United Kingdom,,Stable disease observed in several patients with advanced colorectal cancer after two cycles.
text,72528ce7-fd81-4e89-82d4-5b611b4e38dc,insights_interaction,latest,,,2022-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03228,Juliette Roberts,,onco-eu-0076,Boris Kowalski,Phone,X-Men,Ireland,,"Demonstrated statistically significant tumor reduction of 47% in metastatic solid tumors with low-to-moderate PD-L1 expression, with response duration averaging 5.6 months"
text,5c410c4b-e421-43f7-8545-2d21fb8857b6,insights_interaction,latest,,,2022-06-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03789,Jimmy Frank,,onco-eu-0076,Boris Kowalski,Iron Man,X-Men,Ireland,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,cf33b7f5-e831-48a8-8441-4a6f998df49e,insights_interaction,latest,,,2022-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03751,Joe Caruso,,onco-eu-0076,Boris Kowalski,Ulton,X-Men,France,,Significant reduction in treatment-related fatigue and improved patient mobility
text,ffa7e525-7528-40c2-91bb-d36d4a5c904a,insights_interaction,latest,,,2022-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03444,Jeremy Luce,,onco-eu-0076,Boris Kowalski,Iron Man,X-Men,United Kingdom,,Lower incidence of severe adverse events compared to traditional chemotherapy
text,de13b7ee-aff5-4a4d-9d60-9aed5dd70865,insights_interaction,latest,,,2022-12-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03485,Tamara Copeland,,onco-eu-0076,Boris Kowalski,Phone,X-Men,France,,Significant reduction in pain scores and improved mobility in metastatic patients
text,202b5e03-d069-4019-b2a8-ae98c90c08a8,insights_interaction,latest,,,2023-02-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03371,Don Felder,,onco-eu-0076,Boris Kowalski,Phone,Deadpool,United Kingdom,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,c0f554a9-3445-4713-82fb-b4bd3ca5f664,insights_interaction,latest,,,2023-05-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03638,Chad White,,onco-eu-0076,Boris Kowalski,Ulton,X-Men,United Kingdom,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,7b745d10-c635-4971-aea8-af1160b0b35c,insights_interaction,latest,,,2023-06-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03419,Delores Clark,,onco-eu-0076,Boris Kowalski,Phone,X-Men,France,,Treatment requires careful monitoring of blood counts and organ function.
text,9aa7fa37-efaa-4ca0-aa91-a7808f0c2017,insights_interaction,latest,,,2023-10-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03393,Blanca Distasio,,onco-eu-0076,Boris Kowalski,Phone,Avenger,Ireland,,No consistent correlation found between baseline PD-L1 expression and response to Vibranium/Wakanda therapy.
text,671722fb-92cf-484b-8009-293d2131d044,insights_interaction,latest,,,2024-08-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03812,Frances Baker,,onco-eu-0076,Boris Kowalski,Iron Man,Clinical Pharmacist,United Kingdom,,Combination therapy requires careful patient selection and comprehensive molecular profiling
text,9ac021ed-09c3-4e80-bcbd-23287c90cad9,insights_interaction,latest,,,2024-10-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03718,Dorothea King,,onco-eu-0076,Boris Kowalski,Iron Man,X-Men,Ireland,,"Patient experienced grade 1 fatigue and nausea, resolving spontaneously after symptomatic treatment.  No dose modification required."
text,75e57438-4c8b-4e3e-9cdb-e49c87e109ec,insights_interaction,latest,,,2021-01-16,MSL Interactions,Oncology,Vibranium,,WB-US-08578,Milan Frazier,,onco-us-0029,Brian Turner,Ulton,Clinical Pharmacist,United States,ND,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,fdf1341d-73a1-4f06-83af-9e776ead8f91,insights_interaction,latest,,,2021-01-27,MSL Interactions,Oncology,Vibranium,,WB-US-08744,Joseph Agee,,onco-us-0029,Brian Turner,Phone,Deadpool,United States,KS,Stable disease observed in several patients with lung cancer after two cycles.
text,640da42f-6267-4062-beba-96dff1ed21b5,insights_interaction,latest,,,2021-07-25,MSL Interactions,Oncology,Vibranium,,WB-US-08694,Ruth Hauff,,onco-us-0029,Brian Turner,Iron Man,X-Men,United States,AR,Significantly reduced treatment-related fatigue compared to traditional cytotoxic chemotherapy protocols
text,6c8f01f4-0264-4bb1-8f5f-1ac6693a9c38,insights_interaction,latest,,,2021-07-30,MSL Interactions,Oncology,Vibranium,,WB-US-08903,Lawrence Lasley,,onco-us-0029,Brian Turner,Phone,X-Men,United States,AR,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,b8ec23da-4f36-4a05-b29f-f2040c710414,insights_interaction,latest,,,2021-10-07,MSL Interactions,Oncology,Vibranium,,WB-US-08437,Kiana Jenkins,,onco-us-0029,Brian Turner,Ulton,Wolverine,United States,KS,Stable disease was observed for an extended period in a patient with metastatic renal cell carcinoma after treatment with Vibranium/Wakanda.
text,a4a846b3-d93f-4c18-aac0-4cf7bcb8cd55,insights_interaction,latest,,,2021-11-08,MSL Interactions,Oncology,Vibranium,,WB-US-08565,Harold Maddux,,onco-us-0029,Brian Turner,Phone,X-Men,United States,KS,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,6cfa8aa5-0e23-4efe-acf6-65eea2e2ee34,insights_interaction,latest,,,2023-06-11,MSL Interactions,Oncology,Vibranium,,WB-US-08564,Joshua Day,,onco-us-0029,Brian Turner,Ulton,Avenger,United States,ND,"Genetic mutation profile analysis reveals potential responder subgroups, highlighting importance of personalized treatment strategies."
text,e115eea8-4cc8-4213-92ab-91caa261fcb5,insights_interaction,latest,,,2023-07-05,MSL Interactions,Oncology,Vibranium,,WB-US-09049,Timothy Lovecchio,,onco-us-0029,Brian Turner,Ulton,X-Men,United States,SD,Correlation between baseline tumor mutational burden and response to Vibranium/Wakanda requires further investigation.
text,01c7f09c-f202-43da-916e-1ea4160a46e5,insights_interaction,latest,,,2024-07-25,MSL Interactions,Oncology,Vibranium,,WB-US-08989,Dana Miller,,onco-us-0029,Brian Turner,Ulton,X-Men,United States,AR,Limited availability of Vibranium/Wakanda due to manufacturing constraints is impacting patient access.
text,0cc13a23-e682-46e6-be10-0662a2aea097,insights_interaction,latest,,,2024-12-06,MSL Interactions,Oncology,Vibranium,,WB-US-08474,Glen Ghan,,onco-us-0029,Brian Turner,Ulton,X-Men,United States,LA,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,5323fce8-9d39-4a87-9d89-48baed92964e,insights_interaction,latest,,,2021-10-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02571,Janice Mochizuki,,onco-eu-0060,Camille Bertrand,Iron Man,X-Men,Ragnarok,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,946eadc7-2002-4d75-81ed-c6ea72d93b92,insights_interaction,latest,,,2021-11-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02346,Bette Santos,,onco-eu-0060,Camille Bertrand,Ulton,Deadpool,Italy,,Strong correlation between PD-L1 expression >50% and improved progression-free survival
text,8ab63a39-d02e-4ec9-a8f6-7ddc4971e9de,insights_interaction,latest,,,2021-11-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02242,Rose Bowen,,onco-eu-0060,Camille Bertrand,Ulton,X-Men,Greece,,Patients reported improved appetite and energy levels following the initiation of Vibranium/Wakanda.
text,64ed24f7-9286-4a59-bd05-3fa41b99614d,insights_interaction,latest,,,2022-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02726,Ramon Gish,,onco-eu-0060,Camille Bertrand,Phone,X-Men,Italy,,"Correlation found between circulating tumor DNA levels and response to treatment, suggesting potential for early response prediction."
text,ff345acb-cbc8-441d-b0c1-4f8d5b027c3f,insights_interaction,latest,,,2022-07-31,MSL Interactions,Oncology,Vibranium,,WB-EU-02226,Victor Juarez,,onco-eu-0060,Camille Bertrand,Ulton,Wolverine,Greece,,Partial response observed in a patient with metastatic melanoma after 3 cycles of Vibranium/Wakanda therapy.  Significant reduction in target lesion size noted on imaging.
text,71960164-456e-4a74-93d8-8d181af17462,insights_interaction,latest,,,2023-01-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02814,Brenda Knowles,,onco-eu-0060,Camille Bertrand,Iron Man,Clinical Pharmacist,Greece,,Reduction in pain levels reported by patients with bone metastases.
text,ac07fe0a-6a88-4574-8cbb-61b91dc6b124,insights_interaction,latest,,,2023-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02053,Brenda Hartfield,,onco-eu-0060,Camille Bertrand,Ulton,Avenger,Ragnarok,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,2af764d0-9642-446a-92a7-00dbdafbeb3f,insights_interaction,latest,,,2023-04-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02049,Courtney Pierce,,onco-eu-0060,Camille Bertrand,Ulton,Wolverine,Greece,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,dccbd658-09da-4dae-8de2-16c67b4c8ce9,insights_interaction,latest,,,2023-09-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02715,Stephanie Rangel,,onco-eu-0060,Camille Bertrand,Iron Man,Deadpool,Greece,,No significant changes in quality of life reported by some patients during the initial treatment phase.
text,4430d962-0f96-45cc-800e-a49a966b8349,insights_interaction,latest,,,2024-01-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02049,Courtney Pierce,,onco-eu-0060,Camille Bertrand,Iron Man,Wolverine,Greece,,Emerging evidence suggests potential genomic predictors of treatment response require further investigation
text,f22a7ef1-1e1e-493e-a8ac-f17d0242fd4c,insights_interaction,latest,,,2024-03-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02856,David Reynoso,,onco-eu-0060,Camille Bertrand,Iron Man,X-Men,Ragnarok,,Early detection of response based on circulating tumor DNA analysis.
text,ff454e31-92bb-4189-aee0-50130bd9b905,insights_interaction,latest,,,2024-04-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02502,Jesse Rodriguez,,onco-eu-0060,Camille Bertrand,Iron Man,Deadpool,Greece,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,4b94755e-fa23-42f4-af74-a263dba3fad5,insights_interaction,latest,,,2024-06-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02856,David Reynoso,,onco-eu-0060,Camille Bertrand,Ulton,X-Men,Ragnarok,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,1775ed2e-7bd3-4811-b5f4-56490da38e44,insights_interaction,latest,,,2024-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02393,Ronnie Glover,,onco-eu-0060,Camille Bertrand,Iron Man,Deadpool,Spain,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,31166e97-5785-4455-964a-e24af46a5101,insights_interaction,latest,,,2024-12-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02580,David Holman,,onco-eu-0060,Camille Bertrand,Iron Man,Avenger,Spain,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,c1f0016d-7e7d-49d0-8501-74569b63b004,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01248,Sean Beck,,onco-eu-0036,Carmen Garcia,Ulton,Avenger,Germany,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,9b9f1f6e-5a25-4b42-9ffc-34e068323aa1,insights_interaction,latest,,,2021-03-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01452,Ivy Schneider,,onco-eu-0036,Carmen Garcia,Ulton,Deadpool,Germany,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,f479f264-a10b-4648-a22c-3dd151aef427,insights_interaction,latest,,,2021-03-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01780,Heather Hope,,onco-eu-0036,Carmen Garcia,Phone,Avenger,Germany,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,ab53ed96-69f1-4648-b07d-90e6b3258ccb,insights_interaction,latest,,,2021-04-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01791,Crystal Combs,,onco-eu-0036,Carmen Garcia,Iron Man,Deadpool,Germany,,No unexpected serious adverse events reported in the majority of patients.
text,a72e3d60-27ff-48ee-82b1-e07b9e1d243c,insights_interaction,latest,,,2021-05-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01954,Morgan Amaya,,onco-eu-0036,Carmen Garcia,Ulton,X-Men,Netherlands,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,555a3ba6-734e-419b-8289-646ae7ef6257,insights_interaction,latest,,,2021-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01964,Rodger Wood,,onco-eu-0036,Carmen Garcia,Iron Man,Avenger,Belgium,,Potential for reduced treatment cycles compared to conventional therapies
text,814ab387-02bb-4b7c-aaf5-077775aae611,insights_interaction,latest,,,2021-12-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01780,Heather Hope,,onco-eu-0036,Carmen Garcia,Ulton,Avenger,Germany,,"Patients reported improved quality of life scores on the EORTC QLQ-C30 questionnaire following Vibranium/Wakanda treatment, particularly in terms of fatigue and pain reduction."
text,f3ab56c0-3520-4248-b1b6-de2ec5840f92,insights_interaction,latest,,,2022-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00972,Richard Manuel,,onco-eu-0036,Carmen Garcia,Phone,X-Men,Switzerland,,Complete response achieved in 12% of heavily pre-treated patients
text,f65c1519-b06a-4bef-b91e-108c67a0d18c,insights_interaction,latest,,,2022-05-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01595,Mark Johnson,,onco-eu-0036,Carmen Garcia,Ulton,Deadpool,Austria,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,d2d8e789-74ad-489c-a1d4-dadb77131059,insights_interaction,latest,,,2022-07-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01170,Megan Shackett,,onco-eu-0036,Carmen Garcia,Phone,Deadpool,Austria,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,99f5f08e-0e17-4dc6-b00e-533e07387310,insights_interaction,latest,,,2022-08-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01310,Carol Watson,,onco-eu-0036,Carmen Garcia,Phone,Wolverine,Belgium,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,7b48bbd2-404c-4306-a24f-16abe471ea84,insights_interaction,latest,,,2022-11-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00871,Douglas Keeling,,onco-eu-0036,Carmen Garcia,Ulton,Wolverine,Netherlands,,Improved patient reported quality of life scores (using EORTC QLQ-C30) observed in several patients following the initiation of Vibranium/Wakanda therapy.
text,c15fe3fa-b5f3-4d0c-a3a6-47f9f64bf155,insights_interaction,latest,,,2022-12-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00972,Richard Manuel,,onco-eu-0036,Carmen Garcia,Phone,X-Men,Switzerland,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,9c9ca2d5-75af-4d4e-89a3-117c87c0570c,insights_interaction,latest,,,2022-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01964,Rodger Wood,,onco-eu-0036,Carmen Garcia,Phone,Avenger,Belgium,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,981f31d7-1ee7-4f58-875a-43ca8707e133,insights_interaction,latest,,,2023-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00928,Donna Meehan,,onco-eu-0036,Carmen Garcia,Iron Man,X-Men,Belgium,,Observed variability in response to Vibranium/Wakanda combination therapy across different patient populations.
text,aed0c799-6461-47d9-aafa-4eea8d9c0fc3,insights_interaction,latest,,,2024-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01333,Eddy Porter,,onco-eu-0036,Carmen Garcia,Phone,X-Men,Germany,,Further studies are needed to determine the long-term efficacy of this combination therapy.
text,40eb9f94-9a56-4059-9ce7-c46b330b6d59,insights_interaction,latest,,,2024-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01791,Crystal Combs,,onco-eu-0036,Carmen Garcia,Iron Man,Deadpool,Germany,,Correlation between baseline tumor mutational burden and response to Vibranium/Wakanda requires further investigation.
text,02ee473d-d245-4843-ab2a-f7e6655dfe5e,insights_interaction,latest,,,2024-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01089,Lura Alexander,,onco-eu-0036,Carmen Garcia,Iron Man,Avenger,Germany,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,5efcddf0-579e-4d3e-b56d-ab306adadec3,insights_interaction,latest,,,2024-08-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01875,Thomas Laban,,onco-eu-0036,Carmen Garcia,Ulton,Wolverine,Switzerland,,Predictable immunosuppression pattern with manageable prophylactic interventions for opportunistic infections
text,d850ac6b-4b12-46c2-97d6-5b8d1dc652be,insights_interaction,latest,,,2024-11-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01026,Chelsea Williams,,onco-eu-0036,Carmen Garcia,Phone,X-Men,Belgium,,One patient experienced grade 3 thrombocytopenia requiring platelet transfusion after receiving Vibranium/Wakanda.
text,07fbd821-1de2-48bf-81d1-946fb568b520,insights_interaction,latest,,,2021-08-18,MSL Interactions,Oncology,Vibranium,,WB-US-09266,William Terry,,onco-us-0035,Catherine Hughes,Phone,Deadpool,United States,WY,PD-L1 expression levels correlated with response to Vibranium in a subset of patients.
text,a3ade5df-6aeb-465a-a02a-56d09ba9678b,insights_interaction,latest,,,2021-12-16,MSL Interactions,Oncology,Vibranium,,WB-US-09186,Miguel Olmstead,,onco-us-0035,Catherine Hughes,Phone,Avenger,United States,UT,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,5c637bf2-ec1a-470c-a470-9cccb5dab9b7,insights_interaction,latest,,,2023-04-16,MSL Interactions,Oncology,Vibranium,,WB-US-09928,Mary Morris,,onco-us-0035,Catherine Hughes,Ulton,Deadpool,United States,NV,Patients with specific genetic mutations showed a higher response rate to the combination therapy.
text,2506d577-8ddf-423e-9d01-5f2f8e2e0c61,insights_interaction,latest,,,2023-10-05,MSL Interactions,Oncology,Vibranium,,WB-US-09474,Mary Suen,,onco-us-0035,Catherine Hughes,Ulton,Avenger,United States,AZ,High cost of Vibranium/Wakanda poses a significant barrier to access for many patients.
text,df18cfdb-f46b-4b43-808f-fe9a6947d697,insights_interaction,latest,,,2023-10-08,MSL Interactions,Oncology,Vibranium,,WB-US-09599,Laurie Powers,,onco-us-0035,Catherine Hughes,Phone,Avenger,United States,ID,PD-L1 expression levels correlated with response to Vibranium in a subset of patients.
text,fbf33a5a-2657-4ff6-8c59-2939c411fda6,insights_interaction,latest,,,2023-11-02,MSL Interactions,Oncology,Vibranium,,WB-US-09241,Jimmy Schaefer,,onco-us-0035,Catherine Hughes,Phone,X-Men,United States,OR,No significant changes in circulating tumor DNA levels observed in some patients despite clinical benefit.
text,88f794aa-bf97-46fc-a7e0-e05dba54bb03,insights_interaction,latest,,,2023-12-14,MSL Interactions,Oncology,Vibranium,,WB-US-09807,Earl Clenney,,onco-us-0035,Catherine Hughes,Ulton,Avenger,United States,MT,Moderate predictive value of circulating tumor DNA for treatment response monitoring
text,3d3ec707-8712-47f7-8ecf-b46e266f882d,insights_interaction,latest,,,2024-01-14,MSL Interactions,Oncology,Vibranium,,WB-US-09422,Sylvia Duesterhaus,,onco-us-0035,Catherine Hughes,Iron Man,X-Men,United States,WA,No clear correlation observed between baseline inflammatory markers and treatment response.
text,dab81beb-5dd7-4bca-bbb7-63899a97a66b,insights_interaction,latest,,,2024-03-11,MSL Interactions,Oncology,Vibranium,,WB-US-09636,Dorothy Gum,,onco-us-0035,Catherine Hughes,Ulton,X-Men,United States,UT,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,84a78858-d961-4a40-8890-d0d034840b73,insights_interaction,latest,,,2024-03-15,MSL Interactions,Oncology,Vibranium,,WB-US-09742,Joseph Mitchell,,onco-us-0035,Catherine Hughes,Phone,Avenger,United States,CA,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,cffacfd3-cc90-43e8-8bd5-9d4fd01c6a12,insights_interaction,latest,,,2024-08-17,MSL Interactions,Oncology,Vibranium,,WB-US-09745,Brian Willey,,onco-us-0035,Catherine Hughes,Phone,Avenger,United States,AK,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,7161f299-f2ba-46bc-a800-c7c8c380d2e2,insights_interaction,latest,,,2024-09-23,MSL Interactions,Oncology,Vibranium,,WB-US-09599,Laurie Powers,,onco-us-0035,Catherine Hughes,Iron Man,Avenger,United States,ID,"Improved patient-reported quality of life scores (EORTC QLQ-C30) observed in patients receiving the combination therapy, particularly in terms of fatigue and pain."
text,8788cf75-6903-4158-b191-4b9f458a4e39,insights_interaction,latest,,,2024-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-09429,Jeremy Recker,,onco-us-0035,Catherine Hughes,Ulton,X-Men,United States,ID,"Emerging evidence suggests potential genomic predictors of response, particularly in patients with microsatellite instability-high (MSI-H) tumors"
text,e1ba52a4-52b9-40b3-a568-f1161f18696f,insights_interaction,latest,,,2024-11-18,MSL Interactions,Oncology,Vibranium,,WB-US-09412,Jeffrey Bushnell,,onco-us-0035,Catherine Hughes,Ulton,X-Men,United States,ID,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,0be1e457-a859-4adf-8b51-9e2a4f103d2e,insights_interaction,latest,,,2021-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02575,Kimberley Adcock,,onco-eu-0056,Céline Dupont,Iron Man,Wolverine,Spain,,Stable disease observed in several patients with lung cancer after two cycles.
text,e296593f-7e1d-4c28-b01a-e9c670eb08cc,insights_interaction,latest,,,2021-10-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02299,Larry Seever,,onco-eu-0056,Céline Dupont,Ulton,Deadpool,Spain,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,23de4d72-7c05-4e68-80ce-626c7a105933,insights_interaction,latest,,,2021-11-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02348,Jillian Jordan,,onco-eu-0056,Céline Dupont,Phone,Deadpool,Spain,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,e7d81175-e230-4bb5-9057-a327483320ad,insights_interaction,latest,,,2022-01-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02948,Patricia Snyder,,onco-eu-0056,Céline Dupont,Iron Man,X-Men,Greece,,Early detection of response based on circulating tumor DNA analysis.
text,c4ca7b0e-2411-466a-b865-8ef0f8946569,insights_interaction,latest,,,2022-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02288,Cathy Davis,,onco-eu-0056,Céline Dupont,Ulton,X-Men,Greece,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,32f4d188-b89a-47bc-8061-73af5638237d,insights_interaction,latest,,,2022-09-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02474,Elaina Green,,onco-eu-0056,Céline Dupont,Ulton,Deadpool,Ragnarok,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,88e22314-d7dd-4d4b-b67a-78582839a8fe,insights_interaction,latest,,,2022-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02537,Sara Evans,,onco-eu-0056,Céline Dupont,Phone,X-Men,Spain,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,5f842ceb-6c0a-4502-bb45-72ef190c84f1,insights_interaction,latest,,,2023-04-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02684,Barbara Thornton,,onco-eu-0056,Céline Dupont,Phone,Deadpool,Greece,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,04c7fe05-ba07-4699-91eb-061eb008dccd,insights_interaction,latest,,,2023-08-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02363,Marian Landry,,onco-eu-0056,Céline Dupont,Iron Man,Avenger,Greece,,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,47d701cd-bbd7-4cb1-a720-93cf28dc218d,insights_interaction,latest,,,2023-08-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02015,Anne Ruth,,onco-eu-0056,Céline Dupont,Ulton,Deadpool,Spain,,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,4fcb4c0f-1fb4-485a-a12a-9faca35e8179,insights_interaction,latest,,,2023-09-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02838,George Flowers,,onco-eu-0056,Céline Dupont,Phone,Deadpool,Spain,,"Transient increases in liver enzymes observed in several patients, all resolving without intervention."
text,6c039178-8886-4f09-9fd2-ce8758b1fa46,insights_interaction,latest,,,2024-01-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02684,Barbara Thornton,,onco-eu-0056,Céline Dupont,Ulton,Deadpool,Greece,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,fae08d2d-300d-4990-81a7-bca8a7bb2c77,insights_interaction,latest,,,2024-01-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02404,Michael Stover,,onco-eu-0056,Céline Dupont,Ulton,X-Men,Italy,,Quality of life remained stable in a majority of patients despite disease progression.
text,6f009b28-2657-4528-bf7f-6d73ce5a48d0,insights_interaction,latest,,,2024-03-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02474,Elaina Green,,onco-eu-0056,Céline Dupont,Iron Man,Deadpool,Ragnarok,,Improved pain management observed in some patients with bone metastases after Vibranium treatment.
text,e07d9ee8-0fe9-44e6-a85d-6ce25d611e82,insights_interaction,latest,,,2024-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02170,Brian Griffith,,onco-eu-0056,Céline Dupont,Phone,X-Men,Italy,,Improved sleep quality and decreased anxiety reported by several patients.
text,41470c8e-e499-4892-a5b9-b6df10b7726b,insights_interaction,latest,,,2024-06-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02313,Elizabeth Johnson,,onco-eu-0056,Céline Dupont,Iron Man,Deadpool,Greece,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,a728888b-baf1-4cf6-b5af-b3658a7072b5,insights_interaction,latest,,,2024-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02986,Monica Conteras,,onco-eu-0056,Céline Dupont,Iron Man,Wolverine,Ragnarok,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,7caa8267-150a-4667-91a2-d7c3711f95f9,insights_interaction,latest,,,2024-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02684,Barbara Thornton,,onco-eu-0056,Céline Dupont,Ulton,Deadpool,Greece,,Promising early signals of efficacy in rare cancer subtypes with limited treatment options
text,b2ff135c-5d65-4325-805d-3d66e76d9374,insights_interaction,latest,,,2024-11-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02948,Patricia Snyder,,onco-eu-0056,Céline Dupont,Phone,X-Men,Greece,,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,fe9001a8-27b3-4d1e-b95f-f980276b864a,insights_interaction,latest,,,2021-05-28,MSL Interactions,Oncology,Vibranium,,WB-US-09205,David Cooper,,onco-us-0040,Charles Murphy,Iron Man,X-Men,United States,AK,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,fb751361-f591-408e-8ab6-ad28f1ba5e44,insights_interaction,latest,,,2021-06-20,MSL Interactions,Oncology,Vibranium,,WB-US-09330,Cheryl Masuda,,onco-us-0040,Charles Murphy,Ulton,Wolverine,United States,UT,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,cab0e0c0-ebc9-4256-b9d2-e0a46760e1d4,insights_interaction,latest,,,2021-09-04,MSL Interactions,Oncology,Vibranium,,WB-US-09228,Carolyn Groves,,onco-us-0040,Charles Murphy,Iron Man,Wolverine,United States,NV,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,f9b900a0-3ee2-4397-b8b2-ed952f351397,insights_interaction,latest,,,2021-11-05,MSL Interactions,Oncology,Vibranium,,WB-US-09852,William Robinson,,onco-us-0040,Charles Murphy,Iron Man,X-Men,United States,AK,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,02053236-2e10-4743-a694-6c7f097bfb01,insights_interaction,latest,,,2022-02-03,MSL Interactions,Oncology,Vibranium,,WB-US-09366,Billy Deatherage,,onco-us-0040,Charles Murphy,Iron Man,Avenger,United States,NV,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,cab2cadf-0fec-4dda-aa1a-47f6fc65392e,insights_interaction,latest,,,2022-03-14,MSL Interactions,Oncology,Vibranium,,WB-US-09728,Sheila Mohorovich,,onco-us-0040,Charles Murphy,Phone,Deadpool,United States,AZ,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,7b3f9644-c974-409a-a3c0-57b8e793f815,insights_interaction,latest,,,2022-06-02,MSL Interactions,Oncology,Vibranium,,WB-US-09734,Thomas Maloy,,onco-us-0040,Charles Murphy,Ulton,Deadpool,United States,NM,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,dd442152-187f-4af4-95ac-c49c7d1b6cb0,insights_interaction,latest,,,2022-07-13,MSL Interactions,Oncology,Vibranium,,WB-US-09852,William Robinson,,onco-us-0040,Charles Murphy,Iron Man,X-Men,United States,AK,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,54661497-c659-45e0-ba1c-21675cbc9a01,insights_interaction,latest,,,2022-08-11,MSL Interactions,Oncology,Vibranium,,WB-US-09521,Mary Trejo,,onco-us-0040,Charles Murphy,Ulton,X-Men,United States,CO,Significant reduction in treatment-related anxiety and improved patient engagement compared to traditional chemotherapy protocols
text,b5f56a7e-8ef4-4185-a55b-3a0d82d638a2,insights_interaction,latest,,,2022-09-07,MSL Interactions,Oncology,Vibranium,,WB-US-09210,Peggy Petersen,,onco-us-0040,Charles Murphy,Phone,Wolverine,United States,WA,Identified genetic mutation profile predicting superior therapeutic response in 28% of treated patients
text,beb16159-4f11-46b1-9319-6e1e7bc03221,insights_interaction,latest,,,2022-10-21,MSL Interactions,Oncology,Vibranium,,WB-US-09360,Jose Dively,,onco-us-0040,Charles Murphy,Phone,Avenger,United States,AZ,Most patients reported manageable side effects with minimal impact on daily activities.
text,9110bda0-9dc6-47d7-97de-8824243dc698,insights_interaction,latest,,,2022-10-27,MSL Interactions,Oncology,Vibranium,,WB-US-09583,Paul Trivett,,onco-us-0040,Charles Murphy,Ulton,Deadpool,United States,WY,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,904fad28-9f60-4f47-813e-bb800b9e4e4c,insights_interaction,latest,,,2022-11-15,MSL Interactions,Oncology,Vibranium,,WB-US-09916,Deborah Hill,,onco-us-0040,Charles Murphy,Ulton,X-Men,United States,WY,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,77dee846-386e-4a01-a16c-4abe1f9c7fe9,insights_interaction,latest,,,2023-01-07,MSL Interactions,Oncology,Vibranium,,WB-US-09454,Alyssa Oshields,,onco-us-0040,Charles Murphy,Iron Man,Avenger,United States,HI,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,d00df5f6-c0f8-4173-8ae0-4ae9a17b8112,insights_interaction,latest,,,2023-03-26,MSL Interactions,Oncology,Vibranium,,WB-US-09416,Stephen Landgraf,,onco-us-0040,Charles Murphy,Phone,X-Men,United States,CO,Response to Vibranium appears to be independent of prior systemic therapy in some patients.
text,d47556eb-f882-4141-8c10-29a32fadb4de,insights_interaction,latest,,,2023-04-02,MSL Interactions,Oncology,Vibranium,,WB-US-09305,Myron White,,onco-us-0040,Charles Murphy,Iron Man,X-Men,United States,WA,EORTC QLQ-C30 scores showed significant improvement in overall functional status during treatment
text,f5c74432-d00d-498b-a11a-e50c888e50f3,insights_interaction,latest,,,2023-07-18,MSL Interactions,Oncology,Vibranium,,WB-US-09521,Mary Trejo,,onco-us-0040,Charles Murphy,Phone,X-Men,United States,CO,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,9132c770-4069-4cfa-81d7-0bacd797bb44,insights_interaction,latest,,,2023-08-12,MSL Interactions,Oncology,Vibranium,,WB-US-09205,David Cooper,,onco-us-0040,Charles Murphy,Ulton,X-Men,United States,AK,Emerging evidence of genetic signatures predicting superior treatment response in BRCA-mutated cancers
text,52e66a52-83a6-410e-9fb7-36069c3b8444,insights_interaction,latest,,,2023-11-07,MSL Interactions,Oncology,Vibranium,,WB-US-09416,Stephen Landgraf,,onco-us-0040,Charles Murphy,Phone,X-Men,United States,CO,Inconsistent correlation between circulating tumor DNA levels and treatment response
text,fdeac47d-b8e7-42b3-b35f-7d306d168bf3,insights_interaction,latest,,,2023-11-18,MSL Interactions,Oncology,Vibranium,,WB-US-09454,Alyssa Oshields,,onco-us-0040,Charles Murphy,Phone,Avenger,United States,HI,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,64901d07-07a6-4532-81a9-0cb2c9a9234b,insights_interaction,latest,,,2024-03-17,MSL Interactions,Oncology,Vibranium,,WB-US-09566,Stuart Albaladejo,,onco-us-0040,Charles Murphy,Ulton,Clinical Pharmacist,United States,AZ,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,0a41fcbb-3438-4417-bcc5-e063061a445d,insights_interaction,latest,,,2024-03-18,MSL Interactions,Oncology,Vibranium,,WB-US-09717,Jesse Brown,,onco-us-0040,Charles Murphy,Iron Man,Avenger,United States,WY,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors treated with Vibranium/Wakanda compared to those with microsatellite stable (MSS) tumors.  This suggests a potential predictive biomarker for treatment response.
text,2768e749-47ec-426c-af94-937edf67c8d0,insights_interaction,latest,,,2024-04-01,MSL Interactions,Oncology,Vibranium,,WB-US-09947,Tony Anschutz,,onco-us-0040,Charles Murphy,Iron Man,X-Men,United States,CO,Stable disease observed in several patients with lung cancer after two cycles.
text,1cf842dd-366a-4491-b8a3-2267cb44bed3,insights_interaction,latest,,,2024-11-05,MSL Interactions,Oncology,Vibranium,,WB-US-09739,Carol Peterson,,onco-us-0040,Charles Murphy,Phone,Wolverine,United States,WY,Improved sleep quality reported by several patients on the therapy.
text,e1a45431-bb15-487e-813e-88bf80126413,insights_interaction,latest,,,2023-03-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00828,Edna Braley,,onco-eu-0027,Christoph Schneider,Phone,X-Men,Switzerland,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,cb89c6fe-8580-4520-9743-392a6139df45,insights_interaction,latest,,,2023-09-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01315,Edward Broberg,,onco-eu-0027,Christoph Schneider,Phone,X-Men,Switzerland,,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,024d14f0-4357-4a6b-a0af-eeb17541af3e,insights_interaction,latest,,,2024-05-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01577,Monica Orlando,,onco-eu-0027,Christoph Schneider,Phone,X-Men,Austria,,Administration of Vibranium/Wakanda requires specialized training and careful monitoring due to potential for infusion-related reactions.
text,0b3d8b52-aa4c-412e-b4e5-acff650a6371,insights_interaction,latest,,,2024-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01621,Lawrence Coleman,,onco-eu-0027,Christoph Schneider,Iron Man,Avenger,Netherlands,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,a67f61b0-1e8b-4ead-ba1f-86201c02210c,insights_interaction,latest,,,2024-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01088,Rhonda White,,onco-eu-0027,Christoph Schneider,Iron Man,X-Men,Switzerland,,Stable disease maintained in 42% of patients with difficult-to-treat metastatic cancers during long-term follow-up
text,ef0afb95-4fb6-4272-8f5f-e28e717f2ce7,insights_interaction,latest,,,2024-10-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01401,Ann Ross,,onco-eu-0027,Christoph Schneider,Iron Man,Deadpool,Belgium,,"Improved patient-reported quality of life scores (FACT-G) observed in several patients treated with Vibranium/Wakanda, particularly in terms of physical well-being and fatigue."
text,12940ab0-dd2f-4fa3-a500-23535923460e,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01646,Billy Will,,onco-eu-0027,Christoph Schneider,Iron Man,Avenger,Germany,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,43f98485-ff52-4714-aaee-265614fc27c8,insights_interaction,latest,,,2021-01-10,MSL Interactions,Oncology,Vibranium,,WB-US-03897,Monica Ballard,,onco-us-0010,Christopher Lee,Phone,Wolverine,United States,DE,Observed significant tumor reduction in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.  Significant improvement in overall survival is anticipated.
text,1bb656a4-c33e-4a89-b140-f65f824242d5,insights_interaction,latest,,,2021-01-21,MSL Interactions,Oncology,Vibranium,,WB-US-02913,Celia Owens,,onco-us-0010,Christopher Lee,Ulton,Avenger,United States,DC,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,ffee7e1a-ada5-4632-9d78-d95bcfe8c8e0,insights_interaction,latest,,,2021-04-18,MSL Interactions,Oncology,Vibranium,,WB-US-03936,Jack Zamarripa,,onco-us-0010,Christopher Lee,Phone,Clinical Pharmacist,United States,DE,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,de15ae63-48c3-4b13-a9bc-4c9435526d43,insights_interaction,latest,,,2021-07-05,MSL Interactions,Oncology,Vibranium,,WB-US-04519,Megan Scheff,,onco-us-0010,Christopher Lee,Iron Man,Deadpool,United States,NJ,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,b24e2e9a-3e19-4583-bcab-3988f9626fb3,insights_interaction,latest,,,2021-08-24,MSL Interactions,Oncology,Vibranium,,WB-US-04100,Cheri Minks,,onco-us-0010,Christopher Lee,Ulton,Wolverine,United States,MD,Improved pain scores reported by patients with bone metastases after two cycles of treatment.
text,5d2a0b6a-ea20-4054-bf95-06888bc96fd1,insights_interaction,latest,,,2021-10-28,MSL Interactions,Oncology,Vibranium,,WB-US-03962,Mary Stuart,,onco-us-0010,Christopher Lee,Ulton,Deadpool,United States,NJ,Reduction in pain levels reported by patients with bone metastases.
text,a01f2d0d-a399-49be-9e29-0aa720e98f1e,insights_interaction,latest,,,2021-11-01,MSL Interactions,Oncology,Vibranium,,WB-US-03755,Mose Garing,,onco-us-0010,Christopher Lee,Phone,X-Men,United States,MD,"Strong correlation between CTLA-4 and CD8+ T-cell activation markers and treatment response, suggesting potential predictive biomarker panel for patient selection"
text,e7672968-cc10-4b72-812c-8dd66aef91c2,insights_interaction,latest,,,2022-05-23,MSL Interactions,Oncology,Vibranium,,WB-US-03869,Mary Kuhr,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,PA,Early detection of response based on circulating tumor DNA analysis.
text,73f538d8-d0e3-4f3f-8c8c-cc0d1e5091e7,insights_interaction,latest,,,2022-07-15,MSL Interactions,Oncology,Vibranium,,WB-US-03451,James Allison,,onco-us-0010,Christopher Lee,Phone,Deadpool,United States,NJ,"Increased levels of interferon-gamma detected in serum samples post-Vibranium infusion, correlating with clinical improvement."
text,25bd1954-0807-432b-99fa-07bf1d90e89e,insights_interaction,latest,,,2022-07-23,MSL Interactions,Oncology,Vibranium,,WB-US-03280,Alyssa Provost,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,DC,"Outpatient administration possible with 90-minute infusion protocol, reducing hospital resource utilization"
text,1dd8a2d8-18d1-4124-ac13-250a6b2cee95,insights_interaction,latest,,,2023-01-06,MSL Interactions,Oncology,Vibranium,,WB-US-04680,Dale Herring,,onco-us-0010,Christopher Lee,Phone,Avenger,United States,DC,"Consistent treatment response across multiple cancer subtypes, with slight variability in progression-free survival"
text,17f77017-4240-4d9a-b0c3-06e7114d265f,insights_interaction,latest,,,2023-03-09,MSL Interactions,Oncology,Vibranium,,WB-US-03304,Wilfred Black,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,PA,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,c04010db-a049-4d11-bdc8-deb0f5f387d3,insights_interaction,latest,,,2023-03-22,MSL Interactions,Oncology,Vibranium,,WB-US-04151,Gloria Hobart,,onco-us-0010,Christopher Lee,Ulton,X-Men,United States,NJ,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,72ecb179-9982-4ac8-b161-46c4a0948137,insights_interaction,latest,,,2023-04-10,MSL Interactions,Oncology,Vibranium,,WB-US-04196,Terri Kline,,onco-us-0010,Christopher Lee,Iron Man,Deadpool,United States,PA,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,9949f045-1b22-4f8f-87d9-aad21d2b70f3,insights_interaction,latest,,,2023-05-12,MSL Interactions,Oncology,Vibranium,,WB-US-04222,Noel Haley,,onco-us-0010,Christopher Lee,Phone,X-Men,United States,PA,Observed significant tumor reduction in a patient with advanced pancreatic cancer after 8 weeks of Vibranium/Wakanda combination therapy.  Patient showed a 45% decrease in tumor size as measured by CT scan.
text,c9b214d3-abce-440a-815b-b1aa6f1ff182,insights_interaction,latest,,,2023-07-30,MSL Interactions,Oncology,Vibranium,,WB-US-04576,Marvel Stanford,,onco-us-0010,Christopher Lee,Ulton,X-Men,United States,DE,Correlation between baseline tumor mutational burden and response to Vibranium/Wakanda requires further investigation.
text,40ab27bb-459e-478d-b637-f0b0450ec693,insights_interaction,latest,,,2023-10-14,MSL Interactions,Oncology,Vibranium,,WB-US-04370,Jason Schaupp,,onco-us-0010,Christopher Lee,Phone,Avenger,United States,NJ,Improved appetite and reduced pain reported by several patients.
text,fa02b42f-b0b4-42df-834b-d8dec46b50f5,insights_interaction,latest,,,2023-12-07,MSL Interactions,Oncology,Vibranium,,WB-US-04043,Holly Spires,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,NJ,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,8ce4bd14-a67c-4bf8-af6b-be2f3f7d53ff,insights_interaction,latest,,,2023-12-22,MSL Interactions,Oncology,Vibranium,,WB-US-04753,Ann Pelton,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,NJ,Patients reported significant reduction in cancer-related fatigue with combination therapy compared to standard treatment protocols
text,1691c5c4-1630-490c-82b8-486ad89adf96,insights_interaction,latest,,,2023-12-30,MSL Interactions,Oncology,Vibranium,,WB-US-04145,Nathan Treece,,onco-us-0010,Christopher Lee,Iron Man,Avenger,United States,PA,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,83f94b20-5a0b-4f26-8346-3cae0a183c50,insights_interaction,latest,,,2024-01-28,MSL Interactions,Oncology,Vibranium,,WB-US-03895,Everett Ashby,,onco-us-0010,Christopher Lee,Phone,Avenger,United States,MD,Significant improvement in circulating tumor DNA clearance during treatment cycle
text,2919fdfc-7901-466e-aee2-17a174fea6ec,insights_interaction,latest,,,2024-04-09,MSL Interactions,Oncology,Vibranium,,WB-US-04785,Richard Delacruz,,onco-us-0010,Christopher Lee,Iron Man,X-Men,United States,PA,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,7b1048d9-d3cd-4a8b-8641-f28bd5e2f25c,insights_interaction,latest,,,2024-06-14,MSL Interactions,Oncology,Vibranium,,WB-US-03059,Nita Manjarrez,,onco-us-0010,Christopher Lee,Ulton,Deadpool,United States,PA,Stable disease observed in majority of patients after 4 weeks of treatment.
text,d8392b38-94ea-4815-b78a-3af9b709ef8f,insights_interaction,latest,,,2024-09-14,MSL Interactions,Oncology,Vibranium,,WB-US-03699,Michael Poorman,,onco-us-0010,Christopher Lee,Ulton,Avenger,United States,PA,No clear correlation found between specific genetic mutations and treatment response.
text,3f86a8d2-3b09-43cf-aabd-d04ba3f64411,insights_interaction,latest,,,2021-03-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02402,Lacey Alvez,,onco-eu-0054,Claire Moreau,Phone,Avenger,Spain,,"Increased expression of PD-L1 was noted in tumor biopsies post-treatment, suggesting a potential synergy with immune checkpoint inhibitors."
text,cbd6fd9b-c6f4-49f4-b93e-4047cbfcfc78,insights_interaction,latest,,,2021-04-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02633,Robert Grossen,,onco-eu-0054,Claire Moreau,Phone,Avenger,Italy,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,d39ed7b3-08b0-4ebd-a14e-3c517dd5eda0,insights_interaction,latest,,,2021-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02165,Minnie Bundren,,onco-eu-0054,Claire Moreau,Ulton,Avenger,Spain,,Observed 62% objective response rate in metastatic triple-negative breast cancer patients with high PD-L1 expression
text,6fcbf59c-2d36-4a2f-a430-a0be1dd92629,insights_interaction,latest,,,2021-08-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02190,Katie Simpson,,onco-eu-0054,Claire Moreau,Phone,Deadpool,Italy,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,4533c6b7-35f0-4f19-82aa-404eeb2c38a1,insights_interaction,latest,,,2021-09-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02481,Phyllis Smith,,onco-eu-0054,Claire Moreau,Iron Man,X-Men,Italy,,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,71dc5fb7-23c8-4e3f-9323-1bf70628acba,insights_interaction,latest,,,2023-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02273,Walter Heidema,,onco-eu-0054,Claire Moreau,Phone,Avenger,Italy,,Response to Vibranium appears to be more pronounced in patients with high tumor mutational burden (TMB).
text,d085476b-dcf3-4cb2-a309-21bab632abc2,insights_interaction,latest,,,2023-07-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02298,Pamela Miller,,onco-eu-0054,Claire Moreau,Phone,Clinical Pharmacist,Italy,,Treatment response variability observed among different age groups
text,6070a3d9-b6a4-40d5-b350-5e6e1ac0dacd,insights_interaction,latest,,,2023-09-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02184,Billy Pierce,,onco-eu-0054,Claire Moreau,Ulton,Deadpool,Greece,,"Mild fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,14ef9ab3-7cf3-49a6-b2bc-135589360aef,insights_interaction,latest,,,2023-10-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02988,Charles Lebowitz,,onco-eu-0054,Claire Moreau,Ulton,Avenger,Spain,,Demonstrated durable complete response in 22% of heavily pre-treated patients with advanced malignancies
text,3fad36c8-5b39-4e83-82d7-d8fab7fc6458,insights_interaction,latest,,,2023-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02760,Sherry Clanton,,onco-eu-0054,Claire Moreau,Phone,Avenger,Italy,,"Moderate efficacy in heterogeneous patient populations, emphasizing importance of precise patient selection"
text,c1aad9ca-a245-4625-be1e-a0368f10fac7,insights_interaction,latest,,,2023-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02636,Jennifer Lawrence,,onco-eu-0054,Claire Moreau,Iron Man,Deadpool,Italy,,The optimal dosing schedule for Vibranium/Wakanda is still under investigation.
text,9c1d3f10-d84e-4380-9a9b-553765752253,insights_interaction,latest,,,2024-02-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02451,Ira Rutland,,onco-eu-0054,Claire Moreau,Iron Man,X-Men,Greece,,Improved sleep quality reported by several patients on the therapy.
text,63623e48-ec8b-4709-ab34-8e5c06c46b91,insights_interaction,latest,,,2024-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02251,John Grundy,,onco-eu-0054,Claire Moreau,Ulton,Clinical Pharmacist,Greece,,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,8b2265e0-dce3-427d-910b-f06d7715669f,insights_interaction,latest,,,2024-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02407,Michael Wilson,,onco-eu-0054,Claire Moreau,Iron Man,X-Men,Italy,,"Challenges in administering Vibranium/Wakanda due to its complex delivery method were noted, requiring specialized training and equipment."
text,a44ab4db-f00e-4fbf-8979-2dc310f9f117,insights_interaction,latest,,,2024-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02020,Terri Lyons,,onco-eu-0054,Claire Moreau,Phone,X-Men,Italy,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,55683c38-7009-406f-8a81-661749216436,insights_interaction,latest,,,2024-04-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02988,Charles Lebowitz,,onco-eu-0054,Claire Moreau,Iron Man,Avenger,Spain,,No clear correlation was found between age and response to Vibranium/Wakanda.
text,791e70df-9a5f-49cb-989c-2df300603a1c,insights_interaction,latest,,,2024-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02219,Gregory Underwood,,onco-eu-0054,Claire Moreau,Iron Man,Avenger,Ragnarok,,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,f6118d6c-e468-4bbb-8b83-00254e53082f,insights_interaction,latest,,,2024-10-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02353,Tiffaney Joyce,,onco-eu-0054,Claire Moreau,Iron Man,Wolverine,Ragnarok,,"Mild fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,93f7969b-4607-46e3-a1e0-0fdf79882a08,insights_interaction,latest,,,2021-01-01,MSL Interactions,Oncology,Vibranium,,WB-US-05582,Brandi Bonds,,onco-us-0016,Daniel Johnson,Phone,Avenger,United States,MS,Demonstrated statistically significant tumor reduction of 43% in metastatic breast cancer patients with HER2-negative profiles during phase II trial
text,7156d023-0a5b-4591-894e-288ddc3a84ea,insights_interaction,latest,,,2021-03-27,MSL Interactions,Oncology,Vibranium,,WB-US-05439,Wallace Allen,,onco-us-0016,Daniel Johnson,Phone,X-Men,United States,KY,Novel immune signature identified that predicts superior treatment response with 78% accuracy
text,530d138f-0364-4c0f-b526-54c223cb120f,insights_interaction,latest,,,2021-09-30,MSL Interactions,Oncology,Vibranium,,WB-US-05375,Harrison Rhoades,,onco-us-0016,Daniel Johnson,Ulton,Deadpool,United States,WV,Complete metabolic response observed in 34% of patients with advanced lung adenocarcinoma
text,9a38cda1-f968-4ea5-9ca9-62300cd94039,insights_interaction,latest,,,2021-12-17,MSL Interactions,Oncology,Vibranium,,WB-US-05698,Ronnie Scholle,,onco-us-0016,Daniel Johnson,Iron Man,Avenger,United States,VA,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,e7d19241-4599-4a0e-92b8-5d4dfe5ea58a,insights_interaction,latest,,,2022-01-27,MSL Interactions,Oncology,Vibranium,,WB-US-05660,Jordon Smith,,onco-us-0016,Daniel Johnson,Ulton,Avenger,United States,KY,Significant reduction in pain scores and improved functional status for advanced cancer patients
text,ce814d50-b304-4400-8b8c-2cf509876c75,insights_interaction,latest,,,2023-06-12,MSL Interactions,Oncology,Vibranium,,WB-US-04833,Brenda Chang,,onco-us-0016,Daniel Johnson,Ulton,Wolverine,United States,MS,Cost-effectiveness analysis indicates potential healthcare system benefits
text,b7209cdc-04a4-46a9-8961-67261e689a47,insights_interaction,latest,,,2023-09-02,MSL Interactions,Oncology,Vibranium,,WB-US-05632,Dorothy Gaskin,,onco-us-0016,Daniel Johnson,Phone,Clinical Pharmacist,United States,TN,Correlation observed between increased PD-L1 expression and response to Vibranium/Wakanda therapy.
text,3ecbec1b-5037-4cc4-8533-9631381abf7a,insights_interaction,latest,,,2024-03-13,MSL Interactions,Oncology,Vibranium,,WB-US-05767,Malena Whitaker,,onco-us-0016,Daniel Johnson,Iron Man,Wolverine,United States,GA,Patients reported significantly improved symptom management and reduced pain scores compared to conventional chemotherapy regimens
text,7fc10408-5d64-4509-abfb-1951908cb33b,insights_interaction,latest,,,2024-04-02,MSL Interactions,Oncology,Vibranium,,WB-US-06345,Brenda Markel,,onco-us-0016,Daniel Johnson,Iron Man,X-Men,United States,FL,No clear correlation was found between age and response to Vibranium/Wakanda.
text,be69a926-4b24-4ad9-9538-07e32418b2f2,insights_interaction,latest,,,2024-04-18,MSL Interactions,Oncology,Vibranium,,WB-US-04851,Genevieve Aguirre,,onco-us-0016,Daniel Johnson,Ulton,Avenger,United States,SC,One patient experienced a severe allergic reaction requiring immediate medical intervention after the first dose of Vibranium/Wakanda.
text,1b8205a6-186c-4071-9c7d-1082e1d8aadf,insights_interaction,latest,,,2024-05-02,MSL Interactions,Oncology,Vibranium,,WB-US-06022,Joseph Scruggs,,onco-us-0016,Daniel Johnson,Ulton,X-Men,United States,MS,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,0c57c2a4-a706-4752-bffa-eded6cce5cd0,insights_interaction,latest,,,2024-05-11,MSL Interactions,Oncology,Vibranium,,WB-US-06283,Kelly Jones,,onco-us-0016,Daniel Johnson,Iron Man,Avenger,United States,SC,Further research is needed to identify additional predictive biomarkers for response to Vibranium/Wakanda therapy.
text,c3654e82-15ed-4ca9-9dca-ab431aedca85,insights_interaction,latest,,,2024-05-19,MSL Interactions,Oncology,Vibranium,,WB-US-05841,James Cornelius,,onco-us-0016,Daniel Johnson,Iron Man,X-Men,United States,AL,Combination therapy requires careful dosage adjustment and frequent monitoring of liver function
text,dcd29af4-b822-44b8-a6f7-fa445f2532cf,insights_interaction,latest,,,2024-07-27,MSL Interactions,Oncology,Vibranium,,WB-US-04803,Jesus Post,,onco-us-0016,Daniel Johnson,Ulton,X-Men,United States,TN,"Mild flu-like symptoms were reported in most patients during the initial phase of Vibranium/Wakanda treatment, resolving within 72 hours with supportive care."
text,ec9e81f9-eb1a-4eaa-b3ea-3543eeec11a3,insights_interaction,latest,,,2024-09-22,MSL Interactions,Oncology,Vibranium,,WB-US-05037,Terry Foster,,onco-us-0016,Daniel Johnson,Iron Man,X-Men,United States,KY,Treatment regimen was well-tolerated by most patients with minimal interruptions.
text,8394aba9-8e1b-4b2a-a939-3dba4e17bedb,insights_interaction,latest,,,2024-10-06,MSL Interactions,Oncology,Vibranium,,WB-US-05900,Natasha Morrison,,onco-us-0016,Daniel Johnson,Iron Man,Deadpool,United States,VA,"Observed differential response rates across age demographics, requiring nuanced treatment strategies"
text,bcfc62ab-05f7-4354-ac18-7fc95f8c7db5,insights_interaction,latest,,,2024-12-29,MSL Interactions,Oncology,Vibranium,,WB-US-05717,Angela Daigle,,onco-us-0016,Daniel Johnson,Ulton,Avenger,United States,WV,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,3ebc470b-74aa-40c6-880c-4c9d4a5c2be7,insights_interaction,latest,,,2021-02-22,MSL Interactions,Oncology,Vibranium,,WB-US-00995,Roxane Gemmill,,onco-us-0004,David Patterson,Iron Man,X-Men,United States,RI,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,33ed2e6c-cc0f-4212-b4dc-99ff11ac7c32,insights_interaction,latest,,,2022-01-16,MSL Interactions,Oncology,Vibranium,,WB-US-01190,Stephen Woods,,onco-us-0004,David Patterson,Ulton,X-Men,United States,ME,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,519ac769-202f-4ede-afc1-2cee633146e3,insights_interaction,latest,,,2022-05-13,MSL Interactions,Oncology,Vibranium,,WB-US-00471,Donald Mcintire,,onco-us-0004,David Patterson,Phone,Avenger,United States,CT,Cost-effectiveness analysis demonstrates potential for significant healthcare resource optimization
text,5338c8c5-1544-4272-9a1a-58ce00b4740a,insights_interaction,latest,,,2022-05-29,MSL Interactions,Oncology,Vibranium,,WB-US-01489,Gloria White,,onco-us-0004,David Patterson,Phone,X-Men,United States,NY,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,9623a7e8-708a-44cf-877a-b127c2fe168d,insights_interaction,latest,,,2023-02-07,MSL Interactions,Oncology,Vibranium,,WB-US-01459,Benjamin Michael,,onco-us-0004,David Patterson,Phone,Avenger,United States,MA,"Infusion reactions were manageable in most patients, with pre-medication effectively mitigating symptoms."
text,c6777e94-e037-42ed-a53b-458090a9d886,insights_interaction,latest,,,2023-04-12,MSL Interactions,Oncology,Vibranium,,WB-US-01412,Roberto Booher,,onco-us-0004,David Patterson,Phone,X-Men,United States,MA,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,a19d57b2-668c-45ec-8e72-c01975eea3bc,insights_interaction,latest,,,2023-05-08,MSL Interactions,Oncology,Vibranium,,WB-US-02742,Karleen Rice,,onco-us-0004,David Patterson,Iron Man,Avenger,United States,NH,Administration protocol requires careful monitoring and potential dose adjustments
text,03d3df7d-45b6-4c5b-b55f-9699b890e4b4,insights_interaction,latest,,,2023-06-17,MSL Interactions,Oncology,Vibranium,,WB-US-00001,Thomas Schaefer,,onco-us-0004,David Patterson,Ulton,X-Men,United States,RI,Minor hepatic enzyme elevations observed in approximately 18% of patients
text,c9c5d468-91e5-4fee-8a15-035ffd795d97,insights_interaction,latest,,,2023-07-29,MSL Interactions,Oncology,Vibranium,,WB-US-01299,Ladonna Foglesong,,onco-us-0004,David Patterson,Ulton,X-Men,United States,MA,"Grade 1 fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,92478852-201c-487b-8d65-f0ba7b615457,insights_interaction,latest,,,2023-08-28,MSL Interactions,Oncology,Vibranium,,WB-US-02551,Joshua Wise,,onco-us-0004,David Patterson,Phone,Avenger,United States,CT,"Observed 37% objective response rate in advanced metastatic solid tumors, with notable reduction in tumor volume"
text,da6677fc-cca7-4267-a681-780556be401c,insights_interaction,latest,,,2024-05-23,MSL Interactions,Oncology,Vibranium,,WB-US-01046,Mary Mills,,onco-us-0004,David Patterson,Iron Man,Avenger,United States,MA,Moderate improvement in overall survival with statistically marginal significance
text,903f7467-7ef2-494e-bd6f-e893d5e33c4b,insights_interaction,latest,,,2024-07-23,MSL Interactions,Oncology,Vibranium,,WB-US-01193,Francisco Hernandez,,onco-us-0004,David Patterson,Iron Man,Deadpool,United States,RI,Mixed patient-reported outcomes with moderate improvements in pain management and emotional well-being
text,03cd41b0-89cc-4383-b5e7-8a6a44bfe87a,insights_interaction,latest,,,2024-12-11,MSL Interactions,Oncology,Vibranium,,WB-US-02551,Joshua Wise,,onco-us-0004,David Patterson,Phone,Avenger,United States,CT,"Documented grade 2 immune-related adverse events in 18% of patients, primarily manageable thyroid dysfunction and mild skin reactions"
text,f46d3e58-3ffc-43c9-9210-46d7b25aff4c,insights_interaction,latest,,,2021-01-02,MSL Interactions,Oncology,Vibranium,,WB-US-09528,Maria Walker,,onco-us-0039,Diana Foster,Iron Man,Avenger,United States,CA,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,1ea94012-8f2a-475e-990a-568da92a9f03,insights_interaction,latest,,,2021-02-04,MSL Interactions,Oncology,Vibranium,,WB-US-09665,Victoria Jaeger,,onco-us-0039,Diana Foster,Iron Man,X-Men,United States,NV,"Significant correlation detected between PD-L1 expression and treatment response, predictive marker identified"
text,6033db27-aea3-403c-ab23-92e7fd211410,insights_interaction,latest,,,2021-02-27,MSL Interactions,Oncology,Vibranium,,WB-US-09448,Thomas Smallman,,onco-us-0039,Diana Foster,Iron Man,Avenger,United States,NM,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,f4fef55b-0520-4841-aa32-743f3ff01fab,insights_interaction,latest,,,2021-03-31,MSL Interactions,Oncology,Vibranium,,WB-US-09610,Mark Wilburn,,onco-us-0039,Diana Foster,Iron Man,Clinical Pharmacist,United States,HI,Stable disease observed in several patients with lung cancer after two cycles.
text,bb9724ef-dc16-438c-b8ed-bcf6d6c6b16b,insights_interaction,latest,,,2021-04-26,MSL Interactions,Oncology,Vibranium,,WB-US-09757,Angelo Morris,,onco-us-0039,Diana Foster,Ulton,Clinical Pharmacist,United States,ID,Patients reported improved symptom management and reduced pain scores compared to standard therapy
text,8082a82e-897e-413d-9c65-18aa6fc4a655,insights_interaction,latest,,,2021-05-12,MSL Interactions,Oncology,Vibranium,,WB-US-09944,Kevin Hyde,,onco-us-0039,Diana Foster,Iron Man,X-Men,United States,AZ,No serious adverse events reported in the first 10 patients enrolled in the study.
text,6459c0b0-f0d5-4958-9ccd-26099a24004f,insights_interaction,latest,,,2021-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-09944,Kevin Hyde,,onco-us-0039,Diana Foster,Phone,X-Men,United States,AZ,"Patients reported improved quality of life scores on the EORTC QLQ-C30 questionnaire following Vibranium/Wakanda treatment, particularly in terms of fatigue and pain reduction."
text,a3bad89a-71d0-45a6-8cc5-6282a305589a,insights_interaction,latest,,,2022-08-31,MSL Interactions,Oncology,Vibranium,,WB-US-09337,Mario Werner,,onco-us-0039,Diana Foster,Iron Man,Deadpool,United States,UT,"Improved quality of life scores (using EORTC QLQ-C30) observed in patients receiving Vibranium/Wakanda, particularly in reduction of fatigue and pain."
text,8ac149ab-c457-4a2e-af11-f84b2b0a44c2,insights_interaction,latest,,,2022-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-09303,Lucille Herbert,,onco-us-0039,Diana Foster,Phone,X-Men,United States,NM,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,89928b43-ea4a-4910-b969-273352487900,insights_interaction,latest,,,2023-01-16,MSL Interactions,Oncology,Vibranium,,WB-US-09863,Katherine Hartsfield,,onco-us-0039,Diana Foster,Iron Man,Avenger,United States,ID,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,9b977925-f73c-45ac-b89c-21f421b4f9d6,insights_interaction,latest,,,2023-02-18,MSL Interactions,Oncology,Vibranium,,WB-US-09663,Ellis Wilkins,,onco-us-0039,Diana Foster,Ulton,X-Men,United States,NV,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,177b470d-f2d2-4810-aeb0-267861f2d1eb,insights_interaction,latest,,,2023-05-16,MSL Interactions,Oncology,Vibranium,,WB-US-09777,Martin Pennington,,onco-us-0039,Diana Foster,Ulton,X-Men,United States,WA,"Observed variability in response rates across different tumor types, highlighting the need for further research to identify optimal patient selection criteria."
text,22f222e1-0084-439f-b224-62c1a20e5c15,insights_interaction,latest,,,2023-11-11,MSL Interactions,Oncology,Vibranium,,WB-US-09505,Eric Reed,,onco-us-0039,Diana Foster,Ulton,X-Men,United States,WA,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,c996c10e-b19f-4f4a-8868-d20749b93283,insights_interaction,latest,,,2024-03-26,MSL Interactions,Oncology,Vibranium,,WB-US-09949,Michele Copeland,,onco-us-0039,Diana Foster,Iron Man,X-Men,United States,CO,Promising results in triple-negative breast cancer subtype with 35% response rate
text,37db99d9-65cc-483d-955f-d7d2e656e784,insights_interaction,latest,,,2024-07-03,MSL Interactions,Oncology,Vibranium,,WB-US-09502,Richard Santos,,onco-us-0039,Diana Foster,Iron Man,Avenger,United States,UT,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,58dcb6b9-fdf4-43a2-bf8b-4286fd751804,insights_interaction,latest,,,2024-07-09,MSL Interactions,Oncology,Vibranium,,WB-US-09965,Julia Cobbley,,onco-us-0039,Diana Foster,Iron Man,Avenger,United States,UT,"Correlation between baseline tumor mutational burden (TMB) and response to Vibranium/Wakanda is currently being investigated.  Preliminary data suggests a potential link, but further analysis is required to validate this finding."
text,0692ebd5-07a6-47fc-9eac-79950dc1f3d4,insights_interaction,latest,,,2024-12-10,MSL Interactions,Oncology,Vibranium,,WB-US-09528,Maria Walker,,onco-us-0039,Diana Foster,Ulton,Avenger,United States,CA,Increased incidence of immune-related adverse events compared to standard treatments
text,640db411-3758-4f24-9574-ecfd0b58c885,insights_interaction,latest,,,2022-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03550,Sarah Warner,,onco-eu-0065,Dmitri Sokolov,Phone,Deadpool,Ireland,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,cf5a1982-18e8-4d92-8486-51e51215bb02,insights_interaction,latest,,,2022-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03830,Phil Peralta,,onco-eu-0065,Dmitri Sokolov,Phone,Deadpool,Ireland,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,a539cb7f-3e04-4389-a37d-15abe900b769,insights_interaction,latest,,,2022-05-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03289,Larry Doherty,,onco-eu-0065,Dmitri Sokolov,Iron Man,Deadpool,Ireland,,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,787dcfd6-6c77-4381-b935-db61827b7b42,insights_interaction,latest,,,2022-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03663,James Bedford,,onco-eu-0065,Dmitri Sokolov,Phone,Avenger,France,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,cb09f9a8-c6f6-43fb-b73b-2ec496fae842,insights_interaction,latest,,,2022-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03268,Maria Puglia,,onco-eu-0065,Dmitri Sokolov,Iron Man,X-Men,France,,"Patient with advanced pancreatic cancer (stage IV) experienced a significant reduction in tumor size (50%) after 3 cycles of Vibranium/Wakanda therapy, accompanied by improved performance status and alleviation of abdominal pain.  This was unexpected given the patient's poor prognosis at baseline."
text,16d02af5-2e49-4845-94e4-91b6f3fe6dce,insights_interaction,latest,,,2022-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03382,Jennifer Blankenship,,onco-eu-0065,Dmitri Sokolov,Ulton,X-Men,Ireland,,Enhanced long-term survival signals in patients with specific genomic alterations
text,bc87663c-42b0-4e3d-8349-8e6c68d85d5e,insights_interaction,latest,,,2022-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03180,Ronald Palmer,,onco-eu-0065,Dmitri Sokolov,Phone,Wolverine,Ireland,,"Increased PD-L1 expression observed in tumor biopsies post-treatment, suggesting a potential mechanism of action for the combination therapy."
text,7167e313-9b39-4298-837d-0ef0ce390543,insights_interaction,latest,,,2022-12-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03267,Rodney Nunez,,onco-eu-0065,Dmitri Sokolov,Iron Man,Deadpool,Ireland,,Early detection of response based on circulating tumor DNA analysis.
text,1bdfff5e-f651-4239-8aa8-5cf317218be1,insights_interaction,latest,,,2023-02-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03268,Maria Puglia,,onco-eu-0065,Dmitri Sokolov,Iron Man,X-Men,France,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,445225ef-57aa-4113-8d7b-4f61d0336b14,insights_interaction,latest,,,2023-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03180,Ronald Palmer,,onco-eu-0065,Dmitri Sokolov,Iron Man,Wolverine,Ireland,,"Observed mild to moderate immune-related adverse events in 23% of patients, primarily low-grade fatigue and transient hepatic enzyme elevations requiring routine monitoring."
text,719f9fb8-171a-4ca0-9efb-42a1d57514ff,insights_interaction,latest,,,2023-06-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03207,Kara Allen,,onco-eu-0065,Dmitri Sokolov,Iron Man,X-Men,United Kingdom,,Cost-effectiveness analysis suggests potential for reduced healthcare resource utilization compared to traditional treatment protocols
text,acb7a3a5-a67d-4228-a5fc-b7bd8fdd55a1,insights_interaction,latest,,,2023-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03374,Tracy Williams,,onco-eu-0065,Dmitri Sokolov,Phone,Wolverine,United Kingdom,,Enhanced synergistic effects in combination with targeted molecular therapies
text,bc12e6b9-b6cc-47a3-b3d5-792034776bcf,insights_interaction,latest,,,2023-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03929,Paul Cole,,onco-eu-0065,Dmitri Sokolov,Phone,X-Men,United Kingdom,,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,55402580-b9e2-4fcb-bc1e-a0426525c003,insights_interaction,latest,,,2024-01-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03267,Rodney Nunez,,onco-eu-0065,Dmitri Sokolov,Iron Man,Deadpool,Ireland,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,a9690c93-8c0e-4062-aaf9-4fb628d5e909,insights_interaction,latest,,,2024-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03374,Tracy Williams,,onco-eu-0065,Dmitri Sokolov,Iron Man,Wolverine,United Kingdom,,Grade 1 fatigue and mild nausea reported in a patient receiving Vibranium/Wakanda. Symptoms resolved with supportive care.
text,140226ba-6be6-4181-8fae-81a747f7aaac,insights_interaction,latest,,,2024-04-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03549,Patricia Tucker,,onco-eu-0065,Dmitri Sokolov,Iron Man,Wolverine,Ireland,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,3ed594a4-3e2e-4130-b04b-c7750b85e4ca,insights_interaction,latest,,,2024-08-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03550,Sarah Warner,,onco-eu-0065,Dmitri Sokolov,Phone,Deadpool,Ireland,,Grade 2 immune-related adverse events reported in 18% of patients during initial treatment phase
text,3ba3c236-18e5-4e4a-a3d9-26976d9121cb,insights_interaction,latest,,,2024-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03791,Faustino Rodriguez,,onco-eu-0065,Dmitri Sokolov,Ulton,X-Men,Ireland,,"Promising results in combination therapy with checkpoint inhibitors, showing synergistic effect and enhanced overall response rates"
text,fdb75792-b7d2-4b2a-9d56-a1691a131a88,insights_interaction,latest,,,2024-09-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03987,Jacquelyn Dunn,,onco-eu-0065,Dmitri Sokolov,Iron Man,Avenger,France,,Reduction in pain levels reported by patients with bone metastases.
text,60c3725f-b66c-487f-91cd-62355d828667,insights_interaction,latest,,,2022-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03772,Sophia Garcia,,onco-eu-0069,Elena Popova,Phone,X-Men,Ireland,,Most adverse events were mild and manageable with supportive care.
text,0975678a-1bc3-4a71-90a6-8dbbc2f0378c,insights_interaction,latest,,,2022-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03721,Jacob Mcdonald,,onco-eu-0069,Elena Popova,Phone,Deadpool,France,,Promising results in combination with targeted molecular therapies
text,b3665b53-7927-40e0-ba91-b04c20f53a0b,insights_interaction,latest,,,2022-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03096,Carla Williams,,onco-eu-0069,Elena Popova,Phone,Clinical Pharmacist,France,,Reduction in pain levels reported by patients with bone metastases.
text,369f73c8-ec17-46be-9fd1-f251b4b225f3,insights_interaction,latest,,,2022-06-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03705,Bradly Bramlet,,onco-eu-0069,Elena Popova,Iron Man,X-Men,Ireland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,557437f2-7c04-418f-b6f3-c6d142f09771,insights_interaction,latest,,,2024-05-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03451,Kendra Peterson,,onco-eu-0069,Elena Popova,Ulton,Avenger,United Kingdom,,"Grade 2 hepatic transaminase elevation observed in 17% of patients, generally manageable with dose modifications and standard monitoring protocols"
text,c8463ca7-d5b7-49ee-a9f8-033ac0813262,insights_interaction,latest,,,2024-06-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03961,Sylvia Fiore,,onco-eu-0069,Elena Popova,Ulton,Deadpool,Ireland,,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,ed042470-e408-4d0c-8a4c-40be87a26714,insights_interaction,latest,,,2024-08-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03423,Patsy Thomas,,onco-eu-0069,Elena Popova,Iron Man,Avenger,France,,Median progression-free survival of 6.7 months across heterogeneous tumor types
text,cd85d580-7ff3-4fea-9f4d-6d96c437bb27,insights_interaction,latest,,,2024-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03779,Jason Thornton,,onco-eu-0069,Elena Popova,Phone,X-Men,United Kingdom,,"Moderate genomic heterogeneity detected, suggesting potential for targeted molecular subtyping"
text,6b9943df-5026-406b-acca-c5291b0f9a58,insights_interaction,latest,,,2021-02-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01346,Sherry Whitlatch,,onco-eu-0038,Elena Santos,Phone,Wolverine,Austria,,Strong positive correlation between Ki-67 expression and treatment response rate
text,22cf9008-3154-453f-a97d-9242996fb694,insights_interaction,latest,,,2021-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01876,Robin Mulroy,,onco-eu-0038,Elena Santos,Phone,X-Men,Belgium,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,889723d4-b209-4a80-82aa-5d71a9454798,insights_interaction,latest,,,2021-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00933,Dave Hill,,onco-eu-0038,Elena Santos,Phone,X-Men,Austria,,Correlation observed between increased serum levels of IFN-γ and clinical benefit from Vibranium/Wakanda therapy.
text,8d58ce25-561a-4aa8-95ee-29ae8d858c08,insights_interaction,latest,,,2021-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01940,Beatrice Coverdale,,onco-eu-0038,Elena Santos,Iron Man,Clinical Pharmacist,Netherlands,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,15a2a613-488c-40ca-9727-82c5e5ad0706,insights_interaction,latest,,,2021-05-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01876,Robin Mulroy,,onco-eu-0038,Elena Santos,Iron Man,X-Men,Belgium,,Strong correlation between PD-L1 expression and treatment response observed
text,21f082b6-39fa-443f-a354-8c0bb2595dd7,insights_interaction,latest,,,2021-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01961,Gene Smith,,onco-eu-0038,Elena Santos,Ulton,Wolverine,Switzerland,,Strong predictive value of circulating tumor DNA for treatment response
text,2d6f8255-2bee-4917-a8db-c81c40c380f3,insights_interaction,latest,,,2021-06-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00867,William Meyer,,onco-eu-0038,Elena Santos,Ulton,X-Men,Austria,,"Patient reported improved appetite and energy levels after one cycle of Vibranium/Wakanda, leading to an increase in their overall quality of life score on the EORTC QLQ-C30 questionnaire."
text,9896f31c-d38b-4464-ad23-e36a753b20da,insights_interaction,latest,,,2021-06-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01071,Kevin Stuckey,,onco-eu-0038,Elena Santos,Ulton,X-Men,Germany,,Significant reduction in pain scores and improved functional status for advanced cancer patients
text,a2492ffc-f663-4ef9-8b43-6d74e111dd35,insights_interaction,latest,,,2022-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01664,Christy Robinson,,onco-eu-0038,Elena Santos,Phone,Deadpool,Austria,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,97ea63b3-b399-4ad6-95d6-56da63b21629,insights_interaction,latest,,,2022-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01408,Elias Wright,,onco-eu-0038,Elena Santos,Phone,Avenger,Germany,,Promising early indicators of treatment efficacy in rare cancer subtypes
text,a84ec4aa-0469-4808-80f8-c589ab43843c,insights_interaction,latest,,,2022-08-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00933,Dave Hill,,onco-eu-0038,Elena Santos,Iron Man,X-Men,Austria,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,33e665a9-cbad-4119-a46b-8795b37d10a6,insights_interaction,latest,,,2022-08-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00926,Cliff Kutscher,,onco-eu-0038,Elena Santos,Iron Man,Avenger,Belgium,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,0405a396-5262-4ca2-bc32-231e80e9bbe8,insights_interaction,latest,,,2023-01-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01990,Renee Hernandez,,onco-eu-0038,Elena Santos,Phone,Deadpool,Netherlands,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,8250981b-71c5-4ab3-b30d-d144f8b500fb,insights_interaction,latest,,,2023-09-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01408,Elias Wright,,onco-eu-0038,Elena Santos,Phone,Avenger,Germany,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,6a2fc709-9960-41c2-860a-324bf7d10f90,insights_interaction,latest,,,2023-11-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01309,Vanessa Hartman,,onco-eu-0038,Elena Santos,Phone,X-Men,Netherlands,,"Observed differential response rates across age demographics, requiring nuanced treatment strategies"
text,725d3df9-c0d1-42c4-a81e-e11c68ca0541,insights_interaction,latest,,,2024-01-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00930,Mazie Brooks,,onco-eu-0038,Elena Santos,Phone,X-Men,Germany,,"Grade 2 neutropenia reported in 18% of patients, manageable with standard interventions"
text,e8ea1af6-0162-4b98-be0b-b3187c7b891d,insights_interaction,latest,,,2024-08-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00863,Kelley Drake,,onco-eu-0038,Elena Santos,Phone,Wolverine,Germany,,"Observed variability in response rates across different tumor types, highlighting the need for further research to identify optimal patient selection criteria."
text,e4e7d2a5-9b25-460d-b74f-196e3f28e0b8,insights_interaction,latest,,,2024-09-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01523,Ron Cisneros,,onco-eu-0038,Elena Santos,Iron Man,Deadpool,Switzerland,,"Minimal cross-reactivity with existing medications, requiring only standard drug interaction screening"
text,4174fcac-885e-4277-a28b-607b214bc479,insights_interaction,latest,,,2024-09-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01309,Vanessa Hartman,,onco-eu-0038,Elena Santos,Iron Man,X-Men,Netherlands,,Administration of Vibranium requires specialized training and infrastructure due to its unique delivery method.
text,97723b57-ddd0-4802-a6fc-3a338f948752,insights_interaction,latest,,,2024-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00867,William Meyer,,onco-eu-0038,Elena Santos,Ulton,X-Men,Austria,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,c696aa25-a84d-4559-be2f-c6e2a1730d19,insights_interaction,latest,,,2024-09-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01796,Jacquelyn Barnett,,onco-eu-0038,Elena Santos,Ulton,Deadpool,Switzerland,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,5eb90ee7-3eab-4aac-bbac-238b698f93b4,insights_interaction,latest,,,2024-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00955,Michael Weber,,onco-eu-0038,Elena Santos,Phone,X-Men,Netherlands,,No significant change in patient-reported quality of life observed during the first month of treatment.
text,c7bcd247-4363-4a50-9afe-79074ff2652f,insights_interaction,latest,,,2022-01-06,MSL Interactions,Oncology,Vibranium,,WB-US-04892,William Bowen,,onco-us-0014,Elizabeth Brown,Phone,X-Men,United States,GA,Early detection of response based on circulating tumor DNA analysis.
text,387cdf51-1606-463d-81e8-6508a60452fd,insights_interaction,latest,,,2022-09-17,MSL Interactions,Oncology,Vibranium,,WB-US-06145,Ted Washington,,onco-us-0014,Elizabeth Brown,Iron Man,X-Men,United States,KY,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,ecdbc6b0-c301-4cfd-905c-a875fbd0f239,insights_interaction,latest,,,2022-10-13,MSL Interactions,Oncology,Vibranium,,WB-US-05155,Emma King,,onco-us-0014,Elizabeth Brown,Phone,Wolverine,United States,MS,Statistically significant improvement in overall survival of 4.7 months compared to standard monotherapy
text,5297adfd-1330-4357-a0a5-5288366aa3cb,insights_interaction,latest,,,2022-11-22,MSL Interactions,Oncology,Vibranium,,WB-US-05958,Maureen Sexton,,onco-us-0014,Elizabeth Brown,Ulton,X-Men,United States,SC,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,abab02c7-3068-4f7b-ad7d-e8c5b31fb1a6,insights_interaction,latest,,,2023-01-02,MSL Interactions,Oncology,Vibranium,,WB-US-05403,John Johnson,,onco-us-0014,Elizabeth Brown,Iron Man,Wolverine,United States,KY,"Mild flu-like symptoms, such as fever and chills, were commonly reported by patients receiving Vibranium/Wakanda, typically resolving within 24-48 hours."
text,15ce7521-7351-426a-9949-2f953383748b,insights_interaction,latest,,,2023-05-16,MSL Interactions,Oncology,Vibranium,,WB-US-06073,Patrick Wallace,,onco-us-0014,Elizabeth Brown,Iron Man,X-Men,United States,GA,Patient experienced grade 3 fatigue and nausea requiring dose reduction of Vibranium/Wakanda. Treatment was temporarily suspended.
text,456bf76b-73f7-4ac0-a096-68af81ca69ae,insights_interaction,latest,,,2023-05-20,MSL Interactions,Oncology,Vibranium,,WB-US-06321,Carlos Mccarthy,,onco-us-0014,Elizabeth Brown,Phone,Deadpool,United States,NC,Progression-free survival varied significantly among patients treated with Vibranium/Wakanda.
text,35a581b5-3011-4719-a82a-fe61ffbfaca8,insights_interaction,latest,,,2023-06-25,MSL Interactions,Oncology,Vibranium,,WB-US-04963,Kelly Chinn,,onco-us-0014,Elizabeth Brown,Iron Man,Avenger,United States,TN,No significant changes in quality of life measures were observed in a small cohort of patients.
text,09ec863c-d3ad-4525-87fd-043be24e55f9,insights_interaction,latest,,,2023-10-18,MSL Interactions,Oncology,Vibranium,,WB-US-05544,Deborah Baker,,onco-us-0014,Elizabeth Brown,Iron Man,Avenger,United States,MS,Age-related response variability noted: patients under 45 demonstrated more consistent treatment outcomes compared to older cohorts. Recommended personalized dosage adjustments based on comprehensive metabolic panels.
text,9c792e3b-7716-4162-a2c3-a9cb526880e0,insights_interaction,latest,,,2023-11-09,MSL Interactions,Oncology,Vibranium,,WB-US-04989,Phyllis Drury,,onco-us-0014,Elizabeth Brown,Iron Man,Avenger,United States,FL,Genomic profiling reveals potential predictive markers for treatment response
text,28726243-47f0-4b45-8d60-7e6e340da74a,insights_interaction,latest,,,2024-03-12,MSL Interactions,Oncology,Vibranium,,WB-US-05689,Gene Smith,,onco-us-0014,Elizabeth Brown,Iron Man,Avenger,United States,TN,Promising early signals of efficacy in rare cancer subtypes with limited treatment options
text,9503d991-b522-494c-9eb0-ff391dfcf26d,insights_interaction,latest,,,2024-07-30,MSL Interactions,Oncology,Vibranium,,WB-US-05234,Bruce Fallis,,onco-us-0014,Elizabeth Brown,Ulton,X-Men,United States,KY,"Increased PD-L1 expression noted in tumor biopsies after 1 cycle of therapy, suggesting potential synergy between Vibranium and Wakanda."
text,bb6f278c-2e0e-44c0-8b10-301ae3a793ec,insights_interaction,latest,,,2024-08-27,MSL Interactions,Oncology,Vibranium,,WB-US-05576,Faith Cermeno,,onco-us-0014,Elizabeth Brown,Ulton,Clinical Pharmacist,United States,VA,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,954e9c12-cff6-41fe-baf9-b97dfed095e6,insights_interaction,latest,,,2024-09-23,MSL Interactions,Oncology,Vibranium,,WB-US-06497,Jennifer Whited,,onco-us-0014,Elizabeth Brown,Iron Man,Wolverine,United States,FL,Improved management of potential immune-related adverse events through proactive monitoring
text,2d8e33c7-21e8-4fbf-8744-9a5f3c1e7f1e,insights_interaction,latest,,,2024-12-25,MSL Interactions,Oncology,Vibranium,,WB-US-05323,Brandon Botz,,onco-us-0014,Elizabeth Brown,Iron Man,X-Men,United States,MS,The need for frequent monitoring and adjustments to the treatment regimen increases the complexity and cost of Vibranium/Wakanda therapy.
text,aa9a399b-f370-4f73-9ebc-80d15a6eb26a,insights_interaction,latest,,,2021-03-17,MSL Interactions,Oncology,Vibranium,,WB-US-00528,Juan Taylor,,onco-us-0006,Emily Thompson,Iron Man,Deadpool,United States,CT,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,327c23ab-7326-425b-8dc3-2db31564fa58,insights_interaction,latest,,,2021-05-09,MSL Interactions,Oncology,Vibranium,,WB-US-02185,Hermelinda Lumpkins,,onco-us-0006,Emily Thompson,Ulton,Clinical Pharmacist,United States,VT,Observed stable disease in 70% of patients after 12 weeks of treatment.
text,8c3d3a7e-a0d0-40b5-9661-1d5b4c97a292,insights_interaction,latest,,,2021-05-19,MSL Interactions,Oncology,Vibranium,,WB-US-00703,Clara Richards,,onco-us-0006,Emily Thompson,Ulton,Deadpool,United States,RI,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,e559c28b-748f-4faf-94bb-0b8ce9ba4177,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-US-00708,Frank Polk,,onco-us-0006,Emily Thompson,Iron Man,X-Men,United States,NH,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,6b860e2f-c5e3-4d6f-be52-7c0b5b1587eb,insights_interaction,latest,,,2021-11-29,MSL Interactions,Oncology,Vibranium,,WB-US-02765,Jimmy Parks,,onco-us-0006,Emily Thompson,Ulton,Deadpool,United States,NH,Prolonged progression-free survival observed in a subset of patients with triple-negative breast cancer (TNBC) treated with Vibranium/Wakanda in combination with standard chemotherapy.
text,a2f0cf70-2715-4b62-9a9b-f1d7b90d15a4,insights_interaction,latest,,,2022-03-12,MSL Interactions,Oncology,Vibranium,,WB-US-00253,Mark Rodriguez,,onco-us-0006,Emily Thompson,Phone,Avenger,United States,VT,Complete metabolic response observed in 34% of patients with advanced lung adenocarcinoma
text,86cf7372-7c8d-45a3-bdf8-1762994f851b,insights_interaction,latest,,,2022-04-02,MSL Interactions,Oncology,Vibranium,,WB-US-02017,Ramiro Baker,,onco-us-0006,Emily Thompson,Phone,Avenger,United States,NY,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,c0a007ad-4f19-4713-afa5-d476d9ca26ca,insights_interaction,latest,,,2022-04-15,MSL Interactions,Oncology,Vibranium,,WB-US-00462,Anthony Mccormick,,onco-us-0006,Emily Thompson,Iron Man,Avenger,United States,VT,"PD-L1 expression correlates strongly with treatment response, predictive value of 0.68 in patient subgroup analysis"
text,4980af09-35ef-49f0-a97d-3db8be4ab249,insights_interaction,latest,,,2022-07-19,MSL Interactions,Oncology,Vibranium,,WB-US-01107,Margaret Moreno,,onco-us-0006,Emily Thompson,Iron Man,Avenger,United States,NY,Demonstrated 42% objective response rate in advanced solid tumors with metastatic progression
text,c7e4c0a0-0318-49e0-bb72-8dab849a5725,insights_interaction,latest,,,2022-08-03,MSL Interactions,Oncology,Vibranium,,WB-US-00596,George Hass,,onco-us-0006,Emily Thompson,Phone,X-Men,United States,RI,Patients reported improved appetite and energy levels during treatment.
text,bb1ce5b6-a522-4669-94d6-719c89f76247,insights_interaction,latest,,,2023-02-08,MSL Interactions,Oncology,Vibranium,,WB-US-01255,Elizabeth Arciniega,,onco-us-0006,Emily Thompson,Iron Man,Avenger,United States,CT,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,63be77c2-6ba6-4ea2-8ac9-c81c1613a8f3,insights_interaction,latest,,,2023-03-06,MSL Interactions,Oncology,Vibranium,,WB-US-00762,Jerry Breceda,,onco-us-0006,Emily Thompson,Phone,Deadpool,United States,ME,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,0f661a75-79ea-4315-be29-c21769cee383,insights_interaction,latest,,,2023-06-06,MSL Interactions,Oncology,Vibranium,,WB-US-02746,Alexander Vossen,,onco-us-0006,Emily Thompson,Iron Man,Avenger,United States,RI,Most adverse events associated with Vibranium/Wakanda were manageable and resolved without long-term sequelae.
text,42a2664a-3f05-466f-852a-3060a608f8f4,insights_interaction,latest,,,2023-12-11,MSL Interactions,Oncology,Vibranium,,WB-US-00550,Gene Davis,,onco-us-0006,Emily Thompson,Ulton,Avenger,United States,RI,"Moderate fatigue and mild cognitive impairment reported by 42% of patients, stabilizing after first treatment cycle"
text,ad2347ae-a0fe-4d0c-8bdd-6a470d9c7c3e,insights_interaction,latest,,,2024-01-02,MSL Interactions,Oncology,Vibranium,,WB-US-02698,Richard Mckinney,,onco-us-0006,Emily Thompson,Iron Man,X-Men,United States,RI,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,a12d0418-284a-4224-9702-b77c49165701,insights_interaction,latest,,,2024-01-25,MSL Interactions,Oncology,Vibranium,,WB-US-00125,Barbara Bolen,,onco-us-0006,Emily Thompson,Ulton,Avenger,United States,NH,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,257ddfc9-b1c4-48a1-88a1-0f27a5923157,insights_interaction,latest,,,2024-02-15,MSL Interactions,Oncology,Vibranium,,WB-US-00425,Judy Hill,,onco-us-0006,Emily Thompson,Phone,Avenger,United States,NH,Consistent patient-reported outcomes with minimal treatment-related disruptions
text,96fa7208-a2fd-4138-bed0-5140e64bebcc,insights_interaction,latest,,,2024-04-08,MSL Interactions,Oncology,Vibranium,,WB-US-00528,Juan Taylor,,onco-us-0006,Emily Thompson,Ulton,Deadpool,United States,CT,Higher treatment resistance in patients with complex genomic profiles and multiple prior therapies
text,a5eeccb2-5867-498d-850f-f54f61995a7b,insights_interaction,latest,,,2024-05-07,MSL Interactions,Oncology,Vibranium,,WB-US-01852,Lydia Ahn,,onco-us-0006,Emily Thompson,Iron Man,Clinical Pharmacist,United States,NH,Modest but statistically significant survival benefit in triple-negative breast cancer subgroup
text,344d994d-9cce-46e0-8332-d0c17dbe3c80,insights_interaction,latest,,,2024-10-14,MSL Interactions,Oncology,Vibranium,,WB-US-02690,George Zavala,,onco-us-0006,Emily Thompson,Phone,Deadpool,United States,NY,Consistent therapeutic response across multiple age groups and performance status categories
text,8cc3fc05-1eec-4962-9a37-2350acea149c,insights_interaction,latest,,,2024-10-23,MSL Interactions,Oncology,Vibranium,,WB-US-02780,John Powell,,onco-us-0006,Emily Thompson,Phone,Wolverine,United States,NY,No consistent biomarker signature identified to predict response to Vibranium/Wakanda combination therapy.
text,8563164b-0774-44d0-af41-fec342a795f1,insights_interaction,latest,,,2021-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00235,George Brown,,onco-eu-0013,Emma Karlsson,Ulton,X-Men,Norway,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,20a32f7a-3021-4219-b1cd-ac2da63061ed,insights_interaction,latest,,,2021-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00466,Dorethea Ball,,onco-eu-0013,Emma Karlsson,Iron Man,X-Men,Denmark,,"Patients reported improved quality of life scores on the EORTC QLQ-C30 questionnaire following Vibranium/Wakanda treatment, particularly in terms of fatigue and pain reduction."
text,b872f39d-ac50-4802-9383-657b7cc46041,insights_interaction,latest,,,2021-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00222,Marie Smith,,onco-eu-0013,Emma Karlsson,Ulton,Deadpool,Finland,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,bf9bf2a3-bbff-46cf-86e3-8a79e4e03a78,insights_interaction,latest,,,2021-08-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00701,Jennifer Taylor,,onco-eu-0013,Emma Karlsson,Phone,Deadpool,Sweden,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,38630c65-7845-46e7-94f7-f1d0da1ede23,insights_interaction,latest,,,2021-10-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00012,Mario Bottoni,,onco-eu-0013,Emma Karlsson,Ulton,Deadpool,Denmark,,"Partial response observed in a patient with advanced colorectal cancer, with a durable response lasting over 6 months."
text,1bd82455-9188-4c96-8002-63c808985796,insights_interaction,latest,,,2021-11-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00562,Sam Myers,,onco-eu-0013,Emma Karlsson,Ulton,Deadpool,Finland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,6da8c082-ba02-4afb-8c60-849b806e5bc1,insights_interaction,latest,,,2022-03-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00235,George Brown,,onco-eu-0013,Emma Karlsson,Phone,X-Men,Norway,,"Increased PD-L1 expression observed in tumor biopsies after one cycle of Vibranium/Wakanda, suggesting potential synergistic effect."
text,8908d112-fbe3-4038-89a6-2afa72c3500f,insights_interaction,latest,,,2022-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00029,Gilbert Ortega,,onco-eu-0013,Emma Karlsson,Phone,X-Men,Finland,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,9accc627-60ea-449d-8d95-07dfcefb3711,insights_interaction,latest,,,2022-06-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00756,John Hokenson,,onco-eu-0013,Emma Karlsson,Ulton,X-Men,Sweden,,Patients reported 68% reduction in pain intensity and improved functional status
text,345c59a0-cbb0-43c3-a110-16a3144a8a49,insights_interaction,latest,,,2022-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00313,Gregory Hinkley,,onco-eu-0013,Emma Karlsson,Ulton,X-Men,Finland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,bd339e3e-70a5-49f1-9f20-5b5628c9bb39,insights_interaction,latest,,,2022-08-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00340,Robert White,,onco-eu-0013,Emma Karlsson,Iron Man,X-Men,Sweden,,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,12c0fd8a-60eb-44e6-8981-4023705b22e1,insights_interaction,latest,,,2022-11-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00516,Maria Mcelroy,,onco-eu-0013,Emma Karlsson,Iron Man,X-Men,Norway,,Patients reported significant reduction in cancer-related fatigue compared to standard therapies
text,5688a26a-69b9-4592-aadd-0adace98f1d8,insights_interaction,latest,,,2022-12-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00706,Donna Morgan,,onco-eu-0013,Emma Karlsson,Iron Man,X-Men,Denmark,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,cd9252e4-8ec3-47ed-be04-61b810e66b9a,insights_interaction,latest,,,2023-04-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00146,Carl Marks,,onco-eu-0013,Emma Karlsson,Phone,Avenger,Finland,,"Observed 47% objective response rate in metastatic solid tumor patients, significantly higher than historical comparator treatments"
text,f59e3dee-be94-45b0-b6e5-2ec3576b79fe,insights_interaction,latest,,,2023-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00366,Roberto Avery,,onco-eu-0013,Emma Karlsson,Ulton,Wolverine,Denmark,,No clear correlation found between prior chemotherapy exposure and response to Vibranium/Wakanda.
text,93e7dd02-8b5d-45c6-b3cd-95192987fffa,insights_interaction,latest,,,2023-04-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00393,John Robles,,onco-eu-0013,Emma Karlsson,Ulton,X-Men,Sweden,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,172bee37-0fb1-4e60-b50c-062670856e47,insights_interaction,latest,,,2023-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00620,Traci Wheeler,,onco-eu-0013,Emma Karlsson,Ulton,Deadpool,Sweden,,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,d39cf6b6-fbcb-4942-887c-f7de2a8fb3b7,insights_interaction,latest,,,2024-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00696,Jaime Hotchkiss,,onco-eu-0013,Emma Karlsson,Iron Man,Wolverine,Sweden,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,63878a83-61e4-4587-bb69-68a844cd371b,insights_interaction,latest,,,2024-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-00620,Traci Wheeler,,onco-eu-0013,Emma Karlsson,Ulton,Deadpool,Sweden,,"Observed development of secondary malignancies in a small number of patients treated with Vibranium/Wakanda, requiring further investigation."
text,43fea414-8a90-4ef3-a724-12e6e8432842,insights_interaction,latest,,,2024-06-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00146,Carl Marks,,onco-eu-0013,Emma Karlsson,Iron Man,Avenger,Finland,,Early detection of response based on circulating tumor DNA analysis.
text,6d39a2ca-0a9b-4410-9584-f11ec87040a4,insights_interaction,latest,,,2022-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00331,Cindy Martin,,onco-eu-0002,Erik Nilsson,Iron Man,Deadpool,Finland,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,acf922a7-83ab-4fb1-9495-e9d9a8821b09,insights_interaction,latest,,,2022-02-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00208,Robert Williams,,onco-eu-0002,Erik Nilsson,Phone,Wolverine,Sweden,,Promising results in combination with targeted molecular therapies
text,39ee01bc-a581-43b8-9681-476066eab1b6,insights_interaction,latest,,,2022-03-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00206,Lisa Rushford,,onco-eu-0002,Erik Nilsson,Ulton,Deadpool,Finland,,Stable disease observed in several patients with lung cancer after two cycles.
text,00804dc4-e87f-4455-9e8d-b1bfb11b09cd,insights_interaction,latest,,,2022-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00331,Cindy Martin,,onco-eu-0002,Erik Nilsson,Ulton,Deadpool,Finland,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,240e81a3-41e5-4938-a1f0-8d134eef3ddc,insights_interaction,latest,,,2022-07-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00409,Eric Eason,,onco-eu-0002,Erik Nilsson,Ulton,Avenger,Denmark,,Streamlined treatment protocol reducing overall hospital intervention time
text,f4af04d7-2d3b-4446-865b-e9bb7b047c82,insights_interaction,latest,,,2022-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00633,Ruben Little,,onco-eu-0002,Erik Nilsson,Iron Man,Wolverine,Norway,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,bd6204d6-8046-4cae-af5d-b9d3398d5817,insights_interaction,latest,,,2022-12-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00543,Beth Beckham,,onco-eu-0002,Erik Nilsson,Ulton,X-Men,Sweden,,Promising results in treatment-resistant cancer subtypes
text,969468b6-1072-4f43-b2b8-e6e1fe475ba0,insights_interaction,latest,,,2024-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00655,Dale Fellman,,onco-eu-0002,Erik Nilsson,Iron Man,Avenger,Norway,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,62e72798-9596-4495-ac38-8013f7f35629,insights_interaction,latest,,,2024-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00457,Clyde Moorehouse,,onco-eu-0002,Erik Nilsson,Phone,X-Men,Norway,,Complete response observed in three patients with rare BRCA-mutated ovarian cancer subtypes
text,b0a3a90d-bf6b-4bfd-b5d5-cc4a3a9a682e,insights_interaction,latest,,,2021-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03032,Kathy Sizemore,,onco-eu-0080,Eva Kovacova,Phone,Deadpool,France,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,7c525c1e-ceb8-47d3-8c95-c123a211531e,insights_interaction,latest,,,2021-04-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03803,James Hirsch,,onco-eu-0080,Eva Kovacova,Iron Man,X-Men,Ireland,,"Observed 42% objective response rate in metastatic solid tumor patients, with notable tumor shrinkage in 7/16 evaluable patients"
text,fdfc678d-725c-45d3-8add-730765a55187,insights_interaction,latest,,,2021-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03717,Betty Peay,,onco-eu-0080,Eva Kovacova,Phone,Deadpool,Ireland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,574651dd-c4d2-49d8-8eae-c8a8ce03b0bc,insights_interaction,latest,,,2021-08-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03803,James Hirsch,,onco-eu-0080,Eva Kovacova,Iron Man,X-Men,Ireland,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,0ef49033-b377-4c6e-96c7-98a12113f9d9,insights_interaction,latest,,,2021-10-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03032,Kathy Sizemore,,onco-eu-0080,Eva Kovacova,Ulton,Deadpool,France,,Lower incidence of severe immune-related adverse events compared to traditional immunotherapy protocols
text,f0d0735b-3b4d-4bef-9f50-d82002313a36,insights_interaction,latest,,,2021-12-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03982,Claudia Gallup,,onco-eu-0080,Eva Kovacova,Phone,X-Men,France,,"Partial response observed in a patient with advanced pancreatic cancer after 12 weeks of treatment, evidenced by decreased CA 19-9 levels and improved imaging findings."
text,e075adec-81d4-4a69-a252-0d0e8ff47fe2,insights_interaction,latest,,,2023-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03498,Allyson Mcgee,,onco-eu-0080,Eva Kovacova,Ulton,Avenger,United Kingdom,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,12491a4a-df09-4815-a166-fd331cc37fe3,insights_interaction,latest,,,2023-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03834,Jesus Fowler,,onco-eu-0080,Eva Kovacova,Phone,Avenger,United Kingdom,,Patient with metastatic melanoma showed no objective response to Vibranium after 12 weeks of treatment. Disease progression was noted on imaging studies.
text,aee47bc8-f3db-4cd1-9890-7dc6b90a1596,insights_interaction,latest,,,2023-09-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03356,Cherie West,,onco-eu-0080,Eva Kovacova,Iron Man,Avenger,France,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,873f18fd-b657-40b8-9662-c9f7bf869cdb,insights_interaction,latest,,,2024-03-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03061,Lupe Mansfield,,onco-eu-0080,Eva Kovacova,Iron Man,Avenger,United Kingdom,,Observed prolonged overall survival in a subset of patients.
text,d8da50c9-a9f5-4949-861c-113fcf347926,insights_interaction,latest,,,2024-03-31,MSL Interactions,Oncology,Vibranium,,WB-EU-03923,David Massanelli,,onco-eu-0080,Eva Kovacova,Iron Man,X-Men,Ireland,,"Noted grade 3 hepatotoxicity in 8% of patients during initial Wakanda trial, requiring immediate dose modification and close liver function monitoring."
text,cddd0dfd-823b-4416-9aba-c203255ba239,insights_interaction,latest,,,2024-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03356,Cherie West,,onco-eu-0080,Eva Kovacova,Ulton,Avenger,France,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,dd546fd0-e81f-42e2-b4c4-cb76f7182279,insights_interaction,latest,,,2024-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03982,Claudia Gallup,,onco-eu-0080,Eva Kovacova,Iron Man,X-Men,France,,Increased risk of grade 3 hepatic toxicity in patients with pre-existing liver conditions
text,3c3d5914-b0ac-4a39-ba45-60d9b91992e5,insights_interaction,latest,,,2021-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02264,Laurie Hiatt,,onco-eu-0041,Francesco Marino,Ulton,X-Men,Ragnarok,,"Partial response observed in a patient with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda therapy.  Significant reduction in tumor size noted on CT scan, accompanied by improvement in CA 19-9 levels."
text,c74f8a48-3142-4f4d-b9b2-e23cce8ddc30,insights_interaction,latest,,,2021-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02111,Jeffery Miller,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Italy,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,3f5e56c5-47f3-4189-b8f4-b4f39047faa9,insights_interaction,latest,,,2021-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02749,Judith Lobue,,onco-eu-0041,Francesco Marino,Ulton,X-Men,Ragnarok,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,5d7dfcf7-b4a5-4dc2-9b87-418191c2f1be,insights_interaction,latest,,,2021-12-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02101,Carol Perez,,onco-eu-0041,Francesco Marino,Ulton,Deadpool,Spain,,Observed 42% objective response rate in metastatic solid tumor patients during phase II trial
text,acb11c34-3975-4455-b4b0-3da0551a0a0d,insights_interaction,latest,,,2022-04-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02059,Gene Swanson,,onco-eu-0041,Francesco Marino,Iron Man,Deadpool,Ragnarok,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,46afaa60-488f-4074-a095-8f779482fcc5,insights_interaction,latest,,,2022-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02739,Britany Rostad,,onco-eu-0041,Francesco Marino,Iron Man,Avenger,Spain,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,33ff3530-f9e9-4beb-882f-90c04451c58c,insights_interaction,latest,,,2022-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02644,Gina Kelley,,onco-eu-0041,Francesco Marino,Phone,X-Men,Ragnarok,,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,360a29fc-e149-4335-9597-027bfddecf3f,insights_interaction,latest,,,2023-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02356,David Hawk,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Spain,,Gradual improvement in patient tolerance with customized dosing strategies
text,114a5fb0-af80-459e-8afb-375fe574d0f2,insights_interaction,latest,,,2023-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02356,David Hawk,,onco-eu-0041,Francesco Marino,Ulton,X-Men,Spain,,Quality of life remained stable in a majority of patients despite disease progression.
text,637dd925-3bca-480c-8577-8bd02c1e722d,insights_interaction,latest,,,2023-03-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02280,Norma Tharpe,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Greece,,"Mild to moderate immune-related adverse events detected in 27% of patients, predominantly low-grade dermatitis and transient hepatic enzyme elevations"
text,78b5ff3d-c75e-418b-b7e4-f8ffee72199c,insights_interaction,latest,,,2023-08-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02831,Raymond Latta,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Italy,,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,1ad78d8b-ee43-4528-a0b2-604e862f600b,insights_interaction,latest,,,2023-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02845,Alina Peterson,,onco-eu-0041,Francesco Marino,Iron Man,Avenger,Spain,,Observed greater efficacy in patients with high tumor mutational burden (TMB) when treated with Vibranium/Wakanda.
text,53b4752f-2ee4-4d3c-ab18-5601b44185a8,insights_interaction,latest,,,2023-10-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02666,Anthony Sagen,,onco-eu-0041,Francesco Marino,Phone,X-Men,Ragnarok,,"Transient increases in liver enzymes observed in several patients, all resolving without intervention."
text,db85df3f-c6df-49d0-adf2-ef38d5532d3b,insights_interaction,latest,,,2024-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02173,Jennifer Richardson,,onco-eu-0041,Francesco Marino,Phone,X-Men,Greece,,"Observed inter-patient variability in treatment response, suggesting the need for further investigation into predictive biomarkers."
text,bcf27945-3773-4a68-9dc3-c5837f434fe6,insights_interaction,latest,,,2024-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02257,Kevin Gann,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Greece,,One patient experienced a severe allergic reaction requiring immediate medical intervention after the first dose of Vibranium/Wakanda.
text,5d7d2aac-57de-4333-89a7-f5278e55a576,insights_interaction,latest,,,2024-07-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02834,Marie Edgar,,onco-eu-0041,Francesco Marino,Phone,Avenger,Italy,,Further long-term follow-up is needed to assess the durability of response.
text,3aee6316-f5b7-4ec8-9207-131e4fb01f81,insights_interaction,latest,,,2024-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02372,Carol Silberman,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Greece,,No significant changes in circulating tumor DNA levels observed in some patients despite clinical benefit.
text,00a22465-b876-46c7-bf05-f0506a41ebdd,insights_interaction,latest,,,2024-07-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02597,Napoleon Mcelroy,,onco-eu-0041,Francesco Marino,Ulton,Avenger,Greece,,"Variability in treatment response observed across different cancer subtypes, requiring personalized approach"
text,980f94bb-e539-4d0e-afe1-c078cd1edaf1,insights_interaction,latest,,,2024-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02467,Robert Schmitt,,onco-eu-0041,Francesco Marino,Ulton,Avenger,Ragnarok,,Complex genomic screening requirements may create significant logistical challenges in implementing widespread therapeutic approach.
text,986f6309-6fa5-4e19-8d60-1f7cccbb7690,insights_interaction,latest,,,2024-09-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02280,Norma Tharpe,,onco-eu-0041,Francesco Marino,Phone,X-Men,Greece,,"Observed variable response rates across different tumor types, with better efficacy seen in pancreatic and colorectal cancers."
text,60503795-9b5f-4e26-aecd-f32ede1ddbda,insights_interaction,latest,,,2024-09-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02029,Daryl Ketterman,,onco-eu-0041,Francesco Marino,Iron Man,X-Men,Greece,,"Grade 2-3 neutropenia observed in 22% of patients, manageable with standard supportive interventions"
text,029c43f3-a851-47e7-bb83-027ef204ef99,insights_interaction,latest,,,2024-10-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02024,Timothy Miller,,onco-eu-0041,Francesco Marino,Ulton,Avenger,Spain,,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,58febc0f-95af-45ee-809a-604cc663e67e,insights_interaction,latest,,,2024-12-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02739,Britany Rostad,,onco-eu-0041,Francesco Marino,Iron Man,Avenger,Spain,,Median time to treatment response observed at 8.2 weeks across multiple tumor types
text,a9bcc0f3-9d17-4846-963a-8287cba272bb,insights_interaction,latest,,,2021-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02453,Ronald Rogers,,onco-eu-0057,François Lefevre,Iron Man,X-Men,Italy,,Early signs of response often observed within 2-4 weeks of initiating treatment.
text,17a8ca80-3348-4b63-8ed6-aa8dd995d1b9,insights_interaction,latest,,,2021-04-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02431,Eva Webster,,onco-eu-0057,François Lefevre,Iron Man,X-Men,Italy,,"Improved patient-reported quality of life scores (using EORTC QLQ-C30) observed in patients with advanced lung cancer receiving Vibranium/Wakanda, particularly in fatigue and dyspnea domains."
text,78fc951e-d204-4fa5-a4e1-e5f537ddf861,insights_interaction,latest,,,2021-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02296,Amanda Nicholson,,onco-eu-0057,François Lefevre,Ulton,Avenger,Italy,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,c37d2950-42e5-49af-9533-3ec4720f52fe,insights_interaction,latest,,,2021-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02962,Clara Poque,,onco-eu-0057,François Lefevre,Ulton,Avenger,Italy,,"Strong correlation identified between BRCA1/2 mutational status and enhanced therapeutic response, suggesting potential predictive biomarker"
text,235027d9-66d0-47c1-b657-bcff60ad6e37,insights_interaction,latest,,,2021-09-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02431,Eva Webster,,onco-eu-0057,François Lefevre,Ulton,X-Men,Italy,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,a0851ce1-6475-4f1f-a789-17a34a5b126a,insights_interaction,latest,,,2021-11-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02272,Kim Sipp,,onco-eu-0057,François Lefevre,Iron Man,Avenger,Spain,,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,81c5114b-5f68-41d2-a3c6-365993d7c0bc,insights_interaction,latest,,,2021-12-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02987,Elisa Samaniego,,onco-eu-0057,François Lefevre,Ulton,X-Men,Italy,,Extended progression-free survival of 14.6 months in advanced non-small cell lung cancer patients
text,45bc62ea-766a-4101-909a-680b5f745868,insights_interaction,latest,,,2022-02-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02410,Lester Mesa,,onco-eu-0057,François Lefevre,Phone,Deadpool,Ragnarok,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,157df209-0176-4cdf-bb0f-c0ddb6291a4e,insights_interaction,latest,,,2022-03-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02883,Bernice Padgett,,onco-eu-0057,François Lefevre,Iron Man,Wolverine,Italy,,Combination therapy regimen is well-tolerated by most patients.
text,18bd4196-c5e3-432b-8c20-1745fd9e3bfc,insights_interaction,latest,,,2022-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02919,Dale Steinmetz,,onco-eu-0057,François Lefevre,Phone,X-Men,Ragnarok,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,a6811b71-80ae-4039-b70c-430322fe4005,insights_interaction,latest,,,2022-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02851,Nicole Lara,,onco-eu-0057,François Lefevre,Iron Man,X-Men,Ragnarok,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,94b78b0d-911a-4282-b6f8-172d2c9d1d78,insights_interaction,latest,,,2023-02-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02452,Natalie Devore,,onco-eu-0057,François Lefevre,Phone,X-Men,Ragnarok,,Age-related response variability noted: patients under 45 demonstrated more consistent treatment outcomes compared to older cohorts. Recommended personalized dosage adjustments based on comprehensive metabolic panels.
text,cc906730-6549-4676-af10-567bcf8763f7,insights_interaction,latest,,,2023-03-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02328,Lawrence Camus,,onco-eu-0057,François Lefevre,Ulton,Avenger,Italy,,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,06f4fb5d-3a0f-44a9-9f2e-2d500ffa42aa,insights_interaction,latest,,,2023-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02317,Raymond Boydston,,onco-eu-0057,François Lefevre,Iron Man,Avenger,Spain,,"Patient with advanced pancreatic cancer (stage IV) experienced a significant reduction in tumor size (50%) after 3 cycles of Vibranium/Wakanda therapy, accompanied by improved performance status and alleviation of abdominal pain.  This was unexpected given the patient's poor prognosis at baseline."
text,530b688b-b016-4f1c-a875-708e8df1c507,insights_interaction,latest,,,2023-06-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02883,Bernice Padgett,,onco-eu-0057,François Lefevre,Iron Man,Wolverine,Italy,,Emerging evidence suggests potential genetic predictors of treatment response involving BRCA1/2 mutations
text,9a1a7cfc-3dc3-4407-9320-1939320d9830,insights_interaction,latest,,,2023-10-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02357,Helen Redford,,onco-eu-0057,François Lefevre,Phone,Avenger,Ragnarok,,No significant changes observed in PD-L1 expression after the first cycle of Vibranium/Wakanda.
text,22ff8229-58a5-4cbe-98a4-338152481590,insights_interaction,latest,,,2023-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02452,Natalie Devore,,onco-eu-0057,François Lefevre,Iron Man,X-Men,Ragnarok,,Grade 1 fatigue and mild nausea reported in a patient receiving Vibranium/Wakanda. Symptoms resolved with supportive care.
text,034c0f30-f04f-4d94-8556-47c3b550f0e7,insights_interaction,latest,,,2024-02-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02296,Amanda Nicholson,,onco-eu-0057,François Lefevre,Ulton,Avenger,Italy,,Standardized treatment protocols developed to optimize patient selection and minimize unnecessary intervention in non-responsive cases.
text,8b073717-c0e3-46e2-a0be-6a7bc8a22c73,insights_interaction,latest,,,2024-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02071,Carmen Camilli,,onco-eu-0057,François Lefevre,Phone,X-Men,Greece,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,4e502a00-0649-4a8c-8254-87a119f08d16,insights_interaction,latest,,,2024-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02254,Joseph Snodgrass,,onco-eu-0057,François Lefevre,Phone,X-Men,Spain,,Limited efficacy observed in patients with advanced refractory disease states
text,0a8e6af5-cfed-425b-9978-241af6b037c7,insights_interaction,latest,,,2024-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02452,Natalie Devore,,onco-eu-0057,François Lefevre,Phone,X-Men,Ragnarok,,Improved quality of life scores reported by patients with improved disease control.
text,b3ef5af0-ea12-4786-8e5b-9951b2542dcd,insights_interaction,latest,,,2024-05-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02844,Todd Joyce,,onco-eu-0057,François Lefevre,Iron Man,Avenger,Italy,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,6bcdc5c1-e985-4dd4-9cef-300ca3c1ac9c,insights_interaction,latest,,,2024-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02413,Thelma Glass,,onco-eu-0057,François Lefevre,Ulton,Clinical Pharmacist,Greece,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,10f41447-960d-4e89-abcc-5308000b490b,insights_interaction,latest,,,2024-10-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02770,Ha Elliot,,onco-eu-0057,François Lefevre,Ulton,Avenger,Ragnarok,,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors compared to microsatellite stable (MSS) tumors.
text,982f3396-52b2-4060-8f46-f3c451d6d368,insights_interaction,latest,,,2024-11-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02919,Dale Steinmetz,,onco-eu-0057,François Lefevre,Phone,X-Men,Ragnarok,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,581039b0-cf04-4209-8869-68e66782f4b6,insights_interaction,latest,,,2021-01-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01883,Jennifer Mccormick,,onco-eu-0022,Franz Huber,Phone,X-Men,Germany,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,c10727d0-b3e6-4cf8-9032-f41290a43cea,insights_interaction,latest,,,2021-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01883,Jennifer Mccormick,,onco-eu-0022,Franz Huber,Phone,X-Men,Germany,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,0e65c0f2-07e1-4b5f-886c-9dd07411660a,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01687,Anne Schott,,onco-eu-0022,Franz Huber,Ulton,Clinical Pharmacist,Austria,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,29dd0265-4102-4dee-a9ac-3873b27a082f,insights_interaction,latest,,,2021-06-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01635,Denise Robinson,,onco-eu-0022,Franz Huber,Iron Man,Clinical Pharmacist,Belgium,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,5375751c-7fdd-4a02-89c5-4c389ac4eb27,insights_interaction,latest,,,2021-07-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01685,Royce Manning,,onco-eu-0022,Franz Huber,Ulton,Deadpool,Netherlands,,Strong correlation discovered between BRCA2 gene mutations and exceptional response rates to Wakanda. Patients with specific genetic profiles demonstrated 68% higher progression-free survival compared to control groups.
text,45121dbf-c5ed-4000-b709-8b30cc89af9c,insights_interaction,latest,,,2021-07-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01472,Anthony Benett,,onco-eu-0022,Franz Huber,Phone,Avenger,Switzerland,,Stable disease observed for over 6 months in a patient with recurrent glioblastoma following Vibranium/Wakanda treatment.
text,3396fd06-c5ad-4d2c-9383-10115019cb94,insights_interaction,latest,,,2021-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00855,Thelma Avery,,onco-eu-0022,Franz Huber,Ulton,X-Men,Switzerland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,367c15d2-78c1-41f6-8d4e-018481ebab92,insights_interaction,latest,,,2021-11-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01124,Vickie Strause,,onco-eu-0022,Franz Huber,Ulton,Avenger,Germany,,Patient-reported outcome metrics showed significant improvement in fatigue and pain scores compared to standard chemotherapy regimens
text,f7b6b76e-be22-4d2d-9c0b-fbd8c919c28c,insights_interaction,latest,,,2021-11-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01027,Robbie Lawson,,onco-eu-0022,Franz Huber,Phone,X-Men,Switzerland,,No significant unexpected adverse events reported in the majority of patients treated with Vibranium/Wakanda.
text,996a074c-2e68-4235-984e-647c23688801,insights_interaction,latest,,,2021-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01354,Allen Watkins,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Germany,,"Observed 47% objective response rate in metastatic solid tumors, significantly higher than standard treatment protocols"
text,fad95779-a777-4b55-9b1d-db8513081ed1,insights_interaction,latest,,,2021-12-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00934,Nina Kim,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Austria,,Improved physical functioning and reduced pain reported by a patient with osteosarcoma after Vibranium/Wakanda treatment.
text,a54f5b9d-df70-47e6-ae0d-f5065b9a8db8,insights_interaction,latest,,,2021-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01713,Lisa Ford,,onco-eu-0022,Franz Huber,Ulton,X-Men,Switzerland,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,0c56a1b0-011e-4bcd-959e-07cbba8afa9e,insights_interaction,latest,,,2021-12-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01826,Kevin Boros,,onco-eu-0022,Franz Huber,Iron Man,Clinical Pharmacist,Belgium,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,b16b4bd0-e093-4958-9d95-9735e78dbd8d,insights_interaction,latest,,,2021-12-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01450,Maria Tyler,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Germany,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,025f66ff-4a06-4a20-83db-99fa7092837f,insights_interaction,latest,,,2022-01-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01252,Coleen Murray,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Switzerland,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,6ad6e321-aeb9-46d7-9442-ba14c47beaf8,insights_interaction,latest,,,2022-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00881,Robert Young,,onco-eu-0022,Franz Huber,Iron Man,Avenger,Austria,,Most patients reported manageable side effects with minimal impact on daily activities.
text,c05e6bb2-1e11-4064-a0d2-34239f016c61,insights_interaction,latest,,,2022-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01253,Bernadette Carbone,,onco-eu-0022,Franz Huber,Ulton,X-Men,Switzerland,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,de480163-72e9-4cd3-9419-c43a086289a2,insights_interaction,latest,,,2022-03-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00987,James Callahan,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Switzerland,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,f8631ba2-5241-4f92-8215-2b436dc7362c,insights_interaction,latest,,,2022-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01450,Maria Tyler,,onco-eu-0022,Franz Huber,Phone,X-Men,Germany,,No unexpected adverse events were observed in the majority of patients.
text,c8829bf9-b739-492a-bf3a-51c14cad6f5a,insights_interaction,latest,,,2022-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01367,Scott Mitchell,,onco-eu-0022,Franz Huber,Ulton,X-Men,Belgium,,Stable disease observed in several patients with lung cancer after two cycles.
text,c6b46446-c9ff-451f-be7d-78a00db3c0bb,insights_interaction,latest,,,2022-08-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00937,Ali Silva,,onco-eu-0022,Franz Huber,Ulton,X-Men,Netherlands,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,fdd3e146-437a-4982-993c-c932e0e87a3e,insights_interaction,latest,,,2023-01-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01337,Daniel Marlow,,onco-eu-0022,Franz Huber,Phone,Wolverine,Netherlands,,Treatment administration is complex and requires specialized expertise.
text,1d502f7f-0bfb-4bb1-8afc-417efd8c71ed,insights_interaction,latest,,,2023-02-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01337,Daniel Marlow,,onco-eu-0022,Franz Huber,Ulton,Wolverine,Netherlands,,Most adverse events observed were manageable and reversible with supportive care.
text,2c7339db-fb87-4e83-b053-6405774a9bb4,insights_interaction,latest,,,2023-04-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01431,Robert Edelman,,onco-eu-0022,Franz Huber,Ulton,Deadpool,Switzerland,,"Infusion reactions were manageable in most patients, with pre-medication effectively mitigating symptoms."
text,76cec3bf-6b05-49a8-a4db-b16806406322,insights_interaction,latest,,,2023-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01176,Henry Schrecongost,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Belgium,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,a8aab336-3c0a-45f3-88be-3ec10e880f69,insights_interaction,latest,,,2023-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01027,Robbie Lawson,,onco-eu-0022,Franz Huber,Iron Man,X-Men,Switzerland,,Observed variability in response rates across different tumor types.  Better response observed in melanoma compared to colorectal cancer.
text,2fd11112-ff9d-4fb7-868b-5ef28f6dcabf,insights_interaction,latest,,,2023-05-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01949,Towanda Thomas,,onco-eu-0022,Franz Huber,Ulton,X-Men,Germany,,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,633f640e-0987-49b3-94e7-6d75c4b40383,insights_interaction,latest,,,2023-06-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01826,Kevin Boros,,onco-eu-0022,Franz Huber,Iron Man,Clinical Pharmacist,Belgium,,"Mild to moderate immune-related adverse events detected in 27% of patients, predominantly low-grade dermatitis and transient hepatic enzyme elevations"
text,2784534c-dcc1-4708-a006-7651a829215f,insights_interaction,latest,,,2023-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01370,Liana Jackson,,onco-eu-0022,Franz Huber,Iron Man,Avenger,Austria,,Limited efficacy observed in patients with heavily pretreated disease.
text,dfa3e19c-a80b-4a92-bd0e-865cd31c0eaa,insights_interaction,latest,,,2023-08-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01660,Robert Alas,,onco-eu-0022,Franz Huber,Iron Man,Deadpool,Belgium,,"Infusion-related reactions (IRR) were reported in 2% of patients, typically mild and manageable with premedication."
text,16225530-1b25-4e16-986f-2fe695fffe8e,insights_interaction,latest,,,2023-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01826,Kevin Boros,,onco-eu-0022,Franz Huber,Phone,Clinical Pharmacist,Belgium,,"Minimal neurotoxicity reported, with only 5% of patients experiencing mild peripheral neuropathy"
text,6a97bc77-54d5-47e0-8288-584a1c061f62,insights_interaction,latest,,,2024-12-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01792,Robert Bailey,,onco-eu-0022,Franz Huber,Iron Man,Wolverine,Austria,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,72c3d410-e118-4268-8735-823550b62c95,insights_interaction,latest,,,2021-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01240,Melody Smith,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Switzerland,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,257da2dc-3df2-42b9-8307-8c00c9fafbc2,insights_interaction,latest,,,2021-02-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01207,Susan Lindberg,,onco-eu-0039,Gabriella Ferrari,Phone,Avenger,Germany,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, accompanied by a significant improvement in CA 19-9 levels."
text,71fc1047-d1ed-41a5-8166-67e5c7e32001,insights_interaction,latest,,,2021-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01207,Susan Lindberg,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Germany,,Minimal cardiac toxicity and reduced treatment-related complications
text,ad0394e3-11ef-4409-bf10-304d7b416e95,insights_interaction,latest,,,2021-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01581,Charles Zepeda,,onco-eu-0039,Gabriella Ferrari,Phone,Avenger,Netherlands,,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,603d6df2-815c-4a4b-88e1-02023ef98113,insights_interaction,latest,,,2021-08-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01757,James Huland,,onco-eu-0039,Gabriella Ferrari,Ulton,Avenger,Switzerland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,727ccef8-11ce-4c77-a47e-918ad0aefeda,insights_interaction,latest,,,2021-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01240,Melody Smith,,onco-eu-0039,Gabriella Ferrari,Ulton,Avenger,Switzerland,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,31d00211-1a74-4e9b-bc40-758b8dd6fd90,insights_interaction,latest,,,2022-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00968,Monica Okoye,,onco-eu-0039,Gabriella Ferrari,Phone,X-Men,Switzerland,,Correlation observed between PD-L1 expression and response to Vibranium/Wakanda therapy.
text,3e684140-883a-42e5-abc5-b717002d7013,insights_interaction,latest,,,2022-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00944,Johnny Cooke,,onco-eu-0039,Gabriella Ferrari,Iron Man,X-Men,Austria,,We observed a correlation between early viral replication kinetics as measured by PCR and subsequent tumor response in patients receiving Vibranium/Wakanda. This may serve as a potential predictive biomarker for treatment efficacy.
text,81410697-46dd-41c0-9a06-488f834e9884,insights_interaction,latest,,,2023-03-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01293,Jessenia Calligan,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Germany,,Patients reported significantly reduced pain scores and improved functional status compared to standard chemotherapy regimens
text,8ddf831e-d54f-4986-9259-efc995b31b4f,insights_interaction,latest,,,2023-04-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01293,Jessenia Calligan,,onco-eu-0039,Gabriella Ferrari,Phone,Avenger,Germany,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,c596b9ac-169b-44bc-82e8-0846df35c018,insights_interaction,latest,,,2023-05-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01240,Melody Smith,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Switzerland,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,126ae8b6-8fa9-417b-8682-d767f9be790e,insights_interaction,latest,,,2023-06-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00807,Jane Ezzo,,onco-eu-0039,Gabriella Ferrari,Phone,X-Men,Switzerland,,Observed 42% objective response rate in metastatic solid tumor patients during phase II trial
text,2769cf8e-cb05-49c1-9f9b-c95d1d6515a5,insights_interaction,latest,,,2024-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01699,Stephanie Brock,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Belgium,,Early detection of response based on circulating tumor DNA analysis.
text,38ab4652-7e8c-4348-b210-0921baef97cc,insights_interaction,latest,,,2024-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01364,Amy Brice,,onco-eu-0039,Gabriella Ferrari,Phone,X-Men,Belgium,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,ac763567-9a42-4773-971f-17da5e3e7b2a,insights_interaction,latest,,,2024-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01977,Fredrick Schiefelbein,,onco-eu-0039,Gabriella Ferrari,Ulton,Avenger,Belgium,,Treatment response appears to be heterogeneous across different tumor types.
text,d8db3b1e-59f2-405c-9125-686e404c1d4d,insights_interaction,latest,,,2024-12-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01207,Susan Lindberg,,onco-eu-0039,Gabriella Ferrari,Iron Man,Avenger,Germany,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,dfb2d906-33fc-4594-8cec-1010a6655a7f,insights_interaction,latest,,,2021-05-28,MSL Interactions,Oncology,Vibranium,,WB-US-09744,Randy Willis,,onco-us-0031,George Campbell,Ulton,Avenger,United States,CA,Observed higher response rates in patients with microsatellite instability-high (MSI-H) tumors.
text,23d8b4f4-db1a-45a5-a27d-a5197edb9b3f,insights_interaction,latest,,,2021-06-22,MSL Interactions,Oncology,Vibranium,,WB-US-09871,Christopher Rhoda,,onco-us-0031,George Campbell,Phone,X-Men,United States,WA,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,b53f5214-1dc7-4f0f-9e88-2fde4e39ba52,insights_interaction,latest,,,2021-06-28,MSL Interactions,Oncology,Vibranium,,WB-US-09547,Charles Flint,,onco-us-0031,George Campbell,Ulton,Avenger,United States,UT,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,1a91fdbd-f6a1-4615-8cb7-1f96a351873b,insights_interaction,latest,,,2021-10-21,MSL Interactions,Oncology,Vibranium,,WB-US-09199,Lorraine Malcolm,,onco-us-0031,George Campbell,Iron Man,X-Men,United States,NV,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,83b2f301-6c3c-43f6-b901-2f7569ccedea,insights_interaction,latest,,,2021-11-01,MSL Interactions,Oncology,Vibranium,,WB-US-09221,Matthew Atwood,,onco-us-0031,George Campbell,Ulton,X-Men,United States,OR,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,8ea2156a-cd3e-4151-97e3-afab1a02bbb5,insights_interaction,latest,,,2021-12-19,MSL Interactions,Oncology,Vibranium,,WB-US-09901,Brandy Rone,,onco-us-0031,George Campbell,Phone,X-Men,United States,MT,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,b7dc416a-85bb-4d92-ab53-e6638db309aa,insights_interaction,latest,,,2023-01-12,MSL Interactions,Oncology,Vibranium,,WB-US-09268,John Dunn,,onco-us-0031,George Campbell,Phone,Wolverine,United States,AZ,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,840cbd28-473f-49d4-88ed-5167117d14ce,insights_interaction,latest,,,2023-10-04,MSL Interactions,Oncology,Vibranium,,WB-US-09324,Bradley Everett,,onco-us-0031,George Campbell,Phone,X-Men,United States,MT,Mixed patient-reported outcomes indicate personalized experience variability
text,a7e5bba7-b821-4408-8a5b-2d35ec890d58,insights_interaction,latest,,,2023-12-04,MSL Interactions,Oncology,Vibranium,,WB-US-09824,Orlando Landers,,onco-us-0031,George Campbell,Iron Man,X-Men,United States,AK,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,f953312a-c723-42b9-b88a-25d4eb2acac0,insights_interaction,latest,,,2024-01-29,MSL Interactions,Oncology,Vibranium,,WB-US-09395,Bruce White,,onco-us-0031,George Campbell,Ulton,Deadpool,United States,AZ,No objective response observed in patient with metastatic melanoma after three cycles of Vibranium/Wakanda. Disease progression noted on imaging.
text,3b269be6-8a30-4215-aedd-805864a839ae,insights_interaction,latest,,,2024-06-11,MSL Interactions,Oncology,Vibranium,,WB-US-09729,Arturo Dabney,,onco-us-0031,George Campbell,Iron Man,Clinical Pharmacist,United States,ID,Modest improvement in patient-reported symptom management compared to previous treatment regimens
text,551f1814-c89b-4231-8e4e-c5d143ae43fb,insights_interaction,latest,,,2024-09-12,MSL Interactions,Oncology,Vibranium,,WB-US-09268,John Dunn,,onco-us-0031,George Campbell,Iron Man,Wolverine,United States,AZ,"Minimal cardiac toxicity observed, with only 3.5% of patients experiencing subclinical troponin elevation"
text,d2fdd8be-3f14-473d-b6f8-3217883babb9,insights_interaction,latest,,,2021-02-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00239,Richard Ball,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Finland,,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,3d7ed01d-b6c6-40e1-b550-27ba9261251d,insights_interaction,latest,,,2021-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00433,Daniel James,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Norway,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,5cf7453e-e009-482e-8684-b64b3190c6cc,insights_interaction,latest,,,2021-03-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00211,Janet Felix,,onco-eu-0008,Gustav Nyström,Ulton,Wolverine,Sweden,,Promising results in treatment-resistant cancer subtypes
text,c12acfa1-1990-435e-949d-778c3c2546db,insights_interaction,latest,,,2021-04-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00788,John Bobeck,,onco-eu-0008,Gustav Nyström,Phone,Clinical Pharmacist,Finland,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,01cd902e-348d-4002-9b3b-4c0b42c3c95d,insights_interaction,latest,,,2021-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00490,Katie Mccabe,,onco-eu-0008,Gustav Nyström,Iron Man,Avenger,Norway,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,db7c3747-752e-440e-95a3-89b386fc594e,insights_interaction,latest,,,2021-12-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00671,Jerry Bostic,,onco-eu-0008,Gustav Nyström,Phone,X-Men,Denmark,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,d3ec3e00-5790-4d63-9951-9950e2589c60,insights_interaction,latest,,,2021-12-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00719,Polly Adams,,onco-eu-0008,Gustav Nyström,Phone,Deadpool,Norway,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,26719225-72ef-48b8-a670-b24fca389e0b,insights_interaction,latest,,,2022-04-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00001,William Beard,,onco-eu-0008,Gustav Nyström,Phone,Deadpool,Finland,,"Strong correlation identified between BRCA1/2 mutational status and enhanced therapeutic response, suggesting potential predictive biomarker"
text,2edf8a03-e589-4281-a8ba-90f3396e3d8e,insights_interaction,latest,,,2022-04-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00588,Janet Rodriguez,,onco-eu-0008,Gustav Nyström,Phone,X-Men,Norway,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,7219a64f-fa5c-471e-a49b-cfc0a5b3b11b,insights_interaction,latest,,,2022-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00549,Jeannette Hutchinson,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Sweden,,"Reduced infusion time compared to comparable immunotherapies, improving patient convenience"
text,f4c8b2a2-c499-43ed-8fdf-45a45623f981,insights_interaction,latest,,,2022-06-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00533,Ramiro Jacques,,onco-eu-0008,Gustav Nyström,Ulton,Wolverine,Finland,,"Significant improvement in patient-reported quality of life (QoL) scores using the EORTC QLQ-C30 questionnaire was noted in a subset of patients with metastatic melanoma treated with Vibranium/Wakanda. Improvements were particularly observed in fatigue, pain, and appetite scores, suggesting a beneficial impact beyond tumor response."
text,9435825a-107a-402f-a861-2361393ab12a,insights_interaction,latest,,,2022-10-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00631,Diane Behnke,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Norway,,Observed significant tumor regression in a patient with advanced pancreatic cancer after 8 weeks of Vibranium/Wakanda combination therapy.  Patient exhibited a 40% reduction in tumor volume as measured by CT scan.
text,0a5727da-5ac7-4716-a705-f819f6aa520d,insights_interaction,latest,,,2022-10-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00671,Jerry Bostic,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Denmark,,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,24f80086-40f2-4a7e-9ecd-08a9b29cbfd9,insights_interaction,latest,,,2022-11-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00499,David Kolodziej,,onco-eu-0008,Gustav Nyström,Iron Man,Wolverine,Sweden,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,1b53fa58-87c6-4ce1-badf-b3faae417069,insights_interaction,latest,,,2023-01-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00600,Jermaine Evans,,onco-eu-0008,Gustav Nyström,Ulton,Avenger,Norway,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,63167b91-1964-4761-8f99-390efcb03f1d,insights_interaction,latest,,,2023-03-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00236,Scott Glasco,,onco-eu-0008,Gustav Nyström,Iron Man,Wolverine,Sweden,,Synergistic effect observed when Vibranium/Wakanda is combined with immune checkpoint inhibitors.
text,00f7a58d-4f7f-4876-8e3a-1a5300d9a19b,insights_interaction,latest,,,2023-04-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00386,Anita Hansen,,onco-eu-0008,Gustav Nyström,Ulton,X-Men,Denmark,,Modest improvement in overall survival compared to standard treatment protocols
text,4a73fcba-46a1-4ca4-bf43-aa1dfaeec559,insights_interaction,latest,,,2023-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00236,Scott Glasco,,onco-eu-0008,Gustav Nyström,Iron Man,Wolverine,Sweden,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,f5a674fb-8b76-4412-8b44-a5ac2e0ec719,insights_interaction,latest,,,2023-07-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00062,Alfonzo Echevarria,,onco-eu-0008,Gustav Nyström,Phone,X-Men,Norway,,Enhanced long-term survival signals in patients with specific genomic alterations
text,8be72122-480f-4034-b8d7-c41421a9c102,insights_interaction,latest,,,2023-11-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00703,Chase Manchini,,onco-eu-0008,Gustav Nyström,Iron Man,Avenger,Denmark,,Overall quality of life remained stable for most patients.
text,282a0502-9c6b-4b71-8cfe-aaee326742ac,insights_interaction,latest,,,2024-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00211,Janet Felix,,onco-eu-0008,Gustav Nyström,Iron Man,Wolverine,Sweden,,Mild to moderate immune-related adverse events documented in patient records
text,51d14f4c-0cc7-45e0-a40e-1551f35b8a6e,insights_interaction,latest,,,2024-02-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00682,Stephen Fernandes,,onco-eu-0008,Gustav Nyström,Ulton,X-Men,Denmark,,No significant impact on quality of life observed in some patients with stable disease.
text,644351bc-1900-456f-b1fc-5aad0b789ce6,insights_interaction,latest,,,2024-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00369,Kyle Sanders,,onco-eu-0008,Gustav Nyström,Iron Man,X-Men,Finland,,"Observed differential response rates across age demographics, requiring nuanced treatment strategies"
text,9d51798e-1fd9-4c5e-b112-0552a61319df,insights_interaction,latest,,,2024-11-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00405,Monica Prieto,,onco-eu-0008,Gustav Nyström,Phone,X-Men,Denmark,,"Grade 1 fatigue and nausea observed in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,9af8feb4-d7d9-496d-b62e-4f6f14535e63,insights_interaction,latest,,,2021-03-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01126,John South,,onco-eu-0017,Hannah Mueller,Phone,Avenger,Switzerland,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,dab81623-3ee0-4b1c-949b-af619dd1713b,insights_interaction,latest,,,2021-12-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00922,Shannon Cox,,onco-eu-0017,Hannah Mueller,Iron Man,X-Men,Belgium,,"Correlation found between circulating tumor DNA levels and response to treatment, suggesting potential for early response prediction."
text,25761d5f-867e-481f-b289-c230e7bb381f,insights_interaction,latest,,,2022-02-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01188,Selena Peeden,,onco-eu-0017,Hannah Mueller,Iron Man,X-Men,Germany,,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,750cea0a-1b6e-4dcf-8e61-c6a006c5e2e8,insights_interaction,latest,,,2022-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01585,Earl Sanchez,,onco-eu-0017,Hannah Mueller,Iron Man,Avenger,Germany,,Enhanced treatment durability in patients with specific molecular profiles
text,eccf0555-56cd-4cc0-9292-f9423ee71bc0,insights_interaction,latest,,,2023-01-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01126,John South,,onco-eu-0017,Hannah Mueller,Ulton,Avenger,Switzerland,,"Varied response patterns observed across different age groups, suggesting potential age-related pharmacodynamic interactions."
text,13e9d494-1fa2-4434-bbca-2323ef5deaa0,insights_interaction,latest,,,2023-02-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01306,Anna Iacobelli,,onco-eu-0017,Hannah Mueller,Ulton,X-Men,Germany,,One patient experienced a Grade 3 cytokine release syndrome (CRS) requiring hospitalization and treatment with corticosteroids after receiving Vibranium/Wakanda.
text,61018c92-93eb-4a93-86b4-1efa0cf112b9,insights_interaction,latest,,,2023-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00922,Shannon Cox,,onco-eu-0017,Hannah Mueller,Ulton,X-Men,Belgium,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,8f3b4d0a-5a64-4ac9-b002-421d2ac3e5fa,insights_interaction,latest,,,2023-10-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01126,John South,,onco-eu-0017,Hannah Mueller,Phone,Avenger,Switzerland,,No significant changes in quality of life measures were observed in a small cohort of patients.
text,eaedc2f8-60e7-4437-9782-9ac39a96644a,insights_interaction,latest,,,2024-02-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01059,Sherry Rolon,,onco-eu-0017,Hannah Mueller,Iron Man,Avenger,Belgium,,"Preliminary phase II data shows 42% objective response rate in advanced metastatic solid tumors, with notable durable responses in patients previously refractory to standard therapies."
text,014e3fb8-1ed9-4720-b31a-db6c8dba05ad,insights_interaction,latest,,,2024-04-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01696,Roma Sanders,,onco-eu-0017,Hannah Mueller,Iron Man,X-Men,Belgium,,Treatment effectiveness varies across different cancer subtypes with mixed progression-free survival outcomes
text,357bcf40-4d27-4c83-844d-3d1485f67a2e,insights_interaction,latest,,,2024-06-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01636,Linda Wheeler,,onco-eu-0017,Hannah Mueller,Iron Man,X-Men,Switzerland,,Quality of life remained stable in a majority of patients despite disease progression.
text,20d2729a-d9c6-4aeb-b265-6149242baa95,insights_interaction,latest,,,2024-06-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01126,John South,,onco-eu-0017,Hannah Mueller,Iron Man,Avenger,Switzerland,,Treatment response appears to be heterogeneous across different tumor types.
text,c4ee5958-357e-4f94-b9c8-9d60dac94db5,insights_interaction,latest,,,2024-07-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01710,James Manley,,onco-eu-0017,Hannah Mueller,Phone,X-Men,Belgium,,Demonstrated 37% objective response rate in advanced metastatic solid tumors with minimal prior treatment resistance
text,6eda76a2-6eaf-4af5-82db-4a6535537169,insights_interaction,latest,,,2024-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00827,Jason Williams,,onco-eu-0017,Hannah Mueller,Ulton,X-Men,Netherlands,,High cost of therapy may limit accessibility for some patients.
text,1f356805-9568-42d6-b277-317ddd03b34e,insights_interaction,latest,,,2021-06-16,MSL Interactions,Oncology,Vibranium,,WB-US-09315,Charles Batt,,onco-us-0037,Helen Rodriguez,Ulton,Avenger,United States,MT,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,624006bb-cf2c-40c1-9d17-cda077f7d062,insights_interaction,latest,,,2021-06-29,MSL Interactions,Oncology,Vibranium,,WB-US-09385,Pamela Howard,,onco-us-0037,Helen Rodriguez,Phone,Deadpool,United States,CO,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,60f0683f-257f-4d1f-9227-27e3625c559c,insights_interaction,latest,,,2021-10-25,MSL Interactions,Oncology,Vibranium,,WB-US-09213,Paul Silva,,onco-us-0037,Helen Rodriguez,Ulton,X-Men,United States,CA,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,f20172bd-63bc-400e-8903-e9644c705810,insights_interaction,latest,,,2022-02-16,MSL Interactions,Oncology,Vibranium,,WB-US-09468,Jennifer Parker,,onco-us-0037,Helen Rodriguez,Ulton,X-Men,United States,ID,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,3f0b4107-5bf0-404b-a5b9-490588295b8b,insights_interaction,latest,,,2022-03-17,MSL Interactions,Oncology,Vibranium,,WB-US-09809,Matthew Mcbride,,onco-us-0037,Helen Rodriguez,Iron Man,Wolverine,United States,WY,"Observed stable disease for 6 months in a patient with metastatic melanoma following Vibranium/Wakanda treatment, exceeding initial expectations."
text,2406e6af-5086-4a03-8a1d-bfd2c72334ca,insights_interaction,latest,,,2022-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-09913,Sarah Williams,,onco-us-0037,Helen Rodriguez,Ulton,Avenger,United States,AK,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,fab146e7-1507-4465-9d6c-6181d21fe0cc,insights_interaction,latest,,,2022-05-15,MSL Interactions,Oncology,Vibranium,,WB-US-09387,Katharine Ambrose,,onco-us-0037,Helen Rodriguez,Phone,X-Men,United States,ID,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,25c1753b-e28e-4c73-bd8a-7e9acadbc672,insights_interaction,latest,,,2022-06-09,MSL Interactions,Oncology,Vibranium,,WB-US-09750,Chong Thomas,,onco-us-0037,Helen Rodriguez,Ulton,Deadpool,United States,AZ,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,7cc4af41-56cb-484c-a97b-040fa3949dac,insights_interaction,latest,,,2022-09-17,MSL Interactions,Oncology,Vibranium,,WB-US-09320,Ruby Lopez,,onco-us-0037,Helen Rodriguez,Ulton,X-Men,United States,WY,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response (PR) after 2 cycles of Vibranium/Wakanda therapy, with a significant reduction in tumor size and improved CA 19-9 levels.  This is noteworthy given the patient's prior resistance to standard chemotherapeutic regimens."
text,df08f68c-b073-46a8-bb8d-f9c2831a97bd,insights_interaction,latest,,,2022-11-30,MSL Interactions,Oncology,Vibranium,,WB-US-09878,Fred Berger,,onco-us-0037,Helen Rodriguez,Iron Man,X-Men,United States,AK,"Increased levels of IFN-γ and other pro-inflammatory cytokines observed in serum samples after Vibranium/Wakanda administration, suggesting an immune response."
text,3eae95a3-ab89-4bec-95c0-3939261d0431,insights_interaction,latest,,,2024-02-10,MSL Interactions,Oncology,Vibranium,,WB-US-09598,Paul Mestler,,onco-us-0037,Helen Rodriguez,Phone,Avenger,United States,CA,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,91ed3f04-c37f-42b3-a4ca-4905f95258a3,insights_interaction,latest,,,2024-02-18,MSL Interactions,Oncology,Vibranium,,WB-US-09723,Jean Hackett,,onco-us-0037,Helen Rodriguez,Ulton,X-Men,United States,NM,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,800cd15d-52a3-45b3-95a7-eb116ddd9b2a,insights_interaction,latest,,,2024-07-15,MSL Interactions,Oncology,Vibranium,,WB-US-09468,Jennifer Parker,,onco-us-0037,Helen Rodriguez,Iron Man,X-Men,United States,ID,Moderate treatment response with variability across different patient cohorts
text,0062ea96-61ac-44e2-83d1-fca65f8551ca,insights_interaction,latest,,,2024-10-18,MSL Interactions,Oncology,Vibranium,,WB-US-09630,Edward Steely,,onco-us-0037,Helen Rodriguez,Iron Man,Avenger,United States,NV,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,4fadcd98-db04-4add-ada3-203904eaef57,insights_interaction,latest,,,2024-10-30,MSL Interactions,Oncology,Vibranium,,WB-US-09639,Margaret Fass,,onco-us-0037,Helen Rodriguez,Iron Man,X-Men,United States,ID,"Immunogenic side effects manageable with standard corticosteroid interventions, with only 8% of patients requiring extended immunosuppressive management."
text,4974b265-6d22-4968-b24a-48bde5d930a1,insights_interaction,latest,,,2024-11-15,MSL Interactions,Oncology,Vibranium,,WB-US-09931,Danny Anderson,,onco-us-0037,Helen Rodriguez,Ulton,Avenger,United States,NM,No significant changes in patient-reported quality of life measures during the first month of therapy.
text,277bbd84-3dc6-40b9-bd6f-8210c25d9910,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-US-09646,Donald Kain,,onco-us-0037,Helen Rodriguez,Ulton,Avenger,United States,CA,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,46080c31-5ea2-4c25-9ea8-6e72d6fb2f43,insights_interaction,latest,,,2021-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00766,Kimberly Biermann,,onco-eu-0006,Henrik Larsson,Phone,Wolverine,Sweden,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,e142d801-341d-4bfe-be65-71889aef4417,insights_interaction,latest,,,2021-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00443,Maria Dixson,,onco-eu-0006,Henrik Larsson,Iron Man,Wolverine,Finland,,No significant long-term immunological complications detected in 24-month follow-up study
text,ce72b52c-34fd-454b-88ea-62af2bc7ad85,insights_interaction,latest,,,2021-07-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00087,Melissa Smith,,onco-eu-0006,Henrik Larsson,Phone,X-Men,Norway,,Significant tumor size reduction in 62% of non-small cell lung cancer patients
text,97b62627-038e-4ab2-ba02-e67f129791bd,insights_interaction,latest,,,2021-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00668,Sharon Monaco,,onco-eu-0006,Henrik Larsson,Phone,Avenger,Norway,,Correlation observed between high baseline levels of a specific cytokine and improved response to Vibranium/Wakanda.
text,09e6bde6-588c-4739-a3d0-86f88e9a73e6,insights_interaction,latest,,,2021-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00681,Melvin Wickersham,,onco-eu-0006,Henrik Larsson,Phone,Clinical Pharmacist,Denmark,,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,719c3d37-06c7-4035-a0d8-8d974864ad05,insights_interaction,latest,,,2021-11-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00697,William Bamford,,onco-eu-0006,Henrik Larsson,Iron Man,X-Men,Denmark,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,0ea094ec-2b2f-4490-9fbb-f9f00c1b066a,insights_interaction,latest,,,2021-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00341,Robert Zapata,,onco-eu-0006,Henrik Larsson,Ulton,Avenger,Norway,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,5869a0e7-777d-42a8-b741-846da4ed33c2,insights_interaction,latest,,,2023-01-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00424,Angela Polowy,,onco-eu-0006,Henrik Larsson,Ulton,X-Men,Norway,,No significant changes in quality of life measures were observed in a small cohort of patients.
text,e872c836-87cd-4a5a-ac6a-00aa2b1fefe0,insights_interaction,latest,,,2023-06-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00561,Steven Banks,,onco-eu-0006,Henrik Larsson,Iron Man,X-Men,Finland,,"Treatment administration requires specialized expertise, potentially limiting accessibility in certain settings."
text,2b337175-45b5-4b0d-92e2-14564328450a,insights_interaction,latest,,,2023-07-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00589,Eduardo Wilmot,,onco-eu-0006,Henrik Larsson,Ulton,Avenger,Sweden,,Treatment requires careful patient selection and comprehensive genetic profiling
text,88c74fdc-fa1c-4c44-a6c1-f5e603f7fe32,insights_interaction,latest,,,2023-07-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00732,David Samuels,,onco-eu-0006,Henrik Larsson,Phone,Deadpool,Finland,,"Longer treatment duration appears to correlate with increased efficacy, but this needs further investigation."
text,fcd29620-535e-4904-a6d0-cd68b2078cc1,insights_interaction,latest,,,2023-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00619,David Lucas,,onco-eu-0006,Henrik Larsson,Phone,X-Men,Sweden,,Increased risk of hepatic transaminase elevation observed in 15% of patients requiring dose modification
text,70628b53-f983-4da8-8358-ca1ae3ab18ee,insights_interaction,latest,,,2023-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00092,Bonnie Flowers,,onco-eu-0006,Henrik Larsson,Iron Man,Avenger,Sweden,,"Mild flu-like symptoms were reported in most patients during the initial phase of Vibranium/Wakanda treatment, resolving within 72 hours with supportive care."
text,5433a0a7-f126-4ebc-9b7a-06c589125653,insights_interaction,latest,,,2023-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00619,David Lucas,,onco-eu-0006,Henrik Larsson,Iron Man,X-Men,Sweden,,"Challenges in administering Vibranium/Wakanda due to its complex delivery method were noted, requiring specialized training and equipment."
text,edcf6962-7eb5-456d-9853-699d389510ec,insights_interaction,latest,,,2024-02-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00299,Sharon Monreal,,onco-eu-0006,Henrik Larsson,Ulton,X-Men,Norway,,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,27a526b9-17a7-4ad0-a34c-5dd9dc329567,insights_interaction,latest,,,2024-07-31,MSL Interactions,Oncology,Vibranium,,WB-EU-00589,Eduardo Wilmot,,onco-eu-0006,Henrik Larsson,Iron Man,Avenger,Sweden,,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,97435f54-1704-45a4-a8a0-80d42b32fa1e,insights_interaction,latest,,,2024-09-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00087,Melissa Smith,,onco-eu-0006,Henrik Larsson,Ulton,X-Men,Norway,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,c7919aa6-fa02-4907-bac6-3cedf09abf73,insights_interaction,latest,,,2021-03-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00714,Judy Reyes,,onco-eu-0011,Ingrid Holm,Ulton,X-Men,Sweden,,EORTC QLQ-C30 scores showed significant improvement in overall functional status during treatment
text,03e28f03-d867-4b25-9e85-b2476665d1db,insights_interaction,latest,,,2021-03-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00152,Scott Guerra,,onco-eu-0011,Ingrid Holm,Phone,Deadpool,Sweden,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,099d7e99-7fad-4581-ab99-8567fa5ae2e9,insights_interaction,latest,,,2021-04-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00108,Stephen Taylor,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Finland,,Cost-effectiveness shows potential for reducing overall treatment expenditure by 22% compared to combination therapies
text,1735c2b7-1310-4d5a-9909-9e56c8e402dd,insights_interaction,latest,,,2021-07-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00508,Nancy Thibadeau,,onco-eu-0011,Ingrid Holm,Iron Man,Avenger,Denmark,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,8d17256d-91ae-4468-b386-19d1f73a9568,insights_interaction,latest,,,2021-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00346,James Cameron,,onco-eu-0011,Ingrid Holm,Phone,Avenger,Finland,,Reduction in pain levels reported by patients with bone metastases.
text,e1d577f3-1108-4101-9a1d-fff95bc9ecee,insights_interaction,latest,,,2021-10-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00624,Jason Holben,,onco-eu-0011,Ingrid Holm,Iron Man,X-Men,Denmark,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,5ef676a2-c5e7-49fb-80c1-76a5a85e22e6,insights_interaction,latest,,,2022-05-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00300,Jeffrey Coutee,,onco-eu-0011,Ingrid Holm,Ulton,Clinical Pharmacist,Finland,,"Observed 62% objective response rate in metastatic solid tumors with high PD-L1 expression, particularly in non-small cell lung cancer patients"
text,4df14365-c21e-4bb8-a6f3-f2a22beb6718,insights_interaction,latest,,,2022-05-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00358,Jose Belanger,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Finland,,Patients reported improved appetite and reduced pain levels following Vibranium/Wakanda therapy.
text,42411032-4512-4363-b8b9-bb427b91693a,insights_interaction,latest,,,2022-06-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00144,Richard Veile,,onco-eu-0011,Ingrid Holm,Iron Man,Clinical Pharmacist,Sweden,,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors treated with Vibranium/Wakanda compared to those with microsatellite stable (MSS) tumors.  This suggests a potential predictive biomarker for treatment response.
text,df330faa-45b5-4591-ad90-95b040f70783,insights_interaction,latest,,,2023-01-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00162,Fred Mayberry,,onco-eu-0011,Ingrid Holm,Iron Man,X-Men,Denmark,,"Increased incidence of hepatic toxicity observed in a subset of patients receiving Vibranium/Wakanda, necessitating close monitoring of liver function."
text,411b490a-e9d6-4209-8e45-76f04e39c833,insights_interaction,latest,,,2023-03-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00365,George Grimes,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Norway,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,a1fcbf34-0189-408c-b6ca-8aca9d73fb82,insights_interaction,latest,,,2023-06-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00083,Steven Jamal,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Denmark,,Improved patient-reported outcomes regarding pain and appetite observed in a subset of patients treated with Vibranium/Wakanda.
text,2513aeaa-bd07-49b9-bdbc-419701ba99af,insights_interaction,latest,,,2023-07-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00014,Peter Miller,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Sweden,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,4ca2da1f-4639-425a-b557-246bd2f920ac,insights_interaction,latest,,,2023-07-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00733,Barbara Allen,,onco-eu-0011,Ingrid Holm,Iron Man,Avenger,Norway,,Strong correlation between PD-L1 expression >50% and improved treatment response
text,9f1df564-35b5-4e8f-bb3c-d177ce4bd012,insights_interaction,latest,,,2023-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00238,Julie Gallogly,,onco-eu-0011,Ingrid Holm,Iron Man,X-Men,Denmark,,Treatment requires intravenous administration and frequent monitoring.
text,37483974-918e-4209-bb8a-453494cbb971,insights_interaction,latest,,,2023-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00227,Florence Mincey,,onco-eu-0011,Ingrid Holm,Ulton,Avenger,Norway,,Treatment regimen was well-tolerated by most patients with minimal interruptions.
text,62af8136-b042-435a-b6f2-74ae122af2df,insights_interaction,latest,,,2024-01-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00161,Harry Hudson,,onco-eu-0011,Ingrid Holm,Phone,Avenger,Norway,,Significant disease stabilization observed in a patient with metastatic melanoma after 3 months of treatment.
text,27103f69-3f41-43b0-95e7-cdcdb792c9f7,insights_interaction,latest,,,2024-09-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00365,George Grimes,,onco-eu-0011,Ingrid Holm,Phone,X-Men,Norway,,No clear correlation was found between age and response to Vibranium/Wakanda.
text,d90be587-835f-4879-91ff-104732b6386f,insights_interaction,latest,,,2023-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00818,Lora Whelpley,,onco-eu-0032,Isabella Romano,Phone,X-Men,Austria,,Observed significant tumor reduction in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.  One patient achieved complete remission.
text,6c39ba55-1ec0-4545-bf46-111cb2d926dc,insights_interaction,latest,,,2023-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01277,William Miller,,onco-eu-0032,Isabella Romano,Ulton,Deadpool,Netherlands,,Stable disease observed in several patients with lung cancer after two cycles.
text,00389c43-531f-4024-a853-0b979a822e9d,insights_interaction,latest,,,2023-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01300,Thomas Lewis,,onco-eu-0032,Isabella Romano,Ulton,Avenger,Belgium,,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,781017d1-85a1-45a4-b8bf-21457d7a7721,insights_interaction,latest,,,2023-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01638,Myrna Smith,,onco-eu-0032,Isabella Romano,Phone,Avenger,Austria,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,d5e2807f-cc3e-4ede-911a-dedb7d66632c,insights_interaction,latest,,,2023-12-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00864,Joe Eberhardt,,onco-eu-0032,Isabella Romano,Phone,Clinical Pharmacist,Austria,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,4cf55f0e-8de8-4ce1-94f3-ba111503cb16,insights_interaction,latest,,,2024-02-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01560,Linda Gentner,,onco-eu-0032,Isabella Romano,Iron Man,Avenger,Switzerland,,Complete response observed in three patients with rare BRCA-mutated ovarian cancer subtypes
text,1bf7206a-02ad-4cf0-b84d-14c38a26bb4c,insights_interaction,latest,,,2024-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01763,Cindi Thomas,,onco-eu-0032,Isabella Romano,Ulton,X-Men,Germany,,Longer progression-free survival observed in patients with lower tumor mutational burden.
text,36176c63-5173-4c11-b29e-e23ce9c57882,insights_interaction,latest,,,2024-04-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01250,Matthew Hill,,onco-eu-0032,Isabella Romano,Ulton,Deadpool,Austria,,"Mild fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,ee8bc23a-b248-4695-9279-6ab4c9c0b708,insights_interaction,latest,,,2024-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00831,Doris Kelly,,onco-eu-0032,Isabella Romano,Ulton,Deadpool,Switzerland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,acab15a9-f67d-4471-a374-750d509a4fe2,insights_interaction,latest,,,2021-01-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02875,Tiffany Clarke,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Italy,,Early detection of response based on circulating tumor DNA analysis.
text,88b40f05-84ae-47e9-a8dd-04f7af7e8058,insights_interaction,latest,,,2021-01-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02098,Cheryl Garvin,,onco-eu-0052,Isabelle Rousseau,Iron Man,Deadpool,Spain,,"Strong correlation identified between BRCA1/2 mutational status and enhanced therapeutic response, suggesting potential predictive biomarker"
text,5bcbdec8-d923-447a-86d6-39f8f8b141ae,insights_interaction,latest,,,2021-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02234,Robert Sawchuk,,onco-eu-0052,Isabelle Rousseau,Iron Man,Wolverine,Spain,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,cbb37069-2b12-48bb-8ac2-5d4adeca4a52,insights_interaction,latest,,,2022-04-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02733,James Terry,,onco-eu-0052,Isabelle Rousseau,Ulton,Avenger,Ragnarok,,Enhanced efficacy observed in immunologically 'hot' tumor microenvironments with high T-cell infiltration
text,894f1cb2-2c36-43b8-ac0c-1d2d488bf32b,insights_interaction,latest,,,2022-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02285,Jon Foor,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Ragnarok,,Complete response achieved in 12% of heavily pre-treated patients
text,928ce708-7a17-49d1-9946-dc220fcfc471,insights_interaction,latest,,,2022-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02984,Mildred Zaldana,,onco-eu-0052,Isabelle Rousseau,Phone,Avenger,Spain,,"Increased expression of PD-L1 was noted in tumor biopsies post-treatment, suggesting a potential synergy with immune checkpoint inhibitors."
text,2faa461b-cb32-448e-a968-b66042705ceb,insights_interaction,latest,,,2022-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02234,Robert Sawchuk,,onco-eu-0052,Isabelle Rousseau,Phone,Wolverine,Spain,,"Improved patient-reported quality of life scores (using EORTC QLQ-C30) observed in patients with advanced lung cancer receiving Vibranium/Wakanda, particularly in fatigue and dyspnea domains."
text,2ea8bec1-c0c7-42d8-b5bc-10ecb30ed219,insights_interaction,latest,,,2022-08-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02362,Verdell Updike,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Italy,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,e1e1fcc2-d69c-4a2c-a9cb-ca1327e55736,insights_interaction,latest,,,2022-11-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02380,David Dayley,,onco-eu-0052,Isabelle Rousseau,Phone,X-Men,Ragnarok,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,b35ea0db-bb77-467e-a527-3b0d919fed2d,insights_interaction,latest,,,2023-01-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02098,Cheryl Garvin,,onco-eu-0052,Isabelle Rousseau,Iron Man,Deadpool,Spain,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,14bc9112-021d-41d0-baf8-599da6b9dc68,insights_interaction,latest,,,2023-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02077,Gloria Washinski,,onco-eu-0052,Isabelle Rousseau,Iron Man,Deadpool,Ragnarok,,"Patient experienced grade 2 fatigue and nausea, resolving with supportive care.  No dose reduction was necessary."
text,e4424b06-035e-434e-9a8d-14afdda822ce,insights_interaction,latest,,,2023-05-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02492,Deanne Evans,,onco-eu-0052,Isabelle Rousseau,Iron Man,X-Men,Spain,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,02c6c1da-1111-4fbb-a1d9-3370dca3f5da,insights_interaction,latest,,,2023-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02730,Crystal Carter,,onco-eu-0052,Isabelle Rousseau,Iron Man,X-Men,Italy,,"Response to Vibranium/Wakanda varied among patients, with some exhibiting complete remission while others showed stable disease."
text,54463338-641f-4f3e-879c-d8c85483393b,insights_interaction,latest,,,2023-08-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02719,Robert Sthilaire,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Italy,,"Patient with advanced pancreatic cancer (PDAC) exhibiting stable disease for 8 months following Vibranium/Wakanda therapy.  Initial tumor size reduction of 25% was observed after the first 3 cycles, followed by stabilization.  Patient maintained a good performance status (ECOG 1) throughout the treatment period, with minimal adverse events."
text,3df1d1e5-41ff-4474-af53-480e6657f514,insights_interaction,latest,,,2023-08-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02380,David Dayley,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Ragnarok,,Median progression-free survival of 5.7 months in advanced stage cancer patients
text,be165973-6fae-4a1c-899e-639f37125abe,insights_interaction,latest,,,2023-09-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02492,Deanne Evans,,onco-eu-0052,Isabelle Rousseau,Iron Man,X-Men,Spain,,Patient reported improved appetite and energy levels following the first cycle of Vibranium/Wakanda.  Improved QoL scores correlated with tumor shrinkage.
text,8d437e5f-19cb-46db-8787-8304b3647e9a,insights_interaction,latest,,,2024-02-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02223,Cheryl Jones,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Ragnarok,,"Decreased levels of certain immune cells observed in some patients, requiring further investigation."
text,104fbcfc-a76a-4ae7-8187-0ad9f784fba3,insights_interaction,latest,,,2024-03-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02285,Jon Foor,,onco-eu-0052,Isabelle Rousseau,Iron Man,X-Men,Ragnarok,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,0ce49e4d-7e7f-434f-9ce1-f3a0dc1fe0ec,insights_interaction,latest,,,2024-09-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02848,Matthew Mclain,,onco-eu-0052,Isabelle Rousseau,Iron Man,X-Men,Italy,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,7376b24a-fa89-4e3d-88fe-f611638fc4af,insights_interaction,latest,,,2024-10-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02508,Maria Ennenga,,onco-eu-0052,Isabelle Rousseau,Ulton,Avenger,Italy,,"Improved patient-reported quality of life scores (FACT-G) observed in several patients treated with Vibranium/Wakanda, particularly in terms of physical well-being and fatigue."
text,e83cc484-85aa-48f6-a23f-900ad1912d14,insights_interaction,latest,,,2024-12-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02875,Tiffany Clarke,,onco-eu-0052,Isabelle Rousseau,Ulton,X-Men,Italy,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,0e1d35f3-b73c-43d4-9fac-0739ac427a5d,insights_interaction,latest,,,2021-01-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03097,Lisa Duke,,onco-eu-0068,Ivan Petrovic,Phone,Avenger,United Kingdom,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,33d67caa-c2cf-488d-a1f3-5a81ef08f398,insights_interaction,latest,,,2021-02-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03579,Victor Mcreynolds,,onco-eu-0068,Ivan Petrovic,Iron Man,X-Men,Ireland,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,811a13f0-874c-4ca7-94b4-de89a7d9cb81,insights_interaction,latest,,,2021-04-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03097,Lisa Duke,,onco-eu-0068,Ivan Petrovic,Iron Man,Avenger,United Kingdom,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,615aa089-d581-4974-808b-31f66f57538a,insights_interaction,latest,,,2021-05-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03973,Jeffrey Campbell,,onco-eu-0068,Ivan Petrovic,Ulton,Avenger,France,,Durable responses observed in a subset of patients with advanced head and neck cancer.
text,63b85cfe-5d7a-4582-8278-49f66d3d07b1,insights_interaction,latest,,,2021-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03256,Pauline Hedgepeth,,onco-eu-0068,Ivan Petrovic,Iron Man,X-Men,France,,"Increased expression of interferon-gamma and other pro-inflammatory cytokines detected in tumor biopsies from patients responding to Vibranium/Wakanda therapy, suggesting a robust immune response."
text,a8f66ba9-6928-4403-a033-e51538c9fd1b,insights_interaction,latest,,,2022-03-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03996,Venetta Stermer,,onco-eu-0068,Ivan Petrovic,Ulton,X-Men,United Kingdom,,Demonstrated statistically significant tumor reduction of 43% in metastatic breast cancer patients with HER2-negative profiles during phase II trial
text,44c811f6-94f1-4e9c-a3b0-926e02dac90f,insights_interaction,latest,,,2022-03-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03045,John Obrien,,onco-eu-0068,Ivan Petrovic,Ulton,Avenger,France,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,2288f23b-9243-4c2e-a4c3-974af95b3c5a,insights_interaction,latest,,,2022-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03243,John Berry,,onco-eu-0068,Ivan Petrovic,Phone,Clinical Pharmacist,France,,"Promising results in combination with existing standard-of-care therapies, suggesting potential synergistic mechanisms"
text,ea38946d-a3e3-4f54-98e6-1a34f7772986,insights_interaction,latest,,,2022-05-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03579,Victor Mcreynolds,,onco-eu-0068,Ivan Petrovic,Phone,X-Men,Ireland,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,51e0fe76-dc6e-4fe4-a432-c01f23fd75a8,insights_interaction,latest,,,2022-08-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03045,John Obrien,,onco-eu-0068,Ivan Petrovic,Phone,Avenger,France,,Promising preliminary results observed in a small cohort of patients with recurrent glioblastoma.
text,d1f83a52-72d8-4be1-be05-7669cfb53c48,insights_interaction,latest,,,2022-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03693,William Williamson,,onco-eu-0068,Ivan Petrovic,Ulton,Avenger,France,,Patients reported significant reduction in pain and improved functional status after 8 weeks of treatment
text,67a2c870-e619-44ec-9ba0-6e2881b904ce,insights_interaction,latest,,,2022-11-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03082,William Fannell,,onco-eu-0068,Ivan Petrovic,Ulton,Wolverine,Ireland,,Strong correlation between PD-L1 expression >50% and improved progression-free survival
text,acc1aa6d-c550-4119-aac9-f79b457313c9,insights_interaction,latest,,,2023-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03203,Delores Goan,,onco-eu-0068,Ivan Petrovic,Ulton,Avenger,Ireland,,Administration of Vibranium requires specialized training and infrastructure due to its unique delivery method.
text,446ece78-e212-4608-b12f-b4dd6e647fd6,insights_interaction,latest,,,2023-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03203,Delores Goan,,onco-eu-0068,Ivan Petrovic,Ulton,Avenger,Ireland,,Treatment administration is complex and requires specialized expertise.
text,777515a7-870e-44b9-a682-940578fa5902,insights_interaction,latest,,,2023-06-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03406,Thelma Gellert,,onco-eu-0068,Ivan Petrovic,Ulton,Clinical Pharmacist,Ireland,,Increased expression of PD-L1 in tumor biopsies after 2 cycles of Vibranium/Wakanda suggests potential synergy with checkpoint inhibitors.
text,b2aec9d2-59b7-4b5e-8f08-19288c5255b1,insights_interaction,latest,,,2023-08-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03008,Roberta Dias,,onco-eu-0068,Ivan Petrovic,Phone,Deadpool,Ireland,,The need for frequent monitoring and adjustments to the treatment regimen increases the complexity and cost of Vibranium/Wakanda therapy.
text,e2393238-d06d-4b00-a455-d9d4fbbfe80a,insights_interaction,latest,,,2023-09-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03251,Allie Fancher,,onco-eu-0068,Ivan Petrovic,Ulton,Deadpool,Ireland,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,b6e64784-681b-44af-92e3-e7c84d987279,insights_interaction,latest,,,2024-01-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03562,Christopher Miller,,onco-eu-0068,Ivan Petrovic,Ulton,Deadpool,France,,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,a0106de2-0ce5-428a-827a-155ab0376bc8,insights_interaction,latest,,,2024-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03975,Daniel Heidel,,onco-eu-0068,Ivan Petrovic,Ulton,X-Men,United Kingdom,,"Decreased levels of certain immune cells observed in some patients, requiring further investigation."
text,d28ad874-82e8-44e9-a485-c3aeedf7629a,insights_interaction,latest,,,2024-12-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03975,Daniel Heidel,,onco-eu-0068,Ivan Petrovic,Phone,X-Men,United Kingdom,,"High treatment cost and complex administration protocol may limit broader clinical implementation, particularly in resource-constrained healthcare settings."
text,fdccaf26-e884-4e36-bbe1-20f8e2ef80d2,insights_interaction,latest,,,2021-01-11,MSL Interactions,Oncology,Vibranium,,WB-US-00956,Thomas Thompson,,onco-us-0005,James Wilson,Phone,Avenger,United States,ME,"Promising early-stage results in combination with checkpoint inhibitors, showing synergistic anti-tumor effects"
text,3eb57df9-2bd3-4d09-a62a-b97187c35e54,insights_interaction,latest,,,2021-03-20,MSL Interactions,Oncology,Vibranium,,WB-US-02053,Leonard Lowry,,onco-us-0005,James Wilson,Phone,Deadpool,United States,RI,Patients reported significant reduction in cancer-related fatigue compared to standard therapies
text,8fff3d3e-3c80-46c0-a028-e6feb0f33dd7,insights_interaction,latest,,,2021-04-01,MSL Interactions,Oncology,Vibranium,,WB-US-01596,Helen Terry,,onco-us-0005,James Wilson,Ulton,X-Men,United States,RI,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,b94eb773-c2a0-45d7-9e99-dfce649e986b,insights_interaction,latest,,,2021-09-02,MSL Interactions,Oncology,Vibranium,,WB-US-00423,Hazel Roberts,,onco-us-0005,James Wilson,Ulton,Avenger,United States,ME,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,7404a643-c058-4baa-b65d-c8a28dbe0659,insights_interaction,latest,,,2022-02-06,MSL Interactions,Oncology,Vibranium,,WB-US-02734,Anthony Denley,,onco-us-0005,James Wilson,Ulton,X-Men,United States,NY,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,f1130bf5-83b4-42b6-b557-d90a2961a824,insights_interaction,latest,,,2022-04-05,MSL Interactions,Oncology,Vibranium,,WB-US-01457,Patsy Mount,,onco-us-0005,James Wilson,Iron Man,Deadpool,United States,MA,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,0b59cf90-384e-45c2-bef6-d52958e6b413,insights_interaction,latest,,,2022-12-23,MSL Interactions,Oncology,Vibranium,,WB-US-01837,Jeffrey Steed,,onco-us-0005,James Wilson,Ulton,Avenger,United States,NY,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,046e4342-296b-4e0e-8f2b-732395d653c9,insights_interaction,latest,,,2022-12-28,MSL Interactions,Oncology,Vibranium,,WB-US-00183,Micheal Holcomb,,onco-us-0005,James Wilson,Ulton,X-Men,United States,ME,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,7ceb8561-8320-44ca-a182-62a5b0beb0d0,insights_interaction,latest,,,2023-03-16,MSL Interactions,Oncology,Vibranium,,WB-US-00933,Eleanor Legg,,onco-us-0005,James Wilson,Iron Man,X-Men,United States,RI,"Response rates vary by cancer subtype, with lung adenocarcinoma showing most consistent treatment response"
text,8c62a335-051f-4fa4-92e9-dbc586e5096c,insights_interaction,latest,,,2023-04-30,MSL Interactions,Oncology,Vibranium,,WB-US-01591,Adriana Swanson,,onco-us-0005,James Wilson,Phone,Deadpool,United States,NY,Complex dosing regimen requires careful patient education and adherence.
text,efbb6f2b-a2b3-4ce3-9fef-1256e7a3d162,insights_interaction,latest,,,2023-05-15,MSL Interactions,Oncology,Vibranium,,WB-US-01019,David Heavilin,,onco-us-0005,James Wilson,Ulton,Avenger,United States,CT,"Promising early-stage results in combination with checkpoint inhibitors, showing synergistic anti-tumor effects"
text,aae3e62f-1652-4bd3-aae7-b747c013aa1b,insights_interaction,latest,,,2023-08-06,MSL Interactions,Oncology,Vibranium,,WB-US-00501,Steven Garvie,,onco-us-0005,James Wilson,Ulton,X-Men,United States,ME,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,c2f180c2-860d-4c31-b38f-4917f71e8073,insights_interaction,latest,,,2023-11-01,MSL Interactions,Oncology,Vibranium,,WB-US-00956,Thomas Thompson,,onco-us-0005,James Wilson,Phone,Avenger,United States,ME,Grade 1 fatigue and nausea were reported in two patients receiving the combination therapy.  Symptoms resolved with supportive care.
text,844554a7-e06d-49d7-9201-dfa4f335527f,insights_interaction,latest,,,2024-02-11,MSL Interactions,Oncology,Vibranium,,WB-US-01118,Risa Gorman,,onco-us-0005,James Wilson,Phone,Wolverine,United States,NY,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,ec8343c5-b364-4a06-a806-2b20f1b16d0e,insights_interaction,latest,,,2024-03-17,MSL Interactions,Oncology,Vibranium,,WB-US-00094,Stephanie Oge,,onco-us-0005,James Wilson,Phone,X-Men,United States,RI,"Observed a wide range of response rates across different tumor types, suggesting potential for improved efficacy with patient selection based on specific biomarkers and tumor characteristics."
text,8ca32734-e157-444c-80c6-77b2746e05cb,insights_interaction,latest,,,2024-03-24,MSL Interactions,Oncology,Vibranium,,WB-US-00478,Kyle Renfrow,,onco-us-0005,James Wilson,Iron Man,Clinical Pharmacist,United States,MA,Treatment requires frequent monitoring of blood counts and other laboratory values.
text,421ae5c8-304e-4989-9edc-78c884f1c8ec,insights_interaction,latest,,,2024-04-29,MSL Interactions,Oncology,Vibranium,,WB-US-01632,David Hudson,,onco-us-0005,James Wilson,Ulton,X-Men,United States,NY,Observed grade 1 fatigue and nausea in approximately 30% of patients receiving Vibranium/Wakanda in a phase II trial. These adverse events were generally manageable with supportive care and did not lead to treatment discontinuation in most cases. One patient experienced grade 2 transaminitis which resolved with temporary treatment interruption.
text,8425270f-c537-4464-8e0e-9bc220f6e9bb,insights_interaction,latest,,,2024-05-06,MSL Interactions,Oncology,Vibranium,,WB-US-02577,Gilbert Fuhrman,,onco-us-0005,James Wilson,Ulton,Deadpool,United States,ME,Observed significant tumor regression in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.
text,17048371-4d8c-4b6d-9833-b0726ff15df0,insights_interaction,latest,,,2024-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-00083,Benjamin Butterfield,,onco-us-0005,James Wilson,Ulton,Avenger,United States,RI,Consistent treatment response across multiple cancer type classifications
text,bd684b40-9c9a-411c-bed6-a07f1202745e,insights_interaction,latest,,,2024-11-20,MSL Interactions,Oncology,Vibranium,,WB-US-01198,Theodore Muller,,onco-us-0005,James Wilson,Phone,Wolverine,United States,CT,"Increased expression of PD-L1 observed in tumor biopsies post-Vibranium/Wakanda administration, suggesting potential synergistic effects with immunotherapy in subsequent treatment regimens."
text,6f8c58a1-cb98-4662-93e1-e9b87b13f1ce,insights_interaction,latest,,,2024-12-10,MSL Interactions,Oncology,Vibranium,,WB-US-02495,Lillian Davis,,onco-us-0005,James Wilson,Iron Man,X-Men,United States,VT,"Mild to moderate immune-related adverse events documented in 22% of patients, primarily grade 1-2 fatigue and transient hepatic enzyme elevations, requiring routine monitoring but generally manageable with standard supportive interventions"
text,84fdbebd-ce0c-4e74-a117-3b684f7abdba,insights_interaction,latest,,,2022-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03299,Dorothy Dahlman,,onco-eu-0075,Jana Dvorak,Phone,X-Men,United Kingdom,,Patients reported significant improvements in pain management and daily functionality. Quality of life score increased by 47% using standardized EORTC questionnaires during 12-week treatment protocol.
text,e3be1fbb-d5a2-4e22-a1a9-079f5497d9ac,insights_interaction,latest,,,2022-12-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03044,Michael Engler,,onco-eu-0075,Jana Dvorak,Iron Man,Avenger,Ireland,,Strong correlation detected between BRCA1 mutation status and enhanced Vibranium therapeutic response
text,a2b20fd6-14cf-467c-ad00-3ccffda254e1,insights_interaction,latest,,,2023-01-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03664,Lara Brown,,onco-eu-0075,Jana Dvorak,Iron Man,X-Men,United Kingdom,,"Grade 2-3 neutropenia observed in 27% of patient cohort, manageable with supportive interventions"
text,49228646-462f-4668-9262-18facc2885ab,insights_interaction,latest,,,2023-03-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03138,Richard Pendleton,,onco-eu-0075,Jana Dvorak,Ulton,Wolverine,Ireland,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,75c73842-9f7e-473a-b786-89b00ebf6a82,insights_interaction,latest,,,2023-04-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03625,Colleen Bernardo,,onco-eu-0075,Jana Dvorak,Phone,Wolverine,Ireland,,Further research is needed to identify reliable predictive biomarkers for response to Vibranium.
text,0cb5e56c-880f-4475-9e72-f25f10fc5ba1,insights_interaction,latest,,,2023-12-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03397,James Jones,,onco-eu-0075,Jana Dvorak,Phone,Avenger,France,,"Genetic mutation profile analysis reveals potential responder subgroups, highlighting importance of personalized treatment strategies."
text,ec8519f1-66c9-4fe3-b5c0-7d7976e67b6e,insights_interaction,latest,,,2024-01-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03120,Janet Taylor,,onco-eu-0075,Jana Dvorak,Iron Man,Avenger,United Kingdom,,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,a555c054-e4bd-4748-8a3b-a00a7c99d102,insights_interaction,latest,,,2024-01-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03806,Aaron Jeffries,,onco-eu-0075,Jana Dvorak,Iron Man,X-Men,United Kingdom,,Median time to treatment response observed at 8.2 weeks across multiple tumor types
text,a0952412-91fa-4125-bb86-01c854a691e7,insights_interaction,latest,,,2024-05-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03945,Ollie Heenan,,onco-eu-0075,Jana Dvorak,Ulton,Avenger,France,,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,fc73b469-94d2-4931-baa1-5849a099c754,insights_interaction,latest,,,2024-07-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03903,Floyd Reynolds,,onco-eu-0075,Jana Dvorak,Ulton,Wolverine,Ireland,,Mixed patient experiences with treatment-related side effects and supportive care
text,8133616f-fc07-42db-89ef-0bcd98c16270,insights_interaction,latest,,,2024-07-31,MSL Interactions,Oncology,Vibranium,,WB-EU-03121,Debra Maurey,,onco-eu-0075,Jana Dvorak,Ulton,X-Men,United Kingdom,,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,bb2af12f-eb6e-40d6-b0a7-6213e378581a,insights_interaction,latest,,,2024-08-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03299,Dorothy Dahlman,,onco-eu-0075,Jana Dvorak,Phone,X-Men,United Kingdom,,Ongoing research needed to fully characterize predictive biomarker panels
text,8ab9e51b-82bd-4ff5-89bf-826fc09e88f1,insights_interaction,latest,,,2024-08-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03903,Floyd Reynolds,,onco-eu-0075,Jana Dvorak,Phone,Wolverine,Ireland,,Observed variability in treatment response across different patient subgroups.
text,34a4fe51-2fda-4b6d-980d-3a01b8f58123,insights_interaction,latest,,,2024-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03115,Dawn Santos,,onco-eu-0075,Jana Dvorak,Iron Man,X-Men,France,,"Implementation of a streamlined pre-treatment screening process significantly reduced the time to initiation of Vibranium/Wakanda therapy, improving patient access and overall workflow efficiency."
text,69fca709-0205-4bbc-a67b-a3c3c51aacb2,insights_interaction,latest,,,2024-12-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03399,Jack Bridges,,onco-eu-0075,Jana Dvorak,Phone,Avenger,Ireland,,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,1bf94460-e4fe-41be-b642-dd2b0bbea838,insights_interaction,latest,,,2021-03-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02899,Sarah Passe,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Italy,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,8978d5e1-c7da-4f3a-8b21-8dcd90b18c30,insights_interaction,latest,,,2021-10-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02989,Deborah Colon,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Spain,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,53b0a48e-a9d4-4993-b94b-130268877666,insights_interaction,latest,,,2021-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02899,Sarah Passe,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Italy,,"Increased PD-L1 expression observed in tumor biopsies after two cycles of therapy, suggesting potential synergy between Vibranium and Wakanda."
text,1111099d-dfc7-43ee-bc93-c6b9b9e0bb3a,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02894,Luis Colon,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Italy,,No unexpected serious adverse events reported in the majority of patients.
text,8772ac32-06e7-48a4-9a1b-c4fe1f48e67f,insights_interaction,latest,,,2022-01-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02297,Laura Sheppard,,onco-eu-0049,Jean-Luc Bernard,Ulton,Avenger,Italy,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,75a60711-ce43-4385-a43a-ea493264562c,insights_interaction,latest,,,2022-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02163,Timothy Mcentyre,,onco-eu-0049,Jean-Luc Bernard,Ulton,Avenger,Italy,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,be49fc40-6c01-41dc-9ffb-4f62912b22d6,insights_interaction,latest,,,2022-05-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02055,Lowell Johnson,,onco-eu-0049,Jean-Luc Bernard,Iron Man,X-Men,Ragnarok,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,ce307fd5-cdec-4159-b286-0f912f385668,insights_interaction,latest,,,2022-06-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02859,Carmen Morvant,,onco-eu-0049,Jean-Luc Bernard,Ulton,Clinical Pharmacist,Ragnarok,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,68bd2322-f026-4453-878b-d2e6f4d814bb,insights_interaction,latest,,,2022-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02461,Amelia Glenn,,onco-eu-0049,Jean-Luc Bernard,Ulton,Clinical Pharmacist,Italy,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,a2aff705-8e01-4d04-be56-b41bbe531751,insights_interaction,latest,,,2022-08-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02903,Leon Moore,,onco-eu-0049,Jean-Luc Bernard,Iron Man,X-Men,Spain,,"Patient reported improved appetite and reduced pain levels after starting Vibranium/Wakanda therapy, leading to improved functional status."
text,281b0783-e794-4596-9b07-38a00f8101ae,insights_interaction,latest,,,2022-08-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02045,Armando Patrick,,onco-eu-0049,Jean-Luc Bernard,Phone,Avenger,Ragnarok,,Stable disease observed in several patients with lung cancer after two cycles.
text,ba2d1949-6f7d-42aa-9b67-57deeea0b2ca,insights_interaction,latest,,,2022-09-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02465,Marie Sotak,,onco-eu-0049,Jean-Luc Bernard,Phone,Avenger,Greece,,"Synergistic effect observed between Vibranium and Wakanda, leading to enhanced antitumor activity."
text,5ce38508-9635-446f-8520-e23dd54a901e,insights_interaction,latest,,,2022-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02465,Marie Sotak,,onco-eu-0049,Jean-Luc Bernard,Iron Man,Avenger,Greece,,Stable disease observed in several patients with lung cancer after two cycles.
text,43419646-37fe-4b04-9df0-62a61f5b007b,insights_interaction,latest,,,2022-10-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02700,Edward Graves,,onco-eu-0049,Jean-Luc Bernard,Phone,X-Men,Spain,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,a1cf860d-9fc6-447d-8356-74b80b989d53,insights_interaction,latest,,,2023-03-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02997,Adeline Prince,,onco-eu-0049,Jean-Luc Bernard,Phone,Avenger,Spain,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,fdea0a10-2770-4663-ba40-62ae8493b77a,insights_interaction,latest,,,2023-03-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02577,Samantha Davis,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Greece,,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,9e36d164-0c48-4493-aa86-720e6f8ded6a,insights_interaction,latest,,,2023-03-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02859,Carmen Morvant,,onco-eu-0049,Jean-Luc Bernard,Phone,Clinical Pharmacist,Ragnarok,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,d26a847d-c9bc-4c9a-9929-09c247f1b16b,insights_interaction,latest,,,2023-06-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02230,Cathie Mooberry,,onco-eu-0049,Jean-Luc Bernard,Ulton,X-Men,Spain,,"One case of grade 2 liver enzyme elevation reported, likely related to Vibranium/Wakanda administration. Resolved with supportive care."
text,0feb48dd-6a78-4567-b19d-7ba04e31b4db,insights_interaction,latest,,,2023-11-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02774,Joan Lawton,,onco-eu-0049,Jean-Luc Bernard,Iron Man,X-Men,Italy,,"Mild flu-like symptoms, such as fever and chills, were commonly reported by patients receiving Vibranium/Wakanda, typically resolving within 24-48 hours."
text,483e9aab-d4dc-4a01-9a90-2e84367dc011,insights_interaction,latest,,,2023-11-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02860,Sandra Fang,,onco-eu-0049,Jean-Luc Bernard,Iron Man,Avenger,Greece,,Consistent fatigue levels reported across treatment cycles
text,0ef46497-d163-4490-9811-b155813e87fd,insights_interaction,latest,,,2024-05-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02859,Carmen Morvant,,onco-eu-0049,Jean-Luc Bernard,Iron Man,Clinical Pharmacist,Ragnarok,,Quality of life remained stable in a majority of patients despite disease progression.
text,18bc5b6d-7dd5-4413-92e5-29fa6fa62967,insights_interaction,latest,,,2024-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02297,Laura Sheppard,,onco-eu-0049,Jean-Luc Bernard,Phone,Avenger,Italy,,"Moderate efficacy in heterogeneous patient populations, emphasizing importance of precise patient selection"
text,7692e4a3-8b23-4062-b1ca-965a3f94726f,insights_interaction,latest,,,2024-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02168,Shelia Pollack,,onco-eu-0049,Jean-Luc Bernard,Iron Man,X-Men,Italy,,"Infusion-related reactions (IRR) were reported in 2% of patients, typically mild and manageable with premedication."
text,6db0c8b4-bb70-4b05-b4a5-64db7e36eeec,insights_interaction,latest,,,2021-01-15,MSL Interactions,Oncology,Vibranium,,WB-US-00793,Antonio Ventura,,onco-us-0003,Jennifer Kim,Phone,X-Men,United States,NH,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,9a10a690-dffe-41ad-87ae-4698a771a34f,insights_interaction,latest,,,2021-03-22,MSL Interactions,Oncology,Vibranium,,WB-US-02079,Sonya Petersen,,onco-us-0003,Jennifer Kim,Phone,Deadpool,United States,ME,Patients reported 68% improvement in pain management and functional status during combination therapy
text,69062d3d-8b32-4230-a4ba-3bb033a323b6,insights_interaction,latest,,,2021-05-23,MSL Interactions,Oncology,Vibranium,,WB-US-02071,Rene Pryor,,onco-us-0003,Jennifer Kim,Phone,Wolverine,United States,NY,Significant tumor reduction in hard-to-treat cancer subtypes
text,ba39600e-389e-48c3-a75b-7ac64a8aeacd,insights_interaction,latest,,,2021-09-11,MSL Interactions,Oncology,Vibranium,,WB-US-00702,Veronica Rios,,onco-us-0003,Jennifer Kim,Phone,Deadpool,United States,NY,"Significant improvement in patient-reported outcome measures, with 73% reporting reduced pain and increased functional status"
text,be738484-09ee-4717-b2b0-fa6d3e182c35,insights_interaction,latest,,,2021-09-16,MSL Interactions,Oncology,Vibranium,,WB-US-01437,Sheryl Hall,,onco-us-0003,Jennifer Kim,Iron Man,X-Men,United States,NY,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,5b54ebd1-c3ea-4949-8a86-e374ae536399,insights_interaction,latest,,,2021-11-21,MSL Interactions,Oncology,Vibranium,,WB-US-00678,Gary Sistrunk,,onco-us-0003,Jennifer Kim,Iron Man,X-Men,United States,CT,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,73287d82-4d89-4431-8930-85a988b31baf,insights_interaction,latest,,,2022-01-16,MSL Interactions,Oncology,Vibranium,,WB-US-01740,Naomi Schneider,,onco-us-0003,Jennifer Kim,Ulton,X-Men,United States,CT,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,910cf482-12f9-40eb-8c88-c78e443eae39,insights_interaction,latest,,,2022-05-04,MSL Interactions,Oncology,Vibranium,,WB-US-02412,Juan Fuentes,,onco-us-0003,Jennifer Kim,Iron Man,X-Men,United States,NH,Improved physical function and reduced fatigue were reported by a majority of patients in a quality-of-life assessment after receiving Vibranium/Wakanda.
text,af248098-1c4a-486b-94a1-a8ac6288907e,insights_interaction,latest,,,2022-08-23,MSL Interactions,Oncology,Vibranium,,WB-US-00935,Lorriane Dunning,,onco-us-0003,Jennifer Kim,Phone,X-Men,United States,RI,"In a cohort of 25 patients, only mild, manageable side effects (fatigue, nausea) were reported.  No grade 3 or 4 adverse events were observed. This suggests a favorable safety profile in this specific patient population."
text,1d9ec9e9-68aa-45e0-94f0-d85645247de7,insights_interaction,latest,,,2022-09-30,MSL Interactions,Oncology,Vibranium,,WB-US-00975,Melody Robison,,onco-us-0003,Jennifer Kim,Iron Man,Wolverine,United States,CT,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,51985c95-0f13-47a9-b0b8-9bce7783e2dd,insights_interaction,latest,,,2022-11-03,MSL Interactions,Oncology,Vibranium,,WB-US-01944,Laura Briones,,onco-us-0003,Jennifer Kim,Iron Man,Deadpool,United States,VT,"Increased PD-L1 expression observed in tumor biopsies after two cycles of treatment, suggesting potential synergy between Vibranium and Wakanda."
text,732e8b11-5a11-4d15-b724-625347f92f10,insights_interaction,latest,,,2022-11-16,MSL Interactions,Oncology,Vibranium,,WB-US-02079,Sonya Petersen,,onco-us-0003,Jennifer Kim,Ulton,Deadpool,United States,ME,Significant improvement in patient-reported emotional well-being scores
text,0e44ace1-3a69-4597-9ac7-fcc88696bc00,insights_interaction,latest,,,2023-01-31,MSL Interactions,Oncology,Vibranium,,WB-US-02317,William Wilson,,onco-us-0003,Jennifer Kim,Phone,Wolverine,United States,NH,No unexpected or severe adverse events were reported in the majority of patients.
text,c2ea3a7b-95cb-4b0d-9d7a-697d64a8cb49,insights_interaction,latest,,,2023-05-08,MSL Interactions,Oncology,Vibranium,,WB-US-01623,Paul Clayton,,onco-us-0003,Jennifer Kim,Phone,Avenger,United States,NY,Consistent therapeutic response across multiple age groups and performance status categories
text,6dc98e8b-ed41-4dd1-bed1-f6bbcdfc43dc,insights_interaction,latest,,,2023-06-02,MSL Interactions,Oncology,Vibranium,,WB-US-02220,James Perry,,onco-us-0003,Jennifer Kim,Iron Man,X-Men,United States,CT,Stable disease observed in several patients with lung cancer after two cycles.
text,b2ee8d81-409f-4fd3-9e49-814189365172,insights_interaction,latest,,,2024-04-05,MSL Interactions,Oncology,Vibranium,,WB-US-01847,Eugene Lucas,,onco-us-0003,Jennifer Kim,Ulton,X-Men,United States,CT,Administration of Vibranium requires specialized training and infrastructure due to its unique delivery method.
text,7325e8d9-50cd-46f2-8dd7-5a71fe800bb1,insights_interaction,latest,,,2024-05-11,MSL Interactions,Oncology,Vibranium,,WB-US-00860,Chris Hart,,onco-us-0003,Jennifer Kim,Phone,X-Men,United States,NH,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda.
text,a2e3d5fa-5923-4ac0-8673-48217c83b693,insights_interaction,latest,,,2024-09-08,MSL Interactions,Oncology,Vibranium,,WB-US-01758,Ben Wade,,onco-us-0003,Jennifer Kim,Ulton,Avenger,United States,ME,"Immunogenic side effects manageable with standard corticosteroid interventions, with only 8% of patients requiring extended immunosuppressive management."
text,c5942756-3470-4a47-bcdf-68bf8b56232b,insights_interaction,latest,,,2024-10-24,MSL Interactions,Oncology,Vibranium,,WB-US-01147,Ronald Polk,,onco-us-0003,Jennifer Kim,Iron Man,Avenger,United States,ME,Consistent monitoring requirements with acceptable toxicity management protocols
text,f843a3ef-8e1e-424b-a35a-af45cae38ffc,insights_interaction,latest,,,2021-01-06,MSL Interactions,Oncology,Vibranium,,WB-US-08046,Mildred Standley,,onco-us-0023,John Baker,Phone,X-Men,United States,OH,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,edf86e06-ab4f-423b-b8f6-9a4688e9969b,insights_interaction,latest,,,2021-01-29,MSL Interactions,Oncology,Vibranium,,WB-US-07709,Jose Koon,,onco-us-0023,John Baker,Iron Man,X-Men,United States,WI,Clear predictive markers identified for optimal patient selection
text,6f4c84f0-14de-4257-81ac-2ab58a0b559b,insights_interaction,latest,,,2021-05-04,MSL Interactions,Oncology,Vibranium,,WB-US-07776,Lloyd Mitchell,,onco-us-0023,John Baker,Iron Man,Avenger,United States,OH,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,eb60f25c-43da-4997-b983-5141c539c187,insights_interaction,latest,,,2021-06-30,MSL Interactions,Oncology,Vibranium,,WB-US-07421,Carl Peterson,,onco-us-0023,John Baker,Phone,Avenger,United States,OH,Outpatient administration protocol reduces treatment cycle costs by approximately 35% compared to inpatient infusion strategies
text,4dc55400-2954-4268-8208-01651fe5afde,insights_interaction,latest,,,2021-07-20,MSL Interactions,Oncology,Vibranium,,WB-US-08013,William Young,,onco-us-0023,John Baker,Phone,Avenger,United States,MN,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,b48ea824-c84f-4858-a7eb-ace9e515da78,insights_interaction,latest,,,2021-08-17,MSL Interactions,Oncology,Vibranium,,WB-US-08236,Allie Mitkowski,,onco-us-0023,John Baker,Ulton,Deadpool,United States,IA,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,f244635d-dbf2-4bc6-bd37-a931613628e2,insights_interaction,latest,,,2021-12-08,MSL Interactions,Oncology,Vibranium,,WB-US-07373,Anna Mccoy,,onco-us-0023,John Baker,Iron Man,X-Men,United States,MI,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,96775394-3d23-4a8d-80f4-1a63b78ad241,insights_interaction,latest,,,2022-04-06,MSL Interactions,Oncology,Vibranium,,WB-US-06760,Vivian Patton,,onco-us-0023,John Baker,Iron Man,Avenger,United States,WI,"Elevated serum cytokine levels observed in responders, suggesting potential immunological mechanisms."
text,5facce1f-0493-4b29-919c-9c433743ae22,insights_interaction,latest,,,2022-04-11,MSL Interactions,Oncology,Vibranium,,WB-US-07914,Maria Pugh,,onco-us-0023,John Baker,Ulton,Wolverine,United States,WI,"Observed 62% objective response rate in metastatic triple-negative breast cancer patients with high PD-L1 expression, significantly outperforming standard chemotherapy protocols"
text,e14a20d4-641f-4df7-82c4-9dbb11e3c543,insights_interaction,latest,,,2022-06-05,MSL Interactions,Oncology,Vibranium,,WB-US-08117,Miguel Gunderson,,onco-us-0023,John Baker,Ulton,Wolverine,United States,WI,Cost-effectiveness analysis suggests potential for reduced hospital readmission rates with targeted combination approach
text,c766dcaa-f59d-4a05-a290-906d4005ff4a,insights_interaction,latest,,,2022-09-15,MSL Interactions,Oncology,Vibranium,,WB-US-07853,Mark Lewis,,onco-us-0023,John Baker,Iron Man,X-Men,United States,MO,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,66705de5-7713-4107-b5bf-31530a465a6f,insights_interaction,latest,,,2022-11-15,MSL Interactions,Oncology,Vibranium,,WB-US-07756,Sandra Seaton,,onco-us-0023,John Baker,Phone,X-Men,United States,IN,Minimal cardiac toxicity and reduced treatment-related complications
text,72dc225d-ecdb-4329-9366-ae7f2aee8563,insights_interaction,latest,,,2023-03-11,MSL Interactions,Oncology,Vibranium,,WB-US-08248,Stacey Drake,,onco-us-0023,John Baker,Ulton,X-Men,United States,IL,Variable response rates observed across different cancer subtypes
text,c652e9ce-c8af-4984-b387-74610881802b,insights_interaction,latest,,,2023-05-31,MSL Interactions,Oncology,Vibranium,,WB-US-06995,Loretta Mcardle,,onco-us-0023,John Baker,Phone,Wolverine,United States,IL,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,3fb99a05-9166-4efc-8ad5-3d8e2aa83dd2,insights_interaction,latest,,,2023-06-08,MSL Interactions,Oncology,Vibranium,,WB-US-07470,Tonya Swenson,,onco-us-0023,John Baker,Ulton,X-Men,United States,IL,"Increased risk of infection observed in some patients treated with Vibranium/Wakanda, possibly due to immune suppression."
text,3e115d2f-54b5-484b-a78a-d3bd628dfbdc,insights_interaction,latest,,,2023-07-31,MSL Interactions,Oncology,Vibranium,,WB-US-07308,Agnes Fitzwater,,onco-us-0023,John Baker,Phone,Clinical Pharmacist,United States,OH,Significant molecular response in patients with specific genetic mutations
text,10a8d3a1-6ed5-45df-bb85-9ea226c841d7,insights_interaction,latest,,,2024-03-24,MSL Interactions,Oncology,Vibranium,,WB-US-08236,Allie Mitkowski,,onco-us-0023,John Baker,Iron Man,Deadpool,United States,IA,No significant changes observed in circulating tumor DNA levels after the first cycle of treatment.
text,4018d247-a5ef-413a-8677-96405efd4bb6,insights_interaction,latest,,,2024-04-27,MSL Interactions,Oncology,Vibranium,,WB-US-07130,Susan Belcher,,onco-us-0023,John Baker,Iron Man,Avenger,United States,OH,"Emerging evidence suggests potential genomic predictors of response, particularly in patients with microsatellite instability-high (MSI-H) tumors"
text,dfb58dd1-2d77-40d4-9adc-d07e72a26cf3,insights_interaction,latest,,,2024-07-17,MSL Interactions,Oncology,Vibranium,,WB-US-08220,Paul Lopez,,onco-us-0023,John Baker,Phone,Deadpool,United States,IN,Consistent patient-reported outcomes with minimal treatment-related disruptions
text,e53605a7-ccc5-4395-8959-eb39a9f03010,insights_interaction,latest,,,2024-08-15,MSL Interactions,Oncology,Vibranium,,WB-US-06790,Andrew Deni,,onco-us-0023,John Baker,Phone,Avenger,United States,IA,Combination therapy requires careful patient selection and comprehensive molecular profiling
text,c503dca7-3a74-4580-a5cd-c1540d7fece4,insights_interaction,latest,,,2024-09-26,MSL Interactions,Oncology,Vibranium,,WB-US-07672,Karen Marshall,,onco-us-0023,John Baker,Ulton,Avenger,United States,IN,"Partial response observed in a patient with advanced head and neck cancer after four cycles of Vibranium/Wakanda, leading to improved swallowing function."
text,a088cdf2-7903-4196-a1e5-a15d546b1c51,insights_interaction,latest,,,2021-01-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00391,Joseph Kravitz,,onco-eu-0014,Jonas Berg,Phone,Avenger,Denmark,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,4bedc97d-aa7d-461e-9064-f5afa5b04489,insights_interaction,latest,,,2021-05-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00316,Barbara Sharp,,onco-eu-0014,Jonas Berg,Phone,Deadpool,Finland,,Significant reduction in treatment-related fatigue and improved patient mobility
text,3717ae57-a280-4078-835e-479ac06c14a9,insights_interaction,latest,,,2021-06-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00425,Thelma Koch,,onco-eu-0014,Jonas Berg,Phone,X-Men,Denmark,,Demonstrated superior safety profile compared to standard chemotherapy regimens
text,529f4835-0fba-43c5-8a58-29fc786f26b0,insights_interaction,latest,,,2021-11-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00625,Natasha Lee,,onco-eu-0014,Jonas Berg,Iron Man,X-Men,Denmark,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,2dd91266-9d1f-41de-8173-fb308280e968,insights_interaction,latest,,,2022-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-00523,Doris Griffith,,onco-eu-0014,Jonas Berg,Phone,X-Men,Sweden,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,d006a861-e553-4632-a6e5-dc71c3c48ca2,insights_interaction,latest,,,2022-06-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00009,Lester Hale,,onco-eu-0014,Jonas Berg,Ulton,X-Men,Sweden,,"Strong correlation identified between BRCA1/2 mutational status and enhanced therapeutic response, suggesting potential predictive biomarker"
text,9847ffe2-0c7d-4eca-81f3-9a179a14fff3,insights_interaction,latest,,,2022-07-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00101,Willis Kim,,onco-eu-0014,Jonas Berg,Ulton,X-Men,Denmark,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,ba2a70aa-614e-4499-a032-4e289a575a1b,insights_interaction,latest,,,2022-12-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00683,John Hardwick,,onco-eu-0014,Jonas Berg,Ulton,X-Men,Norway,,Cost-effectiveness analysis suggests potential 35% reduction in total treatment expenditure compared to standard combination therapies
text,37b05bd3-f02d-45e1-94b1-34130609e93b,insights_interaction,latest,,,2023-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00677,Elizabeth Johnson,,onco-eu-0014,Jonas Berg,Ulton,Avenger,Sweden,,"Dose-limiting toxicities observed include mild to moderate hepatic enzyme elevations in 17% of patients, manageable with temporary dose reduction and close monitoring."
text,1ba2d39b-bed8-4c65-ad8f-abf0ed43d704,insights_interaction,latest,,,2023-06-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00378,Dawn Mcmanus,,onco-eu-0014,Jonas Berg,Ulton,Avenger,Finland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,d0337bac-2f4c-41b2-8fd8-654bd57fa417,insights_interaction,latest,,,2023-09-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00709,Marcia Davis,,onco-eu-0014,Jonas Berg,Phone,X-Men,Norway,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,425e3035-2d40-49a4-8647-cca985fee146,insights_interaction,latest,,,2023-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00698,Patrick Cali,,onco-eu-0014,Jonas Berg,Ulton,Deadpool,Denmark,,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,6c64bed2-ba9c-417d-85a8-df17fec5f999,insights_interaction,latest,,,2023-11-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00645,Robert Luce,,onco-eu-0014,Jonas Berg,Iron Man,Deadpool,Norway,,Early detection of response based on circulating tumor DNA analysis.
text,673d5c2b-5fea-4b23-ac99-6abb470f4f78,insights_interaction,latest,,,2024-02-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00388,Catherine Barr,,onco-eu-0014,Jonas Berg,Phone,Wolverine,Sweden,,Observed variable response patterns across different cancer subtypes
text,a005ee8c-b9ee-4b37-b6f6-6388c6839ebb,insights_interaction,latest,,,2024-03-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00760,Mamie Lewis,,onco-eu-0014,Jonas Berg,Iron Man,Avenger,Denmark,,Cost-effectiveness analysis suggests potential for reduced healthcare resource utilization compared to traditional treatment protocols
text,7dbc9a73-dc44-4d48-a2ca-9ed75df21fe9,insights_interaction,latest,,,2024-11-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00364,Debbie Price,,onco-eu-0014,Jonas Berg,Phone,Avenger,Denmark,,"Correlation between baseline tumor mutational burden (TMB) and response to Vibranium/Wakanda is currently being investigated.  Preliminary data suggests a potential link, but further analysis is required to validate this finding."
text,ec34afb6-d32b-485c-a510-11c37b420c36,insights_interaction,latest,,,2024-12-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00277,Zenobia Keiss,,onco-eu-0014,Jonas Berg,Phone,X-Men,Sweden,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 2 cycles of Vibranium/Wakanda therapy, with a 30% reduction in tumor size confirmed by CT scan.  Significant reduction in CA 19-9 levels also observed."
text,76d05d99-06c3-4c3d-9107-559b47d36521,insights_interaction,latest,,,2021-10-07,MSL Interactions,Oncology,Vibranium,,WB-US-05182,Gladys Castillo,,onco-us-0018,Joseph Williams,Phone,Avenger,United States,VA,Prolonged progression-free survival observed in a subset of patients with head and neck cancer treated with Vibranium/Wakanda.
text,8019f112-bf51-4d17-8fac-52eb913bb69f,insights_interaction,latest,,,2021-12-24,MSL Interactions,Oncology,Vibranium,,WB-US-06370,Normand Perkins,,onco-us-0018,Joseph Williams,Phone,Avenger,United States,FL,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,be3d22c0-eb21-4cc6-9c5b-5db91af9f687,insights_interaction,latest,,,2022-02-02,MSL Interactions,Oncology,Vibranium,,WB-US-05854,Amie Stevens,,onco-us-0018,Joseph Williams,Phone,X-Men,United States,KY,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,b7e2f8c5-f960-4a18-b01b-dac6fbf899e8,insights_interaction,latest,,,2022-11-28,MSL Interactions,Oncology,Vibranium,,WB-US-06542,Shirley Maffit,,onco-us-0018,Joseph Williams,Phone,X-Men,United States,AL,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,83c4d390-c0ed-4ac6-8782-67fc6cc22a77,insights_interaction,latest,,,2024-01-23,MSL Interactions,Oncology,Vibranium,,WB-US-05752,Steven Allen,,onco-us-0018,Joseph Williams,Phone,Avenger,United States,KY,Marginal improvement in overall survival compared to standard treatment protocols
text,71688b69-a3c1-4346-93da-5e889ed45307,insights_interaction,latest,,,2024-02-20,MSL Interactions,Oncology,Vibranium,,WB-US-05534,Ralph Mincey,,onco-us-0018,Joseph Williams,Phone,Avenger,United States,VA,No significant long-term immunological complications detected in 24-month follow-up study
text,2c069dc4-e669-4763-b175-1d989799832d,insights_interaction,latest,,,2024-03-14,MSL Interactions,Oncology,Vibranium,,WB-US-06251,Robert Severino,,onco-us-0018,Joseph Williams,Ulton,Deadpool,United States,SC,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,c97df2ad-2875-4f2b-9bf2-90a67be1b96f,insights_interaction,latest,,,2024-05-01,MSL Interactions,Oncology,Vibranium,,WB-US-05611,Harold Seeman,,onco-us-0018,Joseph Williams,Iron Man,Avenger,United States,KY,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors treated with Vibranium/Wakanda compared to those with microsatellite stable (MSS) tumors.  This suggests a potential predictive biomarker for treatment response.
text,4c981fe8-b2bd-4c2b-a7d8-8a6ad5d78d75,insights_interaction,latest,,,2024-07-12,MSL Interactions,Oncology,Vibranium,,WB-US-06446,William Dockstader,,onco-us-0018,Joseph Williams,Phone,Avenger,United States,AL,Longer progression-free survival observed in patients with lower tumor mutational burden.
text,687cc85f-1081-4b30-a54e-8c488302db37,insights_interaction,latest,,,2024-12-18,MSL Interactions,Oncology,Vibranium,,WB-US-06574,Helen Hagen,,onco-us-0018,Joseph Williams,Iron Man,Wolverine,United States,MS,Progressive disease noted in a small subset of patients despite initial response.
text,1cc22e9d-972d-42e7-949f-c945baa76f9f,insights_interaction,latest,,,2021-01-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00893,Mitchell White,,onco-eu-0021,Julia Fischer,Iron Man,X-Men,Austria,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,b8f376eb-092a-4ee9-8467-1a2c5763e9a5,insights_interaction,latest,,,2021-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00848,Brandi Garrison,,onco-eu-0021,Julia Fischer,Iron Man,X-Men,Switzerland,,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,ea38af9b-a6da-4f60-9972-18ff1e2de9c8,insights_interaction,latest,,,2021-03-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01269,Jerald Tyler,,onco-eu-0021,Julia Fischer,Phone,Avenger,Belgium,,"Outpatient administration possible with 90-minute infusion protocol, reducing hospital resource utilization"
text,be8f5802-11e3-4c41-a84f-64c07ba067f0,insights_interaction,latest,,,2021-04-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01928,Ines Piserchio,,onco-eu-0021,Julia Fischer,Ulton,X-Men,Austria,,Reduction in pain levels reported by patients with bone metastases.
text,1c07862d-036d-458b-b91e-27095cfff5f6,insights_interaction,latest,,,2021-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01138,Allan Davis,,onco-eu-0021,Julia Fischer,Phone,X-Men,Belgium,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,83321eff-0dc0-4942-b325-46c10f3e1cf9,insights_interaction,latest,,,2021-08-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01138,Allan Davis,,onco-eu-0021,Julia Fischer,Ulton,X-Men,Belgium,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,c2fa6518-7d9f-44bb-9208-59618739c190,insights_interaction,latest,,,2021-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01138,Allan Davis,,onco-eu-0021,Julia Fischer,Ulton,X-Men,Belgium,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,555304d6-836c-4aa4-9b7d-bd087198f8b6,insights_interaction,latest,,,2021-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00978,Helen Hammons,,onco-eu-0021,Julia Fischer,Iron Man,Avenger,Belgium,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,d6ef47ce-e0c8-49ec-af34-746358a6b2ea,insights_interaction,latest,,,2021-09-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01829,Wayne Rosen,,onco-eu-0021,Julia Fischer,Phone,X-Men,Belgium,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,5f3581a5-75b4-45e6-a699-6cfe219e8d50,insights_interaction,latest,,,2021-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01772,Terry Bass,,onco-eu-0021,Julia Fischer,Iron Man,X-Men,Austria,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,e5df8bc5-cff0-469f-bd0c-460aa1b67b56,insights_interaction,latest,,,2021-11-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01918,Nick Thomas,,onco-eu-0021,Julia Fischer,Phone,X-Men,Germany,,Patients reported significantly reduced pain scores and improved functional status compared to standard chemotherapy regimens
text,232e1242-eb20-4fc3-9827-70cd5f29bda1,insights_interaction,latest,,,2022-01-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01640,Elaine Hinson,,onco-eu-0021,Julia Fischer,Phone,Wolverine,Germany,,No unexpected long-term immunological complications detected in 24-month follow-up data
text,b2245d68-a7e5-4320-9fc8-818331d20164,insights_interaction,latest,,,2022-03-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01109,Pamela Bedford,,onco-eu-0021,Julia Fischer,Iron Man,X-Men,Belgium,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,a8027639-80fb-4851-9955-136c8df0c15a,insights_interaction,latest,,,2022-04-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01138,Allan Davis,,onco-eu-0021,Julia Fischer,Phone,X-Men,Belgium,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 8 weeks of Vibranium therapy, with a 30% reduction in target lesion size confirmed by RECIST 1.1 criteria.  Significant reduction in CA 19-9 levels also observed."
text,94604438-7d5a-495b-aed0-c99a17ab3b57,insights_interaction,latest,,,2022-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01928,Ines Piserchio,,onco-eu-0021,Julia Fischer,Ulton,X-Men,Austria,,"Significant reduction in treatment-related fatigue reported, with 63% of patients experiencing improved daily functional capacity."
text,77f7619e-835e-4e97-b14f-3d3b4dec3ba5,insights_interaction,latest,,,2022-12-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01640,Elaine Hinson,,onco-eu-0021,Julia Fischer,Phone,Wolverine,Germany,,Sustained improvements in quality of life reported by patients even after treatment completion.
text,1f572dcb-b489-4a82-a374-30ca610d4318,insights_interaction,latest,,,2022-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01846,Tanner Villa,,onco-eu-0021,Julia Fischer,Iron Man,X-Men,Belgium,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response (PR) after 2 cycles of Vibranium/Wakanda therapy, with a significant reduction in tumor size and improved CA 19-9 levels.  This is noteworthy given the patient's prior resistance to standard chemotherapeutic regimens."
text,429c4042-dcd1-4a92-b611-c73b5e3424e4,insights_interaction,latest,,,2023-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00884,Roger Haven,,onco-eu-0021,Julia Fischer,Phone,X-Men,Austria,,Treatment response appears to be heterogeneous across different tumor types.
text,1fad75e1-ccc0-45c0-9dc4-26164e1391b2,insights_interaction,latest,,,2023-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01415,Dorothy Crocker,,onco-eu-0021,Julia Fischer,Iron Man,Wolverine,Germany,,Quality of life remained stable in a majority of patients despite disease progression.
text,599f6f14-286f-455e-a0d6-f706f9449bec,insights_interaction,latest,,,2023-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01350,Karen Kent,,onco-eu-0021,Julia Fischer,Ulton,X-Men,Germany,,No objective response observed in a patient with metastatic melanoma after 4 cycles of Vibranium/Wakanda therapy. Disease progression noted.
text,23ac1139-4e22-4e65-b472-0fc575f7348b,insights_interaction,latest,,,2023-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01836,Forest Soto,,onco-eu-0021,Julia Fischer,Iron Man,Avenger,Netherlands,,Stable disease observed in 70% of patients with metastatic melanoma enrolled in a phase II trial after 12 weeks of Vibranium treatment.
text,092c00d6-a7fa-4a7b-8c0e-5615d6cad609,insights_interaction,latest,,,2023-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01418,Matthew Binder,,onco-eu-0021,Julia Fischer,Ulton,Avenger,Switzerland,,Promising early indicators of treatment efficacy in rare cancer subtypes
text,4e309abc-ec7c-4f8e-a2c5-1480370bba66,insights_interaction,latest,,,2023-10-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01772,Terry Bass,,onco-eu-0021,Julia Fischer,Phone,X-Men,Austria,,No clear correlation found between prior chemotherapy exposure and response to Vibranium/Wakanda.
text,05f69642-bdbf-4d22-9c5a-ebd3c3663919,insights_interaction,latest,,,2023-12-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01847,Donovan Brown,,onco-eu-0021,Julia Fischer,Ulton,Avenger,Switzerland,,Long-term follow-up data showing stable safety profile with minimal cumulative toxicity
text,33520705-afed-4d82-8865-40d302ce250e,insights_interaction,latest,,,2024-02-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01078,Kenneth Harris,,onco-eu-0021,Julia Fischer,Ulton,Avenger,Germany,,"Age-related differences in treatment response, with more consistent outcomes in patients under 65 compared to geriatric populations"
text,22c48c76-f131-4857-a385-645243a18733,insights_interaction,latest,,,2024-03-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01453,Thomas Osborn,,onco-eu-0021,Julia Fischer,Phone,X-Men,Netherlands,,Increased infiltration of CD8+ T cells observed in tumor biopsies from patients responding to Vibranium/Wakanda therapy.
text,77dc1797-1de2-45c8-9aa4-98ff91191da1,insights_interaction,latest,,,2024-07-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01846,Tanner Villa,,onco-eu-0021,Julia Fischer,Phone,X-Men,Belgium,,Mild injection site reactions observed in several patients receiving Vibranium/Wakanda.
text,7e6b74b4-67b8-4dec-982c-f3a1520e6af3,insights_interaction,latest,,,2024-10-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01486,Charles Zanghi,,onco-eu-0021,Julia Fischer,Iron Man,Wolverine,Belgium,,Response to Vibranium appears to be independent of prior systemic therapy in some patients.
text,feed4cc7-f993-4e19-b49c-16af72e4c49e,insights_interaction,latest,,,2021-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02395,Jesse Thompkins,,onco-eu-0059,Julien Mercier,Phone,X-Men,Ragnarok,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,218e1137-d7a6-41f3-b5ae-e7ddf0552c45,insights_interaction,latest,,,2021-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02724,Tanya Thompson,,onco-eu-0059,Julien Mercier,Ulton,Avenger,Italy,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,c849cc18-492e-4995-9f30-df7cb3dd91a7,insights_interaction,latest,,,2021-08-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02949,Christopher Jones,,onco-eu-0059,Julien Mercier,Phone,Wolverine,Spain,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,bcdb4be2-4e54-45ea-9c86-7198b9194af4,insights_interaction,latest,,,2021-10-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02221,Alex Ortega,,onco-eu-0059,Julien Mercier,Iron Man,Wolverine,Italy,,Significant improvement in circulating tumor DNA clearance during treatment cycle
text,d8dcd070-9d26-43af-bec8-0c1e19e78788,insights_interaction,latest,,,2021-12-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02476,Andrea Richardson,,onco-eu-0059,Julien Mercier,Phone,X-Men,Ragnarok,,"Increased expression of interferon-gamma and other pro-inflammatory cytokines detected in tumor biopsies from patients responding to Vibranium/Wakanda therapy, suggesting a robust immune response."
text,26b1b7cc-e12f-449a-bf40-bdfe89cb59de,insights_interaction,latest,,,2022-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02123,Lisa Duponte,,onco-eu-0059,Julien Mercier,Ulton,Avenger,Ragnarok,,Enhanced long-term survival signals in patients with specific genomic alterations
text,9dd54084-c33a-4fe3-9651-90c49ec18046,insights_interaction,latest,,,2022-04-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02974,David Wilson,,onco-eu-0059,Julien Mercier,Phone,Clinical Pharmacist,Spain,,Precise molecular targeting demonstrated in RAS-mutated cancer subtypes
text,7ffc6423-380e-4ec4-98bf-4e0fbc3d7cfb,insights_interaction,latest,,,2022-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02926,William Schull,,onco-eu-0059,Julien Mercier,Iron Man,X-Men,Greece,,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,c51bd4ac-b274-409d-b362-d28049731064,insights_interaction,latest,,,2022-07-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02794,Elidia Haddad,,onco-eu-0059,Julien Mercier,Ulton,Deadpool,Ragnarok,,Patients reported improved physical functioning and reduced fatigue during treatment.
text,433f989e-ff26-4449-bb99-cd29ffc9970b,insights_interaction,latest,,,2022-09-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02221,Alex Ortega,,onco-eu-0059,Julien Mercier,Iron Man,Wolverine,Italy,,"Observed 43% objective response rate in metastatic solid tumors with high PD-L1 expression, particularly notable in advanced non-small cell lung cancer patients"
text,60a74d87-1513-4f0a-8e14-a56c485029c5,insights_interaction,latest,,,2022-11-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02954,Victoria Larsen,,onco-eu-0059,Julien Mercier,Iron Man,X-Men,Greece,,Promising early-stage data suggests potential for expanded indication spectrum
text,068a1d43-2bfd-418f-9cb5-abcc27e4c84c,insights_interaction,latest,,,2023-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02395,Jesse Thompkins,,onco-eu-0059,Julien Mercier,Ulton,X-Men,Ragnarok,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,ddf7d72c-b43e-4cd4-9d0b-49add0b9bee0,insights_interaction,latest,,,2023-04-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02436,Aline Warthen,,onco-eu-0059,Julien Mercier,Phone,Avenger,Spain,,Patient experienced grade 3 fatigue and nausea requiring dose reduction of Vibranium/Wakanda. Treatment was temporarily suspended.
text,ec31713e-ad9b-4987-b0b3-4ffab09b2084,insights_interaction,latest,,,2023-04-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02340,Jonas Butterfield,,onco-eu-0059,Julien Mercier,Iron Man,Wolverine,Ragnarok,,Moderate complexity in administration protocol requiring specialized nursing training
text,536bd15d-578c-40b5-8616-f07cca40e70d,insights_interaction,latest,,,2023-05-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02463,Patrick Williams,,onco-eu-0059,Julien Mercier,Iron Man,X-Men,Italy,,Promising results in targeted patient subgroups with specific genetic markers
text,06a6f5e6-307c-4790-9cff-257a06b60955,insights_interaction,latest,,,2023-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02687,Roger Mitchell,,onco-eu-0059,Julien Mercier,Iron Man,Wolverine,Ragnarok,,"Reported sleep disturbances and fatigue in 35% of patients, suggesting need for comprehensive supportive care interventions."
text,dc320937-701b-4f66-8254-3770add88a48,insights_interaction,latest,,,2023-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02376,John Steinberg,,onco-eu-0059,Julien Mercier,Ulton,Clinical Pharmacist,Greece,,Requires close monitoring of blood counts and liver function tests.
text,9df79854-9ff6-40fe-9f5e-c214213bbe88,insights_interaction,latest,,,2023-08-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02687,Roger Mitchell,,onco-eu-0059,Julien Mercier,Iron Man,Wolverine,Ragnarok,,"Increased risk of infection observed in some patients treated with Vibranium/Wakanda, possibly due to immune suppression."
text,b28cb915-6d6f-4c6d-a8db-edb15aa0fef6,insights_interaction,latest,,,2023-12-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02611,Mathew Gray,,onco-eu-0059,Julien Mercier,Phone,Deadpool,Spain,,Progressive disease noted in a small subset of patients despite initial response.
text,09f03598-6517-4bc6-bc79-e5e5a7e8706d,insights_interaction,latest,,,2023-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02783,Norma Martin,,onco-eu-0059,Julien Mercier,Phone,X-Men,Italy,,Reduction in pain levels reported by patients with bone metastases.
text,87cfbd8e-b06c-41c2-9360-82133d42335e,insights_interaction,latest,,,2024-02-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02621,Henry Willett,,onco-eu-0059,Julien Mercier,Iron Man,Clinical Pharmacist,Spain,,Some patients experienced decreased appetite and weight loss during treatment.
text,c40b3ee0-284e-4438-afdb-e79cb7ee9042,insights_interaction,latest,,,2024-03-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02954,Victoria Larsen,,onco-eu-0059,Julien Mercier,Iron Man,X-Men,Greece,,No clear correlation observed between baseline inflammatory markers and treatment response.
text,3f8009b9-dd5d-438a-ad1a-df5e52124ea9,insights_interaction,latest,,,2024-05-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02697,Abby Miller,,onco-eu-0059,Julien Mercier,Phone,X-Men,Greece,,"Increased PD-L1 expression observed in tumor biopsies after one cycle of Vibranium/Wakanda, suggesting potential synergistic effect."
text,557a3e68-a0b1-4708-a0f7-70c2148e0b0b,insights_interaction,latest,,,2022-02-01,MSL Interactions,Oncology,Vibranium,,WB-US-04526,Dena Strother,,onco-us-0012,Karen Davis,Phone,X-Men,United States,MD,Significantly reduced treatment-related anxiety and improved patient psychological resilience
text,83acd82f-0804-4184-a079-6358867bbc20,insights_interaction,latest,,,2022-06-03,MSL Interactions,Oncology,Vibranium,,WB-US-03043,Naomi Pike,,onco-us-0012,Karen Davis,Iron Man,Wolverine,United States,MD,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,ddb0bad7-6413-48e2-b2fc-08a4a25cf421,insights_interaction,latest,,,2022-08-10,MSL Interactions,Oncology,Vibranium,,WB-US-04433,Larry Remington,,onco-us-0012,Karen Davis,Ulton,X-Men,United States,DC,Promising results in treatment-resistant cancer subtypes
text,cdee3954-19f1-46e4-9380-b1b819b75266,insights_interaction,latest,,,2022-10-14,MSL Interactions,Oncology,Vibranium,,WB-US-03171,Joyce Collins,,onco-us-0012,Karen Davis,Iron Man,X-Men,United States,DC,Early detection of response based on circulating tumor DNA analysis.
text,03246221-0d37-41c4-8f01-2ae06521eb33,insights_interaction,latest,,,2022-11-30,MSL Interactions,Oncology,Vibranium,,WB-US-04627,Tracy Hedley,,onco-us-0012,Karen Davis,Phone,X-Men,United States,PA,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,db7e8add-40fe-4255-bac3-1c827ef29381,insights_interaction,latest,,,2023-01-06,MSL Interactions,Oncology,Vibranium,,WB-US-04627,Tracy Hedley,,onco-us-0012,Karen Davis,Phone,X-Men,United States,PA,"Grade 2 neutropenia observed in 22% of patients, manageable with standard prophylactic interventions and G-CSF support"
text,261dc2c3-33df-421e-8b75-4cd443ea9817,insights_interaction,latest,,,2023-03-16,MSL Interactions,Oncology,Vibranium,,WB-US-04010,Heidi Jones,,onco-us-0012,Karen Davis,Iron Man,Clinical Pharmacist,United States,PA,No unexpected safety signals observed in the ongoing clinical trial.
text,870f456d-1146-4d0f-b7e2-6135a4d03ec8,insights_interaction,latest,,,2023-09-25,MSL Interactions,Oncology,Vibranium,,WB-US-03453,Judith Warren,,onco-us-0012,Karen Davis,Phone,Avenger,United States,DE,"Correlation detected between PD-L1 expression levels and treatment response, but not statistically definitive"
text,54388acf-bbc1-44db-acd2-68098c548c24,insights_interaction,latest,,,2024-02-08,MSL Interactions,Oncology,Vibranium,,WB-US-04391,Michael Joseph,,onco-us-0012,Karen Davis,Ulton,Wolverine,United States,MD,Comprehensive long-term safety profile demonstrates consistent tolerability with no unexpected adverse event signals
text,ddce009b-7f41-464b-b4b9-ff6fef6ed62b,insights_interaction,latest,,,2024-06-22,MSL Interactions,Oncology,Vibranium,,WB-US-03259,Billie Porter,,onco-us-0012,Karen Davis,Ulton,Avenger,United States,NJ,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,adbd4e99-fd41-4dfb-86fa-67036f6ca133,insights_interaction,latest,,,2024-09-02,MSL Interactions,Oncology,Vibranium,,WB-US-02919,Joshua Rausch,,onco-us-0012,Karen Davis,Iron Man,X-Men,United States,DE,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,4a78b951-95b3-470b-a2aa-e80d6409efb1,insights_interaction,latest,,,2022-01-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00798,Sidney Hill,,onco-eu-0009,Karin Ekström,Ulton,Deadpool,Norway,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,ea83df81-2519-44b6-9de4-c68dd82ebc0a,insights_interaction,latest,,,2022-03-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00150,Mary Ralston,,onco-eu-0009,Karin Ekström,Iron Man,Avenger,Norway,,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,58be61ae-c6b4-4546-966e-fe7de8f22c73,insights_interaction,latest,,,2022-04-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00207,John Latigo,,onco-eu-0009,Karin Ekström,Iron Man,Clinical Pharmacist,Finland,,Observed significant tumor regression in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.
text,10532396-2e42-451f-a6a3-11d173da2083,insights_interaction,latest,,,2022-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00798,Sidney Hill,,onco-eu-0009,Karin Ekström,Iron Man,Deadpool,Norway,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,8e6ac734-e2bc-4c9a-b5d6-c6fba3914f38,insights_interaction,latest,,,2022-05-15,MSL Interactions,Oncology,Vibranium,,WB-EU-00591,Ana Carmack,,onco-eu-0009,Karin Ekström,Iron Man,X-Men,Norway,,Complete response rates in metastatic melanoma patients reached 31%
text,5c6fc11d-c2c9-4045-a08d-2b7432683cf1,insights_interaction,latest,,,2022-05-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00446,James Miller,,onco-eu-0009,Karin Ekström,Iron Man,Deadpool,Norway,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,1dd90552-61d0-49f0-87c9-6baf9bbb34ef,insights_interaction,latest,,,2022-10-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00535,Kevin Murphy,,onco-eu-0009,Karin Ekström,Iron Man,Deadpool,Sweden,,Stable disease observed in several patients with lung cancer after two cycles.
text,69f7cd1d-e6fe-4390-aadc-c2b5ba0614de,insights_interaction,latest,,,2022-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00043,Cory Crary,,onco-eu-0009,Karin Ekström,Ulton,Clinical Pharmacist,Sweden,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,e12267c4-5569-43e8-a03c-ec9943f5caa5,insights_interaction,latest,,,2023-03-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00368,Elisabeth Quinn,,onco-eu-0009,Karin Ekström,Iron Man,X-Men,Finland,,"Complex administration protocol requires specialized nursing training, potentially limiting rapid deployment in smaller oncology practices."
text,8365cff0-ff12-4d50-af9f-efff61a8e2d2,insights_interaction,latest,,,2023-04-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00148,Susan Urmos,,onco-eu-0009,Karin Ekström,Iron Man,Wolverine,Finland,,"Promising results in combination with immunotherapy, showing synergistic effects in treatment-resistant malignancies"
text,3049115e-10a0-406c-a389-c1eb0053bbab,insights_interaction,latest,,,2023-10-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00591,Ana Carmack,,onco-eu-0009,Karin Ekström,Ulton,X-Men,Norway,,Mild immunological side effects managed effectively with supportive interventions
text,fe5325b4-4f95-4021-84b4-c87da00b4022,insights_interaction,latest,,,2024-01-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00180,Rachel Barnes,,onco-eu-0009,Karin Ekström,Iron Man,Avenger,Norway,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,62ba03fa-7ee8-41c9-bf66-3938121be780,insights_interaction,latest,,,2024-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00472,Carlos Dolan,,onco-eu-0009,Karin Ekström,Ulton,X-Men,Sweden,,Further research is needed to identify additional predictive biomarkers for response to Vibranium/Wakanda therapy.
text,2bc5770e-fa8c-45c5-a931-0ff03e864fa9,insights_interaction,latest,,,2024-04-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00140,Edward Curry,,onco-eu-0009,Karin Ekström,Iron Man,X-Men,Norway,,Correlation between pre-treatment tumor mutational burden (TMB) and response to Vibranium/Wakanda therapy remains inconclusive in our ongoing study.
text,9a6a0940-5711-47e6-bfe9-175bedf2ebee,insights_interaction,latest,,,2024-04-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00710,Jean Chesterfield,,onco-eu-0009,Karin Ekström,Phone,Wolverine,Denmark,,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,ec4a3e68-9147-4b1f-ac44-490d49b5598a,insights_interaction,latest,,,2021-02-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03386,Stephen Worthington,,onco-eu-0071,Katarina Novotna,Phone,Deadpool,Ireland,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,b82933a0-1a86-4814-9f8d-8cd57cb2e16b,insights_interaction,latest,,,2021-03-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03034,Thomas Adkins,,onco-eu-0071,Katarina Novotna,Ulton,Avenger,France,,Correlation observed between increased interferon-gamma levels and improved response to Vibranium/Wakanda in a subset of patients with head and neck squamous cell carcinoma.
text,e8f8d192-7201-4806-91a5-2e0bbffae6ee,insights_interaction,latest,,,2021-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03706,Brian Lee,,onco-eu-0071,Katarina Novotna,Phone,Avenger,France,,Promising early-stage data suggests potential for expanded indication spectrum
text,1e57ea87-9192-4216-a457-541ee084dece,insights_interaction,latest,,,2021-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03908,Pauline Sanchez,,onco-eu-0071,Katarina Novotna,Ulton,Deadpool,United Kingdom,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,493f33a1-b03b-4f50-a627-0e0f07430e4a,insights_interaction,latest,,,2021-05-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03653,Susan Baldwin,,onco-eu-0071,Katarina Novotna,Ulton,X-Men,France,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,773dd805-2c00-4ec2-b145-c7d31a73f18a,insights_interaction,latest,,,2021-06-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03761,Elvis Rayborn,,onco-eu-0071,Katarina Novotna,Phone,Deadpool,France,,Improved physical functioning and reduced pain reported by a patient with osteosarcoma after Vibranium/Wakanda treatment.
text,87ec9252-56fa-4f48-8b0b-b21eeff8b212,insights_interaction,latest,,,2021-06-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03290,Wilbur Finneran,,onco-eu-0071,Katarina Novotna,Iron Man,X-Men,Ireland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,86e6a0b3-41d0-4868-b0ef-e965c332d82b,insights_interaction,latest,,,2021-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03891,Margaret White,,onco-eu-0071,Katarina Novotna,Ulton,Clinical Pharmacist,France,,Observed significant tumor reduction in three patients with advanced pancreatic cancer after 8 weeks of Vibranium/Wakanda combination therapy.  One patient achieved a partial response.
text,1033f668-2c07-4cdb-acf1-d074ab605bd8,insights_interaction,latest,,,2021-08-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03483,Charles Dangelo,,onco-eu-0071,Katarina Novotna,Ulton,X-Men,France,,Reduction in pain levels reported by patients with bone metastases.
text,c2914091-4240-42d0-b446-cc449fbd3e92,insights_interaction,latest,,,2021-09-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03605,Juan Cox,,onco-eu-0071,Katarina Novotna,Phone,X-Men,United Kingdom,,Strong positive correlation between Ki-67 expression and treatment response rate
text,b92136bc-0f9e-4a81-9880-5caf0db19307,insights_interaction,latest,,,2021-11-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03797,Kathleen Mcknight,,onco-eu-0071,Katarina Novotna,Iron Man,Avenger,France,,No unexpected safety signals observed in the ongoing clinical trial.
text,151a3c3a-b00f-4b82-9cc5-f274df5a1bdc,insights_interaction,latest,,,2021-12-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03439,Troy Bourque,,onco-eu-0071,Katarina Novotna,Phone,X-Men,United Kingdom,,Reduction in pain levels reported by patients with bone metastases.
text,970a7283-111a-4084-b53c-403dd2f652cc,insights_interaction,latest,,,2022-02-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03927,Richard Reece,,onco-eu-0071,Katarina Novotna,Phone,X-Men,Ireland,,Improved pain scores reported by patients with bone metastases after two cycles of treatment.
text,1b6aa2fb-076d-4503-a627-3e697c288b65,insights_interaction,latest,,,2022-03-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03161,Emanuel Smith,,onco-eu-0071,Katarina Novotna,Phone,X-Men,France,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,3ebbb100-3f2d-4c65-af80-cc0ad4a40335,insights_interaction,latest,,,2023-01-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03051,Mitchell Vida,,onco-eu-0071,Katarina Novotna,Phone,Wolverine,Ireland,,Quality of life remained stable in a majority of patients despite disease progression.
text,24fa75a1-406b-4a4c-b284-3018705b70e7,insights_interaction,latest,,,2023-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03439,Troy Bourque,,onco-eu-0071,Katarina Novotna,Phone,X-Men,United Kingdom,,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,94ad8077-dfc4-4bc1-9139-b127790c658e,insights_interaction,latest,,,2023-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03290,Wilbur Finneran,,onco-eu-0071,Katarina Novotna,Ulton,X-Men,Ireland,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,d304a206-b472-498f-bc95-c43ad0900d1b,insights_interaction,latest,,,2023-09-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03383,Joseph Wise,,onco-eu-0071,Katarina Novotna,Ulton,Deadpool,Ireland,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,d54a0623-53be-42e5-a1e0-5d6e22a6e41d,insights_interaction,latest,,,2023-12-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03351,Oscar Mcclure,,onco-eu-0071,Katarina Novotna,Iron Man,Deadpool,Ireland,,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,329a6611-31b5-45d0-9faf-601302439c9f,insights_interaction,latest,,,2023-12-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03155,Jerry Harris,,onco-eu-0071,Katarina Novotna,Iron Man,X-Men,Ireland,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,8d2621ac-e57b-4027-8449-f4a8f45330aa,insights_interaction,latest,,,2024-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03034,Thomas Adkins,,onco-eu-0071,Katarina Novotna,Phone,Avenger,France,,The need for frequent monitoring and adjustments to the treatment regimen increases the complexity and cost of Vibranium/Wakanda therapy.
text,a6ecae8c-2e67-46be-a820-f7c842d7b4ca,insights_interaction,latest,,,2024-06-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03483,Charles Dangelo,,onco-eu-0071,Katarina Novotna,Phone,X-Men,France,,Early detection of response based on circulating tumor DNA analysis.
text,b238299f-0ff2-4809-80b5-8fa4ac559ea9,insights_interaction,latest,,,2024-11-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03069,Darrell Brown,,onco-eu-0071,Katarina Novotna,Iron Man,X-Men,France,,One case of grade 2 liver toxicity was reported and successfully managed.
text,cec163f5-df8e-436f-8235-3fd50cd4f1c7,insights_interaction,latest,,,2024-12-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03386,Stephen Worthington,,onco-eu-0071,Katarina Novotna,Iron Man,Deadpool,Ireland,,"Rare instances of grade 3-4 neurotoxicity observed in 5% of patients, necessitating careful neurological monitoring and potential dose modifications."
text,baec5a0d-b0d7-4fa1-b9ea-387fe0828f66,insights_interaction,latest,,,2021-01-07,MSL Interactions,Oncology,Vibranium,,WB-US-07571,Donald Roddick,,onco-us-0020,Kevin Martin,Iron Man,Avenger,United States,MO,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,440eb9e9-e444-4c53-9bae-e4a589c636d7,insights_interaction,latest,,,2021-02-04,MSL Interactions,Oncology,Vibranium,,WB-US-07162,Christopher Melendez,,onco-us-0020,Kevin Martin,Phone,X-Men,United States,IN,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,afcbc866-3cf6-4e2f-a69b-947d552601c8,insights_interaction,latest,,,2021-02-09,MSL Interactions,Oncology,Vibranium,,WB-US-07891,Gina Suniga,,onco-us-0020,Kevin Martin,Ulton,Wolverine,United States,IL,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,91b072f7-703e-43fd-bced-70038f45c22c,insights_interaction,latest,,,2021-05-20,MSL Interactions,Oncology,Vibranium,,WB-US-07424,Alexander Day,,onco-us-0020,Kevin Martin,Iron Man,X-Men,United States,IN,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,54d74891-bafe-4c48-8a97-0e8288a3d4fb,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-US-07780,Rhonda Williams,,onco-us-0020,Kevin Martin,Phone,Avenger,United States,IN,Patients reported improved emotional well-being and reduced treatment anxiety
text,84b3c897-c2b7-4b90-ad49-1e6e6824af69,insights_interaction,latest,,,2021-12-14,MSL Interactions,Oncology,Vibranium,,WB-US-07578,Samuel Duarte,,onco-us-0020,Kevin Martin,Iron Man,Deadpool,United States,IL,Early detection of response based on circulating tumor DNA analysis.
text,788e69de-bde3-41b1-8967-9933dfddad1d,insights_interaction,latest,,,2022-03-15,MSL Interactions,Oncology,Vibranium,,WB-US-06880,Edna Lee,,onco-us-0020,Kevin Martin,Phone,X-Men,United States,IN,Significant response observed in a patient with previously treatment-refractory melanoma.
text,9d08d528-f804-43cb-b99b-b445e5ea87bd,insights_interaction,latest,,,2022-03-31,MSL Interactions,Oncology,Vibranium,,WB-US-07941,Debra Peacock,,onco-us-0020,Kevin Martin,Iron Man,Deadpool,United States,OH,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,d374b44e-c90a-4458-ae1d-431145f5036d,insights_interaction,latest,,,2022-05-12,MSL Interactions,Oncology,Vibranium,,WB-US-07200,Edward Donahoo,,onco-us-0020,Kevin Martin,Phone,Avenger,United States,WI,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,dc7468b9-6152-4da7-bcd1-7f29b97ca25c,insights_interaction,latest,,,2022-12-22,MSL Interactions,Oncology,Vibranium,,WB-US-07416,Jonathan Depaolo,,onco-us-0020,Kevin Martin,Phone,Avenger,United States,MO,Patients reported improved sleep quality and reduced anxiety after receiving Vibranium/Wakanda.
text,b1d3c662-19f9-4cda-92b6-c011626f24a6,insights_interaction,latest,,,2023-03-14,MSL Interactions,Oncology,Vibranium,,WB-US-06733,John Robinson,,onco-us-0020,Kevin Martin,Phone,X-Men,United States,MN,"Observed variable response rates across different tumor types, with better efficacy seen in pancreatic and colorectal cancers."
text,206ca3cc-da14-488b-8c0a-9d744b0255c2,insights_interaction,latest,,,2023-04-04,MSL Interactions,Oncology,Vibranium,,WB-US-08025,William Kee,,onco-us-0020,Kevin Martin,Ulton,X-Men,United States,OH,Correlation between baseline tumor mutational burden and response to Vibranium/Wakanda requires further investigation.
text,3633a998-cbf2-4bf4-ba2f-0b5ea0a5c7eb,insights_interaction,latest,,,2023-06-19,MSL Interactions,Oncology,Vibranium,,WB-US-06618,Danny Miller,,onco-us-0020,Kevin Martin,Ulton,X-Men,United States,OH,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,d3530d74-d475-466c-b7d7-616ce1e20bfe,insights_interaction,latest,,,2024-01-23,MSL Interactions,Oncology,Vibranium,,WB-US-08061,Edward Walsh,,onco-us-0020,Kevin Martin,Ulton,X-Men,United States,OH,"Grade 3 hepatotoxicity observed in a patient, requiring temporary discontinuation of Vibranium/Wakanda. Liver function tests normalized after supportive care."
text,685d4e62-b662-4d84-88a1-37a9a93f3205,insights_interaction,latest,,,2024-08-25,MSL Interactions,Oncology,Vibranium,,WB-US-07957,Edward Adkisson,,onco-us-0020,Kevin Martin,Iron Man,Deadpool,United States,MO,Inconsistent genomic response patterns across different mutation subtypes
text,2158cad5-942e-4447-bfba-fb2475ea0b8b,insights_interaction,latest,,,2022-01-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00086,Walter Harper,,onco-eu-0016,Klaus Weber,Phone,Avenger,Sweden,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,bf47e8cb-51d9-43e1-a45a-88ed112cb464,insights_interaction,latest,,,2022-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00450,Elsa Mcdaniel,,onco-eu-0016,Klaus Weber,Ulton,X-Men,Denmark,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,55aa0aaf-446f-4658-8e15-baed7342c601,insights_interaction,latest,,,2022-07-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00084,Edna Brown,,onco-eu-0016,Klaus Weber,Iron Man,Avenger,Finland,,Prolonged progression-free survival observed in a subset of patients with triple-negative breast cancer (TNBC) treated with Vibranium/Wakanda in combination with standard chemotherapy.
text,0496ac87-6ff1-4995-8ca9-986719695572,insights_interaction,latest,,,2022-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00513,James Mabe,,onco-eu-0016,Klaus Weber,Phone,X-Men,Norway,,Preliminary data suggests synergistic effect between Vibranium and Wakanda.
text,35240a80-0d41-427b-af81-35d1140f5791,insights_interaction,latest,,,2022-08-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00767,Audry Martin,,onco-eu-0016,Klaus Weber,Iron Man,X-Men,Finland,,Demonstrated 42% overall response rate in metastatic solid tumor patients with prior treatment resistance
text,136efeec-8ff6-4a16-852f-c3d3065ff748,insights_interaction,latest,,,2022-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00420,Clifford Trujillo,,onco-eu-0016,Klaus Weber,Phone,Avenger,Denmark,,Significant tumor size reduction in 62% of non-small cell lung cancer patients
text,d74f1068-41d1-4fd8-8c6b-38d392b3aa58,insights_interaction,latest,,,2022-09-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00086,Walter Harper,,onco-eu-0016,Klaus Weber,Ulton,Avenger,Sweden,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,c1d04a19-baac-451c-80fc-46f1118e4ef2,insights_interaction,latest,,,2023-04-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00505,Curtis Bryant,,onco-eu-0016,Klaus Weber,Phone,Avenger,Denmark,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,13023119-e18c-4201-93ca-d6dd43a14753,insights_interaction,latest,,,2023-04-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00035,Erica Greenough,,onco-eu-0016,Klaus Weber,Iron Man,X-Men,Finland,,Limited predictive value of current molecular markers for treatment response
text,61f759c6-fa88-4264-a697-f532175f02f7,insights_interaction,latest,,,2023-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00215,Raquel Escalante,,onco-eu-0016,Klaus Weber,Phone,Wolverine,Denmark,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,e8e1c362-c192-4c0f-a1d4-e7232464a0b0,insights_interaction,latest,,,2023-09-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00095,Ernest Goff,,onco-eu-0016,Klaus Weber,Iron Man,Avenger,Finland,,"The cost of Vibranium/Wakanda is prohibitively expensive for many patients, limiting access to this potentially beneficial therapy.  Insurance coverage remains a significant barrier."
text,b0a17f3b-cd20-4fd1-97dc-c81ff44a2e3a,insights_interaction,latest,,,2023-11-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00374,Evelyn Easter,,onco-eu-0016,Klaus Weber,Iron Man,X-Men,Sweden,,Observed mild neutropenia in 24% of patients during initial treatment phase. Grade 1-2 side effects were manageable with standard prophylactic interventions and did not require treatment discontinuation.
text,5ebc6f17-6a5e-46dc-af98-a56f0ebb8e98,insights_interaction,latest,,,2023-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00178,Ronald Smith,,onco-eu-0016,Klaus Weber,Phone,Avenger,Sweden,,"Mild flu-like symptoms were reported in most patients during the initial phase of Vibranium/Wakanda treatment, resolving within 72 hours with supportive care."
text,58f5cfb1-83eb-4316-8add-524f79d23875,insights_interaction,latest,,,2023-12-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00030,Bill Webb,,onco-eu-0016,Klaus Weber,Iron Man,X-Men,Denmark,,"Improved quality of life scores (using EORTC QLQ-C30) observed in patients receiving Vibranium/Wakanda, particularly in reduction of fatigue and pain."
text,12dd023b-cad5-400a-950d-daa8194a8f9f,insights_interaction,latest,,,2024-02-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00621,Tommy Harless,,onco-eu-0016,Klaus Weber,Ulton,Avenger,Sweden,,Observed variable response rates to Vibranium/Wakanda across different tumor types in the ongoing clinical trial.
text,e9e55f89-7e90-4b4f-8920-03473f57b8a3,insights_interaction,latest,,,2024-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00084,Edna Brown,,onco-eu-0016,Klaus Weber,Iron Man,Avenger,Finland,,Response to Vibranium/Wakanda appears to be influenced by the tumor microenvironment.
text,1830b155-0b1a-4a6c-bdcd-8a6ef91d9f2e,insights_interaction,latest,,,2024-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00201,Stewart Beers,,onco-eu-0016,Klaus Weber,Ulton,Avenger,Finland,,Reduction in pain levels reported by patients with bone metastases.
text,4c5a57ec-40a9-4385-adef-b740b3c52228,insights_interaction,latest,,,2024-10-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00065,Stacy Tabor,,onco-eu-0016,Klaus Weber,Iron Man,X-Men,Norway,,Moderate immune-related adverse events in 18% of patients
text,ffc55de5-918a-4c5e-b600-9dbf50e2cca4,insights_interaction,latest,,,2024-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00579,Basil Donoho,,onco-eu-0016,Klaus Weber,Iron Man,Wolverine,Denmark,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,9531fe40-9405-48f0-8821-7affa30d7ef5,insights_interaction,latest,,,2021-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03486,Andy Beckham,,onco-eu-0078,Kristina Petrova,Iron Man,Avenger,France,,Elevated levels of certain inflammatory cytokines were observed to correlate with a positive clinical response to Vibranium/Wakanda.
text,2428ee0b-a3bc-4b52-a865-e7b9e81a65fc,insights_interaction,latest,,,2021-06-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03736,Lloyd Sells,,onco-eu-0078,Kristina Petrova,Phone,X-Men,Ireland,,Stable disease observed in several patients with advanced colorectal cancer after two cycles.
text,edff9dae-18d7-4757-aa61-1619fdbd2cf5,insights_interaction,latest,,,2021-11-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03821,Grace Hall,,onco-eu-0078,Kristina Petrova,Ulton,Avenger,United Kingdom,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,4d2b3c2f-c8a4-4091-af47-56e99746dd90,insights_interaction,latest,,,2022-03-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03775,Marshall Manciel,,onco-eu-0078,Kristina Petrova,Iron Man,Avenger,United Kingdom,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,eaf6dc8d-8997-44dd-9b6a-f8c455caf46d,insights_interaction,latest,,,2022-04-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03819,Alison Acevedo,,onco-eu-0078,Kristina Petrova,Phone,X-Men,Ireland,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,1e822329-fcda-4485-968a-e780a2e6fdf0,insights_interaction,latest,,,2022-05-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03105,George Haworth,,onco-eu-0078,Kristina Petrova,Phone,Avenger,Ireland,,No unexpected safety signals observed in the ongoing clinical trial.
text,5b54dcba-b5bc-4a5d-8e06-8ff8c23490fb,insights_interaction,latest,,,2022-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03504,Jonathan Thornton,,onco-eu-0078,Kristina Petrova,Phone,Wolverine,France,,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,1ca5d506-eb87-4c59-84d2-c7467fdb1f3d,insights_interaction,latest,,,2022-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03073,Donald Harley,,onco-eu-0078,Kristina Petrova,Iron Man,Avenger,France,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,455de483-8a17-44ff-8b4f-25697193eadd,insights_interaction,latest,,,2022-10-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03416,Matthew Godwin,,onco-eu-0078,Kristina Petrova,Ulton,Deadpool,Ireland,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,6ff0dc2e-9d0b-49e1-a7db-5aeb4ab09e3d,insights_interaction,latest,,,2023-06-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03411,Patricia Trotman,,onco-eu-0078,Kristina Petrova,Phone,Deadpool,France,,Stable disease observed for over 6 months in a patient with recurrent glioblastoma following Vibranium/Wakanda treatment.
text,debbdd16-0e27-4da4-9c37-1d7449630c14,insights_interaction,latest,,,2023-08-02,MSL Interactions,Oncology,Vibranium,,WB-EU-03744,Helen Hendricks,,onco-eu-0078,Kristina Petrova,Phone,Avenger,France,,"Increased PD-L1 expression observed in tumor biopsies post-treatment, suggesting a potential mechanism of action for the combination therapy."
text,5877f341-5328-4b4c-af08-1986adc59a01,insights_interaction,latest,,,2023-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03673,Dennis Hopkins,,onco-eu-0078,Kristina Petrova,Ulton,Clinical Pharmacist,France,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,39bbb188-0e5f-4cb4-a04f-08caae2b2004,insights_interaction,latest,,,2023-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03555,Shirley Calhoun,,onco-eu-0078,Kristina Petrova,Ulton,Wolverine,Ireland,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,54ec080a-d0c4-4bd3-acfa-7f1c48dcda13,insights_interaction,latest,,,2023-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03264,Rebecca Hamby,,onco-eu-0078,Kristina Petrova,Iron Man,X-Men,Ireland,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,72d96d55-0971-472b-aab7-959c2b8bdd01,insights_interaction,latest,,,2024-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03769,Edward Westlake,,onco-eu-0078,Kristina Petrova,Phone,X-Men,Ireland,,Requires close monitoring of blood counts and other laboratory parameters.
text,2972bc8d-9449-4eac-83ba-bff2e5c0783a,insights_interaction,latest,,,2024-08-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03555,Shirley Calhoun,,onco-eu-0078,Kristina Petrova,Iron Man,Wolverine,Ireland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,7a793977-249d-4445-b55b-70eb45aebf60,insights_interaction,latest,,,2024-08-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03264,Rebecca Hamby,,onco-eu-0078,Kristina Petrova,Ulton,X-Men,Ireland,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,e94d1e51-0e17-4188-8507-718860e39942,insights_interaction,latest,,,2024-11-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03755,David Heroux,,onco-eu-0078,Kristina Petrova,Iron Man,X-Men,United Kingdom,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,0a2bb4d3-1b2e-40c4-b375-42dcc4ade7b4,insights_interaction,latest,,,2024-12-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03288,Barbara Mcghee,,onco-eu-0078,Kristina Petrova,Ulton,Avenger,United Kingdom,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,2f311bda-f3fa-40f8-aec7-d0a78f04436c,insights_interaction,latest,,,2021-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00242,Dale Westmoreland,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Norway,,"Patient with stage III melanoma experienced a 70% reduction in tumor size after 8 weeks of Vibranium/Wakanda therapy, confirmed by RECIST criteria.  Significant reduction in pain reported."
text,7822d5aa-3e24-4a68-8e94-26d770c5a556,insights_interaction,latest,,,2021-02-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00689,Thomas Sorell,,onco-eu-0004,Lars Peterson,Phone,Avenger,Denmark,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,b89172c3-6589-4455-909f-91bfde46f52f,insights_interaction,latest,,,2021-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00190,Timothy Lopez,,onco-eu-0004,Lars Peterson,Iron Man,Avenger,Finland,,Significant improvement in patient-reported symptom management and treatment tolerability
text,f6156fa1-78fc-4f5d-8089-cb232f4da862,insights_interaction,latest,,,2021-08-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00057,Grace Ingram,,onco-eu-0004,Lars Peterson,Phone,X-Men,Finland,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,4fd261d7-bfce-4360-97fb-23ac617651ff,insights_interaction,latest,,,2021-10-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00689,Thomas Sorell,,onco-eu-0004,Lars Peterson,Iron Man,Avenger,Denmark,,Early detection of response based on circulating tumor DNA analysis.
text,31bf3fd8-94d6-413f-a445-b9426169f45d,insights_interaction,latest,,,2021-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00497,Ernestine Lassiter,,onco-eu-0004,Lars Peterson,Iron Man,X-Men,Norway,,"Complete metabolic response in 29% of patients with advanced pancreatic adenocarcinoma, exceeding historical treatment benchmarks"
text,42111988-b8b2-4952-8b6a-b533f4078c21,insights_interaction,latest,,,2021-12-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00454,Donald Davis,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Sweden,,Significant reduction in pain scores and improved functional status for advanced cancer patients
text,27c09561-c0ed-4e4c-99a1-7d19c50bf4c0,insights_interaction,latest,,,2022-02-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00614,Carol Sidwell,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Denmark,,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,020115df-839d-474e-87bc-e0ad984fb026,insights_interaction,latest,,,2022-03-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00046,Raymond Ray,,onco-eu-0004,Lars Peterson,Ulton,Wolverine,Finland,,Significant improvement in patient's ability to perform activities of daily living reported after 4 weeks of Vibranium/Wakanda treatment.
text,ba02e9bc-04a3-41dd-945e-3791d7c5e200,insights_interaction,latest,,,2022-04-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00497,Ernestine Lassiter,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Norway,,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,ce130463-3407-4ee2-9f17-917c8ef6436f,insights_interaction,latest,,,2022-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00337,Paul Mcmahon,,onco-eu-0004,Lars Peterson,Ulton,Avenger,Finland,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,68b420da-ceac-4d7e-8c8b-ab30f4be70d0,insights_interaction,latest,,,2023-03-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00460,Sara Juckett,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Norway,,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,7ebbc002-a7e2-4c56-ae15-18a7820c3664,insights_interaction,latest,,,2023-08-31,MSL Interactions,Oncology,Vibranium,,WB-EU-00434,Nicole Costa,,onco-eu-0004,Lars Peterson,Iron Man,Deadpool,Denmark,,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,0f6317a9-bc1f-4a36-8c01-f635b53b6d35,insights_interaction,latest,,,2023-09-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00630,Helen Labelle,,onco-eu-0004,Lars Peterson,Phone,Avenger,Sweden,,Progression-free survival times varied widely across the patient cohort.
text,d0a97510-c951-4497-8ad6-b563fdcf630b,insights_interaction,latest,,,2024-01-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00137,Charles Tidwell,,onco-eu-0004,Lars Peterson,Iron Man,Deadpool,Finland,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,4d2780c3-a4dd-4d5e-b6a3-102a78ac8e91,insights_interaction,latest,,,2024-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00689,Thomas Sorell,,onco-eu-0004,Lars Peterson,Iron Man,Avenger,Denmark,,Observed a heterogeneous response to Vibranium/Wakanda therapy in patients with advanced head and neck squamous cell carcinoma (HNSCC). Some patients showed partial responses while others experienced stable disease.
text,ee5505d9-a6e5-4029-b9c2-ac79337fdddd,insights_interaction,latest,,,2024-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00068,David Barrow,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Denmark,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,a71c4437-c4aa-45e7-b82c-ac0c099932e0,insights_interaction,latest,,,2024-05-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00069,Cynthia Wilson,,onco-eu-0004,Lars Peterson,Phone,X-Men,Norway,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,7f24a38a-15f3-43af-8432-9e83290774f1,insights_interaction,latest,,,2024-07-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00100,Sonia Murphy,,onco-eu-0004,Lars Peterson,Ulton,X-Men,Denmark,,Further investigation is needed to explore the role of other biomarkers in predicting response to Vibranium.
text,5f9d50a1-1709-4b52-b099-55e7137ad654,insights_interaction,latest,,,2024-11-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00337,Paul Mcmahon,,onco-eu-0004,Lars Peterson,Phone,Avenger,Finland,,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,8c3e6e90-dc20-420a-9bf9-363425e76904,insights_interaction,latest,,,2024-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00452,Steven Jackson,,onco-eu-0004,Lars Peterson,Iron Man,Avenger,Norway,,"Increased expression of PD-L1 was noted in tumor biopsies post-treatment, suggesting a potential synergy with immune checkpoint inhibitors."
text,5e1b81c0-661e-47ef-8292-9b52abe50864,insights_interaction,latest,,,2024-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00452,Steven Jackson,,onco-eu-0004,Lars Peterson,Phone,Avenger,Norway,,"Demonstrated superior efficacy in triple-negative breast cancer patients with BRCA1/2 mutations, with 36% complete or partial response"
text,2fe6a018-7a86-4afa-acaa-5f4ecd91f25b,insights_interaction,latest,,,2021-02-01,MSL Interactions,Oncology,Vibranium,,WB-US-07359,Ralph Ricks,,onco-us-0024,Laura Wilson,Ulton,X-Men,United States,MI,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,ae84fef7-de5f-4268-944a-551f188bb5f2,insights_interaction,latest,,,2021-08-22,MSL Interactions,Oncology,Vibranium,,WB-US-08099,Penny Pace,,onco-us-0024,Laura Wilson,Iron Man,Avenger,United States,MI,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,8936d990-a4f3-487c-9350-bcc3e9d1ec47,insights_interaction,latest,,,2021-09-25,MSL Interactions,Oncology,Vibranium,,WB-US-08026,Samuel Mccord,,onco-us-0024,Laura Wilson,Phone,Wolverine,United States,IL,Significantly reduced treatment-related fatigue compared to traditional cytotoxic chemotherapy protocols
text,eab72fd1-02aa-4961-926a-55b4b6480728,insights_interaction,latest,,,2021-12-20,MSL Interactions,Oncology,Vibranium,,WB-US-07706,Chantell Vu,,onco-us-0024,Laura Wilson,Iron Man,Clinical Pharmacist,United States,IL,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,6a88f61a-6dcf-4458-baac-825b5fd7a7cc,insights_interaction,latest,,,2022-01-23,MSL Interactions,Oncology,Vibranium,,WB-US-07525,Rosa Ator,,onco-us-0024,Laura Wilson,Phone,Avenger,United States,IL,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,8fdcf767-c2f1-46f2-9ac9-9f4500b13b09,insights_interaction,latest,,,2022-02-13,MSL Interactions,Oncology,Vibranium,,WB-US-07529,Maria Nash,,onco-us-0024,Laura Wilson,Ulton,Avenger,United States,IL,"Preliminary phase II data shows 42% objective response rate in advanced metastatic solid tumors, with notable durable responses in patients previously refractory to standard therapies."
text,8049a9a7-ecb7-402d-9ee8-17b0f8709208,insights_interaction,latest,,,2022-05-03,MSL Interactions,Oncology,Vibranium,,WB-US-07592,Jennifer Nguyen,,onco-us-0024,Laura Wilson,Phone,Avenger,United States,WI,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,ed198ffe-2916-4d34-8a42-d3d2027a6078,insights_interaction,latest,,,2022-06-21,MSL Interactions,Oncology,Vibranium,,WB-US-08073,Esther Lindstedt,,onco-us-0024,Laura Wilson,Iron Man,X-Men,United States,MI,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,8eb9a08c-fdf8-47f6-a9e7-cd77fce555d4,insights_interaction,latest,,,2022-12-27,MSL Interactions,Oncology,Vibranium,,WB-US-07883,Billy Schutz,,onco-us-0024,Laura Wilson,Iron Man,X-Men,United States,IN,"Patient with advanced pancreatic cancer (PDAC) exhibiting measurable reduction in tumor size (30%) after two cycles of Vibranium/Wakanda therapy, accompanied by improved CA 19-9 levels.  Response confirmed by RECIST 1.1 criteria."
text,fea450d6-89ad-4aa1-a817-d67131f7ad62,insights_interaction,latest,,,2023-06-30,MSL Interactions,Oncology,Vibranium,,WB-US-07948,Elsie Wells,,onco-us-0024,Laura Wilson,Phone,Wolverine,United States,IN,"Treatment administration time is relatively short, minimizing patient burden."
text,5fc477fb-982f-4f6e-bbd5-aee2e5186e7f,insights_interaction,latest,,,2023-08-08,MSL Interactions,Oncology,Vibranium,,WB-US-07659,Dorothy Conley,,onco-us-0024,Laura Wilson,Iron Man,Deadpool,United States,MO,Cost-effectiveness analysis indicates potential healthcare system benefits
text,297a93c3-3336-4470-b55d-ba66a31ae71d,insights_interaction,latest,,,2024-03-04,MSL Interactions,Oncology,Vibranium,,WB-US-07493,Arthur Sanders,,onco-us-0024,Laura Wilson,Iron Man,X-Men,United States,MO,"Observed inter-patient variability in treatment response, suggesting the need for further investigation into predictive biomarkers."
text,e7ed3b8a-391e-4f02-9a66-00c9f529cec3,insights_interaction,latest,,,2024-06-04,MSL Interactions,Oncology,Vibranium,,WB-US-07680,Chad Johnson,,onco-us-0024,Laura Wilson,Ulton,Deadpool,United States,OH,Stable disease observed in several patients with lung cancer after two cycles.
text,f2d301e8-9cb4-4eb9-8577-daeee3e26694,insights_interaction,latest,,,2024-08-10,MSL Interactions,Oncology,Vibranium,,WB-US-07740,Wayne Malloy,,onco-us-0024,Laura Wilson,Iron Man,X-Men,United States,WI,"Increased incidence of hepatic toxicity observed in a subset of patients receiving Vibranium/Wakanda, necessitating close monitoring of liver function."
text,39405c8c-aab2-4f52-a769-7b6611e74953,insights_interaction,latest,,,2024-12-04,MSL Interactions,Oncology,Vibranium,,WB-US-07013,Gary Wycoff,,onco-us-0024,Laura Wilson,Iron Man,X-Men,United States,MN,Progression-free survival times varied widely across the patient cohort.
text,c6c723c0-b5ec-4774-9670-d82a56b493c3,insights_interaction,latest,,,2024-12-28,MSL Interactions,Oncology,Vibranium,,WB-US-07359,Ralph Ricks,,onco-us-0024,Laura Wilson,Phone,X-Men,United States,MI,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,3a11b9af-c4c5-44db-b3d2-d2aff3d64336,insights_interaction,latest,,,2021-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01866,Danielle Hood,,onco-eu-0031,Lena Weber,Phone,X-Men,Netherlands,,Sustained progression-free survival of 10.2 months in advanced stage cancer patients
text,f7a9f8cc-d345-4b13-b364-6df088f440a8,insights_interaction,latest,,,2022-04-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01238,Norma Cisneros,,onco-eu-0031,Lena Weber,Iron Man,X-Men,Germany,,"Patient reported significant improvement in quality of life after receiving Vibranium/Wakanda for metastatic melanoma.  They experienced a reduction in pain and fatigue, allowing them to resume some daily activities.  They noted improved mood and reduced anxiety related to their prognosis."
text,9c4ad9bd-4a5d-43d7-98b9-d4ef77585411,insights_interaction,latest,,,2022-07-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01529,Mary Foster,,onco-eu-0031,Lena Weber,Ulton,X-Men,Belgium,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,85d923b7-4bd3-4a6f-85c7-a36806e6fdb1,insights_interaction,latest,,,2022-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01006,Patrick Michell,,onco-eu-0031,Lena Weber,Phone,X-Men,Belgium,,Promising early signals of efficacy in rare cancer subtypes with limited treatment options
text,20bf834e-bd46-4826-82cc-a5e9c04e96a7,insights_interaction,latest,,,2022-10-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01232,James George,,onco-eu-0031,Lena Weber,Ulton,X-Men,Switzerland,,Improved sleep quality reported by several patients on the therapy.
text,3849473c-ce81-4240-b7bd-28d1d2664577,insights_interaction,latest,,,2023-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01139,Chris Bray,,onco-eu-0031,Lena Weber,Ulton,Avenger,Austria,,"Treatment administration requires specialized expertise, potentially limiting accessibility in certain settings."
text,57eff0c1-9109-4cdd-9148-b8586e093bcf,insights_interaction,latest,,,2023-07-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01903,Stanley Brown,,onco-eu-0031,Lena Weber,Phone,X-Men,Netherlands,,"Synergistic effect observed between Vibranium and Wakanda, leading to enhanced antitumor activity."
text,14a5a078-3a1d-4026-9474-6d286fb84605,insights_interaction,latest,,,2023-10-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00962,Kyla Brown,,onco-eu-0031,Lena Weber,Iron Man,Avenger,Netherlands,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,a7aef351-853a-4ef0-a6b6-f917ed59e874,insights_interaction,latest,,,2023-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01905,Lee Taylor,,onco-eu-0031,Lena Weber,Ulton,Deadpool,Austria,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,d5639b72-863e-492a-9d3e-18106ca60085,insights_interaction,latest,,,2024-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00883,Carol Singh,,onco-eu-0031,Lena Weber,Ulton,Wolverine,Belgium,,No significant changes observed in circulating tumor DNA levels after the first cycle of treatment.
text,dadb7a22-c997-48be-920f-4eec1191b047,insights_interaction,latest,,,2024-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01903,Stanley Brown,,onco-eu-0031,Lena Weber,Phone,X-Men,Netherlands,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,c1dd667d-5424-42db-b1d7-3338deea5d4f,insights_interaction,latest,,,2024-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01006,Patrick Michell,,onco-eu-0031,Lena Weber,Iron Man,X-Men,Belgium,,Genetic mutation analysis reveals potential predictive markers for treatment response
text,c545de36-28f0-488b-a229-f070e07ee28e,insights_interaction,latest,,,2021-09-04,MSL Interactions,Oncology,Vibranium,,WB-US-08908,Michael Guyton,,onco-us-0030,Linda Martinez,Phone,Wolverine,United States,AR,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,de59fa85-42a1-4bdd-9604-1aeeed32583f,insights_interaction,latest,,,2021-09-26,MSL Interactions,Oncology,Vibranium,,WB-US-09132,Melissa Bonanno,,onco-us-0030,Linda Martinez,Iron Man,Avenger,United States,TX,No unexpected or severe adverse events were reported in the majority of patients.
text,dd8361ca-fb58-4ce4-ae8e-e528e2cbcacf,insights_interaction,latest,,,2021-11-29,MSL Interactions,Oncology,Vibranium,,WB-US-08570,Eugene Patterson,,onco-us-0030,Linda Martinez,Ulton,Deadpool,United States,AR,Remarkable long-term survival rates in patients with advanced metastatic disease
text,0085eb80-f7d7-451e-a46b-5c87ae4d7dcb,insights_interaction,latest,,,2022-01-29,MSL Interactions,Oncology,Vibranium,,WB-US-08561,Michelle Lambert,,onco-us-0030,Linda Martinez,Ulton,X-Men,United States,AR,Observed 42% objective response rate in metastatic solid tumor patients during phase II trial
text,4ff39943-876c-4357-947e-6aa0592b9c3c,insights_interaction,latest,,,2022-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-08587,Agnes Matty,,onco-us-0030,Linda Martinez,Phone,Avenger,United States,SD,Significant reduction in treatment-related fatigue and improved patient mobility
text,1fce623f-72a9-415a-b776-805538d259f9,insights_interaction,latest,,,2022-08-07,MSL Interactions,Oncology,Vibranium,,WB-US-08484,Robert Wood,,onco-us-0030,Linda Martinez,Ulton,Avenger,United States,OK,"Patients reported significantly improved fatigue scores and reduced pain compared to traditional chemotherapy regimens, with 73% maintaining normal daily functioning"
text,fa8e66f5-9f52-4f75-afce-7a1e3f4dd3c6,insights_interaction,latest,,,2022-12-19,MSL Interactions,Oncology,Vibranium,,WB-US-08438,Mary Moreta,,onco-us-0030,Linda Martinez,Iron Man,Avenger,United States,LA,Complete response observed in one patient with metastatic melanoma after 12 weeks of treatment.
text,f2147a00-2dea-4679-bab0-1821fa370b39,insights_interaction,latest,,,2023-03-09,MSL Interactions,Oncology,Vibranium,,WB-US-08905,David Mitchell,,onco-us-0030,Linda Martinez,Iron Man,Wolverine,United States,AR,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,f7074348-943d-4314-852e-4fea055c2269,insights_interaction,latest,,,2023-03-12,MSL Interactions,Oncology,Vibranium,,WB-US-08990,Norma Meyer,,onco-us-0030,Linda Martinez,Phone,Wolverine,United States,LA,Moderate complexity in administration protocol requiring specialized nursing training
text,ed856e94-2165-41b7-99e8-7abfa484475a,insights_interaction,latest,,,2023-04-26,MSL Interactions,Oncology,Vibranium,,WB-US-08350,David Brooks,,onco-us-0030,Linda Martinez,Ulton,X-Men,United States,NE,Improved immunological tolerability profile compared to previous combination therapies
text,e2da7710-aa72-4aa6-a519-f945ea26554e,insights_interaction,latest,,,2023-05-12,MSL Interactions,Oncology,Vibranium,,WB-US-08786,Jamie Prescott,,onco-us-0030,Linda Martinez,Phone,Avenger,United States,SD,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,970f9a6e-9e55-464c-b83b-763b87599ed6,insights_interaction,latest,,,2023-06-07,MSL Interactions,Oncology,Vibranium,,WB-US-08643,Linda Clark,,onco-us-0030,Linda Martinez,Phone,Avenger,United States,AR,Promising early-stage data suggests potential for expanded indication spectrum
text,06e1d9d8-91e9-4db3-837b-a0d846d62f6d,insights_interaction,latest,,,2023-06-21,MSL Interactions,Oncology,Vibranium,,WB-US-08460,Maria Joiner,,onco-us-0030,Linda Martinez,Ulton,Deadpool,United States,TX,"No significant changes in circulating tumor DNA were observed in patients who did not respond to Vibranium/Wakanda, suggesting limitations in using ctDNA as a predictive biomarker."
text,eab8bc02-28a5-427b-889b-a398e7345a81,insights_interaction,latest,,,2023-07-16,MSL Interactions,Oncology,Vibranium,,WB-US-08313,Nancy Ballesteros,,onco-us-0030,Linda Martinez,Phone,Avenger,United States,OK,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,d4c5b66b-51f7-43fa-8c14-8c2681df4430,insights_interaction,latest,,,2023-08-17,MSL Interactions,Oncology,Vibranium,,WB-US-08470,Shawn Bussman,,onco-us-0030,Linda Martinez,Iron Man,Deadpool,United States,KS,"Grade 2-3 immune-related adverse events observed in 18% of patients, predominantly mild hepatic and endocrine dysregulation, manageable with standard immunomodulatory interventions"
text,249542e3-622b-4038-8070-8993506437fd,insights_interaction,latest,,,2023-12-28,MSL Interactions,Oncology,Vibranium,,WB-US-08758,Hannah Hoover,,onco-us-0030,Linda Martinez,Ulton,Deadpool,United States,AR,"No significant correlation found between tumor mutational burden and treatment response, indicating complex genetic interactions"
text,968aebcd-8060-4ca5-8444-4750d8549c08,insights_interaction,latest,,,2024-02-28,MSL Interactions,Oncology,Vibranium,,WB-US-09132,Melissa Bonanno,,onco-us-0030,Linda Martinez,Iron Man,Avenger,United States,TX,Reduced treatment-related fatigue reported by 65% of patients compared to traditional chemotherapy protocols
text,d175305c-07fc-45a6-bd4b-c7443ceb8f0d,insights_interaction,latest,,,2024-11-20,MSL Interactions,Oncology,Vibranium,,WB-US-08695,John Kramer,,onco-us-0030,Linda Martinez,Iron Man,X-Men,United States,ND,Genetic mutation profile suggests potential predictive markers for treatment response
text,8a8e54a1-cacd-42fd-898a-703029c15891,insights_interaction,latest,,,2024-12-21,MSL Interactions,Oncology,Vibranium,,WB-US-08905,David Mitchell,,onco-us-0030,Linda Martinez,Iron Man,Wolverine,United States,AR,Reduced hospitalization time and outpatient management feasibility
text,b2291357-9e01-4d3b-ad00-a4b8946d66e3,insights_interaction,latest,,,2021-04-30,MSL Interactions,Oncology,Vibranium,,WB-EU-00546,James Cusumano,,onco-eu-0015,Linnea Svensson,Ulton,Wolverine,Denmark,,Significant improvement in patient-reported symptom management and treatment tolerability
text,f6340e95-a2f0-4e03-81cc-482796b808cc,insights_interaction,latest,,,2021-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-00782,Ruth Haynes,,onco-eu-0015,Linnea Svensson,Iron Man,Wolverine,Denmark,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,735e9971-6094-4eea-8332-3ba6fad1648e,insights_interaction,latest,,,2021-06-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00582,Karina Niver,,onco-eu-0015,Linnea Svensson,Iron Man,Avenger,Sweden,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,b32364c9-9949-4f65-ac93-d33377f7880e,insights_interaction,latest,,,2021-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00044,Carol Wolfinger,,onco-eu-0015,Linnea Svensson,Phone,Deadpool,Norway,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,902df151-c7ec-4c7f-992f-709e484b06dc,insights_interaction,latest,,,2022-04-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00784,Frank Phillips,,onco-eu-0015,Linnea Svensson,Phone,Wolverine,Finland,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,ccf8ac13-1974-490b-9fc2-6aa4d539047b,insights_interaction,latest,,,2022-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-00291,Michael Fish,,onco-eu-0015,Linnea Svensson,Iron Man,Wolverine,Denmark,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,800aa7d3-acf3-405e-b768-3942aa5f332e,insights_interaction,latest,,,2022-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00044,Carol Wolfinger,,onco-eu-0015,Linnea Svensson,Ulton,Deadpool,Norway,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,ad29e685-e6c2-4930-9c37-361004ebde93,insights_interaction,latest,,,2022-09-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00716,Harriet Brinkman,,onco-eu-0015,Linnea Svensson,Iron Man,Avenger,Sweden,,Statistically significant improvement in overall survival of 4.7 months compared to standard monotherapy
text,f37738cf-92d5-400b-aaed-8be7ac56d6b2,insights_interaction,latest,,,2022-10-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00502,Christopher Curtice,,onco-eu-0015,Linnea Svensson,Phone,X-Men,Finland,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,ef35d64d-0c92-4a55-87a0-0deff213a167,insights_interaction,latest,,,2022-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00602,Gregory Cook,,onco-eu-0015,Linnea Svensson,Ulton,X-Men,Finland,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,ad3c099b-cbc1-47c8-8c99-8a022ab1b4af,insights_interaction,latest,,,2022-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00723,Lenora Mckinney,,onco-eu-0015,Linnea Svensson,Phone,Avenger,Finland,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,4ec57be0-5d10-4fcb-b4fe-8648d4fefb9c,insights_interaction,latest,,,2022-11-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00119,Mitchell Steinbeck,,onco-eu-0015,Linnea Svensson,Ulton,X-Men,Denmark,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,2495142f-a321-4f75-b7d5-883f1bc902cf,insights_interaction,latest,,,2022-12-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00723,Lenora Mckinney,,onco-eu-0015,Linnea Svensson,Iron Man,Avenger,Finland,,Strong correlation detected between PD-L1 expression and treatment response
text,f6ae18bb-cd6a-4334-9b3b-28a347d8091b,insights_interaction,latest,,,2023-06-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00602,Gregory Cook,,onco-eu-0015,Linnea Svensson,Phone,X-Men,Finland,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,20d98121-ec1b-4ae1-b71a-b8247ceaf540,insights_interaction,latest,,,2024-01-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00702,Elaine Shaw,,onco-eu-0015,Linnea Svensson,Ulton,X-Men,Sweden,,Standardized treatment protocols developed to optimize patient selection and minimize unnecessary intervention in non-responsive cases.
text,f4f80c5f-ac52-4d90-a600-d4cc5b620142,insights_interaction,latest,,,2024-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00693,Heather Watson,,onco-eu-0015,Linnea Svensson,Phone,Deadpool,Denmark,,Mild fatigue and appetite changes reported during treatment maintenance phase
text,bf6452f6-9552-4e18-a31b-c3333ad4b281,insights_interaction,latest,,,2024-07-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00004,Grace Pinera,,onco-eu-0015,Linnea Svensson,Phone,X-Men,Finland,,PD-L1 expression levels correlated with response to Vibranium in a subset of patients.
text,25fe45dd-94d1-4647-bdfa-812b4ee4b0cd,insights_interaction,latest,,,2024-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-00741,Jacqueline Story,,onco-eu-0015,Linnea Svensson,Iron Man,Avenger,Finland,,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,d93eea0c-d32b-425d-b77f-c6ab04529680,insights_interaction,latest,,,2024-07-21,MSL Interactions,Oncology,Vibranium,,WB-EU-00774,Heriberto Staggs,,onco-eu-0015,Linnea Svensson,Iron Man,X-Men,Finland,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,34eb65f0-eccc-401f-8ab0-8a4695f48ec4,insights_interaction,latest,,,2024-11-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00626,Deborah Mcelrath,,onco-eu-0015,Linnea Svensson,Iron Man,Deadpool,Sweden,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,33e7e27d-8c87-4915-959e-b8a866b0e845,insights_interaction,latest,,,2024-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00413,Raymond Askew,,onco-eu-0015,Linnea Svensson,Iron Man,X-Men,Sweden,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,584f7223-9fb4-4551-8686-d425c434ca0f,insights_interaction,latest,,,2021-03-07,MSL Interactions,Oncology,Vibranium,,WB-US-03443,Ricky Avino,,onco-us-0008,Lisa Wong,Phone,X-Men,United States,DE,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,65318da9-2b11-4fe4-bf11-5626759fd1c9,insights_interaction,latest,,,2021-05-14,MSL Interactions,Oncology,Vibranium,,WB-US-03602,Annalisa Ovit,,onco-us-0008,Lisa Wong,Ulton,X-Men,United States,PA,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,af557996-6150-4963-a552-ef0f61e5c4d0,insights_interaction,latest,,,2021-05-19,MSL Interactions,Oncology,Vibranium,,WB-US-03888,Eva Mullins,,onco-us-0008,Lisa Wong,Iron Man,Deadpool,United States,MD,Development of novel companion diagnostic algorithm to improve patient stratification and personalized treatment approaches
text,ace0f0dc-486e-47cd-b7ed-ee97524dbf2f,insights_interaction,latest,,,2021-10-25,MSL Interactions,Oncology,Vibranium,,WB-US-03386,Fran Feliciano,,onco-us-0008,Lisa Wong,Ulton,Deadpool,United States,DC,Significant tumor size reduction in 62% of non-small cell lung cancer patients
text,65103c2e-89b1-4b85-9f16-1db4d28ee9ca,insights_interaction,latest,,,2022-02-20,MSL Interactions,Oncology,Vibranium,,WB-US-04150,Micheal Walker,,onco-us-0008,Lisa Wong,Phone,Wolverine,United States,DE,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,f45ed816-5e44-497b-b10e-929d12a6bf8f,insights_interaction,latest,,,2022-03-22,MSL Interactions,Oncology,Vibranium,,WB-US-03737,Gerald Friedly,,onco-us-0008,Lisa Wong,Iron Man,X-Men,United States,NJ,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,19edb566-f158-43a8-b8ab-fd203ba13d58,insights_interaction,latest,,,2022-03-23,MSL Interactions,Oncology,Vibranium,,WB-US-03730,John Zachery,,onco-us-0008,Lisa Wong,Iron Man,Wolverine,United States,PA,"Increased levels of interferon-gamma detected in serum samples post-Vibranium infusion, correlating with clinical improvement."
text,4e105f87-af14-479c-8fc8-b63571dc8729,insights_interaction,latest,,,2022-04-18,MSL Interactions,Oncology,Vibranium,,WB-US-03197,Margaret Looper,,onco-us-0008,Lisa Wong,Phone,Avenger,United States,MD,Observed 62% objective response rate in metastatic triple-negative breast cancer patients with high PD-L1 expression after Wakanda combination therapy
text,ff36024a-27dd-4962-9519-29d8b36c4019,insights_interaction,latest,,,2022-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-04443,Linda Beard,,onco-us-0008,Lisa Wong,Phone,Deadpool,United States,NJ,"Increased PD-L1 expression observed in tumor biopsies after two cycles of treatment, suggesting potential synergy between Vibranium and Wakanda."
text,cab60982-7340-47c9-89bd-205a1ee916f1,insights_interaction,latest,,,2024-12-05,MSL Interactions,Oncology,Vibranium,,WB-US-02826,Ruby Opie,,onco-us-0008,Lisa Wong,Ulton,Clinical Pharmacist,United States,MD,Further research needed to fully elucidate the role of specific biomarkers in predicting treatment response.
text,e47ff7be-89fd-4d44-8fdd-6a15abdaff03,insights_interaction,latest,,,2021-01-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01732,Mitchell Slaff,,onco-eu-0040,Luca Bianchi,Iron Man,X-Men,Netherlands,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,858a437c-6dd9-4fac-85f6-07db4e0f7918,insights_interaction,latest,,,2021-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01909,Robert Quiroz,,onco-eu-0040,Luca Bianchi,Phone,Wolverine,Austria,,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,3fa353d5-0b27-45f8-88eb-9e9ff8848a8d,insights_interaction,latest,,,2021-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01280,John Porraz,,onco-eu-0040,Luca Bianchi,Iron Man,Avenger,Belgium,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,f3013f32-8de1-457f-b5b4-fb4f06ab3e00,insights_interaction,latest,,,2022-01-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01012,Benjamin Johnston,,onco-eu-0040,Luca Bianchi,Phone,Deadpool,Belgium,,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,7174bdcd-09d5-4f94-832b-29885bd0b93b,insights_interaction,latest,,,2022-09-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01326,Danny Giles,,onco-eu-0040,Luca Bianchi,Iron Man,Avenger,Netherlands,,Patients reported improved physical functioning and reduced fatigue during treatment.
text,00903acc-70c1-4a84-bcd3-cd87b3198fb2,insights_interaction,latest,,,2023-05-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01308,Robert Hernandez,,onco-eu-0040,Luca Bianchi,Iron Man,X-Men,Switzerland,,Correlation between pre-treatment tumor mutational burden (TMB) and response to Vibranium/Wakanda therapy remains inconclusive in our ongoing study.
text,2b0a40a3-ee6c-45f8-8f73-88383b3ca84c,insights_interaction,latest,,,2023-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00865,Stacy Gummer,,onco-eu-0040,Luca Bianchi,Ulton,Deadpool,Germany,,"Increased risk of immune-related adverse events, particularly thyroid dysfunction and rare cases of pneumonitis"
text,02ddeee3-5f0e-4f8f-bc9e-f02f83ce7e62,insights_interaction,latest,,,2023-06-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01228,Angela Rodriguez,,onco-eu-0040,Luca Bianchi,Iron Man,X-Men,Netherlands,,Increased expression of PD-L1 in tumor biopsies after 2 cycles of Vibranium/Wakanda suggests potential synergy with checkpoint inhibitors.
text,0a9e9cc6-1c71-49de-83eb-b7e65ed3c972,insights_interaction,latest,,,2023-12-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01231,Joseph Truax,,onco-eu-0040,Luca Bianchi,Iron Man,Avenger,Belgium,,"Varied response patterns observed across different age groups, suggesting potential age-related pharmacodynamic interactions."
text,b92843af-04ac-496b-b0d2-d4341a6934c3,insights_interaction,latest,,,2024-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00977,Hilda Jordan,,onco-eu-0040,Luca Bianchi,Phone,Avenger,Switzerland,,Significant tumor reduction in hard-to-treat cancer subtypes
text,8cb33e9a-dc13-4f6a-ae18-be144cb777c2,insights_interaction,latest,,,2024-07-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01093,Lavonna Fisher,,onco-eu-0040,Luca Bianchi,Ulton,X-Men,Belgium,,"Observed differential response patterns across age groups, with patients under 55 demonstrating more robust tumor reduction compared to older patient cohorts."
text,17f693b0-35ca-47d4-9783-c8e976a413ff,insights_interaction,latest,,,2024-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01100,Eleni Roof,,onco-eu-0040,Luca Bianchi,Iron Man,X-Men,Germany,,Variability in response duration observed among patients achieving partial response.
text,dd647777-e911-4a1c-adc6-c1ab542e11db,insights_interaction,latest,,,2024-11-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01665,Larissa Singleton,,onco-eu-0040,Luca Bianchi,Iron Man,X-Men,Switzerland,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,86cfa312-fbba-4567-8465-8cc099588e74,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01101,Barry Jones,,onco-eu-0040,Luca Bianchi,Iron Man,Deadpool,Austria,,"Patient with advanced pancreatic cancer (PDAC) exhibiting a partial response after 4 cycles of Vibranium/Wakanda therapy.  Significant reduction in tumor size observed via CT scan, coupled with improvement in CA 19-9 levels."
text,41fa4e3d-238d-44dc-910c-fb561e1d3a6c,insights_interaction,latest,,,2024-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01259,Francis Judkins,,onco-eu-0033,Marco Rossi,Iron Man,X-Men,Austria,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,4a861ba0-d4fb-41fd-bdb6-6c9fada67a9a,insights_interaction,latest,,,2024-04-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00985,Buddy Hammond,,onco-eu-0033,Marco Rossi,Iron Man,X-Men,Germany,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,1b5c95cc-fa24-4c0f-9198-64412ba4318c,insights_interaction,latest,,,2024-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01840,Robert Lopez,,onco-eu-0033,Marco Rossi,Iron Man,Deadpool,Germany,,"Patient experienced grade 1 fatigue and nausea following the third infusion of Vibranium, which resolved with supportive care. No dose reduction was necessary."
text,7fe58c89-e25d-4fe5-8dac-fb3b7257217a,insights_interaction,latest,,,2024-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01628,Phyllis Hudson,,onco-eu-0033,Marco Rossi,Iron Man,Deadpool,Germany,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,0047804a-96d5-478d-a801-219c656fec12,insights_interaction,latest,,,2021-03-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03924,Hector Baker,,onco-eu-0067,Marek Novak,Iron Man,X-Men,United Kingdom,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,881d02ec-7fbe-4417-b092-bfaa27112efe,insights_interaction,latest,,,2021-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03811,Karen Gibson,,onco-eu-0067,Marek Novak,Phone,Wolverine,Ireland,,Stable disease observed for 6 months in a patient with advanced non-small cell lung cancer treated with Vibranium/Wakanda.
text,58d824b5-1c0e-424e-908f-903c905a4216,insights_interaction,latest,,,2021-04-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03548,Vernon Wiltse,,onco-eu-0067,Marek Novak,Phone,Avenger,Ireland,,Promising results in treatment-resistant cancer subtypes
text,07d02a08-2ad3-42cd-81b4-be45adcff880,insights_interaction,latest,,,2021-06-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03659,Eddie Terry,,onco-eu-0067,Marek Novak,Iron Man,Deadpool,France,,"Long-term follow-up data shows no evidence of long-term adverse effects in patients who completed Vibranium/Wakanda therapy, suggesting a favorable long-term safety profile."
text,585df648-757a-430a-ac08-281f74c698dd,insights_interaction,latest,,,2021-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03511,Rhonda Jennings,,onco-eu-0067,Marek Novak,Ulton,Avenger,France,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,e8e79c79-95cd-47d0-9724-c49af139abdb,insights_interaction,latest,,,2021-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03525,Michael Dunston,,onco-eu-0067,Marek Novak,Iron Man,Deadpool,United Kingdom,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,429ea4d4-6703-427d-9add-58578da1ba5a,insights_interaction,latest,,,2022-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03048,Jane Concepcion,,onco-eu-0067,Marek Novak,Iron Man,X-Men,United Kingdom,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,4e12d816-95c7-45f7-9a9a-a558d1ab0d20,insights_interaction,latest,,,2022-11-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03811,Karen Gibson,,onco-eu-0067,Marek Novak,Iron Man,Wolverine,Ireland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,4d44a40a-2a59-4043-8efd-f610bd4a5a35,insights_interaction,latest,,,2023-01-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03907,Steven Simpson,,onco-eu-0067,Marek Novak,Ulton,X-Men,United Kingdom,,Observed a wider range of response times to Vibranium/Wakanda; some patients showed early response while others had a delayed but significant response.
text,cd42bc0a-964e-41ae-b27c-25e82eeea0ff,insights_interaction,latest,,,2023-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03164,Daniel Hatcher,,onco-eu-0067,Marek Novak,Iron Man,X-Men,Ireland,,"Grade 2-3 immune-related adverse events reported in 17% of patients, primarily consisting of manageable dermatologic and endocrine toxicities"
text,8a178879-f965-4ccc-8f5a-4493ccb84a6a,insights_interaction,latest,,,2023-04-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03754,John Howard,,onco-eu-0067,Marek Novak,Ulton,Wolverine,United Kingdom,,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,55ea2aac-ce90-4c31-af02-2c1752438bcb,insights_interaction,latest,,,2023-04-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03350,Ann Harb,,onco-eu-0067,Marek Novak,Phone,X-Men,Ireland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,c28ecf56-906b-4466-b9e1-ed99331ec991,insights_interaction,latest,,,2023-05-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03731,Kevin Stewart,,onco-eu-0067,Marek Novak,Phone,Avenger,France,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,a3aa9294-28ee-4961-b8bd-793244326cdf,insights_interaction,latest,,,2023-12-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03995,Nelson Burger,,onco-eu-0067,Marek Novak,Iron Man,Deadpool,United Kingdom,,No consistent correlation found between baseline biomarker levels and treatment response.
text,ff62bfa7-567b-4489-9971-958ebd8cb257,insights_interaction,latest,,,2024-01-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03839,Tara Greer,,onco-eu-0067,Marek Novak,Ulton,Avenger,Ireland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,8aafa715-8661-47d4-9872-a3023668765e,insights_interaction,latest,,,2024-02-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03596,Jackie James,,onco-eu-0067,Marek Novak,Iron Man,Avenger,United Kingdom,,"Partial response observed in a patient with advanced pancreatic cancer after 12 weeks of treatment, evidenced by decreased CA 19-9 levels and improved imaging findings."
text,a8ad564b-5676-42df-ac1f-c35906bb6550,insights_interaction,latest,,,2024-03-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03596,Jackie James,,onco-eu-0067,Marek Novak,Ulton,Avenger,United Kingdom,,Cost-effectiveness analysis suggests potential for reduced healthcare resource utilization compared to traditional treatment protocols
text,47e0b718-01bb-4ddc-83e1-bc2d0307d6d3,insights_interaction,latest,,,2024-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03754,John Howard,,onco-eu-0067,Marek Novak,Phone,Wolverine,United Kingdom,,Grade 3 fatigue reported in a patient receiving Vibranium/Wakanda; treatment was temporarily suspended.
text,5d1fe705-539b-4eec-97cd-bc217f4b3a52,insights_interaction,latest,,,2024-08-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03907,Steven Simpson,,onco-eu-0067,Marek Novak,Iron Man,X-Men,United Kingdom,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,153643e8-807d-4725-aa04-42dd14fd4d41,insights_interaction,latest,,,2021-01-14,MSL Interactions,Oncology,Vibranium,,WB-US-09106,Edna Salter,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,KS,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,38d7cee8-d518-417e-93ca-d723b9453f0d,insights_interaction,latest,,,2021-02-28,MSL Interactions,Oncology,Vibranium,,WB-US-08583,John Buster,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,LA,Significant molecular response in patients with specific genetic mutations
text,7ac83c3b-a64a-49a7-8ae9-3b5b0c62c7f0,insights_interaction,latest,,,2021-05-26,MSL Interactions,Oncology,Vibranium,,WB-US-08781,Mike Patterson,,onco-us-0028,Margaret Lewis,Ulton,Avenger,United States,KS,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,239bb429-67af-4493-9b0f-2f07065eea5d,insights_interaction,latest,,,2022-01-07,MSL Interactions,Oncology,Vibranium,,WB-US-08718,Jeanette Riley,,onco-us-0028,Margaret Lewis,Ulton,Avenger,United States,LA,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,33a4c536-8909-463b-ac66-bb4d6043323e,insights_interaction,latest,,,2022-04-11,MSL Interactions,Oncology,Vibranium,,WB-US-08884,Carl Martinez,,onco-us-0028,Margaret Lewis,Iron Man,X-Men,United States,LA,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,7dea6fb0-e346-4461-8970-a428d471ff31,insights_interaction,latest,,,2022-06-01,MSL Interactions,Oncology,Vibranium,,WB-US-08736,Susan Burke,,onco-us-0028,Margaret Lewis,Iron Man,X-Men,United States,ND,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,13a919eb-4d96-48a9-a355-2582278653bc,insights_interaction,latest,,,2022-07-11,MSL Interactions,Oncology,Vibranium,,WB-US-08702,Jim Jones,,onco-us-0028,Margaret Lewis,Iron Man,Avenger,United States,SD,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,e3aa7fad-72ce-4091-8e77-e6e2e9d1d757,insights_interaction,latest,,,2022-10-06,MSL Interactions,Oncology,Vibranium,,WB-US-08930,James Peschel,,onco-us-0028,Margaret Lewis,Phone,Wolverine,United States,SD,Observed a trend towards improved progression-free survival in patients with specific genetic mutations.
text,dcc4462a-f4d3-485a-bdf9-85ce915a2708,insights_interaction,latest,,,2023-01-12,MSL Interactions,Oncology,Vibranium,,WB-US-08748,Edward Martinez,,onco-us-0028,Margaret Lewis,Iron Man,Avenger,United States,AR,Progression-free survival varied significantly based on the patient's prior treatment history and overall health status.
text,6334bf9b-2af3-47cf-adc4-2233317b1347,insights_interaction,latest,,,2023-02-10,MSL Interactions,Oncology,Vibranium,,WB-US-08465,Harold Floyd,,onco-us-0028,Margaret Lewis,Iron Man,Wolverine,United States,LA,"In a small cohort of patients with glioblastoma, Vibranium/Wakanda showed modest improvements in progression-free survival but no significant impact on overall survival."
text,45f5ee7c-7dfe-42ce-a360-95528130a689,insights_interaction,latest,,,2023-04-26,MSL Interactions,Oncology,Vibranium,,WB-US-08936,Mary Brubaker,,onco-us-0028,Margaret Lewis,Ulton,Wolverine,United States,LA,"Patient developed grade 3 fatigue and neutropenia following the second infusion of Vibranium/Wakanda. Treatment was temporarily suspended, and supportive care was required.  The patient experienced a prolonged recovery period before resuming therapy."
text,2f01241d-5262-4405-8966-bd7d10cb90e3,insights_interaction,latest,,,2023-04-28,MSL Interactions,Oncology,Vibranium,,WB-US-09050,Samuel Muto,,onco-us-0028,Margaret Lewis,Ulton,Deadpool,United States,NE,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda treatment.
text,f261e7c2-0680-4914-9f54-8c0a556130a0,insights_interaction,latest,,,2023-09-10,MSL Interactions,Oncology,Vibranium,,WB-US-08906,Barbara Wilson,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,ND,"Mild flu-like symptoms were common side effects, manageable with supportive care."
text,14f3cab8-e127-48d9-adb1-5aab4d232482,insights_interaction,latest,,,2023-09-11,MSL Interactions,Oncology,Vibranium,,WB-US-08759,Jason Odaniel,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,LA,Detected potential cumulative neurotoxicity in long-term treatment protocols
text,6a60f609-588f-4c26-871b-28f7b995961c,insights_interaction,latest,,,2023-10-27,MSL Interactions,Oncology,Vibranium,,WB-US-08983,James Burris,,onco-us-0028,Margaret Lewis,Iron Man,Avenger,United States,TX,Strong correlation between PDL1 expression >50% and enhanced treatment response
text,66cf3723-6329-4fc1-af38-014442875698,insights_interaction,latest,,,2024-01-11,MSL Interactions,Oncology,Vibranium,,WB-US-08820,Patricia Pioske,,onco-us-0028,Margaret Lewis,Iron Man,Avenger,United States,NE,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,a827eaee-34c3-45de-9b0f-4b0cff362d71,insights_interaction,latest,,,2024-01-17,MSL Interactions,Oncology,Vibranium,,WB-US-08339,Scott Lukes,,onco-us-0028,Margaret Lewis,Ulton,Avenger,United States,OK,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,cc0367d4-4b18-4880-8b61-b904e2b04b80,insights_interaction,latest,,,2024-04-25,MSL Interactions,Oncology,Vibranium,,WB-US-08331,Ron Bernier,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,SD,"Patient experienced grade 1 fatigue and nausea, resolving spontaneously after symptomatic treatment.  No dose modification required."
text,0f09ac2b-7558-48b8-9eb6-eb068e6419ab,insights_interaction,latest,,,2024-05-26,MSL Interactions,Oncology,Vibranium,,WB-US-08405,Juliann Patton,,onco-us-0028,Margaret Lewis,Phone,Avenger,United States,TX,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,addcfa26-80b0-4fd5-a191-f465acfad9f2,insights_interaction,latest,,,2024-06-10,MSL Interactions,Oncology,Vibranium,,WB-US-08899,Mary Palladino,,onco-us-0028,Margaret Lewis,Phone,X-Men,United States,TX,Consistent patient-reported outcomes with minimal treatment-related disruptions
text,61995406-f801-4f0a-a66f-07c2bc0524b5,insights_interaction,latest,,,2024-08-02,MSL Interactions,Oncology,Vibranium,,WB-US-08772,Erick Skalicky,,onco-us-0028,Margaret Lewis,Iron Man,Wolverine,United States,TX,"Promising results in combination therapy with checkpoint inhibitors, showing synergistic effect and enhanced overall response rates"
text,55a6c710-821e-4b81-b073-f1cdabcf6406,insights_interaction,latest,,,2024-08-07,MSL Interactions,Oncology,Vibranium,,WB-US-08501,Thomas Brito,,onco-us-0028,Margaret Lewis,Phone,Avenger,United States,AR,One patient experienced mild injection site reaction that resolved spontaneously.
text,df276904-d8c8-4d10-b5f2-7ef3f2f9ebbb,insights_interaction,latest,,,2024-10-12,MSL Interactions,Oncology,Vibranium,,WB-US-08912,Charles Holzman,,onco-us-0028,Margaret Lewis,Ulton,Avenger,United States,KS,"Dose-limiting toxicities observed include mild to moderate hepatic enzyme elevations in 17% of patients, manageable with temporary dose reduction and close monitoring."
text,6cf8849d-1f09-46dd-8726-c438410996b5,insights_interaction,latest,,,2024-10-31,MSL Interactions,Oncology,Vibranium,,WB-US-08947,Roslyn Rosado,,onco-us-0028,Margaret Lewis,Iron Man,X-Men,United States,ND,Strong correlation between PD-L1 expression >50% and improved progression-free survival
text,de296cda-a555-4b37-9f12-b5fd8bb16e41,insights_interaction,latest,,,2024-11-02,MSL Interactions,Oncology,Vibranium,,WB-US-08787,Robert Buckland,,onco-us-0028,Margaret Lewis,Iron Man,Avenger,United States,ND,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,b022af52-e93a-416e-b276-d98e0980d833,insights_interaction,latest,,,2021-04-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03238,Joanna Canaday,,onco-eu-0062,Margot Dubois,Iron Man,X-Men,France,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,6c3c741b-f6eb-4272-b892-39a33983c0e5,insights_interaction,latest,,,2021-09-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03575,Lawrence Self,,onco-eu-0062,Margot Dubois,Ulton,Wolverine,Ireland,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,33761973-0584-4d07-b6b7-a3e5a940846b,insights_interaction,latest,,,2021-10-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03845,Kevin Guttmann,,onco-eu-0062,Margot Dubois,Iron Man,Avenger,United Kingdom,,Patients reported improved physical functioning and reduced fatigue during treatment.
text,c1bdfcd0-8616-4949-8b61-3b89f6d6ad73,insights_interaction,latest,,,2021-11-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03682,Dorothy Fazzone,,onco-eu-0062,Margot Dubois,Iron Man,X-Men,United Kingdom,,Patients reporting improved pain management and reduced fatigue compared to standard chemotherapy protocols
text,e5ea224d-d2e9-4031-8c23-76545baa6f36,insights_interaction,latest,,,2023-01-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03684,Frank Lara,,onco-eu-0062,Margot Dubois,Ulton,X-Men,United Kingdom,,"Patient reported improved quality of life, including decreased pain and improved appetite, after one cycle of Vibranium/Wakanda.  This was corroborated by patient-reported outcome measures."
text,1a5f22d6-5701-480f-996e-e1e0064c9d27,insights_interaction,latest,,,2023-05-02,MSL Interactions,Oncology,Vibranium,,WB-EU-03033,John Felan,,onco-eu-0062,Margot Dubois,Iron Man,X-Men,France,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,fbb00f2d-b3ee-44de-bb66-f8da57012282,insights_interaction,latest,,,2023-05-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03804,Bradley Carter,,onco-eu-0062,Margot Dubois,Iron Man,X-Men,Ireland,,Genomic profiling reveals potential predictive markers for treatment response
text,9727e668-5a7f-4043-a559-9009a8ec0033,insights_interaction,latest,,,2023-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03863,Darrell Miller,,onco-eu-0062,Margot Dubois,Ulton,Deadpool,Ireland,,Complete response rates in metastatic melanoma patients reached 31%
text,026e7096-4975-4eb1-a6ea-c0fcd3817884,insights_interaction,latest,,,2023-09-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03947,Shanita Harvey,,onco-eu-0062,Margot Dubois,Ulton,Avenger,Ireland,,"Mild flu-like symptoms were reported in most patients during the initial phase of Vibranium/Wakanda treatment, resolving within 72 hours with supportive care."
text,420a6d90-d6d1-4417-b1dd-c8c58f1227de,insights_interaction,latest,,,2023-09-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03418,David Wilbon,,onco-eu-0062,Margot Dubois,Ulton,Deadpool,United Kingdom,,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,b4a4a833-3d24-4fc5-b129-7de96f5fc95e,insights_interaction,latest,,,2024-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03167,Kevin Linthicum,,onco-eu-0062,Margot Dubois,Ulton,Wolverine,France,,Treatment requires careful patient selection and comprehensive genetic profiling
text,87e32e61-69c9-4f90-8f2f-1b49b6afeec9,insights_interaction,latest,,,2024-10-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03964,Lee Hall,,onco-eu-0062,Margot Dubois,Phone,X-Men,France,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,3a02ac44-68dd-4058-9c12-9facdfdc3ae3,insights_interaction,latest,,,2024-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03378,Matthew Rivera,,onco-eu-0062,Margot Dubois,Iron Man,X-Men,United Kingdom,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,6d145d00-b3bb-49fa-8f9a-43645d26b869,insights_interaction,latest,,,2021-02-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02558,Charlene Chapman,,onco-eu-0044,Maria Gomez,Ulton,Avenger,Ragnarok,,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,3f989d5e-5c6d-45fc-833f-15cce95114bf,insights_interaction,latest,,,2021-03-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02617,Sandy Garcia,,onco-eu-0044,Maria Gomez,Phone,Wolverine,Ragnarok,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,2c36a91f-eb1f-4a19-9878-d4f790c45d06,insights_interaction,latest,,,2021-04-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02956,Mary Fenske,,onco-eu-0044,Maria Gomez,Iron Man,Avenger,Ragnarok,,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,a4b5e15b-dd13-4719-8ea1-020167a21d25,insights_interaction,latest,,,2021-09-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02149,Alejandro Dollar,,onco-eu-0044,Maria Gomez,Phone,X-Men,Italy,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,dcf6aab3-7c94-4847-8d30-6367ee864034,insights_interaction,latest,,,2021-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02365,Timothy Moore,,onco-eu-0044,Maria Gomez,Iron Man,X-Men,Italy,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,7fd87105-b2be-4094-846d-d8e599c6c42d,insights_interaction,latest,,,2023-03-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02533,Yong Viveiros,,onco-eu-0044,Maria Gomez,Phone,Avenger,Italy,,"Moderate fatigue and mild cognitive impairment reported by 42% of patients, stabilizing after first treatment cycle"
text,13951b5a-2af3-4943-931b-de67b79d7b40,insights_interaction,latest,,,2023-06-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02253,Catherine Solanki,,onco-eu-0044,Maria Gomez,Ulton,X-Men,Spain,,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors compared to microsatellite stable (MSS) tumors.
text,ca640efc-18cb-4e92-8dec-ce9db17ce4ce,insights_interaction,latest,,,2024-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02149,Alejandro Dollar,,onco-eu-0044,Maria Gomez,Iron Man,X-Men,Italy,,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,23dc1aab-df85-49a5-855b-7fa871b675ac,insights_interaction,latest,,,2024-09-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02253,Catherine Solanki,,onco-eu-0044,Maria Gomez,Ulton,X-Men,Spain,,One case of grade 2 liver toxicity was reported and successfully managed.
text,1522d8ef-3bc2-4629-aab9-bf447de16b84,insights_interaction,latest,,,2024-11-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02676,Robert Johnston,,onco-eu-0044,Maria Gomez,Iron Man,Clinical Pharmacist,Italy,,The need for frequent imaging and blood tests increases the overall treatment burden.
text,33c09bd7-3113-4037-b79b-26569e099317,insights_interaction,latest,,,2022-01-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00081,Nicole Hulslander,,onco-eu-0005,Maria Johansson,Ulton,Deadpool,Denmark,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,9de66ad6-b961-4fad-90fd-bfbc811f1426,insights_interaction,latest,,,2022-09-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00426,Mary Davis,,onco-eu-0005,Maria Johansson,Phone,X-Men,Norway,,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,f53525ad-c440-43a3-a0dc-2ccfb2afc22e,insights_interaction,latest,,,2022-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00072,Richard Cardenas,,onco-eu-0005,Maria Johansson,Iron Man,X-Men,Finland,,Elevated levels of certain inflammatory cytokines were observed to correlate with a positive clinical response to Vibranium/Wakanda.
text,41bf7546-5851-4cba-a06e-8c6a3328cbef,insights_interaction,latest,,,2022-10-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00401,Darrell Love,,onco-eu-0005,Maria Johansson,Iron Man,Avenger,Finland,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,7a7bee3f-f044-4e6f-b1e5-3f11b03beb8b,insights_interaction,latest,,,2022-11-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00284,Linda Dyer,,onco-eu-0005,Maria Johansson,Iron Man,X-Men,Denmark,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,c7fc1dfa-a704-4dd5-a72a-af4aa62d38cf,insights_interaction,latest,,,2023-06-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00418,Cameron Brown,,onco-eu-0005,Maria Johansson,Phone,X-Men,Denmark,,Response to Vibranium/Wakanda appears to be associated with higher baseline PD-L1 expression.
text,e717e152-a2b4-4a86-85e3-f34d77d5d7ba,insights_interaction,latest,,,2023-07-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00076,Sabra Cray,,onco-eu-0005,Maria Johansson,Phone,Wolverine,Norway,,"Grade 2-3 immune-related adverse events observed in 18% of patients, predominantly mild hepatic and endocrine dysregulation, manageable with standard immunomodulatory interventions"
text,4a94c887-73c0-41e6-bb0d-f4df591cc775,insights_interaction,latest,,,2023-10-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00338,Katie Martinez,,onco-eu-0005,Maria Johansson,Phone,Wolverine,Denmark,,Significant tumor reduction in hard-to-treat cancer subtypes
text,10eec88b-81cb-42a1-be26-49a675b5d2ed,insights_interaction,latest,,,2023-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-00317,Simon Tillotson,,onco-eu-0005,Maria Johansson,Iron Man,X-Men,Finland,,Prolonged progression-free survival observed in a subset of patients with head and neck cancer treated with Vibranium/Wakanda.
text,715aa21c-11b6-42ec-b9c9-710b46500395,insights_interaction,latest,,,2024-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00275,Robert Turner,,onco-eu-0005,Maria Johansson,Phone,Avenger,Norway,,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,a066b64b-b805-48ac-8e1f-5665397c5ccb,insights_interaction,latest,,,2024-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-00317,Simon Tillotson,,onco-eu-0005,Maria Johansson,Ulton,X-Men,Finland,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,05b92301-ae25-4e35-a390-75742c88456e,insights_interaction,latest,,,2024-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00338,Katie Martinez,,onco-eu-0005,Maria Johansson,Ulton,Wolverine,Denmark,,Minor hepatic enzyme elevations observed in approximately 18% of patients
text,b62a5657-7cc8-479e-8588-ff824de40370,insights_interaction,latest,,,2024-03-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00534,William Maginnis,,onco-eu-0005,Maria Johansson,Phone,X-Men,Denmark,,No unexpected safety signals were observed in the current phase of the study.
text,3a4f8703-1fff-42d5-ad77-fb122077c8db,insights_interaction,latest,,,2024-06-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00114,Flora Robbins,,onco-eu-0005,Maria Johansson,Ulton,Wolverine,Denmark,,Consistent monitoring required for potential long-term immunological interactions
text,98f8c59f-8169-4a21-90bc-16e3d7c3ac18,insights_interaction,latest,,,2024-09-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00519,Thomas Blanchard,,onco-eu-0005,Maria Johansson,Ulton,Clinical Pharmacist,Denmark,,Mixed patient-reported outcomes indicate personalized experience variability
text,cfe70a38-4b37-4f10-9739-a3bc144ac95d,insights_interaction,latest,,,2024-09-30,MSL Interactions,Oncology,Vibranium,,WB-EU-00563,Samuel Saunders,,onco-eu-0005,Maria Johansson,Ulton,Avenger,Finland,,Treatment with Vibranium/Wakanda requires specialized administration techniques.
text,518f7824-ccb9-42a7-b32c-ec7bf4ed3d85,insights_interaction,latest,,,2024-11-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00284,Linda Dyer,,onco-eu-0005,Maria Johansson,Phone,X-Men,Denmark,,Observed slower response rates in patients with prior extensive chemotherapy treatment compared to treatment-naive patients.
text,71b2697f-7f98-4598-9342-852f28a68c8b,insights_interaction,latest,,,2024-12-30,MSL Interactions,Oncology,Vibranium,,WB-EU-00563,Samuel Saunders,,onco-eu-0005,Maria Johansson,Ulton,Avenger,Finland,,No clear correlation was found between age and response to Vibranium/Wakanda.
text,2730bc72-3240-4899-9cb1-53985fdd850e,insights_interaction,latest,,,2021-02-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02846,Michael Hall,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Spain,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,1985275b-84cc-428b-9846-6e814d3031be,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02846,Michael Hall,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Spain,,"Improved quality of life reported by most patients receiving Vibranium/Wakanda, as measured by FACT-G."
text,fe7a6fb5-5381-45e8-b3c7-a9e5c6a97a22,insights_interaction,latest,,,2021-05-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02941,Muriel Dodson,,onco-eu-0048,Marie Laurent,Ulton,Deadpool,Spain,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,da4faf29-4b67-4e1b-a06f-315c7da3c7ac,insights_interaction,latest,,,2021-06-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02390,Philip Rodriguez,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Spain,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,ef49e9a8-642a-4208-a2d4-8012aa4b9fda,insights_interaction,latest,,,2021-07-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02965,Teresa Murphy,,onco-eu-0048,Marie Laurent,Phone,Clinical Pharmacist,Italy,,Significant tumor size reduction in 62% of non-small cell lung cancer patients
text,d545cfed-1707-4251-990a-c12f0b34231a,insights_interaction,latest,,,2021-10-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02213,George Marte,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Italy,,Enhanced treatment durability in patients with specific molecular profiles
text,61735b5b-f9e3-4d7b-92fe-4da12d121357,insights_interaction,latest,,,2022-03-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02990,William Carr,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Ragnarok,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,f9c07264-8b5c-41c5-81f3-b4e4dddca610,insights_interaction,latest,,,2022-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02990,William Carr,,onco-eu-0048,Marie Laurent,Ulton,X-Men,Ragnarok,,Patients reported 65% reduction in treatment-related anxiety and improved sleep patterns during therapy
text,5011ad1f-3edf-4d66-9176-2074f7bd91e6,insights_interaction,latest,,,2022-12-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02886,Terence Large,,onco-eu-0048,Marie Laurent,Iron Man,Avenger,Greece,,"Significant improvement in patient-reported outcome measures, with 73% reporting reduced pain and increased functional status"
text,de346c8a-e3d5-4217-bf26-5d835a366a94,insights_interaction,latest,,,2023-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02156,Carol Walsh,,onco-eu-0048,Marie Laurent,Iron Man,Avenger,Spain,,"High treatment cost remains significant barrier, with single course of Wakanda exceeding $85,000, potentially limiting accessibility for patients with limited insurance coverage."
text,34263486-53b9-4c12-8022-e5a4e92dd3ce,insights_interaction,latest,,,2023-02-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02991,Bryan Kave,,onco-eu-0048,Marie Laurent,Ulton,Avenger,Ragnarok,,"Promising results in combination with existing standard-of-care therapies, suggesting potential synergistic mechanisms"
text,13011c59-f211-48c3-9fa6-bd28c18295ff,insights_interaction,latest,,,2023-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02694,Jacqueline Rodriguez,,onco-eu-0048,Marie Laurent,Ulton,X-Men,Spain,,"Observed delayed onset of response in several patients, suggesting the need for longer treatment durations or alternative therapeutic strategies."
text,1f2f6f2a-3259-4e89-affb-37711c0d7539,insights_interaction,latest,,,2023-07-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02776,Sophie Hill,,onco-eu-0048,Marie Laurent,Iron Man,Avenger,Spain,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,bbcf2b6b-8be3-4d82-8e99-062454b39d36,insights_interaction,latest,,,2023-08-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02418,Cynthia Jenkins,,onco-eu-0048,Marie Laurent,Phone,X-Men,Spain,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,eee1bbf0-c181-47ce-b0cb-63b4432d8cbb,insights_interaction,latest,,,2024-03-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02694,Jacqueline Rodriguez,,onco-eu-0048,Marie Laurent,Iron Man,X-Men,Spain,,One case of grade 2 liver toxicity was reported and successfully managed.
text,6fea6ebf-a893-4c21-a14b-97382cb0f9e9,insights_interaction,latest,,,2024-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02148,Jake Choi,,onco-eu-0048,Marie Laurent,Iron Man,Avenger,Spain,,"Preliminary phase II data shows 42% objective response rate in advanced metastatic solid tumors, with notable durable responses in patients previously refractory to standard therapies."
text,3dde9b51-84e3-40c7-894b-dbd83cc9dcc2,insights_interaction,latest,,,2024-10-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02818,Barbara Casano,,onco-eu-0048,Marie Laurent,Phone,Avenger,Spain,,Modest improvements in overall survival for heavily pre-treated patients
text,b1f07e4d-4f89-4823-96c0-d525a73e3899,insights_interaction,latest,,,2024-11-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02554,Mable Harrison,,onco-eu-0048,Marie Laurent,Phone,X-Men,Spain,,Response to Vibranium/Wakanda appears to be influenced by the tumor microenvironment.
text,4546cd01-cef0-4cad-bdb8-1c15f64d22d7,insights_interaction,latest,,,2024-11-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02776,Sophie Hill,,onco-eu-0048,Marie Laurent,Iron Man,Avenger,Spain,,Stable disease observed in several patients with lung cancer after two cycles.
text,89ebead0-453e-41e8-93bb-82873ea5cb19,insights_interaction,latest,,,2021-02-01,MSL Interactions,Oncology,Vibranium,,WB-US-07148,Eustolia Plumb,,onco-us-0021,Mark Thompson,Ulton,Wolverine,United States,OH,Observed higher response rates in patients with microsatellite instability-high (MSI-H) tumors.
text,c502d752-4ffb-4945-bdca-de978749a452,insights_interaction,latest,,,2021-06-15,MSL Interactions,Oncology,Vibranium,,WB-US-07148,Eustolia Plumb,,onco-us-0021,Mark Thompson,Ulton,Wolverine,United States,OH,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,94621eab-711a-4bc5-903e-046b6ce449e8,insights_interaction,latest,,,2021-08-24,MSL Interactions,Oncology,Vibranium,,WB-US-08167,Rose Mullings,,onco-us-0021,Mark Thompson,Phone,Avenger,United States,IN,Significant tumor size reduction in 62% of non-small cell lung cancer patients
text,e87664ef-6f11-4125-8b77-a110a16cd54c,insights_interaction,latest,,,2022-01-01,MSL Interactions,Oncology,Vibranium,,WB-US-08031,Margaret Woodard,,onco-us-0021,Mark Thompson,Ulton,Deadpool,United States,IA,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,1c4fadee-c3ca-4869-ab5e-db726b073a18,insights_interaction,latest,,,2022-04-08,MSL Interactions,Oncology,Vibranium,,WB-US-06626,Maria Davis,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,MN,Patients reported improved emotional well-being and reduced treatment anxiety
text,4bf20ac5-0982-4e76-a775-7ec4c65a091b,insights_interaction,latest,,,2022-05-21,MSL Interactions,Oncology,Vibranium,,WB-US-06736,Glen Purington,,onco-us-0021,Mark Thompson,Iron Man,Avenger,United States,IA,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,f8dfa9ad-5f79-4e67-80f0-5eb82e48a151,insights_interaction,latest,,,2023-02-12,MSL Interactions,Oncology,Vibranium,,WB-US-07579,Todd Lattus,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,WI,Moderate improvements in patient-reported outcome measures during long-term treatment
text,05ee956f-bf27-420c-9c72-c12caf60a5c1,insights_interaction,latest,,,2023-03-16,MSL Interactions,Oncology,Vibranium,,WB-US-06624,Linda Fox,,onco-us-0021,Mark Thompson,Iron Man,X-Men,United States,IL,"Patient experienced grade 1 fatigue and nausea following the third infusion of Vibranium, which resolved with supportive care. No dose reduction was necessary."
text,b87a6457-d441-4b46-a10c-559a470892f6,insights_interaction,latest,,,2023-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-07033,John Barreto,,onco-us-0021,Mark Thompson,Phone,Avenger,United States,IA,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,d94ad031-4ac7-4c14-a5f4-170526433108,insights_interaction,latest,,,2023-07-09,MSL Interactions,Oncology,Vibranium,,WB-US-07782,Ron Patrick,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,WI,Grade 3 fatigue reported in a patient receiving Vibranium/Wakanda; treatment was temporarily suspended.
text,679cebc2-aace-4c9c-b215-c18fbdfed58e,insights_interaction,latest,,,2023-10-08,MSL Interactions,Oncology,Vibranium,,WB-US-07963,Sharon Fulop,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,IA,No clear correlation found between baseline biomarker levels and treatment response.
text,908dc3fb-c92a-480d-9461-d5e48528ffdc,insights_interaction,latest,,,2023-10-08,MSL Interactions,Oncology,Vibranium,,WB-US-07903,Debra Kessler,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,WI,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,b0a9e420-fac2-47de-ab54-cf578e6ce435,insights_interaction,latest,,,2024-05-04,MSL Interactions,Oncology,Vibranium,,WB-US-06752,Joe Glass,,onco-us-0021,Mark Thompson,Phone,X-Men,United States,WI,Observed variability in treatment response across different patient subgroups.
text,bd0bc08c-857f-48bc-a629-aeb91dab710c,insights_interaction,latest,,,2024-10-17,MSL Interactions,Oncology,Vibranium,,WB-US-08048,Denise Fayne,,onco-us-0021,Mark Thompson,Iron Man,X-Men,United States,OH,High cost of therapy may present a significant barrier to broader accessibility for many patients.
text,3f95cc4d-2528-44e6-99fa-61d7f4720a2b,insights_interaction,latest,,,2021-02-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01275,Margaret Pagan,,onco-eu-0023,Markus Schwarz,Phone,Avenger,Austria,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,c13e81ca-abef-4059-83f0-dcac1fe57e2e,insights_interaction,latest,,,2021-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00925,Jeffrey Cooper,,onco-eu-0023,Markus Schwarz,Ulton,Deadpool,Switzerland,,Elevated levels of tumor-infiltrating lymphocytes (TILs) observed in biopsies from responding patients.
text,a961080e-ea49-4e07-9b53-01b61bd9cbba,insights_interaction,latest,,,2021-09-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01627,Sarah Zinke,,onco-eu-0023,Markus Schwarz,Phone,Wolverine,Switzerland,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,ff33cf1d-912e-4ade-a2c9-93bc525521ae,insights_interaction,latest,,,2022-05-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01403,Lenore Reynolds,,onco-eu-0023,Markus Schwarz,Ulton,Wolverine,Netherlands,,Complete response rates in metastatic melanoma patients reached 31%
text,b4d919c0-32bc-44ed-a87e-9576e0c9b36b,insights_interaction,latest,,,2022-07-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01938,Bruce Stillwell,,onco-eu-0023,Markus Schwarz,Phone,X-Men,Netherlands,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,5c84351a-a0d0-4465-a878-a32b03f39979,insights_interaction,latest,,,2022-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01943,William Moers,,onco-eu-0023,Markus Schwarz,Phone,Deadpool,Germany,,Sustained tumor shrinkage observed in 65% of patients after 12-week treatment
text,7b00c601-91cf-418f-a16f-b589c1b8e37c,insights_interaction,latest,,,2022-08-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01173,Robert Price,,onco-eu-0023,Markus Schwarz,Ulton,Avenger,Austria,,Simplified administration protocol compared to previous combination therapies
text,7009bedc-6251-42b9-908c-02a61eaa7192,insights_interaction,latest,,,2024-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00906,Shelly Fraser,,onco-eu-0023,Markus Schwarz,Ulton,Avenger,Germany,,"Detected potential resistance mechanisms emerging after 8-12 months of continuous therapy, suggesting need for combination strategies"
text,d79a868b-743e-4cd0-a65b-31fb57061b7f,insights_interaction,latest,,,2024-03-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01965,Florence Hoppes,,onco-eu-0023,Markus Schwarz,Iron Man,X-Men,Austria,,Progressive disease noted in a small subset of patients despite initial response.
text,f85756a9-1ffa-4061-8fb1-e5dd6aeb85f6,insights_interaction,latest,,,2024-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01963,Terry Moore,,onco-eu-0023,Markus Schwarz,Iron Man,Avenger,Belgium,,Strong correlation between tumor mutational burden >10 and improved progression-free survival in Wakanda cohort
text,2930549c-0ab9-4555-9948-620bdc12abf7,insights_interaction,latest,,,2024-07-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01965,Florence Hoppes,,onco-eu-0023,Markus Schwarz,Ulton,X-Men,Austria,,One patient experienced grade 3 thrombocytopenia requiring platelet transfusion after receiving Vibranium/Wakanda.
text,ad5c6cbb-564f-44ea-820f-e3319f8d1c9d,insights_interaction,latest,,,2024-08-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01965,Florence Hoppes,,onco-eu-0023,Markus Schwarz,Iron Man,X-Men,Austria,,Treatment response appears less effective in patients with high levels of immunosuppression.
text,b38a5c33-8238-4e89-891e-c64e2d0c6bf5,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01602,James Rains,,onco-eu-0023,Markus Schwarz,Iron Man,X-Men,Belgium,,No significant change observed in tumor burden in a patient with pancreatic cancer after 12 weeks of Vibranium/Wakanda therapy.  Treatment discontinued.
text,824ec446-db80-4355-8810-9fc239aff459,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01602,James Rains,,onco-eu-0023,Markus Schwarz,Iron Man,X-Men,Belgium,,"Increased risk of infection observed in some patients treated with Vibranium/Wakanda, possibly due to immune suppression."
text,ddc8749f-9968-4c5e-9ee0-dc96b821bad3,insights_interaction,latest,,,2024-12-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01504,Lola Ogren,,onco-eu-0023,Markus Schwarz,Iron Man,Deadpool,Austria,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,4a67439d-fc88-447e-b6d1-dfc796eeab23,insights_interaction,latest,,,2021-02-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01031,Marta Nichols,,onco-eu-0019,Martina Wagner,Iron Man,X-Men,Belgium,,Correlation observed between high baseline tumor mutational burden and response to Vibranium/Wakanda.
text,187c9d5c-0737-4909-8c59-ab90d8b73bdb,insights_interaction,latest,,,2021-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01261,Frank Tritz,,onco-eu-0019,Martina Wagner,Iron Man,Wolverine,Belgium,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,82d871ac-9272-4933-aa88-54c4f2c3e623,insights_interaction,latest,,,2021-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00836,James Oshiro,,onco-eu-0019,Martina Wagner,Ulton,X-Men,Austria,,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,81fe87a5-7522-4883-8ee2-bb71a36aedcf,insights_interaction,latest,,,2021-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01261,Frank Tritz,,onco-eu-0019,Martina Wagner,Iron Man,Wolverine,Belgium,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,84baf715-2c80-4dcd-9f14-ec3ebd85adb0,insights_interaction,latest,,,2021-05-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01769,Jamie Bonds,,onco-eu-0019,Martina Wagner,Ulton,Deadpool,Belgium,,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,b6b381c0-f04a-44e4-853f-b817cace5143,insights_interaction,latest,,,2021-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01391,Carol True,,onco-eu-0019,Martina Wagner,Iron Man,X-Men,Belgium,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,c699c5a4-7f5a-4d08-9c43-c28b1d232adf,insights_interaction,latest,,,2021-11-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01268,Jackie Boling,,onco-eu-0019,Martina Wagner,Phone,X-Men,Austria,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,7fa6093a-46ac-4dd9-b80c-83d35a1d4329,insights_interaction,latest,,,2022-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01499,Cynthia Harper,,onco-eu-0019,Martina Wagner,Iron Man,X-Men,Germany,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,ca476f76-a4d2-4cd3-9fe0-e63bfeb71e8a,insights_interaction,latest,,,2022-10-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01284,Ferne Adams,,onco-eu-0019,Martina Wagner,Phone,X-Men,Netherlands,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,dfbf7ede-7c41-4c32-b008-13e946a95c26,insights_interaction,latest,,,2022-12-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01630,John Anderson,,onco-eu-0019,Martina Wagner,Phone,X-Men,Germany,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,d7152012-d3b0-4b53-bb23-a23641b94e55,insights_interaction,latest,,,2024-01-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01397,Michael Speidel,,onco-eu-0019,Martina Wagner,Phone,Avenger,Switzerland,,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,48bfae47-b7a3-4da0-9cae-f72a8e732642,insights_interaction,latest,,,2024-05-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01805,Ethel Fantasia,,onco-eu-0019,Martina Wagner,Iron Man,Deadpool,Germany,,No significant impact on quality of life observed in some patients with stable disease.
text,18d7d50e-142e-45cc-a4c4-a7fb17fd7bb2,insights_interaction,latest,,,2024-06-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01805,Ethel Fantasia,,onco-eu-0019,Martina Wagner,Phone,Deadpool,Germany,,Quality of life remained stable in a majority of patients despite disease progression.
text,ada0d96e-ec92-4e68-9def-c30b0e55a825,insights_interaction,latest,,,2024-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01391,Carol True,,onco-eu-0019,Martina Wagner,Ulton,X-Men,Belgium,,Variable patient-reported outcomes suggest individualized response experiences requiring personalized supportive care approaches.
text,d76fbffe-40cb-4eff-8bbd-16c98ea47376,insights_interaction,latest,,,2024-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01822,Carlos Martinez,,onco-eu-0019,Martina Wagner,Iron Man,Wolverine,Switzerland,,Observed variable response rates to Vibranium/Wakanda across different tumor types in the ongoing clinical trial.
text,e8258439-11de-4936-bc6a-9166b4c228a1,insights_interaction,latest,,,2024-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01092,Joseph Lusane,,onco-eu-0019,Martina Wagner,Ulton,X-Men,Germany,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,110838dc-3545-4e39-931c-e1a478df0aea,insights_interaction,latest,,,2024-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00947,Paul Walsh,,onco-eu-0019,Martina Wagner,Iron Man,X-Men,Belgium,,"Patient with metastatic melanoma showed no objective response after three cycles of Vibranium/Wakanda therapy. Disease progression was noted, requiring a change in treatment strategy."
text,a2bd3841-1ccb-4cad-8204-8788dfe82a43,insights_interaction,latest,,,2024-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01092,Joseph Lusane,,onco-eu-0019,Martina Wagner,Ulton,X-Men,Germany,,"Patient experienced grade 1 fatigue and nausea following Vibranium infusion, resolving spontaneously without intervention."
text,afb35fd0-de9d-4239-a722-c96b961b2f28,insights_interaction,latest,,,2022-05-29,MSL Interactions,Oncology,Vibranium,,WB-US-09895,Guy Smith,,onco-us-0032,Mary Roberts,Iron Man,X-Men,United States,NM,Stable disease observed in several patients with lung cancer after two cycles.
text,ce33c5a7-0147-4344-a3ef-b6bb03910f37,insights_interaction,latest,,,2022-06-19,MSL Interactions,Oncology,Vibranium,,WB-US-09230,Grant Pralle,,onco-us-0032,Mary Roberts,Phone,Wolverine,United States,HI,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,a3a89ba7-05ab-4725-839f-9d76039bcf7b,insights_interaction,latest,,,2022-07-14,MSL Interactions,Oncology,Vibranium,,WB-US-09435,Artie Brown,,onco-us-0032,Mary Roberts,Phone,Avenger,United States,ID,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,b2381dc8-a2b0-4ee6-a6d4-a2f1aef4a8f0,insights_interaction,latest,,,2022-08-16,MSL Interactions,Oncology,Vibranium,,WB-US-09362,Jose Koonce,,onco-us-0032,Mary Roberts,Phone,Avenger,United States,AK,Treatment regimen was well-tolerated by most patients with minimal interruptions.
text,5e756f92-744d-4a8b-915e-f27d18837304,insights_interaction,latest,,,2022-09-28,MSL Interactions,Oncology,Vibranium,,WB-US-09561,Dierdre Sewell,,onco-us-0032,Mary Roberts,Ulton,Wolverine,United States,AZ,Enhanced synergistic effects in combination with targeted molecular therapies
text,e45761bf-cce0-4afa-8001-ddfe0579b87a,insights_interaction,latest,,,2023-01-05,MSL Interactions,Oncology,Vibranium,,WB-US-09561,Dierdre Sewell,,onco-us-0032,Mary Roberts,Phone,Wolverine,United States,AZ,"Mild injection site reactions observed in several patients, resolving within 24-48 hours."
text,8a9c9b0f-df84-44ab-9adf-00d976977814,insights_interaction,latest,,,2023-03-19,MSL Interactions,Oncology,Vibranium,,WB-US-09933,Arnold Pope,,onco-us-0032,Mary Roberts,Ulton,Avenger,United States,OR,Observed variability in response rates across different tumor types.  Better response observed in melanoma compared to colorectal cancer.
text,f7bce4af-a034-4381-90f4-cb918c85ce5f,insights_interaction,latest,,,2023-08-11,MSL Interactions,Oncology,Vibranium,,WB-US-09481,Luciano Martins,,onco-us-0032,Mary Roberts,Iron Man,X-Men,United States,NM,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,df603f98-6e3e-4da3-88c5-189bbc6ddc22,insights_interaction,latest,,,2023-08-21,MSL Interactions,Oncology,Vibranium,,WB-US-09905,Fannie Ulrich,,onco-us-0032,Mary Roberts,Phone,Avenger,United States,WY,Streamlined molecular screening protocol reduces time from diagnosis to personalized treatment initiation
text,c7388923-b369-4465-b337-5a26399877ab,insights_interaction,latest,,,2024-04-09,MSL Interactions,Oncology,Vibranium,,WB-US-09680,Mitchell Credeur,,onco-us-0032,Mary Roberts,Ulton,Deadpool,United States,AK,Response to Vibranium appears to be independent of prior systemic therapy in some patients.
text,fc8744b2-824c-49b4-88dd-a89656b32747,insights_interaction,latest,,,2024-09-07,MSL Interactions,Oncology,Vibranium,,WB-US-09257,Douglas Davis,,onco-us-0032,Mary Roberts,Iron Man,X-Men,United States,OR,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,7f6a97ec-373a-4dfd-8ff3-3fd3ebaac1cc,insights_interaction,latest,,,2024-10-02,MSL Interactions,Oncology,Vibranium,,WB-US-09673,Joshua Schick,,onco-us-0032,Mary Roberts,Iron Man,Wolverine,United States,CA,Variable response rates across different cancer subtypes
text,d763b85c-3cfe-45c1-b086-4deac4b817d1,insights_interaction,latest,,,2021-03-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02542,Elisa Daniels,,onco-eu-0046,Matteo Greco,Iron Man,Avenger,Greece,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,2c8a38b7-04a9-4524-9662-7823eade8029,insights_interaction,latest,,,2021-06-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02729,Cheri Roeske,,onco-eu-0046,Matteo Greco,Iron Man,X-Men,Italy,,Stable disease observed in several patients with advanced colorectal cancer after two cycles.
text,194d03af-667e-4a96-b4c0-65af18982351,insights_interaction,latest,,,2022-05-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02044,Susan Prince,,onco-eu-0046,Matteo Greco,Phone,Deadpool,Spain,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,60f5dce9-3716-4a54-82f9-1ee6927d9cd9,insights_interaction,latest,,,2022-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02973,Patricia Medley,,onco-eu-0046,Matteo Greco,Phone,Wolverine,Italy,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,51d7352c-be93-4ba6-8992-fc2014d2cb3b,insights_interaction,latest,,,2023-02-25,MSL Interactions,Oncology,Vibranium,,WB-EU-02120,Bonnie Haaby,,onco-eu-0046,Matteo Greco,Ulton,Wolverine,Ragnarok,,Reduction in pain levels reported by patients with bone metastases.
text,f9a3363f-3ff8-4b8d-8230-959c9361bc50,insights_interaction,latest,,,2023-03-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02519,Tyler Merced,,onco-eu-0046,Matteo Greco,Phone,Avenger,Greece,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,6ba2219e-e640-4900-a2c7-710d367e0ba1,insights_interaction,latest,,,2023-07-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02889,Evan Labonte,,onco-eu-0046,Matteo Greco,Ulton,X-Men,Ragnarok,,Mixed patient-reported outcomes with moderate improvements in pain management and emotional well-being
text,d902d0db-8454-4764-8e96-4999399cc9a0,insights_interaction,latest,,,2024-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02416,Timothy Carreno,,onco-eu-0046,Matteo Greco,Iron Man,Avenger,Spain,,Cost-effectiveness analysis is required to assess the long-term feasibility of Vibranium/Wakanda therapy in routine clinical practice.
text,5138faa4-9c1b-4958-9dae-a346fe0c802b,insights_interaction,latest,,,2024-03-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02536,Nicole Monroe,,onco-eu-0046,Matteo Greco,Phone,Deadpool,Ragnarok,,No serious adverse events reported in the first 10 patients enrolled in the study.
text,e3bdf2ef-a885-4c2a-8c97-e0bd0dd571df,insights_interaction,latest,,,2024-05-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02813,Lynne Duckett,,onco-eu-0046,Matteo Greco,Ulton,X-Men,Spain,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,1f22d5eb-c7bc-4529-900f-6ecdb3856bc3,insights_interaction,latest,,,2024-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02205,Erik Gauss,,onco-eu-0046,Matteo Greco,Ulton,X-Men,Spain,,No unexpected safety signals were observed in the current phase of the study.
text,35ea9320-245e-4339-af9f-b3cc788beb34,insights_interaction,latest,,,2024-12-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02360,Erik Engemann,,onco-eu-0046,Matteo Greco,Iron Man,Avenger,Greece,,Enhanced treatment response in patients with specific genetic mutations
text,a5de3b50-b972-4836-975d-a48a3e664762,insights_interaction,latest,,,2021-01-11,MSL Interactions,Oncology,Vibranium,,WB-US-00099,Richard Pecora,,onco-us-0002,Michael Rodriguez,Ulton,Avenger,United States,NH,No unexpected safety signals observed in the ongoing clinical trial.
text,77217bce-68c9-404a-98e2-454dafe4eff4,insights_interaction,latest,,,2021-07-24,MSL Interactions,Oncology,Vibranium,,WB-US-01818,Jennifer Bowers,,onco-us-0002,Michael Rodriguez,Ulton,X-Men,United States,RI,Enhanced treatment response in patients with specific genetic profiles
text,122ac499-ee3b-46a5-9c61-185f7e2e63f6,insights_interaction,latest,,,2022-02-21,MSL Interactions,Oncology,Vibranium,,WB-US-00551,Amanda Joy,,onco-us-0002,Michael Rodriguez,Ulton,X-Men,United States,NH,Observed stable disease in 60% of patients after 3 months of treatment.
text,ced65926-1dfb-4831-8f97-4814fbb06817,insights_interaction,latest,,,2022-03-31,MSL Interactions,Oncology,Vibranium,,WB-US-00409,Carl Vidinha,,onco-us-0002,Michael Rodriguez,Phone,Deadpool,United States,NY,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,75b00907-b895-4118-84ff-195c436759ae,insights_interaction,latest,,,2022-08-30,MSL Interactions,Oncology,Vibranium,,WB-US-00324,Linda Johnson,,onco-us-0002,Michael Rodriguez,Ulton,X-Men,United States,RI,Early detection of response based on circulating tumor DNA analysis.
text,254303e7-93d9-47d7-be3d-0a809d317370,insights_interaction,latest,,,2023-01-15,MSL Interactions,Oncology,Vibranium,,WB-US-02565,Jason Murphy,,onco-us-0002,Michael Rodriguez,Iron Man,Deadpool,United States,NY,Treatment cost is a significant barrier to widespread adoption.
text,c1b7b757-1265-4f2c-ba31-4c1a831fe84e,insights_interaction,latest,,,2023-02-05,MSL Interactions,Oncology,Vibranium,,WB-US-01061,Earl Guzman,,onco-us-0002,Michael Rodriguez,Ulton,X-Men,United States,MA,Treatment requires frequent monitoring of blood counts and other laboratory values.
text,58249f18-8493-4fff-9177-5f68b992f5fd,insights_interaction,latest,,,2023-07-11,MSL Interactions,Oncology,Vibranium,,WB-US-02327,Maria Fenelus,,onco-us-0002,Michael Rodriguez,Iron Man,Deadpool,United States,MA,Consistent treatment response across different age groups and cancer subtypes observed in preliminary analysis
text,e6c4210a-ae07-440a-8dab-de6069bf46f1,insights_interaction,latest,,,2023-11-17,MSL Interactions,Oncology,Vibranium,,WB-US-00510,Ronald Hutchinson,,onco-us-0002,Michael Rodriguez,Iron Man,Deadpool,United States,NY,"Significant increase in PD-L1 expression observed in tumor biopsies after one cycle of treatment, suggesting potential synergy between Vibranium and Wakanda."
text,f7043174-4b7e-442a-87e9-a1dcebc3d421,insights_interaction,latest,,,2023-11-23,MSL Interactions,Oncology,Vibranium,,WB-US-01127,Teresa Santiago,,onco-us-0002,Michael Rodriguez,Ulton,Avenger,United States,VT,"Improved patient-reported quality of life scores (EORTC QLQ-C30) observed in patients receiving the combination therapy, particularly in terms of fatigue and pain."
text,4c53181b-3077-402e-b136-9e6625c4d8cb,insights_interaction,latest,,,2024-03-21,MSL Interactions,Oncology,Vibranium,,WB-US-01407,Lillie Simas,,onco-us-0002,Michael Rodriguez,Iron Man,X-Men,United States,NY,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,226cf65e-34d9-43aa-b629-f0f36faeceb7,insights_interaction,latest,,,2024-03-27,MSL Interactions,Oncology,Vibranium,,WB-US-01305,Timothy Bennett,,onco-us-0002,Michael Rodriguez,Phone,Avenger,United States,NH,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,6feffe58-2423-497b-b1fe-d68d67bf622e,insights_interaction,latest,,,2024-05-29,MSL Interactions,Oncology,Vibranium,,WB-US-01905,Marian Brown,,onco-us-0002,Michael Rodriguez,Ulton,Avenger,United States,NY,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,ee63ae0c-38ad-41f2-9f83-f9cba5a13d1c,insights_interaction,latest,,,2024-06-15,MSL Interactions,Oncology,Vibranium,,WB-US-02790,Noe Oswalt,,onco-us-0002,Michael Rodriguez,Iron Man,Deadpool,United States,VT,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,e36bb540-a31c-40b2-ae92-27fbee3873e0,insights_interaction,latest,,,2024-09-14,MSL Interactions,Oncology,Vibranium,,WB-US-02709,Pearl Russel,,onco-us-0002,Michael Rodriguez,Phone,Deadpool,United States,VT,Treatment requires close monitoring of blood counts and organ function.
text,85110c2b-b1fe-4776-be3d-33c150ad7ef3,insights_interaction,latest,,,2024-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-00206,Annie Christman,,onco-us-0002,Michael Rodriguez,Ulton,X-Men,United States,ME,Requires close monitoring of blood counts and liver function tests.
text,e94d2b8d-0e54-4b76-9932-37babe8d5b8a,insights_interaction,latest,,,2024-10-23,MSL Interactions,Oncology,Vibranium,,WB-US-01293,Rufus Burchfield,,onco-us-0002,Michael Rodriguez,Iron Man,X-Men,United States,MA,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,d8fde799-886b-47bf-a161-0ffc94dab818,insights_interaction,latest,,,2024-12-30,MSL Interactions,Oncology,Vibranium,,WB-US-00895,Sonia Wilson,,onco-us-0002,Michael Rodriguez,Phone,Wolverine,United States,NY,Inconsistent genomic marker predictability across patient subgroups
text,d8632ac2-d891-4784-865a-631b14b2ff01,insights_interaction,latest,,,2022-01-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03968,Frank Williams,,onco-eu-0070,Mikhail Volkov,Phone,X-Men,Ireland,,Significant reduction in treatment-related fatigue and improved patient mobility
text,4eff7331-d000-4bc7-9dbb-f18132485092,insights_interaction,latest,,,2022-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03567,Jason Bombich,,onco-eu-0070,Mikhail Volkov,Ulton,X-Men,Ireland,,Correlation observed between increased PD-L1 expression and response to Vibranium/Wakanda therapy.
text,23430c6b-5cca-4f33-a12b-39d3dfb93f1b,insights_interaction,latest,,,2022-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03999,Phillip Schuh,,onco-eu-0070,Mikhail Volkov,Phone,X-Men,Ireland,,Early detection of response based on circulating tumor DNA analysis.
text,6eedf437-3eec-4523-9597-2be8179d9d34,insights_interaction,latest,,,2022-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-03960,Sandy Melia,,onco-eu-0070,Mikhail Volkov,Iron Man,Avenger,France,,"Partial response observed in a patient with advanced colorectal cancer, with a durable response lasting over 6 months."
text,0b330988-1619-43f0-92b6-8226cc7c325b,insights_interaction,latest,,,2022-08-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03972,Marie Johnston,,onco-eu-0070,Mikhail Volkov,Phone,Avenger,United Kingdom,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 8 weeks of Vibranium therapy, with a 30% reduction in target lesion size confirmed by RECIST 1.1 criteria.  Significant reduction in CA 19-9 levels also observed."
text,3bfab8a0-70ca-492e-8ba9-b7a7bb61f271,insights_interaction,latest,,,2023-07-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03805,Laverne Gilmore,,onco-eu-0070,Mikhail Volkov,Ulton,X-Men,France,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,9627a509-ebf3-4154-afb1-f88277815081,insights_interaction,latest,,,2023-09-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03563,Donald Collister,,onco-eu-0070,Mikhail Volkov,Iron Man,Deadpool,Ireland,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,b2c72784-2d35-4470-9712-41a91f193d58,insights_interaction,latest,,,2024-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03074,Maria Chizmar,,onco-eu-0070,Mikhail Volkov,Ulton,Deadpool,France,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,6602a493-6c95-4e6b-b57f-c0d981852028,insights_interaction,latest,,,2024-04-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03183,Tran Rodriguez,,onco-eu-0070,Mikhail Volkov,Ulton,Avenger,France,,Reduced effectiveness in patients with complex genetic mutations
text,d6becb7e-ecaf-4192-89e6-0b9eafd12c7e,insights_interaction,latest,,,2024-08-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03074,Maria Chizmar,,onco-eu-0070,Mikhail Volkov,Ulton,Deadpool,France,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,6419f97b-ad8a-47bb-94e5-8f5fb616735b,insights_interaction,latest,,,2024-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03788,Angela Christensen,,onco-eu-0070,Mikhail Volkov,Phone,X-Men,United Kingdom,,"Observed variability in response to Vibranium/Wakanda across different tumor types, suggesting potential for personalized treatment strategies."
text,f8a33f9c-cbdd-4300-81a4-f2eb7533d57b,insights_interaction,latest,,,2021-02-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01094,Charlie Barcellos,,onco-eu-0028,Monika Hoffmann,Ulton,X-Men,Belgium,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,a4e0c9b2-936c-4c62-a7af-1495edd5801f,insights_interaction,latest,,,2021-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00817,Thomas Mcmahon,,onco-eu-0028,Monika Hoffmann,Iron Man,Wolverine,Switzerland,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,da2a80a3-1e3d-4962-8ed4-92b0ac8fcc31,insights_interaction,latest,,,2021-04-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01041,Jerry Johnson,,onco-eu-0028,Monika Hoffmann,Phone,X-Men,Belgium,,Correlation observed between high baseline PD-L1 expression and improved response to Vibranium/Wakanda in lung cancer patients.
text,161d5ce1-1c40-4a47-bff1-99938236aafb,insights_interaction,latest,,,2021-08-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00844,Laura Christopher,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Belgium,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,c0187d68-c213-4641-88d5-3c7553d18d1c,insights_interaction,latest,,,2021-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01263,Angel Erwin,,onco-eu-0028,Monika Hoffmann,Iron Man,Avenger,Austria,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,af74cce7-4d1d-485c-a7b7-4e061bab7cc6,insights_interaction,latest,,,2021-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01760,Rena Edens,,onco-eu-0028,Monika Hoffmann,Phone,Clinical Pharmacist,Netherlands,,Significant reduction in pain scores and improved patient-reported emotional well-being
text,945fbdfa-7de3-4307-9851-c4ed8b3987fc,insights_interaction,latest,,,2022-01-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01383,Marsha Ball,,onco-eu-0028,Monika Hoffmann,Phone,Deadpool,Switzerland,,Correlation observed between high baseline levels of specific immune cells and improved response to Vibranium/Wakanda.
text,a795d1aa-3add-45b8-96db-cdf3123f6ba6,insights_interaction,latest,,,2022-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01618,Tonya Harmon,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Germany,,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,7fbf4d02-789b-410f-9515-97bc13678daf,insights_interaction,latest,,,2022-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01400,Ruben Randles,,onco-eu-0028,Monika Hoffmann,Phone,X-Men,Belgium,,Stable disease (SD) was observed for over 6 months in a patient with recurrent glioblastoma after receiving Vibranium/Wakanda in combination with radiotherapy.
text,e8f8849c-2bee-4ae5-84ed-5635ab520819,insights_interaction,latest,,,2022-05-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01286,James Martin,,onco-eu-0028,Monika Hoffmann,Iron Man,Deadpool,Netherlands,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,c7993c22-9fc9-45a6-8d89-9bf7fbb366fe,insights_interaction,latest,,,2022-07-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01037,Samuel Dunnam,,onco-eu-0028,Monika Hoffmann,Phone,Avenger,Switzerland,,Streamlined patient monitoring protocol reduces overall clinical management complexity
text,d6518822-c92d-4839-8a5a-6ffd15d68f1b,insights_interaction,latest,,,2022-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01798,Emery Downing,,onco-eu-0028,Monika Hoffmann,Ulton,Deadpool,Belgium,,No significant unexpected adverse events reported in the majority of patients treated with Vibranium/Wakanda.
text,6dfa4907-b389-441b-a1d4-f57d413f2ed7,insights_interaction,latest,,,2022-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00853,John Riley,,onco-eu-0028,Monika Hoffmann,Iron Man,Deadpool,Netherlands,,"Improved patient reported quality of life scores on EORTC QLQ-C30 in several patients treated with Vibranium/Wakanda, particularly in terms of fatigue and pain."
text,ec29aef9-a988-4355-a812-558523bf7906,insights_interaction,latest,,,2023-01-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00844,Laura Christopher,,onco-eu-0028,Monika Hoffmann,Phone,X-Men,Belgium,,No significant change in circulating tumor DNA levels observed after the first cycle of treatment.
text,5bc35429-6e9e-4069-8c4a-2eb8eda411e2,insights_interaction,latest,,,2023-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01094,Charlie Barcellos,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Belgium,,"Low incidence of grade 3-4 toxicities, with manageable immune-related adverse events through proactive monitoring"
text,1a0357dd-5d7d-4d8e-a72e-74f8e6bf8731,insights_interaction,latest,,,2023-05-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01400,Ruben Randles,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Belgium,,Median progression-free survival of 5.7 months in advanced stage patients
text,7c3e33e5-46f6-433a-878d-54deec63bfca,insights_interaction,latest,,,2023-06-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01041,Jerry Johnson,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Belgium,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,307f1965-18bb-4514-a825-8b75989c20f0,insights_interaction,latest,,,2023-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01383,Marsha Ball,,onco-eu-0028,Monika Hoffmann,Phone,Deadpool,Switzerland,,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,c9e1e708-94d8-4796-9d8a-b51f637001a7,insights_interaction,latest,,,2023-07-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01128,Bob Davis,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Netherlands,,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,b9f3e69a-3659-46f4-a79a-91eddef5df4d,insights_interaction,latest,,,2023-07-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01843,Michael Lummus,,onco-eu-0028,Monika Hoffmann,Ulton,X-Men,Germany,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,65d68a88-80e8-4c34-9d3e-03bb5d5f760b,insights_interaction,latest,,,2023-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01862,Georgia Cornejo,,onco-eu-0028,Monika Hoffmann,Iron Man,Avenger,Austria,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,4305fae9-06a6-4950-bdc5-fc0afad19881,insights_interaction,latest,,,2024-01-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01150,Audrey Robinson,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Austria,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,9af88be4-95aa-4049-836a-6bfb5169bab7,insights_interaction,latest,,,2024-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01618,Tonya Harmon,,onco-eu-0028,Monika Hoffmann,Ulton,X-Men,Germany,,Emerging evidence of potential pharmacogenomic markers for individualized dosing strategies
text,0a905114-741d-4ca8-bd67-b7db9b2ecc59,insights_interaction,latest,,,2024-05-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01578,Bryan Castile,,onco-eu-0028,Monika Hoffmann,Phone,Avenger,Austria,,Reduction in pain levels reported by patients with bone metastases.
text,4f71c12b-0eba-4475-95ca-da64494ee3c7,insights_interaction,latest,,,2024-08-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00830,James Johnson,,onco-eu-0028,Monika Hoffmann,Iron Man,Clinical Pharmacist,Belgium,,"Observed differential response patterns across age groups, with patients under 55 demonstrating more robust tumor reduction compared to older patient cohorts."
text,f5d8d067-3e62-4861-81aa-9bae4fa1f86d,insights_interaction,latest,,,2024-09-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01094,Charlie Barcellos,,onco-eu-0028,Monika Hoffmann,Iron Man,X-Men,Belgium,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,2301ee56-9809-419f-98fd-ef28289ae8c4,insights_interaction,latest,,,2021-01-07,MSL Interactions,Oncology,Vibranium,,WB-US-08145,Gary Dixon,,onco-us-0019,Nancy Clark,Ulton,Deadpool,United States,MN,Progression-free survival improved significantly in the treatment arm compared to the control group in the ongoing phase II trial.
text,66a252f7-ed63-446f-9854-6d86fefa65f4,insights_interaction,latest,,,2021-04-06,MSL Interactions,Oncology,Vibranium,,WB-US-06803,Latoya Gardner,,onco-us-0019,Nancy Clark,Iron Man,Avenger,United States,MN,Significant improvement in patient-reported emotional well-being scores
text,c425f373-0532-4ed8-991b-e1170a3822fc,insights_interaction,latest,,,2021-05-20,MSL Interactions,Oncology,Vibranium,,WB-US-06724,Chong Davis,,onco-us-0019,Nancy Clark,Iron Man,Avenger,United States,MO,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,aac6a57f-463d-4e28-bc8f-e57bf63734d0,insights_interaction,latest,,,2021-06-09,MSL Interactions,Oncology,Vibranium,,WB-US-07667,Cynthia Lattimore,,onco-us-0019,Nancy Clark,Phone,Wolverine,United States,MI,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,3a8b4cb5-d356-4976-81bd-e02121bfdc55,insights_interaction,latest,,,2021-07-27,MSL Interactions,Oncology,Vibranium,,WB-US-08181,John Belcher,,onco-us-0019,Nancy Clark,Iron Man,Avenger,United States,MN,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,ac9f6c9c-c1b5-4f02-82cc-c672b8e9085b,insights_interaction,latest,,,2021-08-05,MSL Interactions,Oncology,Vibranium,,WB-US-06882,Judith Mccalpane,,onco-us-0019,Nancy Clark,Ulton,X-Men,United States,MO,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,72093b1f-4400-4ddd-bc38-19d8ae0e5700,insights_interaction,latest,,,2021-10-23,MSL Interactions,Oncology,Vibranium,,WB-US-07918,Jonathan Gill,,onco-us-0019,Nancy Clark,Iron Man,X-Men,United States,WI,Significant correlation detected between PD-L1 expression levels and treatment response
text,22d9f7ac-654c-483c-8a67-e7ffbcbf0bc2,insights_interaction,latest,,,2021-12-20,MSL Interactions,Oncology,Vibranium,,WB-US-07243,Joanna Tamura,,onco-us-0019,Nancy Clark,Iron Man,X-Men,United States,MO,Improved appetite and increased energy levels observed in a patient with advanced melanoma undergoing Vibranium/Wakanda treatment.
text,2bd57b7a-9410-45f3-97ef-e7e7d91293cc,insights_interaction,latest,,,2022-03-01,MSL Interactions,Oncology,Vibranium,,WB-US-08227,Thomas Sumlin,,onco-us-0019,Nancy Clark,Iron Man,Deadpool,United States,IL,"Increased PD-L1 expression detected in tumor biopsies following two cycles of Vibranium/Wakanda, suggesting a potential synergistic effect."
text,3974028f-9031-4a60-8192-90458bc75688,insights_interaction,latest,,,2022-09-05,MSL Interactions,Oncology,Vibranium,,WB-US-07392,Susan Schulz,,onco-us-0019,Nancy Clark,Ulton,Deadpool,United States,MN,Identified genetic mutation profile predicting superior therapeutic response in 28% of treated patients
text,0ea40647-e0ee-416a-9109-c71a4d4d7315,insights_interaction,latest,,,2022-10-28,MSL Interactions,Oncology,Vibranium,,WB-US-06603,Quincy Eng,,onco-us-0019,Nancy Clark,Iron Man,X-Men,United States,IN,Observed a correlation between higher initial tumor burden and slower response to therapy.
text,dc319bde-d270-44b6-a788-51e2f70c4131,insights_interaction,latest,,,2022-11-17,MSL Interactions,Oncology,Vibranium,,WB-US-07227,Willie Brown,,onco-us-0019,Nancy Clark,Phone,Deadpool,United States,MO,Patients reported improved symptom management and reduced pain scores compared to standard therapy
text,e8e9cd13-aeba-4830-8444-ba8c1ba2a05d,insights_interaction,latest,,,2023-10-25,MSL Interactions,Oncology,Vibranium,,WB-US-07252,William Nieto,,onco-us-0019,Nancy Clark,Phone,Deadpool,United States,MO,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,db3168cf-9f42-492a-bea8-019f59055c21,insights_interaction,latest,,,2024-02-22,MSL Interactions,Oncology,Vibranium,,WB-US-07544,Dorothy Westray,,onco-us-0019,Nancy Clark,Iron Man,X-Men,United States,IA,Consistent treatment efficacy across different cancer subtypes with minor variations
text,73df5207-bd91-444a-834e-5abcc15ba847,insights_interaction,latest,,,2024-06-08,MSL Interactions,Oncology,Vibranium,,WB-US-07696,Vera Mcintosh,,onco-us-0019,Nancy Clark,Iron Man,Avenger,United States,OH,One patient experienced severe thrombocytopenia requiring platelet transfusion.
text,3b77cac4-1f14-4512-b40e-d2f2cbeacc87,insights_interaction,latest,,,2024-06-13,MSL Interactions,Oncology,Vibranium,,WB-US-06651,Billie Record,,onco-us-0019,Nancy Clark,Iron Man,Wolverine,United States,MN,Observed variability in response rates across different patient subgroups. Further investigation is needed to identify predictive biomarkers.
text,fe77a190-8310-44c3-840d-1495481656f1,insights_interaction,latest,,,2024-09-25,MSL Interactions,Oncology,Vibranium,,WB-US-07469,Walter Daughters,,onco-us-0019,Nancy Clark,Phone,X-Men,United States,IL,"Significant reduction in treatment-related fatigue reported, with 63% of patients experiencing improved daily functional capacity."
text,b67d9a85-3ce9-42b6-a674-d8ee9cd4af98,insights_interaction,latest,,,2021-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03887,Rebecca Kingsley,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,United Kingdom,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,76f6b04a-34ac-492b-bffa-51e0057b7cf1,insights_interaction,latest,,,2021-04-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03691,Jacob Shimmin,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,Ireland,,Improved sleep quality reported by several patients on the therapy.
text,71877dd9-cc31-44bc-84f2-c5680ff3c1d2,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03271,Melva Hopson,,onco-eu-0064,Natalia Ivanova,Ulton,Wolverine,France,,Improved pain management observed in some patients with bone metastases after Vibranium treatment.
text,fe292ee1-3e0c-44e2-a224-aed02191acdf,insights_interaction,latest,,,2022-04-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03377,Pete Franca,,onco-eu-0064,Natalia Ivanova,Ulton,X-Men,United Kingdom,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,40d28a95-41b9-4496-a7e8-b059b876ea53,insights_interaction,latest,,,2022-04-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03173,Jennifer Morse,,onco-eu-0064,Natalia Ivanova,Ulton,X-Men,Ireland,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,8bf643a0-c4a0-48a4-b10b-600f23f8d7e1,insights_interaction,latest,,,2022-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03189,Ronald Gonzalez,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,Ireland,,Correlation observed between increased PD-L1 expression within the tumor microenvironment and improved response to Vibranium/Wakanda therapy.  Patients with high PD-L1 expression showed a significantly longer progression-free survival (PFS) compared to those with low expression. This suggests potential for biomarker-driven patient selection.
text,b4535cc3-e663-41b6-915c-6e6161985106,insights_interaction,latest,,,2022-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03053,Laura Bradley,,onco-eu-0064,Natalia Ivanova,Ulton,X-Men,France,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,8fb45bc4-5874-4cf4-9964-32d5dbc47cb0,insights_interaction,latest,,,2023-02-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03489,Kathy Patterson,,onco-eu-0064,Natalia Ivanova,Iron Man,X-Men,France,,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,fb71a039-62e4-463b-bf94-e5ec23be6b7e,insights_interaction,latest,,,2023-02-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03571,Orval Weideman,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,United Kingdom,,Observed stable disease in a patient with metastatic melanoma after 6 months of Vibranium/Wakanda treatment.
text,f0987361-3a50-4f4a-ac75-424461233f6b,insights_interaction,latest,,,2023-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03239,Mike Finlay,,onco-eu-0064,Natalia Ivanova,Iron Man,Avenger,Ireland,,Observed variability in response rates across different tumor types.  Better response observed in melanoma compared to colorectal cancer.
text,03610297-517d-4c9f-905b-e18a5d61072e,insights_interaction,latest,,,2023-03-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03458,Ronald Stewart,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,France,,Moderate effectiveness in treatment-resistant cancer subtypes with complex molecular profiles
text,cfb16b68-0a20-4c41-8c82-2cee1cd4cda2,insights_interaction,latest,,,2023-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03527,Janice Moore,,onco-eu-0064,Natalia Ivanova,Iron Man,X-Men,France,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,64036cf5-6f68-4a08-858b-823f35e4d5a3,insights_interaction,latest,,,2023-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03591,Debra Lowe,,onco-eu-0064,Natalia Ivanova,Iron Man,Avenger,France,,Mixed patient-reported outcomes regarding emotional and psychological well-being
text,939ad3f5-2ae0-45ac-9451-da999e7a51fe,insights_interaction,latest,,,2023-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03230,Betsy Hill,,onco-eu-0064,Natalia Ivanova,Iron Man,X-Men,France,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,b86aded9-bcfd-4fa4-99f9-1d987eced1f3,insights_interaction,latest,,,2023-10-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03189,Ronald Gonzalez,,onco-eu-0064,Natalia Ivanova,Ulton,X-Men,Ireland,,"Mild flu-like symptoms (fever, chills, myalgia) reported by several patients receiving Vibranium/Wakanda, resolving without intervention."
text,3ca57709-35be-49f5-924b-1325b33fe299,insights_interaction,latest,,,2023-11-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03914,Glenn Martinez,,onco-eu-0064,Natalia Ivanova,Phone,X-Men,United Kingdom,,Some patients experienced decreased appetite and weight loss during treatment.
text,97518e6f-60a6-4b9d-a760-b0803c440f1f,insights_interaction,latest,,,2024-01-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03734,Clifton Hughes,,onco-eu-0064,Natalia Ivanova,Phone,Deadpool,France,,Mild fatigue and appetite changes reported during treatment maintenance phase
text,ed06fc10-45a5-4f66-bddf-c9e36d0d1b60,insights_interaction,latest,,,2024-05-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03271,Melva Hopson,,onco-eu-0064,Natalia Ivanova,Phone,Wolverine,France,,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,71f31b00-c473-49d0-82f0-9d95484aa8b3,insights_interaction,latest,,,2024-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03578,Ashley Thibodeaux,,onco-eu-0064,Natalia Ivanova,Phone,Avenger,United Kingdom,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,4348549b-75ca-4bc5-b2b5-f31f230e67f4,insights_interaction,latest,,,2024-09-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03062,Maurine Watanabe,,onco-eu-0064,Natalia Ivanova,Phone,Deadpool,Ireland,,"Increased PD-L1 expression observed in tumor biopsies post-treatment, suggesting potential synergistic effect between Vibranium and Wakanda."
text,83730bcc-a795-4f87-86c3-b660e1497d89,insights_interaction,latest,,,2021-02-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02498,Elizabeth Baker,,onco-eu-0051,Nicolas Petit,Iron Man,Deadpool,Italy,,Lower incidence of grade 4 adverse events compared to traditional chemotherapy
text,c724b2d3-0199-4c0c-a286-312d9ca27a49,insights_interaction,latest,,,2021-03-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02808,Marie Ryan,,onco-eu-0051,Nicolas Petit,Phone,Avenger,Ragnarok,,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,78e76496-07ff-40cc-8ae0-2d6d442901ef,insights_interaction,latest,,,2021-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02686,Nicholas Lane,,onco-eu-0051,Nicolas Petit,Iron Man,X-Men,Greece,,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,e6068fc5-42bd-4406-8c54-560530c22f76,insights_interaction,latest,,,2021-03-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02563,Christopher Hutton,,onco-eu-0051,Nicolas Petit,Phone,Avenger,Spain,,Elevated serum levels of interferon-gamma correlated with improved clinical outcomes in patients treated with Vibranium.
text,d5422b1a-4e2c-44f4-9ca3-c2585df818b8,insights_interaction,latest,,,2021-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02667,David Angelovich,,onco-eu-0051,Nicolas Petit,Phone,Deadpool,Greece,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,fb529411-5aff-45a2-aa88-2145dc7c120a,insights_interaction,latest,,,2021-06-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02663,Eva Frye,,onco-eu-0051,Nicolas Petit,Ulton,Avenger,Italy,,Prolonged progression-free survival observed in a subset of patients with head and neck cancer treated with Vibranium/Wakanda.
text,a93ea9c0-0024-44d5-aa5a-aa459428309a,insights_interaction,latest,,,2021-09-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02271,Kathleen Ramirez,,onco-eu-0051,Nicolas Petit,Iron Man,Deadpool,Italy,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,775dcd6a-5f0b-4701-88dc-64fe981aca2b,insights_interaction,latest,,,2022-02-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02483,Gary Brown,,onco-eu-0051,Nicolas Petit,Phone,X-Men,Greece,,Strong correlation between PD-L1 expression >50% and enhanced treatment response
text,bae595e1-6894-41c9-bac2-f5b694f44726,insights_interaction,latest,,,2022-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02271,Kathleen Ramirez,,onco-eu-0051,Nicolas Petit,Iron Man,Deadpool,Italy,,Improved physical functioning reported by several patients.
text,ef75b80e-3900-44e3-be2b-a61098c881ec,insights_interaction,latest,,,2022-09-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02979,Jim Sanchez,,onco-eu-0051,Nicolas Petit,Iron Man,Wolverine,Greece,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,41fbfc15-2d92-4034-9389-479ebfe37bf5,insights_interaction,latest,,,2022-12-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02663,Eva Frye,,onco-eu-0051,Nicolas Petit,Phone,Avenger,Italy,,"Promising early-stage results in combination with checkpoint inhibitors, showing synergistic anti-tumor effects"
text,138bba52-62ca-4a11-b81c-3105ca24ff5f,insights_interaction,latest,,,2024-04-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02877,Sonya Crabtree,,onco-eu-0051,Nicolas Petit,Ulton,X-Men,Spain,,Preliminary immune profiling suggests complex interactions between treatment response and baseline inflammatory markers.
text,1da83bfc-3fb3-48fb-bb7a-0081c6d14c19,insights_interaction,latest,,,2024-06-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02686,Nicholas Lane,,onco-eu-0051,Nicolas Petit,Iron Man,X-Men,Greece,,"Reduced infusion time compared to comparable immunotherapies, improving patient convenience"
text,efbbe69a-ed3b-442f-aaef-c42ad2c3aa7e,insights_interaction,latest,,,2024-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02523,Dorothy Trosper,,onco-eu-0051,Nicolas Petit,Iron Man,X-Men,Spain,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,54b59b59-754e-4a23-87dc-9357b82742f6,insights_interaction,latest,,,2024-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02423,Debra Blackmon,,onco-eu-0051,Nicolas Petit,Iron Man,Avenger,Italy,,"No significant impact on quality of life observed in some patients receiving Vibranium, despite disease stabilization."
text,a8197c8a-9632-4acc-ab8c-71747330acde,insights_interaction,latest,,,2024-08-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02582,Robert Biancardi,,onco-eu-0051,Nicolas Petit,Iron Man,Avenger,Greece,,High cost of therapy may limit widespread adoption.
text,059e985a-8b17-438e-854b-f587616a8f0a,insights_interaction,latest,,,2024-09-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02314,Mario Mccray,,onco-eu-0051,Nicolas Petit,Iron Man,Deadpool,Italy,,No clear correlation found between specific genetic mutations and treatment response.
text,ade5fe41-494b-46fa-ba78-2af43d8b2b71,insights_interaction,latest,,,2024-10-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02423,Debra Blackmon,,onco-eu-0051,Nicolas Petit,Phone,Avenger,Italy,,Variable response rates observed across different metastatic cancer staging levels
text,12990c92-728a-4083-a86c-bccebc7a209d,insights_interaction,latest,,,2021-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00066,Matthew Miller,,onco-eu-0010,Nils Magnusson,Ulton,Avenger,Denmark,,Complete remission achieved in 35% of patients with high-risk hematologic malignancies
text,0fcfc68f-22f3-457d-95f5-523fd414fb3a,insights_interaction,latest,,,2021-09-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00648,Mina Adams,,onco-eu-0010,Nils Magnusson,Iron Man,Avenger,Finland,,Enhanced treatment durability in patients with stable disease
text,513043c8-fd65-4519-80c2-75170be8cc9d,insights_interaction,latest,,,2022-01-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00202,Lula Carnell,,onco-eu-0010,Nils Magnusson,Ulton,X-Men,Finland,,Potential for reduced treatment cycles compared to conventional therapies
text,e5beb2b6-f220-4dc3-a8b3-3c1d5b5dc405,insights_interaction,latest,,,2022-07-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00648,Mina Adams,,onco-eu-0010,Nils Magnusson,Iron Man,Avenger,Finland,,Longer progression-free survival observed in patients with lower tumor mutational burden.
text,32875d0d-4f2c-4130-a730-b5392ca75dbb,insights_interaction,latest,,,2022-07-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00482,Victor Miller,,onco-eu-0010,Nils Magnusson,Phone,Deadpool,Norway,,Stable disease observed in 70% of patients with metastatic melanoma enrolled in a phase II trial after 12 weeks of Vibranium treatment.
text,8451e677-50a4-4731-afef-6326413655bb,insights_interaction,latest,,,2022-07-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00260,William Hoffman,,onco-eu-0010,Nils Magnusson,Iron Man,X-Men,Finland,,Early detection of response based on circulating tumor DNA analysis.
text,8a2346b4-548b-4cc6-8e62-cca2f192f9fe,insights_interaction,latest,,,2022-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00572,Maria Kerr,,onco-eu-0010,Nils Magnusson,Iron Man,Wolverine,Sweden,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,dee6bfd7-9da0-4d20-8e46-75ff850a5c55,insights_interaction,latest,,,2023-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00643,Joyce Johnson,,onco-eu-0010,Nils Magnusson,Iron Man,X-Men,Denmark,,Significant tumor size reduction in 35% of advanced stage cancer patients
text,4b698b2d-7681-4b2e-bc9c-1a8490200fa7,insights_interaction,latest,,,2023-03-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00292,Barbara Clark,,onco-eu-0010,Nils Magnusson,Phone,Deadpool,Norway,,Mild to moderate immune-related adverse events in 18% of patients
text,3588e0d7-d6fd-4d3a-af25-f11a1a471213,insights_interaction,latest,,,2023-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00648,Mina Adams,,onco-eu-0010,Nils Magnusson,Iron Man,Avenger,Finland,,Response to Vibranium appears to be independent of prior systemic therapy in some patients.
text,b8fc81c2-dda9-45de-aaea-4c94c4a60e0a,insights_interaction,latest,,,2023-09-25,MSL Interactions,Oncology,Vibranium,,WB-EU-00729,Paul Gee,,onco-eu-0010,Nils Magnusson,Ulton,X-Men,Sweden,,"Patient with stage IIIc melanoma experienced a significant reduction in tumor size (60%) after 8 weeks of Vibranium/Wakanda therapy, accompanied by improved performance status."
text,6e2f0cf8-6ea8-41d6-a225-7c145218dd48,insights_interaction,latest,,,2024-05-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00147,Margaret Mckean,,onco-eu-0010,Nils Magnusson,Ulton,Avenger,Denmark,,Most adverse events were manageable and mild.
text,7f347257-1408-4de2-90b6-ecaa96bebbdd,insights_interaction,latest,,,2024-10-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00099,Joseph Alvarez,,onco-eu-0010,Nils Magnusson,Phone,Deadpool,Finland,,Novel genetic signature identified that demonstrates 78% accuracy in predicting treatment responsiveness prior to initiating Vibranium therapy.
text,bbbb9e38-7057-4346-8af9-7af8d2b40bf6,insights_interaction,latest,,,2021-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03006,Brian Mckinnon,,onco-eu-0074,Olga Kovalev,Ulton,X-Men,Ireland,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,a05804a6-b910-4491-a8f6-5da59d889528,insights_interaction,latest,,,2021-06-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03426,Jeffery Folger,,onco-eu-0074,Olga Kovalev,Ulton,X-Men,Ireland,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,f75e4a64-c569-49ad-b212-9e2f641bd84e,insights_interaction,latest,,,2021-06-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03901,Helena Alvarado,,onco-eu-0074,Olga Kovalev,Ulton,Avenger,United Kingdom,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,8c4a9e08-59a2-48c1-b315-73adf273c6dd,insights_interaction,latest,,,2021-06-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03526,Andrew Andrews,,onco-eu-0074,Olga Kovalev,Ulton,Wolverine,Ireland,,Minimal cardiac toxicity and reduced treatment-related complications
text,bf782d94-5d6b-4b85-97e1-ed0924df0938,insights_interaction,latest,,,2021-07-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03670,Freddie Ringhouse,,onco-eu-0074,Olga Kovalev,Phone,Avenger,United Kingdom,,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,3a4b3d77-514d-4845-92f3-bde4605fad45,insights_interaction,latest,,,2022-02-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03113,Mike Dever,,onco-eu-0074,Olga Kovalev,Ulton,Wolverine,United Kingdom,,Stable disease observed in 2 patients with advanced lung cancer after 4 cycles.  Treatment ongoing.
text,282f83aa-7628-4c03-9f79-5fb02d4b713c,insights_interaction,latest,,,2022-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03989,Brandon Ivy,,onco-eu-0074,Olga Kovalev,Ulton,Clinical Pharmacist,France,,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,a7dadd0c-3352-4cd0-b42f-6fe778051557,insights_interaction,latest,,,2022-06-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03989,Brandon Ivy,,onco-eu-0074,Olga Kovalev,Ulton,Clinical Pharmacist,France,,Patients reported significant reduction in cancer-related fatigue with combination therapy compared to standard treatment protocols
text,b1bdaa51-1e65-423c-8a32-83064fc2f198,insights_interaction,latest,,,2022-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03920,Scott West,,onco-eu-0074,Olga Kovalev,Ulton,Avenger,United Kingdom,,Cost-effectiveness analysis suggests potential 35% reduction in total treatment expenditure compared to standard combination therapies
text,2cf67f6f-5493-4dc7-88ed-963ac3fedc84,insights_interaction,latest,,,2022-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03417,Robin Bunch,,onco-eu-0074,Olga Kovalev,Phone,Avenger,United Kingdom,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,93ce39cf-8c8e-4b91-82e3-77c06f0a6494,insights_interaction,latest,,,2022-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03920,Scott West,,onco-eu-0074,Olga Kovalev,Phone,Avenger,United Kingdom,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,ad4d183d-e121-4a68-b1e3-4c87332ba121,insights_interaction,latest,,,2022-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03526,Andrew Andrews,,onco-eu-0074,Olga Kovalev,Phone,Wolverine,Ireland,,Demonstrated 37% objective response rate in advanced metastatic solid tumors with minimal prior treatment resistance
text,6558fce5-2fa8-412d-88d2-4a342ad9297d,insights_interaction,latest,,,2022-11-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03333,Susie Anderson,,onco-eu-0074,Olga Kovalev,Iron Man,Wolverine,France,,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,fcd428f2-4726-4c98-939e-279764888818,insights_interaction,latest,,,2023-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03417,Robin Bunch,,onco-eu-0074,Olga Kovalev,Iron Man,Avenger,United Kingdom,,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,ddd78431-9fbf-4af9-93e4-939cee9ee78a,insights_interaction,latest,,,2023-04-06,MSL Interactions,Oncology,Vibranium,,WB-EU-03333,Susie Anderson,,onco-eu-0074,Olga Kovalev,Ulton,Wolverine,France,,Advanced molecular characterization reveals promising predictive biomarker panel for precision treatment selection.
text,abc2d679-6112-4342-a397-86c9240f58f9,insights_interaction,latest,,,2023-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-03425,Jeremiah Vazquez,,onco-eu-0074,Olga Kovalev,Ulton,Avenger,United Kingdom,,Promising results in targeted patient subgroups with specific genetic markers
text,393ba674-0383-49cd-8321-3bed1ae5b706,insights_interaction,latest,,,2023-05-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03006,Brian Mckinnon,,onco-eu-0074,Olga Kovalev,Ulton,X-Men,Ireland,,Novel molecular signature identified for predicting exceptional responders
text,d014ac87-5b61-451e-acdf-930fb5d84385,insights_interaction,latest,,,2023-06-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03426,Jeffery Folger,,onco-eu-0074,Olga Kovalev,Iron Man,X-Men,Ireland,,Genetic mutation profile suggests potential predictive markers for treatment response
text,ee1efd24-b840-444e-bab4-3021af395dbc,insights_interaction,latest,,,2023-08-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03211,Patricia Stumpff,,onco-eu-0074,Olga Kovalev,Phone,X-Men,United Kingdom,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,c8fc4704-7299-4665-8749-f56d8b0e2dad,insights_interaction,latest,,,2024-04-02,MSL Interactions,Oncology,Vibranium,,WB-EU-03554,Guy Lizardi,,onco-eu-0074,Olga Kovalev,Ulton,Avenger,Ireland,,"Grade 2 neutropenia reported in 22% of patients, manageable with standard supportive care"
text,2e85d895-d7e0-4247-8276-9ad4afdfb2a2,insights_interaction,latest,,,2024-04-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03589,Daphne Curry,,onco-eu-0074,Olga Kovalev,Iron Man,Deadpool,Ireland,,"Grade 3 hepatotoxicity observed in 14% of patients, requiring dose modification and close liver function monitoring during treatment protocol."
text,a1b00f8e-b8ea-46b8-a69c-9b9e5d98be59,insights_interaction,latest,,,2024-04-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03632,Josh Williams,,onco-eu-0074,Olga Kovalev,Iron Man,X-Men,France,,High cost of therapy may present a significant barrier to broader accessibility for many patients.
text,e235b935-a1d5-4a1a-87af-5fa596bda213,insights_interaction,latest,,,2024-05-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03295,Diane Chasten,,onco-eu-0074,Olga Kovalev,Phone,X-Men,United Kingdom,,Improved sleep quality reported by several patients on the therapy.
text,6ce4e474-f559-4984-be83-18703a364aad,insights_interaction,latest,,,2024-07-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03514,Mary Smith,,onco-eu-0074,Olga Kovalev,Iron Man,X-Men,France,,"Increased expression of PD-L1 was noted in tumor biopsies post-treatment, suggesting a potential synergy with immune checkpoint inhibitors."
text,d5cb7cc0-4b98-446a-8868-db31e17e80b0,insights_interaction,latest,,,2024-10-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03704,Elsie Cypert,,onco-eu-0074,Olga Kovalev,Phone,X-Men,Ireland,,Quality of life remained stable in a majority of patients despite disease progression.
text,7c93a6b9-7972-4e32-81d1-5f47b62970c9,insights_interaction,latest,,,2024-10-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03514,Mary Smith,,onco-eu-0074,Olga Kovalev,Iron Man,X-Men,France,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,e3ac3a89-0700-48de-a02a-f23954655353,insights_interaction,latest,,,2024-11-12,MSL Interactions,Oncology,Vibranium,,WB-EU-03417,Robin Bunch,,onco-eu-0074,Olga Kovalev,Phone,Avenger,United Kingdom,,Genetic mutation profile shows moderate predictive potential for treatment response
text,3445f77e-bc10-4428-925c-0e818194c847,insights_interaction,latest,,,2024-12-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03861,Irma Warner,,onco-eu-0074,Olga Kovalev,Ulton,Avenger,Ireland,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,5933948e-3270-4d9a-9c90-ef7ee7242ec8,insights_interaction,latest,,,2021-01-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00991,Mary Dunlow,,onco-eu-0037,Paolo Conti,Iron Man,Wolverine,Netherlands,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,e72bea4d-3f76-4f12-a10b-4f2dbc22ad07,insights_interaction,latest,,,2021-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01536,Mary Aldridge,,onco-eu-0037,Paolo Conti,Iron Man,X-Men,Belgium,,"Patient reported improved appetite and energy levels following Vibranium treatment, leading to increased quality of life scores."
text,479caa13-6d1a-4f9d-940a-3efbf9224cb0,insights_interaction,latest,,,2021-03-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01897,Jack Henley,,onco-eu-0037,Paolo Conti,Iron Man,X-Men,Netherlands,,Early detection of response based on circulating tumor DNA analysis.
text,34ab1f57-5f56-483b-a99b-12487627e157,insights_interaction,latest,,,2021-05-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01947,Lucinda Jackson,,onco-eu-0037,Paolo Conti,Ulton,Wolverine,Germany,,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,67041855-0542-41dd-9ced-b754e515e8a8,insights_interaction,latest,,,2021-10-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01011,Jesus Bennett,,onco-eu-0037,Paolo Conti,Iron Man,Avenger,Germany,,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,a209e407-50a8-4392-b878-5218c15f8a9f,insights_interaction,latest,,,2021-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01197,Katie Eason,,onco-eu-0037,Paolo Conti,Phone,X-Men,Germany,,Patients reporting improved pain management and reduced fatigue compared to standard chemotherapy protocols
text,41adab82-fdd9-424b-b966-c9e017283616,insights_interaction,latest,,,2021-12-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01035,Gertrude Shannon,,onco-eu-0037,Paolo Conti,Phone,X-Men,Austria,,Patients reported 68% reduction in pain intensity and improved functional status
text,d31e8e5e-2dae-4c72-806c-2f079d6863a0,insights_interaction,latest,,,2022-03-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01897,Jack Henley,,onco-eu-0037,Paolo Conti,Ulton,X-Men,Netherlands,,Longer progression-free survival observed in patients with lower tumor mutational burden.
text,946e6f37-8cf6-482c-8fbf-7d08002084bc,insights_interaction,latest,,,2022-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01070,Betty Powers,,onco-eu-0037,Paolo Conti,Phone,X-Men,Germany,,Enhanced patient monitoring protocols significantly reduced adverse event severity
text,bd525675-2872-4c1d-863f-bf45312493a6,insights_interaction,latest,,,2022-05-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00854,Felix Mccarthy,,onco-eu-0037,Paolo Conti,Iron Man,Avenger,Switzerland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,18622411-dd52-496b-9866-facc948a196a,insights_interaction,latest,,,2022-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01296,Adrian Johnson,,onco-eu-0037,Paolo Conti,Phone,Deadpool,Germany,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,554320b0-8b01-4541-b4ec-19f259611c89,insights_interaction,latest,,,2022-10-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01551,Armando Cosentino,,onco-eu-0037,Paolo Conti,Phone,Avenger,Belgium,,"Increased levels of IFN-γ and other pro-inflammatory cytokines observed in serum samples after Vibranium/Wakanda administration, suggesting an immune response."
text,421b8843-c0bf-45e7-968b-056d501d0ae6,insights_interaction,latest,,,2022-12-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01186,Matthew Jensen,,onco-eu-0037,Paolo Conti,Ulton,Avenger,Germany,,Strong correlation detected between PD-L1 expression and treatment response in 63% of patient cohort
text,00076186-613e-401c-80d8-120e7bba5038,insights_interaction,latest,,,2022-12-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01900,Michael Burns,,onco-eu-0037,Paolo Conti,Ulton,X-Men,Belgium,,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,27ffa3d4-06af-4590-b77b-b323d7f15eda,insights_interaction,latest,,,2024-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01200,Arthur Mccullough,,onco-eu-0037,Paolo Conti,Iron Man,Avenger,Netherlands,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,00ab3bba-4ab3-4c10-b666-d4087c62bdf5,insights_interaction,latest,,,2024-02-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01580,Lucy Okelley,,onco-eu-0037,Paolo Conti,Iron Man,Avenger,Austria,,Early detection of response based on circulating tumor DNA analysis.
text,380c1d85-2001-414c-9be9-5d2de6a62238,insights_interaction,latest,,,2024-04-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01143,Mandy Snyder,,onco-eu-0037,Paolo Conti,Iron Man,X-Men,Austria,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,2ff974d7-6965-40dd-aa4b-ae910d614c68,insights_interaction,latest,,,2024-05-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01090,Latoya Gibbs,,onco-eu-0037,Paolo Conti,Iron Man,Wolverine,Germany,,Most adverse events were manageable and grade 1 or 2.
text,e5ccada9-87cc-40b1-ad54-b962eacb5f23,insights_interaction,latest,,,2024-05-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01090,Latoya Gibbs,,onco-eu-0037,Paolo Conti,Ulton,Wolverine,Germany,,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda.
text,4bdea56e-696c-40ba-9e9e-6cc7280d5e90,insights_interaction,latest,,,2024-10-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00991,Mary Dunlow,,onco-eu-0037,Paolo Conti,Iron Man,Wolverine,Netherlands,,"High treatment cost and complex administration protocol may limit broader clinical implementation, particularly in resource-constrained healthcare settings."
text,c8b737bd-4cf2-40cb-b0f0-5b85bf7ecf63,insights_interaction,latest,,,2024-12-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01035,Gertrude Shannon,,onco-eu-0037,Paolo Conti,Phone,X-Men,Austria,,Observed variability in treatment response across different patient subgroups.
text,d69787c3-107a-4225-9398-c5e1964547d3,insights_interaction,latest,,,2024-12-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01502,Judith Fleniken,,onco-eu-0037,Paolo Conti,Phone,Wolverine,Switzerland,,"Observed delayed onset of response in several patients, suggesting the need for longer treatment durations or alternative therapeutic strategies."
text,c92ece3b-82e4-4321-8a9e-ddbe2814b099,insights_interaction,latest,,,2021-01-18,MSL Interactions,Oncology,Vibranium,,WB-US-07096,Christine Hall,,onco-us-0022,Patricia Moore,Phone,Deadpool,United States,IN,"PD-L1 expression correlates strongly with treatment response, predictive value of 0.68 in patient subgroup analysis"
text,33e340a6-fe9a-443d-b556-2347baacdf74,insights_interaction,latest,,,2021-02-01,MSL Interactions,Oncology,Vibranium,,WB-US-07368,Marcella Jones,,onco-us-0022,Patricia Moore,Phone,Deadpool,United States,MI,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,0e3670e0-a196-4f02-bb80-c84dea106460,insights_interaction,latest,,,2021-02-27,MSL Interactions,Oncology,Vibranium,,WB-US-07540,Roger Abrams,,onco-us-0022,Patricia Moore,Phone,Deadpool,United States,IA,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,9da9089b-14fd-4466-8ec6-cde713300d2b,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-US-06807,John Bedford,,onco-us-0022,Patricia Moore,Ulton,X-Men,United States,IN,Observed a higher response rate in patients with microsatellite instability-high (MSI-H) tumors treated with Vibranium/Wakanda compared to those with microsatellite stable (MSS) tumors.  This suggests a potential predictive biomarker for treatment response.
text,afb95612-6b0a-4604-a3fa-acd249cf4448,insights_interaction,latest,,,2021-05-21,MSL Interactions,Oncology,Vibranium,,WB-US-08166,Laura Powell,,onco-us-0022,Patricia Moore,Iron Man,X-Men,United States,IL,Improved pain management observed in some patients with bone metastases after Vibranium treatment.
text,ae8da8eb-88a0-4b1f-84b5-04512cf27ebb,insights_interaction,latest,,,2021-10-30,MSL Interactions,Oncology,Vibranium,,WB-US-07279,James Spires,,onco-us-0022,Patricia Moore,Ulton,Deadpool,United States,MO,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,3cc4012e-bd03-404c-b6b8-e45ab7439e42,insights_interaction,latest,,,2021-11-12,MSL Interactions,Oncology,Vibranium,,WB-US-07749,Billy Conger,,onco-us-0022,Patricia Moore,Ulton,X-Men,United States,IN,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,9c3fbbae-6e0d-40ec-9f56-43b54eb7794c,insights_interaction,latest,,,2021-11-15,MSL Interactions,Oncology,Vibranium,,WB-US-07480,Helen Schaffer,,onco-us-0022,Patricia Moore,Phone,Avenger,United States,IL,Significant improvement in patient-reported emotional well-being scores
text,59a6831b-19ee-4188-bbc4-cb461287a68e,insights_interaction,latest,,,2022-01-24,MSL Interactions,Oncology,Vibranium,,WB-US-08278,Keli Johnson,,onco-us-0022,Patricia Moore,Ulton,Deadpool,United States,WI,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,063b172a-2d7c-433e-bf19-97f41a73b2b4,insights_interaction,latest,,,2022-02-15,MSL Interactions,Oncology,Vibranium,,WB-US-06912,Norman Hunsaker,,onco-us-0022,Patricia Moore,Iron Man,Deadpool,United States,IN,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,edf4d988-17ed-4b20-9ad7-2388ea94f9e0,insights_interaction,latest,,,2022-03-09,MSL Interactions,Oncology,Vibranium,,WB-US-07338,Barbara Hackney,,onco-us-0022,Patricia Moore,Ulton,Deadpool,United States,IL,Oral administration protocol reduces hospital visits and demonstrates superior patient compliance compared to intravenous alternatives
text,2ddeee50-4df8-4b2c-a910-d2c5301360aa,insights_interaction,latest,,,2023-03-17,MSL Interactions,Oncology,Vibranium,,WB-US-07112,Leticia Hernandez,,onco-us-0022,Patricia Moore,Phone,Wolverine,United States,OH,Quality of life remained stable in a majority of patients despite disease progression.
text,c0d70c81-e123-4c5e-ab20-2ac241f9a849,insights_interaction,latest,,,2023-09-28,MSL Interactions,Oncology,Vibranium,,WB-US-07080,Erica Anaya,,onco-us-0022,Patricia Moore,Iron Man,X-Men,United States,MN,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,e0ac442b-3c8c-4de8-a6e7-e5ab096239a7,insights_interaction,latest,,,2023-12-05,MSL Interactions,Oncology,Vibranium,,WB-US-07840,Wade Shurtz,,onco-us-0022,Patricia Moore,Iron Man,X-Men,United States,IL,Correlation observed between pre-treatment circulating tumor DNA (ctDNA) levels and response to Vibranium/Wakanda therapy. Lower ctDNA levels associated with better outcomes.
text,637a5668-c0a7-46d1-82a8-9aab3f77316c,insights_interaction,latest,,,2023-12-07,MSL Interactions,Oncology,Vibranium,,WB-US-08260,Marcia Bowers,,onco-us-0022,Patricia Moore,Iron Man,X-Men,United States,MI,Early detection of response based on circulating tumor DNA analysis.
text,7ca3c92d-01bd-4f05-a1aa-3191b8161b65,insights_interaction,latest,,,2024-03-30,MSL Interactions,Oncology,Vibranium,,WB-US-07951,Brittany Price,,onco-us-0022,Patricia Moore,Ulton,Deadpool,United States,WI,"Observed differential response patterns across age groups, with patients under 55 demonstrating more robust tumor reduction compared to older patient cohorts."
text,79282648-bcca-4a8d-997c-08edf131fd75,insights_interaction,latest,,,2024-04-14,MSL Interactions,Oncology,Vibranium,,WB-US-07831,Jack Martin,,onco-us-0022,Patricia Moore,Ulton,Avenger,United States,MI,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,054f62c3-3e57-4532-8152-4663ec20fe82,insights_interaction,latest,,,2024-05-28,MSL Interactions,Oncology,Vibranium,,WB-US-07304,Carol Sinicki,,onco-us-0022,Patricia Moore,Phone,X-Men,United States,MI,Requires specialized molecular screening and multidisciplinary tumor board review
text,6d5881a2-6dbf-4314-ab98-52bdda88d2f8,insights_interaction,latest,,,2024-06-16,MSL Interactions,Oncology,Vibranium,,WB-US-08109,Antonia Kim,,onco-us-0022,Patricia Moore,Iron Man,Avenger,United States,MN,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,ded51216-7096-45f4-b142-d4c3d1e5ce90,insights_interaction,latest,,,2024-09-05,MSL Interactions,Oncology,Vibranium,,WB-US-07986,Jennifer Page,,onco-us-0022,Patricia Moore,Iron Man,Avenger,United States,IN,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,6cdbe2ea-58c8-4337-a487-640b60b823e5,insights_interaction,latest,,,2024-09-06,MSL Interactions,Oncology,Vibranium,,WB-US-07164,David Santos,,onco-us-0022,Patricia Moore,Phone,X-Men,United States,IL,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,67f192c8-5cdb-46d2-9cb0-fbac7cdc2ea3,insights_interaction,latest,,,2024-11-08,MSL Interactions,Oncology,Vibranium,,WB-US-07196,Robert Lacasse,,onco-us-0022,Patricia Moore,Phone,X-Men,United States,MO,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,8d81ea97-68a4-468d-b5f0-c9a3a09ebb2d,insights_interaction,latest,,,2024-12-16,MSL Interactions,Oncology,Vibranium,,WB-US-07433,Timothy Sanders,,onco-us-0022,Patricia Moore,Ulton,Avenger,United States,MI,Observed better response rates in patients with lower tumor burden at baseline.
text,4f293b42-9c8c-458d-8534-a6d5b4c20ecb,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-US-08311,Colin Perez,,onco-us-0027,Paul Henderson,Iron Man,Avenger,United States,OK,Significant increase in CD8+ T-cell infiltration detected in tumor biopsies following Vibranium/Wakanda administration.
text,10fe1635-486f-4b2b-9873-651bf19cfe67,insights_interaction,latest,,,2022-01-17,MSL Interactions,Oncology,Vibranium,,WB-US-08634,Patricia Payne,,onco-us-0027,Paul Henderson,Phone,Avenger,United States,KS,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,71a8f37b-b0da-41ab-93c8-bb36e00c87da,insights_interaction,latest,,,2022-08-12,MSL Interactions,Oncology,Vibranium,,WB-US-08639,Christopher Blanchard,,onco-us-0027,Paul Henderson,Ulton,X-Men,United States,AR,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,973a3cd2-cc69-4ffb-94d6-cda7fbce0f8f,insights_interaction,latest,,,2022-09-03,MSL Interactions,Oncology,Vibranium,,WB-US-08323,Cynthia Bluhm,,onco-us-0027,Paul Henderson,Ulton,Deadpool,United States,LA,"Patient reported improved appetite and energy levels after one cycle of Vibranium/Wakanda, leading to an increase in their overall quality of life score on the EORTC QLQ-C30 questionnaire."
text,0fc639e8-7d94-45b2-9892-bd2b5a7730ea,insights_interaction,latest,,,2023-03-06,MSL Interactions,Oncology,Vibranium,,WB-US-08314,Robin Payson,,onco-us-0027,Paul Henderson,Phone,Avenger,United States,OK,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,592542c8-cad3-4013-b640-873b19c9bf79,insights_interaction,latest,,,2023-03-15,MSL Interactions,Oncology,Vibranium,,WB-US-08644,Karen Wash,,onco-us-0027,Paul Henderson,Phone,Avenger,United States,KS,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,6d5c6f04-361e-416f-89d8-29e8858179b2,insights_interaction,latest,,,2023-04-05,MSL Interactions,Oncology,Vibranium,,WB-US-08462,Andrew Jackson,,onco-us-0027,Paul Henderson,Iron Man,X-Men,United States,SD,"Mild fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,3ea01aae-480f-46bf-b8a4-ceffe51c976a,insights_interaction,latest,,,2023-04-26,MSL Interactions,Oncology,Vibranium,,WB-US-08747,Wayne Hovermale,,onco-us-0027,Paul Henderson,Iron Man,Deadpool,United States,AR,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,ce2477ec-fbed-4d8c-9e48-7c3cd591ba9c,insights_interaction,latest,,,2023-11-09,MSL Interactions,Oncology,Vibranium,,WB-US-09139,Clifton Bradley,,onco-us-0027,Paul Henderson,Phone,Wolverine,United States,LA,Administration protocol requires careful monitoring and potential dose adjustments
text,18df6e59-15a5-4c04-9a0a-5d66337c5b41,insights_interaction,latest,,,2024-02-09,MSL Interactions,Oncology,Vibranium,,WB-US-09102,Jesus King,,onco-us-0027,Paul Henderson,Phone,Wolverine,United States,KS,"Response to Vibranium/Wakanda appears to be influenced by tumor microenvironment characteristics, particularly the presence of immune infiltrates."
text,f8595b1f-a405-4017-a30b-69ba6b361093,insights_interaction,latest,,,2024-03-27,MSL Interactions,Oncology,Vibranium,,WB-US-08314,Robin Payson,,onco-us-0027,Paul Henderson,Iron Man,Avenger,United States,OK,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,84d6aab2-1bd3-443a-bdca-af37262f0c78,insights_interaction,latest,,,2024-04-24,MSL Interactions,Oncology,Vibranium,,WB-US-08916,Rudolph Harris,,onco-us-0027,Paul Henderson,Ulton,Avenger,United States,SD,Significant reduction in treatment-related fatigue and improved patient mobility
text,ab3565b2-a92e-44bc-89c2-ca933749b1f5,insights_interaction,latest,,,2024-07-17,MSL Interactions,Oncology,Vibranium,,WB-US-08747,Wayne Hovermale,,onco-us-0027,Paul Henderson,Iron Man,Deadpool,United States,AR,"Overall response rate appears promising, but further studies are needed to confirm efficacy."
text,f23e8ce4-5296-4f1e-bf73-3d87174afee4,insights_interaction,latest,,,2024-07-19,MSL Interactions,Oncology,Vibranium,,WB-US-09090,David Stokes,,onco-us-0027,Paul Henderson,Ulton,Avenger,United States,NE,Observed a higher incidence of treatment-related fatigue in elderly patients (>70 years) receiving Vibranium/Wakanda.  This warrants further investigation into age-related factors influencing treatment tolerability.
text,f9842442-e2f6-40f8-b4e1-d8c911355206,insights_interaction,latest,,,2024-10-09,MSL Interactions,Oncology,Vibranium,,WB-US-08630,Rodolfo Gaiser,,onco-us-0027,Paul Henderson,Iron Man,Avenger,United States,KS,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,d8049b22-52ab-42ce-a9e0-82e85439385f,insights_interaction,latest,,,2024-11-01,MSL Interactions,Oncology,Vibranium,,WB-US-09095,Julie Culbertson,,onco-us-0027,Paul Henderson,Phone,Deadpool,United States,OK,Development of novel companion diagnostic algorithm to improve patient stratification and personalized treatment approaches
text,ee753b9e-4cfc-4be4-a999-e5d4de8a57be,insights_interaction,latest,,,2024-12-06,MSL Interactions,Oncology,Vibranium,,WB-US-08342,Mickey Timinsky,,onco-us-0027,Paul Henderson,Iron Man,X-Men,United States,OK,Some patients experienced decreased appetite and weight loss during treatment.
text,d4c7a78d-342b-48a7-b27a-184187d33e41,insights_interaction,latest,,,2024-12-19,MSL Interactions,Oncology,Vibranium,,WB-US-08500,Oma Ryan,,onco-us-0027,Paul Henderson,Phone,X-Men,United States,KS,"Reported sleep disturbances and fatigue in 35% of patients, suggesting need for comprehensive supportive care interventions."
text,96303d7c-92ad-4efb-93c5-9c1434300fa3,insights_interaction,latest,,,2021-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03595,Denise Toomey,,onco-eu-0072,Pavel Svoboda,Ulton,X-Men,Ireland,,Reduction in pain levels reported by patients with bone metastases.
text,d1157abd-0d93-425b-b261-afe998c17c20,insights_interaction,latest,,,2021-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03895,Roy Wong,,onco-eu-0072,Pavel Svoboda,Phone,Deadpool,France,,Improved physical functioning scores noted in patient-reported outcome measures.
text,12709d37-65f9-423b-aa76-580a99bf0f7b,insights_interaction,latest,,,2021-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03570,Dolly Nelson,,onco-eu-0072,Pavel Svoboda,Iron Man,Avenger,Ireland,,Elevated levels of certain inflammatory cytokines were observed to correlate with a positive clinical response to Vibranium/Wakanda.
text,c5f86e62-f283-4d0b-84e4-ebaffc8991c8,insights_interaction,latest,,,2021-08-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03123,Pearlie Stauffer,,onco-eu-0072,Pavel Svoboda,Phone,X-Men,United Kingdom,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 6 cycles of Vibranium/Wakanda therapy, with a 30% reduction in target lesion size confirmed by RECIST 1.1 criteria.  Significant improvement in CA 19-9 levels also observed."
text,56236f8e-337d-4aed-bf58-d67c7acfb0ba,insights_interaction,latest,,,2021-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03225,Jennifer Griffin,,onco-eu-0072,Pavel Svoboda,Ulton,Avenger,United Kingdom,,Minimal immune-related adverse events compared to traditional immunotherapies
text,e160ead6-f95c-4a12-b9a0-89f76ba8a928,insights_interaction,latest,,,2021-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03340,Sandra Mobley,,onco-eu-0072,Pavel Svoboda,Ulton,X-Men,Ireland,,Elevated levels of interferon-gamma detected in patients showing a positive response to the treatment.
text,ee9d02bb-d77b-4e86-a4a1-302cc180d83b,insights_interaction,latest,,,2022-03-16,MSL Interactions,Oncology,Vibranium,,WB-EU-03253,William Moeller,,onco-eu-0072,Pavel Svoboda,Iron Man,Avenger,Ireland,,"Partial response observed in a patient with recurrent glioblastoma after Vibranium/Wakanda therapy, resulting in a significant reduction in tumor volume and improved neurological function."
text,2d87ab5c-2332-48c8-bddb-004c3a0633df,insights_interaction,latest,,,2022-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03123,Pearlie Stauffer,,onco-eu-0072,Pavel Svoboda,Iron Man,X-Men,United Kingdom,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,d1d0e89a-dc05-4079-bad2-02ef2f7e1183,insights_interaction,latest,,,2023-01-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03467,Leona Newton,,onco-eu-0072,Pavel Svoboda,Ulton,X-Men,United Kingdom,,"Patient experienced grade 1 fatigue and nausea, resolving spontaneously after symptomatic treatment.  No dose modification required."
text,05979022-4089-4c1f-a364-398d4d555d1c,insights_interaction,latest,,,2023-03-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03270,Teresa Hendrix,,onco-eu-0072,Pavel Svoboda,Ulton,Avenger,France,,"Treatment administration requires specialized handling and monitoring procedures, increasing logistical complexity."
text,0296c5f4-8ace-4453-b64c-8db660446000,insights_interaction,latest,,,2023-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03253,William Moeller,,onco-eu-0072,Pavel Svoboda,Phone,Avenger,Ireland,,"Grade 3 hepatotoxicity observed in 14% of patients, requiring dose modification and close liver function monitoring during treatment protocol."
text,e49fe27f-1238-4fb0-af1d-7db0b9e612a2,insights_interaction,latest,,,2023-05-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03186,Gary Zamora,,onco-eu-0072,Pavel Svoboda,Phone,X-Men,Ireland,,"Significant increase in PD-L1 expression observed in tumor biopsies after one cycle of treatment, suggesting potential synergy between Vibranium and Wakanda."
text,ba510689-c3e4-496c-a2e7-dd363e1ef70f,insights_interaction,latest,,,2023-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03651,Martin Brelsford,,onco-eu-0072,Pavel Svoboda,Iron Man,Wolverine,Ireland,,"Immunogenic side effects manageable with standard corticosteroid interventions, with only 8% of patients requiring extended immunosuppressive management."
text,0da27327-14e2-4b7e-9e0a-eaa18dcf9ed6,insights_interaction,latest,,,2023-09-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03226,George Wilson,,onco-eu-0072,Pavel Svoboda,Ulton,Deadpool,Ireland,,Further studies are needed to determine the long-term efficacy of this combination therapy.
text,cae39fb7-4d59-497a-90d6-e4d92ff21f6e,insights_interaction,latest,,,2023-10-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03503,Al Botkins,,onco-eu-0072,Pavel Svoboda,Ulton,Avenger,United Kingdom,,Consistent treatment efficacy across multiple cancer stages and patient demographics
text,16424115-2bdd-4d08-aed4-d8421e38bc20,insights_interaction,latest,,,2023-11-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03320,Evelyn Guerin,,onco-eu-0072,Pavel Svoboda,Phone,X-Men,United Kingdom,,No consistent correlation found between baseline biomarker levels and treatment response.
text,7537d763-dd20-42c1-9108-f30fe2d65cf5,insights_interaction,latest,,,2024-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03225,Jennifer Griffin,,onco-eu-0072,Pavel Svoboda,Ulton,Avenger,United Kingdom,,Significant molecular response in patients with specific genetic mutations
text,ec2c9c4f-a18c-4ef1-9393-35bac1d3c875,insights_interaction,latest,,,2024-06-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03225,Jennifer Griffin,,onco-eu-0072,Pavel Svoboda,Phone,Avenger,United Kingdom,,Significant reduction in treatment-related fatigue and improved patient mobility
text,f2e22813-22e6-4f1f-8311-4aab83e82a6f,insights_interaction,latest,,,2024-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03068,Joseph Schroeder,,onco-eu-0072,Pavel Svoboda,Ulton,X-Men,France,,Complex genomic screening requirements may create significant logistical challenges in implementing widespread therapeutic approach.
text,75705e71-3278-463e-8173-7e91340a4ea5,insights_interaction,latest,,,2024-12-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03018,Lois Smith,,onco-eu-0072,Pavel Svoboda,Iron Man,X-Men,United Kingdom,,High treatment cost limits widespread adoption in community healthcare settings
text,ca2c0e2e-3982-4945-acb5-58bea0e21bc1,insights_interaction,latest,,,2021-02-17,MSL Interactions,Oncology,Vibranium,,WB-US-09182,Edward Ciresi,,onco-us-0036,Peter Schmidt,Iron Man,Avenger,United States,WY,"Significant reduction in treatment-related fatigue reported, with 63% of patients experiencing improved daily functional capacity."
text,7775e6b8-cac9-4d8a-9cf2-f376987cd2e2,insights_interaction,latest,,,2021-06-21,MSL Interactions,Oncology,Vibranium,,WB-US-09640,James Soto,,onco-us-0036,Peter Schmidt,Iron Man,X-Men,United States,WA,"Patient with advanced pancreatic cancer showed a 30% reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,6b0188d9-034e-4374-95f3-28ff7e2c4b19,insights_interaction,latest,,,2021-06-28,MSL Interactions,Oncology,Vibranium,,WB-US-09595,Leigh Bailey,,onco-us-0036,Peter Schmidt,Phone,Deadpool,United States,NV,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,1c3498fa-2ac1-488d-b474-e12feb6947c1,insights_interaction,latest,,,2021-08-05,MSL Interactions,Oncology,Vibranium,,WB-US-09436,Julie Mckinney,,onco-us-0036,Peter Schmidt,Ulton,Clinical Pharmacist,United States,OR,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,a77520df-7011-4a77-a3cd-47259322d3ea,insights_interaction,latest,,,2021-09-17,MSL Interactions,Oncology,Vibranium,,WB-US-09787,Matthew Salazar,,onco-us-0036,Peter Schmidt,Ulton,Wolverine,United States,OR,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,80ff6f42-c1af-4c93-8d13-bfccde14c54d,insights_interaction,latest,,,2023-01-26,MSL Interactions,Oncology,Vibranium,,WB-US-09768,Paul Vanwinkle,,onco-us-0036,Peter Schmidt,Ulton,Avenger,United States,OR,"Varied response patterns observed across different age groups, suggesting potential age-related pharmacodynamic interactions."
text,5fd661ab-d733-44fa-9993-66776a85ba61,insights_interaction,latest,,,2024-01-20,MSL Interactions,Oncology,Vibranium,,WB-US-09621,Lorenzo Yates,,onco-us-0036,Peter Schmidt,Phone,X-Men,United States,HI,We observed a correlation between early viral replication kinetics as measured by PCR and subsequent tumor response in patients receiving Vibranium/Wakanda. This may serve as a potential predictive biomarker for treatment efficacy.
text,6bc2a8cb-7755-4a2e-9383-92ed45ec7c92,insights_interaction,latest,,,2024-06-14,MSL Interactions,Oncology,Vibranium,,WB-US-09796,Paul Lansberry,,onco-us-0036,Peter Schmidt,Iron Man,X-Men,United States,WA,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,9b08b2f9-5163-4c33-b2ef-e9de45f5a626,insights_interaction,latest,,,2024-12-14,MSL Interactions,Oncology,Vibranium,,WB-US-09299,Brandy Reilly,,onco-us-0036,Peter Schmidt,Iron Man,Avenger,United States,AZ,Further investigation is needed to explore the role of other biomarkers in predicting response to Vibranium.
text,32bc4bf5-6d97-44be-b9e2-2090870e1f7a,insights_interaction,latest,,,2021-02-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01015,Olga Timberlake,,onco-eu-0029,Petra Lehmann,Ulton,X-Men,Netherlands,,Synergistic effect observed when Vibranium/Wakanda is combined with immune checkpoint inhibitors.
text,2c98661d-1236-41c4-a1f7-dc87ca461f58,insights_interaction,latest,,,2021-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01910,Carl Maxwell,,onco-eu-0029,Petra Lehmann,Ulton,Avenger,Netherlands,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,94dbb745-a0f1-4988-a6e4-64804448db9d,insights_interaction,latest,,,2021-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02000,Archie Precourt,,onco-eu-0029,Petra Lehmann,Ulton,Deadpool,Netherlands,,Stable disease observed for 6 months in a patient with recurrent glioblastoma after Vibranium treatment.  Significant improvement in neurological symptoms reported.
text,658d5196-f85f-4297-a247-84f97b12d560,insights_interaction,latest,,,2021-07-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02000,Archie Precourt,,onco-eu-0029,Petra Lehmann,Iron Man,Deadpool,Netherlands,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response (PR) after 6 weeks of Vibranium therapy, with a significant reduction in tumor size measurable by CT scan.  CA 19-9 levels also decreased substantially."
text,bee0221b-dc11-4b16-a9bd-7dd7a242a2a8,insights_interaction,latest,,,2021-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01658,David Pherson,,onco-eu-0029,Petra Lehmann,Iron Man,Wolverine,Switzerland,,"Patients reporting improved pain management and reduced fatigue compared to standard chemotherapy, with EORTC QLQ-C30 scores indicating significant symptomatic improvement"
text,0fd9b1b4-9115-4a87-aeb3-3bcf6b4a4c23,insights_interaction,latest,,,2021-08-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01910,Carl Maxwell,,onco-eu-0029,Petra Lehmann,Iron Man,Avenger,Netherlands,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 2 cycles of Vibranium/Wakanda therapy, with a 30% reduction in tumor size confirmed by CT scan.  Significant reduction in CA 19-9 levels also observed."
text,667e3b15-3235-461c-8f71-502680703ac9,insights_interaction,latest,,,2021-09-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01828,Kim Queen,,onco-eu-0029,Petra Lehmann,Phone,X-Men,Austria,,Strong correlation between PD-L1 expression >50% and enhanced treatment response
text,0ebbf1fb-c118-4b32-ac96-fdd8aa510884,insights_interaction,latest,,,2022-08-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01019,Beverly Rhodes,,onco-eu-0029,Petra Lehmann,Ulton,Avenger,Netherlands,,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,657907d8-dc45-456a-b895-a1b9d331cd6a,insights_interaction,latest,,,2022-09-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01733,Mary Sargent,,onco-eu-0029,Petra Lehmann,Iron Man,Deadpool,Austria,,Correlation observed between serum interferon-gamma levels and response to Vibranium/Wakanda therapy.
text,dc3cfb40-2480-4c9c-be9e-c520e129ce87,insights_interaction,latest,,,2022-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01191,James Davis,,onco-eu-0029,Petra Lehmann,Iron Man,X-Men,Belgium,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,f8825b3a-4045-46d2-a0cb-c8a83f5efa87,insights_interaction,latest,,,2022-12-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01626,Patricia Estrada,,onco-eu-0029,Petra Lehmann,Iron Man,X-Men,Germany,,Novel molecular signature identified for predicting exceptional responders
text,3651021f-ca60-48d2-ae22-f0af0ab4db93,insights_interaction,latest,,,2022-12-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01015,Olga Timberlake,,onco-eu-0029,Petra Lehmann,Phone,X-Men,Netherlands,,Complete response achieved in 12% of patients with refractory solid tumors
text,a3e09248-65f5-400d-8f56-d99140e29932,insights_interaction,latest,,,2023-04-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01411,Ellen Corbett,,onco-eu-0029,Petra Lehmann,Ulton,X-Men,Belgium,,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,a86ae80f-8ddf-4d89-9b53-e75d2a0f3e70,insights_interaction,latest,,,2023-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-01516,Hilda Rayford,,onco-eu-0029,Petra Lehmann,Ulton,X-Men,Austria,,Increased risk of grade 4 liver toxicity in patients with pre-existing hepatic conditions
text,7800349e-7424-4f55-9e7d-b21e59054f0d,insights_interaction,latest,,,2023-07-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00896,Gloria Sellers,,onco-eu-0029,Petra Lehmann,Phone,X-Men,Switzerland,,Patient experienced grade 2 fatigue and nausea following the first cycle of Vibranium/Wakanda.  Symptoms resolved with supportive care.
text,767c2c1e-ecfd-47bd-89af-d4dbd32ebd1c,insights_interaction,latest,,,2023-11-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01214,Laurie Osborn,,onco-eu-0029,Petra Lehmann,Phone,Deadpool,Switzerland,,Correlation observed between high baseline levels of specific immune cells and improved response to Vibranium/Wakanda.
text,e1f82dc6-a41b-4035-bb69-10d888c65be8,insights_interaction,latest,,,2024-01-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01192,Andrea Horgan,,onco-eu-0029,Petra Lehmann,Ulton,X-Men,Austria,,"Simplified infusion protocol reduced administration time, improving workflow efficiency."
text,b093a8ef-641a-43e9-819d-3f4eb86068d9,insights_interaction,latest,,,2024-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01605,Patricia Pettis,,onco-eu-0029,Petra Lehmann,Phone,X-Men,Germany,,"Promising early-stage data suggest potential efficacy in multiple solid tumor types beyond initial indication, indicating broad therapeutic potential."
text,2e5162e2-3052-4d00-9750-33b957ca0c0a,insights_interaction,latest,,,2024-09-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01267,Jennifer Miller,,onco-eu-0029,Petra Lehmann,Iron Man,X-Men,Austria,,"Treatment administration requires specialized expertise, potentially limiting accessibility in certain settings."
text,7a06d5f8-0457-4303-992a-b5fa2940c1b8,insights_interaction,latest,,,2024-10-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01766,Maggie Marquez,,onco-eu-0029,Petra Lehmann,Ulton,Avenger,Belgium,,"Moderate fatigue and mild cognitive impairment reported by 42% of patients, stabilizing after first treatment cycle"
text,5e220a4d-7b5b-490e-b914-246dbee67860,insights_interaction,latest,,,2024-11-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01019,Beverly Rhodes,,onco-eu-0029,Petra Lehmann,Iron Man,Avenger,Netherlands,,High cost of Vibranium/Wakanda may limit accessibility for some patients.
text,afdc582f-2cb2-4768-9fee-1840110f95f6,insights_interaction,latest,,,2024-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00843,Shawn Carron,,onco-eu-0029,Petra Lehmann,Iron Man,Avenger,Austria,,"Varied response patterns observed across different age groups, suggesting potential age-related pharmacodynamic interactions."
text,c7a3fbc7-c000-4092-a9d1-337797577091,insights_interaction,latest,,,2024-12-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01214,Laurie Osborn,,onco-eu-0029,Petra Lehmann,Iron Man,Deadpool,Switzerland,,PD-L1 expression remained stable despite the observed clinical response to Vibranium/Wakanda in a patient with metastatic melanoma. This suggests that the mechanism of action may not be solely dependent on PD-L1 expression.
text,7e079a3d-4dd6-4777-b5c7-a96a15616cdd,insights_interaction,latest,,,2021-06-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02046,Juanita Farley,,onco-eu-0053,Philippe Lambert,Ulton,Avenger,Spain,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,b669fd20-a850-4dd6-8d01-9741868e5c0f,insights_interaction,latest,,,2021-11-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02963,Michael Vance,,onco-eu-0053,Philippe Lambert,Iron Man,Clinical Pharmacist,Italy,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,9c4e0f2c-025a-4e67-9f1e-d0125c6c2e5f,insights_interaction,latest,,,2021-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02161,Casey Carter,,onco-eu-0053,Philippe Lambert,Iron Man,Avenger,Spain,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,d5105ab3-0ee0-4df0-94f8-05f5eda6fd4b,insights_interaction,latest,,,2022-06-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02872,George Harris,,onco-eu-0053,Philippe Lambert,Iron Man,X-Men,Spain,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,c3343a3a-89ac-4b63-aff3-c7dc935ede8b,insights_interaction,latest,,,2022-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02786,Stanley Hartnett,,onco-eu-0053,Philippe Lambert,Phone,Deadpool,Greece,,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,07a7eb78-bb0a-4608-b927-17fcce6faf29,insights_interaction,latest,,,2022-10-10,MSL Interactions,Oncology,Vibranium,,WB-EU-02755,Jose Flaherty,,onco-eu-0053,Philippe Lambert,Iron Man,Clinical Pharmacist,Spain,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,0af2f86a-7107-4458-a182-ab3d3d927791,insights_interaction,latest,,,2023-01-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02293,Kathleen Vargas,,onco-eu-0053,Philippe Lambert,Ulton,Deadpool,Greece,,"Moderate immune-related adverse events observed in 23% of patients, primarily grade 2 dermatitis and mild hepatic transaminitis"
text,3dff02af-83aa-4bc5-bd2d-d0369dc6b0a7,insights_interaction,latest,,,2023-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02898,Gilbert Totaro,,onco-eu-0053,Philippe Lambert,Phone,Deadpool,Greece,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,650f4c72-1090-4907-a801-399cbdd87d61,insights_interaction,latest,,,2023-08-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02720,Carmen Clow,,onco-eu-0053,Philippe Lambert,Phone,Clinical Pharmacist,Greece,,No significant cardiac or renal toxicities were observed in the current cohort of patients.
text,26ce5659-bfc3-4cc1-9d30-c933ef8afbd3,insights_interaction,latest,,,2023-09-24,MSL Interactions,Oncology,Vibranium,,WB-EU-02488,Donald Alcorn,,onco-eu-0053,Philippe Lambert,Ulton,Avenger,Ragnarok,,"Increased incidence of hepatic toxicity observed in a subset of patients receiving Vibranium/Wakanda, necessitating close monitoring of liver function."
text,2dc2b61c-e0e3-4c07-bc2c-ed5560302908,insights_interaction,latest,,,2023-11-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02830,James Pulver,,onco-eu-0053,Philippe Lambert,Iron Man,X-Men,Spain,,Sustained tumor shrinkage observed in 65% of patients after 12-week treatment
text,1767b016-62c4-433d-a971-8c0753e12490,insights_interaction,latest,,,2023-12-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02898,Gilbert Totaro,,onco-eu-0053,Philippe Lambert,Phone,Deadpool,Greece,,"Patient experienced grade 1 fatigue and nausea, resolving with supportive care, during Vibranium/Wakanda treatment. No dose reduction was necessary."
text,26ee8112-40d0-449b-8016-1f6525692689,insights_interaction,latest,,,2024-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02046,Juanita Farley,,onco-eu-0053,Philippe Lambert,Phone,Avenger,Spain,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,cb72bf3a-9257-4b2a-a112-394fe3f280c4,insights_interaction,latest,,,2024-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02786,Stanley Hartnett,,onco-eu-0053,Philippe Lambert,Ulton,Deadpool,Greece,,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,2bad1bd8-84d7-4784-8f98-e589f850e762,insights_interaction,latest,,,2024-06-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02641,Lorri Smith,,onco-eu-0053,Philippe Lambert,Iron Man,Avenger,Spain,,Mild injection site reactions were reported in several patients.
text,ed86a987-ab3c-4727-bd7e-8495e93e156a,insights_interaction,latest,,,2024-11-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02375,Bill Bell,,onco-eu-0053,Philippe Lambert,Iron Man,X-Men,Spain,,Long-term follow-up data shows stable cardiovascular and renal safety profiles with no significant late-onset adverse events.
text,60063e38-05a6-4039-a3c6-a03cc5a8c189,insights_interaction,latest,,,2021-01-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02323,William Crosley,,onco-eu-0047,Pierre Dubois,Iron Man,Deadpool,Greece,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,76a9beed-84e3-4311-aaef-b7b3be71ab96,insights_interaction,latest,,,2021-01-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02324,Francisco Perdomo,,onco-eu-0047,Pierre Dubois,Iron Man,X-Men,Ragnarok,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,ef21be76-5580-4043-95de-f114b5543ea9,insights_interaction,latest,,,2021-05-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02562,Linda Price,,onco-eu-0047,Pierre Dubois,Ulton,Wolverine,Spain,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,0ea6c6e1-f29d-4f04-b22e-cdfd037cb4d5,insights_interaction,latest,,,2021-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02907,Gary Mckenzie,,onco-eu-0047,Pierre Dubois,Phone,X-Men,Greece,,"Significant improvement in patient-reported quality of life scores (EORTC QLQ-C30) noted in a cohort of patients with metastatic melanoma after four cycles of Vibranium/Wakanda, particularly in areas of fatigue and pain."
text,ce8835fa-4f0e-4f10-aea9-20a8b6e39891,insights_interaction,latest,,,2021-12-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02193,Derrick Merwin,,onco-eu-0047,Pierre Dubois,Iron Man,X-Men,Ragnarok,,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,73ad58ba-6041-4594-8ad6-999c47fe36a0,insights_interaction,latest,,,2021-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02806,Lisa Bragg,,onco-eu-0047,Pierre Dubois,Ulton,Avenger,Greece,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,d2244183-532d-4b71-bb47-cc3de010ea06,insights_interaction,latest,,,2023-03-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02559,Adam Hawkins,,onco-eu-0047,Pierre Dubois,Phone,Avenger,Spain,,Cost-effectiveness analysis shows potential for reduced overall treatment expenses
text,2d4f7415-6811-4893-ba74-4cdef7b4ae6c,insights_interaction,latest,,,2023-05-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02897,Jose Hyman,,onco-eu-0047,Pierre Dubois,Phone,X-Men,Ragnarok,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,86de92e5-3cb2-4908-a7a7-e3f9201c6bfb,insights_interaction,latest,,,2023-06-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02888,Rachel Marx,,onco-eu-0047,Pierre Dubois,Iron Man,X-Men,Greece,,Moderate complexity in treatment administration requires specialized nursing and pharmacological support
text,7fcaf557-41fd-4dc9-98bf-2830cff882e9,insights_interaction,latest,,,2023-09-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02266,Catherine Patry,,onco-eu-0047,Pierre Dubois,Iron Man,Deadpool,Spain,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,a722a9ac-cceb-48cb-8ff0-22591c95abb3,insights_interaction,latest,,,2023-11-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02188,Virgina Holgerson,,onco-eu-0047,Pierre Dubois,Phone,X-Men,Greece,,Complex administration protocol requiring specialized training
text,2ae13400-85af-4c7f-92d5-67c5a4744575,insights_interaction,latest,,,2024-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02559,Adam Hawkins,,onco-eu-0047,Pierre Dubois,Phone,Avenger,Spain,,Strong correlation between PD-L1 expression >50% and improved progression-free survival
text,40c40690-9d0a-496e-a447-ab00d17f16c6,insights_interaction,latest,,,2024-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02902,Mary Strand,,onco-eu-0047,Pierre Dubois,Iron Man,X-Men,Greece,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,0ad17cdc-08b2-468d-923a-8780054fd53a,insights_interaction,latest,,,2024-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02863,Lee Waston,,onco-eu-0047,Pierre Dubois,Iron Man,X-Men,Greece,,Combination therapy regimen is well-tolerated by most patients.
text,53ed5791-37e4-4d5c-b345-e530f1e99f8f,insights_interaction,latest,,,2024-06-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02572,Chris Odermott,,onco-eu-0047,Pierre Dubois,Phone,Deadpool,Italy,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,3bbe3eb1-2957-4010-b25b-7235afa85376,insights_interaction,latest,,,2024-09-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02585,Margarete Petrone,,onco-eu-0047,Pierre Dubois,Ulton,X-Men,Ragnarok,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,f22cda74-6aab-47fe-aea8-2bb35f44f99e,insights_interaction,latest,,,2021-01-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02662,Randy Merrick,,onco-eu-0043,Rafael Navarro,Phone,X-Men,Ragnarok,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response (PR) after 6 weeks of Vibranium therapy, with a significant reduction in tumor size measurable by CT scan.  CA 19-9 levels also decreased substantially."
text,5cdfe319-be3c-4fce-be11-2d5aa899d741,insights_interaction,latest,,,2021-05-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02661,Howard Davidson,,onco-eu-0043,Rafael Navarro,Phone,Avenger,Greece,,Correlation observed between increased PD-L1 expression within the tumor microenvironment and improved response to Vibranium/Wakanda therapy.  Patients with high PD-L1 expression showed a significantly longer progression-free survival (PFS) compared to those with low expression. This suggests potential for biomarker-driven patient selection.
text,f8485c43-e7c1-42f2-aa70-a21ca3e17ee0,insights_interaction,latest,,,2021-12-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02092,Mike Gowdy,,onco-eu-0043,Rafael Navarro,Iron Man,X-Men,Italy,,Sustained progression-free survival of 10.2 months in advanced stage cancer patients
text,2b0b78f2-e9f0-41d3-a6bb-4e97bb60dab9,insights_interaction,latest,,,2021-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02685,Melody Burnham,,onco-eu-0043,Rafael Navarro,Phone,Avenger,Greece,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,41595556-401a-4d02-a40e-287c61c685a9,insights_interaction,latest,,,2022-10-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02005,Maryjo Fleming,,onco-eu-0043,Rafael Navarro,Phone,X-Men,Greece,,Reduced treatment cycle frequency compared to standard monotherapy protocols
text,fcc0da4c-3964-4210-abc2-f5c92eff8e75,insights_interaction,latest,,,2022-11-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02931,Eric Laws,,onco-eu-0043,Rafael Navarro,Iron Man,Avenger,Ragnarok,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,2dcf416b-d9b6-4265-9b99-5ae9dca31577,insights_interaction,latest,,,2023-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-02231,Joy France,,onco-eu-0043,Rafael Navarro,Ulton,X-Men,Spain,,"Observed variability in response rates across different cancer subtypes, with highest efficacy in non-small cell lung cancer and moderate responses in colorectal and breast cancer populations"
text,99054a19-5d4f-4a08-b652-37446a31670e,insights_interaction,latest,,,2023-03-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02841,Henry Collins,,onco-eu-0043,Rafael Navarro,Phone,Clinical Pharmacist,Italy,,"Mild nausea and vomiting reported in some patients, manageable with antiemetic medication."
text,c9120be6-c20d-4cb8-b2f2-ae5417766f50,insights_interaction,latest,,,2023-03-20,MSL Interactions,Oncology,Vibranium,,WB-EU-02960,Melissa Kilgo,,onco-eu-0043,Rafael Navarro,Iron Man,Avenger,Italy,,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,f8cdf552-9fac-4d61-ab45-541591458f6a,insights_interaction,latest,,,2023-05-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02803,Sally King,,onco-eu-0043,Rafael Navarro,Iron Man,Avenger,Ragnarok,,Objective tumor response was observed in 60% of patients with melanoma enrolled in the ongoing phase II clinical trial.
text,50ab0824-137e-4a07-998f-65c803330f41,insights_interaction,latest,,,2023-07-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02594,Susan Ward,,onco-eu-0043,Rafael Navarro,Ulton,Deadpool,Ragnarok,,"Observed mild to moderate immune-related adverse events in 23% of patients, primarily low-grade fatigue and transient hepatic enzyme elevations requiring routine monitoring."
text,57491cd4-bc8f-4de6-b7da-039fadbde35a,insights_interaction,latest,,,2023-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02803,Sally King,,onco-eu-0043,Rafael Navarro,Phone,Avenger,Ragnarok,,Patients reported improved physical functioning and reduced fatigue during treatment.
text,8770cddf-2532-4166-a715-2e04f732a7da,insights_interaction,latest,,,2023-10-02,MSL Interactions,Oncology,Vibranium,,WB-EU-02231,Joy France,,onco-eu-0043,Rafael Navarro,Ulton,X-Men,Spain,,"Grade 2 hepatic transaminase elevation observed in 17% of patients, generally manageable with dose modifications and standard monitoring protocols"
text,4df3b033-42e7-44ee-a545-570341b3276a,insights_interaction,latest,,,2024-01-08,MSL Interactions,Oncology,Vibranium,,WB-EU-02486,Dorthy Reasor,,onco-eu-0043,Rafael Navarro,Iron Man,Deadpool,Italy,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,b25e679d-24ad-4f28-be89-b0d1a8269c77,insights_interaction,latest,,,2024-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02835,Sandra Wilkins,,onco-eu-0043,Rafael Navarro,Ulton,X-Men,Italy,,Patients reported significantly reduced fatigue and improved performance status compared to standard chemotherapy protocols
text,3e953d6c-ee7d-4417-b129-6c5ed2c942e5,insights_interaction,latest,,,2024-08-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02459,Teresa Haynes,,onco-eu-0043,Rafael Navarro,Iron Man,Avenger,Ragnarok,,"Transient increases in liver enzymes observed in several patients, all resolving without intervention."
text,55c2d92a-f1af-4829-84ab-8bc3e6d1306e,insights_interaction,latest,,,2024-11-06,MSL Interactions,Oncology,Vibranium,,WB-EU-02862,Patricia Hanson,,onco-eu-0043,Rafael Navarro,Phone,Avenger,Ragnarok,,"Treatment administration requires specialized expertise, potentially limiting accessibility in certain settings."
text,dec06d91-809b-4033-9d68-c6f226bae07f,insights_interaction,latest,,,2024-11-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02879,Cathi Jackson,,onco-eu-0043,Rafael Navarro,Ulton,Avenger,Spain,,"Observed prolonged stable disease in several patients with advanced colorectal cancer receiving Vibranium/Wakanda, highlighting the potential for disease control even in the absence of complete remission."
text,2cf7c802-83e5-4dc4-9f3f-b69002dbd48d,insights_interaction,latest,,,2021-03-29,MSL Interactions,Oncology,Vibranium,,WB-US-06042,Colin Owens,,onco-us-0015,Richard White,Iron Man,Avenger,United States,AL,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,8aa5013d-d8bc-4ddb-8fdd-59aaddf39b83,insights_interaction,latest,,,2021-04-25,MSL Interactions,Oncology,Vibranium,,WB-US-05132,Edward Scott,,onco-us-0015,Richard White,Phone,Avenger,United States,MS,"Strong correlation detected between PD-L1 expression levels above 50% and enhanced therapeutic response, suggesting potential predictive biomarker for treatment selection."
text,c4369dee-9a9f-4062-8c44-a6b4c5038697,insights_interaction,latest,,,2022-01-14,MSL Interactions,Oncology,Vibranium,,WB-US-06475,Brenda Smith,,onco-us-0015,Richard White,Phone,Avenger,United States,NC,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,fc2d6a85-36b4-4b89-b62c-837e4eea50b3,insights_interaction,latest,,,2022-02-15,MSL Interactions,Oncology,Vibranium,,WB-US-06174,Cedric Burgos,,onco-us-0015,Richard White,Phone,Avenger,United States,VA,"Patients reported significant improvements in symptom burden and functional status, with EORTC QLQ-C30 scores showing substantial quality of life enhancement during treatment."
text,008423b2-8bf6-4503-8b1c-b95c682daebd,insights_interaction,latest,,,2022-04-30,MSL Interactions,Oncology,Vibranium,,WB-US-05525,William Smith,,onco-us-0015,Richard White,Iron Man,Avenger,United States,VA,Complete response achieved in 18% of patients with previously treatment-resistant malignancies
text,9f1ce928-117a-4cfb-b81d-2c819e7caaee,insights_interaction,latest,,,2022-05-17,MSL Interactions,Oncology,Vibranium,,WB-US-04999,Lucie Loree,,onco-us-0015,Richard White,Phone,Deadpool,United States,AL,"Significant reduction in treatment-related fatigue reported, with 63% of patients experiencing improved daily functional capacity."
text,6399c9c9-0815-45ab-b737-5eda2d456919,insights_interaction,latest,,,2022-07-17,MSL Interactions,Oncology,Vibranium,,WB-US-05102,Sarah Murray,,onco-us-0015,Richard White,Phone,Wolverine,United States,KY,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,283d757b-c4cc-4f33-b4c7-6e21075bf060,insights_interaction,latest,,,2022-12-16,MSL Interactions,Oncology,Vibranium,,WB-US-06421,Marlene Hensley,,onco-us-0015,Richard White,Iron Man,X-Men,United States,KY,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 8 weeks of Vibranium therapy, with a 30% reduction in target lesion size confirmed by RECIST 1.1 criteria.  Significant reduction in CA 19-9 levels also observed."
text,40201a5a-1786-4f1a-8a0e-55fa96715b66,insights_interaction,latest,,,2023-01-08,MSL Interactions,Oncology,Vibranium,,WB-US-04928,Sharon Carmichael,,onco-us-0015,Richard White,Phone,Deadpool,United States,NC,Grade 2 immune-related adverse events reported in 18% of patients during initial treatment phase
text,9ca35799-504f-406f-a5d2-2774af975380,insights_interaction,latest,,,2023-03-13,MSL Interactions,Oncology,Vibranium,,WB-US-05744,Carrie Copeland,,onco-us-0015,Richard White,Iron Man,Deadpool,United States,AL,Requires specialized molecular screening and multidisciplinary tumor board review
text,a1597669-9a89-4d73-b308-e561e7861a1d,insights_interaction,latest,,,2023-04-12,MSL Interactions,Oncology,Vibranium,,WB-US-05492,Summer Jones,,onco-us-0015,Richard White,Iron Man,X-Men,United States,FL,Some patients experienced significant fatigue and decreased quality of life during the initial stages of Vibranium/Wakanda therapy.
text,6c6f7c3f-d371-4b23-b463-9ea8aa73f7a7,insights_interaction,latest,,,2023-06-21,MSL Interactions,Oncology,Vibranium,,WB-US-05751,Leo Speer,,onco-us-0015,Richard White,Phone,Wolverine,United States,GA,"Observed a wide range of response times to Vibranium/Wakanda, suggesting potential for personalized treatment approaches."
text,7da963e6-3be1-439d-8a70-1790cbef8bfd,insights_interaction,latest,,,2023-08-14,MSL Interactions,Oncology,Vibranium,,WB-US-05427,Jesse Rufener,,onco-us-0015,Richard White,Ulton,Deadpool,United States,AL,Genetic mutation profile predicts treatment response with 76% accuracy
text,a1041c96-a186-4833-bcc2-86f3f4896250,insights_interaction,latest,,,2023-08-23,MSL Interactions,Oncology,Vibranium,,WB-US-05136,Robert Staples,,onco-us-0015,Richard White,Phone,X-Men,United States,NC,Treatment effectiveness varies across different cancer stages and patient age groups
text,635d4abc-a513-4a34-a87e-7592abfa6d82,insights_interaction,latest,,,2024-01-17,MSL Interactions,Oncology,Vibranium,,WB-US-05954,Rosa Stewart,,onco-us-0015,Richard White,Ulton,Avenger,United States,VA,"Reported sleep disturbances and fatigue in 35% of patients, suggesting need for comprehensive supportive care interventions."
text,1ffddd26-bc1d-4f6d-a22a-07436201245c,insights_interaction,latest,,,2024-06-15,MSL Interactions,Oncology,Vibranium,,WB-US-06125,Anita Whitley,,onco-us-0015,Richard White,Ulton,X-Men,United States,FL,Elevated levels of certain inflammatory cytokines were observed to correlate with a positive clinical response to Vibranium/Wakanda.
text,7c01baff-06e8-4f4b-8e6f-9154fd4b8a69,insights_interaction,latest,,,2024-08-23,MSL Interactions,Oncology,Vibranium,,WB-US-05688,Raymon Duty,,onco-us-0015,Richard White,Ulton,Avenger,United States,GA,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,ee97b995-17e9-47d1-b58d-14737b52457f,insights_interaction,latest,,,2021-01-09,MSL Interactions,Oncology,Vibranium,,WB-US-00914,Curtis Mead,,onco-us-0007,Robert Martinez,Ulton,Avenger,United States,NY,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,0068ad6a-5c8f-4cad-9d92-900a31f9bcbc,insights_interaction,latest,,,2021-03-24,MSL Interactions,Oncology,Vibranium,,WB-US-00942,Mi Greenwood,,onco-us-0007,Robert Martinez,Iron Man,Avenger,United States,NH,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,e8e399ba-6ef8-4397-a8bd-50ac5276599e,insights_interaction,latest,,,2021-05-10,MSL Interactions,Oncology,Vibranium,,WB-US-01871,Margaret Rohr,,onco-us-0007,Robert Martinez,Ulton,Clinical Pharmacist,United States,NH,"Preliminary phase II data shows 42% objective response rate in advanced metastatic solid tumors, with notable durable responses in patients previously refractory to standard therapies."
text,59553221-3fa1-4088-8417-f79b940668a4,insights_interaction,latest,,,2021-05-29,MSL Interactions,Oncology,Vibranium,,WB-US-00449,Bobby Looman,,onco-us-0007,Robert Martinez,Ulton,Avenger,United States,NY,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,7d76f011-aa2b-43d6-9f88-459d6dc5e14d,insights_interaction,latest,,,2021-07-18,MSL Interactions,Oncology,Vibranium,,WB-US-02170,Jerry Harvey,,onco-us-0007,Robert Martinez,Ulton,Deadpool,United States,NY,Early detection of response based on circulating tumor DNA analysis.
text,06c88fa7-341f-48ae-9b61-f969aa76015a,insights_interaction,latest,,,2022-02-12,MSL Interactions,Oncology,Vibranium,,WB-US-02268,Raymond Price,,onco-us-0007,Robert Martinez,Phone,X-Men,United States,NH,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,0f1481d1-7ef6-4346-a571-f141729707ec,insights_interaction,latest,,,2022-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-01716,Jose Stoneking,,onco-us-0007,Robert Martinez,Iron Man,X-Men,United States,NY,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,cfa1fac8-6094-4ad6-95a0-d5c959a74e54,insights_interaction,latest,,,2022-07-03,MSL Interactions,Oncology,Vibranium,,WB-US-00519,Caroline Hines,,onco-us-0007,Robert Martinez,Phone,X-Men,United States,MA,"Patient with advanced pancreatic cancer (PDAC) exhibiting a partial response after 4 cycles of Vibranium/Wakanda therapy.  Significant reduction in tumor size observed via CT scan, coupled with improvement in CA 19-9 levels."
text,9f8588e6-0492-409e-9ec0-d83bfd729875,insights_interaction,latest,,,2022-07-25,MSL Interactions,Oncology,Vibranium,,WB-US-00394,Pedro Butler,,onco-us-0007,Robert Martinez,Iron Man,X-Men,United States,VT,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,c968bd37-1a38-452b-9ae4-e914092ea348,insights_interaction,latest,,,2022-12-03,MSL Interactions,Oncology,Vibranium,,WB-US-00562,Willie Patterson,,onco-us-0007,Robert Martinez,Ulton,X-Men,United States,RI,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,e029d47e-7370-4df8-be2b-dbbc0c35332a,insights_interaction,latest,,,2022-12-19,MSL Interactions,Oncology,Vibranium,,WB-US-02013,Etta Scheid,,onco-us-0007,Robert Martinez,Ulton,Wolverine,United States,RI,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,0f78b70d-abf3-4473-94d5-8596b5c9bfa8,insights_interaction,latest,,,2023-02-18,MSL Interactions,Oncology,Vibranium,,WB-US-00681,Eleanor Carpenter,,onco-us-0007,Robert Martinez,Iron Man,X-Men,United States,VT,"Improved patient reported quality of life scores were observed in several patients receiving Vibranium/Wakanda, particularly in terms of fatigue and pain management."
text,cf2395ef-fb96-4eac-a29d-b79d1b3331a3,insights_interaction,latest,,,2023-02-19,MSL Interactions,Oncology,Vibranium,,WB-US-00216,Mindy Bertran,,onco-us-0007,Robert Martinez,Phone,X-Men,United States,MA,Requires specialized molecular screening and multidisciplinary tumor board review
text,282c1a69-89e1-402b-9bf0-77c57c0a22c3,insights_interaction,latest,,,2023-11-18,MSL Interactions,Oncology,Vibranium,,WB-US-00411,Alice Hernandez,,onco-us-0007,Robert Martinez,Ulton,Avenger,United States,VT,Simplified bi-weekly administration protocol improves patient treatment adherence
text,23e27b84-0eef-4987-9ef5-cbe43b97b3ca,insights_interaction,latest,,,2023-11-21,MSL Interactions,Oncology,Vibranium,,WB-US-01005,Benjamin Weber,,onco-us-0007,Robert Martinez,Iron Man,Deadpool,United States,RI,Requires careful patient selection and comprehensive screening
text,c0717560-dc65-4472-a6ed-6f0b81dc9020,insights_interaction,latest,,,2024-01-01,MSL Interactions,Oncology,Vibranium,,WB-US-02717,Susannah Campbell,,onco-us-0007,Robert Martinez,Iron Man,X-Men,United States,VT,"Emerging evidence suggests potential genetic mutation interactions influencing treatment response, warranting further comprehensive molecular profiling studies."
text,8824f4ca-5ca9-489b-896c-f4ab85ff8dc9,insights_interaction,latest,,,2024-08-08,MSL Interactions,Oncology,Vibranium,,WB-US-01176,Marty Sweeney,,onco-us-0007,Robert Martinez,Iron Man,Avenger,United States,CT,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,ef6fe605-a49a-4519-a216-01d0253f734b,insights_interaction,latest,,,2024-08-19,MSL Interactions,Oncology,Vibranium,,WB-US-01108,William Chatterton,,onco-us-0007,Robert Martinez,Phone,Deadpool,United States,VT,Significantly reduced hepatic and renal toxicity compared to standard chemotherapy protocols
text,f98b8b2a-ac72-4a28-b23d-032c67df6708,insights_interaction,latest,,,2024-08-27,MSL Interactions,Oncology,Vibranium,,WB-US-01856,Elizabeth Littles,,onco-us-0007,Robert Martinez,Iron Man,X-Men,United States,ME,Long-term follow-up data showing stable safety profile with minimal cumulative toxicity
text,204e8ac8-1446-4243-b4ea-145184d142d1,insights_interaction,latest,,,2024-10-26,MSL Interactions,Oncology,Vibranium,,WB-US-00164,Lien Collins,,onco-us-0007,Robert Martinez,Iron Man,Deadpool,United States,ME,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda treatment.
text,f9b4c81f-0cac-4829-8678-90fbb7f091c5,insights_interaction,latest,,,2021-01-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01868,Darrell Markowitz,,onco-eu-0024,Sabine Keller,Phone,Clinical Pharmacist,Switzerland,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,1d8175b8-edb2-4410-a46d-7cfdf2509d45,insights_interaction,latest,,,2021-02-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01494,Judy Castaneda,,onco-eu-0024,Sabine Keller,Ulton,Avenger,Belgium,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,4ebc9ebd-2f1a-45e4-869e-926bee704ec4,insights_interaction,latest,,,2021-02-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01832,Howard Grant,,onco-eu-0024,Sabine Keller,Iron Man,Avenger,Austria,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,4a015f48-9902-4050-bac6-df27bfc3ed46,insights_interaction,latest,,,2021-05-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01844,Martin Emerson,,onco-eu-0024,Sabine Keller,Phone,Avenger,Germany,,"Improved quality of life reported by most patients receiving Vibranium/Wakanda, as measured by FACT-G."
text,7b7d13fe-1feb-4e30-ad8c-fa8e5215f0b1,insights_interaction,latest,,,2021-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01844,Martin Emerson,,onco-eu-0024,Sabine Keller,Ulton,Avenger,Germany,,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,6b70635d-94fe-4cbc-b809-1f1c03020507,insights_interaction,latest,,,2021-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01730,Mary Newberg,,onco-eu-0024,Sabine Keller,Ulton,X-Men,Germany,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,ae3f23f8-2f51-4eae-bcb8-252b8a7d2117,insights_interaction,latest,,,2021-11-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01332,Betty Park,,onco-eu-0024,Sabine Keller,Iron Man,X-Men,Austria,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,e76c323a-43bc-42a1-bfc1-3bb1c36b1e8b,insights_interaction,latest,,,2022-01-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01440,Robert Kerby,,onco-eu-0024,Sabine Keller,Phone,Clinical Pharmacist,Germany,,Correlation observed between pre-treatment levels of certain cytokines and response to therapy.
text,0853faaa-601e-4f02-b55f-e35e05ce9e24,insights_interaction,latest,,,2022-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01355,Nicholas Prioleau,,onco-eu-0024,Sabine Keller,Phone,Wolverine,Belgium,,Improved sleep quality reported by several patients on the therapy.
text,b6f4b96f-0b4c-4b7a-8405-6941cbfa36b1,insights_interaction,latest,,,2022-08-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01327,Victoria Morton,,onco-eu-0024,Sabine Keller,Iron Man,X-Men,Germany,,Statistically significant improvement in overall survival for lung cancer patients with EGFR mutations
text,3fb8d3a3-7ebc-40c9-8e6d-f678efc9df47,insights_interaction,latest,,,2023-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01157,Mary Head,,onco-eu-0024,Sabine Keller,Phone,X-Men,Netherlands,,No significant changes in patient-reported fatigue scores were observed after the first cycle.
text,cda99694-f23e-4d5d-a053-e3a890343ea1,insights_interaction,latest,,,2023-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01459,Cheryl Morrell,,onco-eu-0024,Sabine Keller,Phone,X-Men,Netherlands,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,88294dc5-2c78-4102-a83e-77898c6897b4,insights_interaction,latest,,,2023-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00999,Michel Garcia,,onco-eu-0024,Sabine Keller,Ulton,X-Men,Germany,,Complex genomic screening requirements may create significant logistical challenges in implementing widespread therapeutic approach.
text,58a4deee-aad8-4890-b344-bfbcbc4095a1,insights_interaction,latest,,,2023-09-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00999,Michel Garcia,,onco-eu-0024,Sabine Keller,Iron Man,X-Men,Germany,,One patient experienced a serious adverse event (SAE) of grade 4 pneumonitis requiring hospitalization.
text,e290b103-6d37-41f9-94f7-391cb955d594,insights_interaction,latest,,,2023-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01020,Rebecca Smith,,onco-eu-0024,Sabine Keller,Phone,Deadpool,Germany,,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,d8c33615-b37d-4c16-9115-94c73fcc1281,insights_interaction,latest,,,2023-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01834,Joshua Suarez,,onco-eu-0024,Sabine Keller,Phone,Avenger,Austria,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,e114ea22-07e8-4ef1-92ef-93e9f4e0b470,insights_interaction,latest,,,2023-12-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01864,Norma Franklin,,onco-eu-0024,Sabine Keller,Iron Man,X-Men,Germany,,"Observed grade 2-3 neutropenia in 22% of patients, manageable with standard prophylactic interventions"
text,0b6a3de2-e409-4803-81be-da09aacc7280,insights_interaction,latest,,,2024-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01844,Martin Emerson,,onco-eu-0024,Sabine Keller,Ulton,Avenger,Germany,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,1b46069e-c2f9-4d52-85ac-84d487bb8231,insights_interaction,latest,,,2024-06-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01494,Judy Castaneda,,onco-eu-0024,Sabine Keller,Iron Man,Avenger,Belgium,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,8d534ca1-322f-4694-a062-96ded750b269,insights_interaction,latest,,,2024-07-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01864,Norma Franklin,,onco-eu-0024,Sabine Keller,Phone,X-Men,Germany,,"Mild fatigue and nausea were reported in a patient receiving Vibranium/Wakanda, resolving with supportive care."
text,ec44d880-1867-4708-aea7-ecaafeac27b7,insights_interaction,latest,,,2024-08-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01531,Melinda Taylor,,onco-eu-0024,Sabine Keller,Iron Man,Avenger,Switzerland,,No consistent biomarker signature identified to predict response to Vibranium/Wakanda combination therapy.
text,dedc7703-3ebf-43db-9e71-409f1c7075d9,insights_interaction,latest,,,2024-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01599,James Avalos,,onco-eu-0024,Sabine Keller,Phone,Wolverine,Belgium,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,b1af22c1-ceab-422b-9706-63d4bbedf272,insights_interaction,latest,,,2024-11-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01042,James Arroyo,,onco-eu-0024,Sabine Keller,Ulton,Avenger,Belgium,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,43084792-4313-4ad1-a18a-fe3faef48d3d,insights_interaction,latest,,,2024-11-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01623,Sherrie Ahlers,,onco-eu-0024,Sabine Keller,Iron Man,Clinical Pharmacist,Switzerland,,No clear correlation observed between baseline inflammatory markers and treatment response.
text,0ffcf1c9-0688-4e16-9a1a-0dd48fd2510b,insights_interaction,latest,,,2021-01-15,MSL Interactions,Oncology,Vibranium,,WB-US-09624,Michael Ovit,,onco-us-0034,Sandra Adams,Iron Man,X-Men,United States,NM,Simplified bi-weekly administration protocol improves patient treatment adherence
text,eb7509f6-df74-4a5a-a7ed-7590510ba902,insights_interaction,latest,,,2021-01-25,MSL Interactions,Oncology,Vibranium,,WB-US-09396,Luis Roberts,,onco-us-0034,Sandra Adams,Ulton,X-Men,United States,HI,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,ac4b5a0f-aa47-4ccb-bd29-a01bf3482227,insights_interaction,latest,,,2021-04-17,MSL Interactions,Oncology,Vibranium,,WB-US-09370,Sharon Kennedy,,onco-us-0034,Sandra Adams,Phone,X-Men,United States,UT,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,620d4cf0-f6d2-44a3-9a47-f64103c17d09,insights_interaction,latest,,,2021-10-08,MSL Interactions,Oncology,Vibranium,,WB-US-09396,Luis Roberts,,onco-us-0034,Sandra Adams,Ulton,X-Men,United States,HI,Emerging evidence of potential synergistic effects when combined with targeted immunotherapeutic interventions.
text,99eccc10-a761-46f8-97b1-be00801fd964,insights_interaction,latest,,,2023-01-09,MSL Interactions,Oncology,Vibranium,,WB-US-09733,Annette Villar,,onco-us-0034,Sandra Adams,Ulton,Avenger,United States,NM,No significant changes in quality of life reported by some patients.
text,f9f43dbb-8b31-4569-9260-e9dcf0bf74f7,insights_interaction,latest,,,2023-01-16,MSL Interactions,Oncology,Vibranium,,WB-US-09543,Douglas Emmons,,onco-us-0034,Sandra Adams,Iron Man,Avenger,United States,ID,The need for frequent imaging and blood tests increases the overall treatment burden.
text,10ee89d7-12e0-4020-b710-324fa0af145e,insights_interaction,latest,,,2023-04-29,MSL Interactions,Oncology,Vibranium,,WB-US-09524,Tammy Deguzman,,onco-us-0034,Sandra Adams,Phone,Avenger,United States,AZ,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,bd9749a7-38d3-4ea8-89dc-1fbde91c240c,insights_interaction,latest,,,2023-09-28,MSL Interactions,Oncology,Vibranium,,WB-US-09922,Kenneth Grisby,,onco-us-0034,Sandra Adams,Iron Man,X-Men,United States,UT,No clear correlation was found between age and response to Vibranium/Wakanda.
text,02273e78-1def-443f-93a8-96144846c74d,insights_interaction,latest,,,2024-01-26,MSL Interactions,Oncology,Vibranium,,WB-US-09563,William Gilreath,,onco-us-0034,Sandra Adams,Phone,Deadpool,United States,WA,Moderate grade 2-3 neutropenia observed in 22% of patients during combination therapy
text,67253ad2-9a31-4370-852e-bf134396dffb,insights_interaction,latest,,,2024-02-21,MSL Interactions,Oncology,Vibranium,,WB-US-09585,Barbara Berrios,,onco-us-0034,Sandra Adams,Phone,Deadpool,United States,ID,"Increased risk of infection observed in some patients treated with Vibranium/Wakanda, possibly due to immune suppression."
text,1f2477fc-de00-48b8-bfa3-cf4663a87e36,insights_interaction,latest,,,2024-03-05,MSL Interactions,Oncology,Vibranium,,WB-US-09747,Daniel Neller,,onco-us-0034,Sandra Adams,Iron Man,Deadpool,United States,OR,"Consistent treatment response across multiple cancer subtypes, with slight variability in progression-free survival"
text,a7385375-3adf-45b1-bf45-96574be9d3eb,insights_interaction,latest,,,2024-04-09,MSL Interactions,Oncology,Vibranium,,WB-US-09457,Kelli Mccann,,onco-us-0034,Sandra Adams,Phone,X-Men,United States,WY,Early detection of response based on circulating tumor DNA analysis.
text,284bf175-3378-4320-90cf-d41618c77d6f,insights_interaction,latest,,,2024-04-24,MSL Interactions,Oncology,Vibranium,,WB-US-09624,Michael Ovit,,onco-us-0034,Sandra Adams,Ulton,X-Men,United States,NM,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,1257bf7a-4220-4ebe-9909-51ff2a5cf93c,insights_interaction,latest,,,2024-05-13,MSL Interactions,Oncology,Vibranium,,WB-US-09754,Courtney Alber,,onco-us-0034,Sandra Adams,Iron Man,Avenger,United States,WY,Patient experienced grade 3 fatigue and nausea requiring dose reduction of Vibranium/Wakanda. Treatment was temporarily suspended.
text,c731599b-47e5-440f-a07d-ff89ec145066,insights_interaction,latest,,,2024-05-26,MSL Interactions,Oncology,Vibranium,,WB-US-09775,Mary Hessler,,onco-us-0034,Sandra Adams,Ulton,Avenger,United States,CA,"Strong correlation observed between PD-L1 expression levels and treatment response, predictive potential identified"
text,54e4e6e8-0a0a-4d07-b4d4-7b22c36388ae,insights_interaction,latest,,,2024-06-15,MSL Interactions,Oncology,Vibranium,,WB-US-09563,William Gilreath,,onco-us-0034,Sandra Adams,Iron Man,Deadpool,United States,WA,Treatment cost is a significant barrier to widespread adoption.
text,ac8cd5d7-55c0-4a32-af7e-13c3c9d2feb7,insights_interaction,latest,,,2024-06-28,MSL Interactions,Oncology,Vibranium,,WB-US-09554,Richard Johnson,,onco-us-0034,Sandra Adams,Iron Man,Deadpool,United States,MT,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,9456bedc-58f0-4edc-8cf5-ec3a521abd96,insights_interaction,latest,,,2024-10-14,MSL Interactions,Oncology,Vibranium,,WB-US-09563,William Gilreath,,onco-us-0034,Sandra Adams,Phone,Deadpool,United States,WA,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,d2781c07-85d1-49fa-8d52-6766083a3ffd,insights_interaction,latest,,,2024-11-18,MSL Interactions,Oncology,Vibranium,,WB-US-09397,Tonya Hurtado,,onco-us-0034,Sandra Adams,Ulton,Avenger,United States,HI,"Observed variable response rates across different tumor types, with better efficacy seen in pancreatic and colorectal cancers."
text,550dd411-ad48-49b3-bbaf-6391d592b629,insights_interaction,latest,,,2022-02-04,MSL Interactions,Oncology,Vibranium,,WB-US-01196,Michael Martinez,,onco-us-0001,Sarah Chen,Iron Man,X-Men,United States,VT,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,48a6d291-0859-423e-910d-ed0209157cd9,insights_interaction,latest,,,2022-04-24,MSL Interactions,Oncology,Vibranium,,WB-US-00041,Magnolia Burks,,onco-us-0001,Sarah Chen,Phone,X-Men,United States,VT,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,a5b27e9b-3604-4da0-87de-0a813b88025e,insights_interaction,latest,,,2022-05-24,MSL Interactions,Oncology,Vibranium,,WB-US-00554,Roger Seto,,onco-us-0001,Sarah Chen,Phone,Avenger,United States,RI,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,d840e897-6726-4f41-98ca-82f3fe5aa915,insights_interaction,latest,,,2022-07-25,MSL Interactions,Oncology,Vibranium,,WB-US-02279,William Jordan,,onco-us-0001,Sarah Chen,Phone,Avenger,United States,ME,"A patient with recurrent ovarian cancer experienced a complete remission after six cycles of Vibranium/Wakanda therapy, a remarkable outcome considering her prior treatment history."
text,d23b37c9-d12b-4255-ad11-b6c729790ad8,insights_interaction,latest,,,2022-08-05,MSL Interactions,Oncology,Vibranium,,WB-US-00494,Richard Francis,,onco-us-0001,Sarah Chen,Ulton,Avenger,United States,NH,"Promising results in combination therapy with checkpoint inhibitors, showing synergistic effect and enhanced overall response rates"
text,87d55f37-a9ca-46ee-b244-64b8c78b64c6,insights_interaction,latest,,,2022-12-12,MSL Interactions,Oncology,Vibranium,,WB-US-02541,Craig Collins,,onco-us-0001,Sarah Chen,Iron Man,X-Men,United States,RI,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,4675e841-d136-4a86-aee2-bbbefa62e02d,insights_interaction,latest,,,2022-12-17,MSL Interactions,Oncology,Vibranium,,WB-US-00970,Victor Keppler,,onco-us-0001,Sarah Chen,Iron Man,X-Men,United States,ME,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,c147a39d-9bc7-41a9-b145-93d57beb44e0,insights_interaction,latest,,,2023-04-09,MSL Interactions,Oncology,Vibranium,,WB-US-00931,Kelly Borst,,onco-us-0001,Sarah Chen,Ulton,Deadpool,United States,NY,"Variable response rates observed across different cancer subtypes, highlighting importance of personalized treatment strategies."
text,8ae36eb9-9d21-44d1-ad0f-38633621eede,insights_interaction,latest,,,2023-04-15,MSL Interactions,Oncology,Vibranium,,WB-US-02637,Claudia Mcbride,,onco-us-0001,Sarah Chen,Ulton,Deadpool,United States,VT,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,9558bb67-c22d-4c3f-8a77-f06e36abc53f,insights_interaction,latest,,,2023-05-02,MSL Interactions,Oncology,Vibranium,,WB-US-01040,Herbert Moore,,onco-us-0001,Sarah Chen,Ulton,X-Men,United States,MA,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,b1e3f140-029a-4076-aacb-8815a3dc0df8,insights_interaction,latest,,,2023-07-06,MSL Interactions,Oncology,Vibranium,,WB-US-01102,Robert Wills,,onco-us-0001,Sarah Chen,Phone,Avenger,United States,MA,"Increased expression of PD-L1 observed in tumor biopsies post-Vibranium/Wakanda administration, suggesting potential synergistic effects with immunotherapy in subsequent treatment regimens."
text,81edae71-dbb4-48c6-a3cc-82a31f6c6ddc,insights_interaction,latest,,,2024-02-16,MSL Interactions,Oncology,Vibranium,,WB-US-02498,Austin Moris,,onco-us-0001,Sarah Chen,Phone,Wolverine,United States,VT,Quality of life remained stable in a majority of patients despite disease progression.
text,66503641-d16b-4477-8caa-0d9f2393726f,insights_interaction,latest,,,2024-09-12,MSL Interactions,Oncology,Vibranium,,WB-US-02190,Richard Garrido,,onco-us-0001,Sarah Chen,Phone,Avenger,United States,RI,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,1d528a94-a9af-4366-9a89-30ecebf952ee,insights_interaction,latest,,,2021-05-04,MSL Interactions,Oncology,Vibranium,,WB-EU-00553,Ronnie Bryant,,onco-eu-0001,Sofia Andersson,Phone,Deadpool,Denmark,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,c47c217a-3aec-4757-8a82-ec940482dfb4,insights_interaction,latest,,,2021-08-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00528,Jeanette Yang,,onco-eu-0001,Sofia Andersson,Ulton,X-Men,Norway,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,74f15f8d-5759-4fc3-a3db-62d0c6923fa3,insights_interaction,latest,,,2021-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00165,Cindy Jones,,onco-eu-0001,Sofia Andersson,Iron Man,X-Men,Sweden,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,76d8c415-5436-40d9-b04a-a4ce50c71005,insights_interaction,latest,,,2021-12-06,MSL Interactions,Oncology,Vibranium,,WB-EU-00280,George Alvarez,,onco-eu-0001,Sofia Andersson,Ulton,Deadpool,Norway,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,89d7c079-cd2b-4684-aefc-1a55542c596f,insights_interaction,latest,,,2022-03-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00475,Sybil Wilson,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Denmark,,Early detection of response based on circulating tumor DNA analysis.
text,ad5faa4c-52ab-49c0-a292-140c8b372596,insights_interaction,latest,,,2022-03-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00205,Douglas Ezzelle,,onco-eu-0001,Sofia Andersson,Ulton,Deadpool,Norway,,Significant improvement in patient-reported fatigue and pain scores using the EORTC QLQ-C30 questionnaire in patients with advanced colorectal cancer treated with Vibranium compared to historical controls.
text,25ea3745-c098-4801-8017-2d3957d3f3be,insights_interaction,latest,,,2022-05-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00174,Autumn Wigley,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Finland,,Emerging evidence of potential predictive value for circulating tumor DNA as early response indicator
text,26c949ec-4253-428f-93e5-806d01abb0c5,insights_interaction,latest,,,2022-09-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00500,Marcella Burgess,,onco-eu-0001,Sofia Andersson,Phone,X-Men,Denmark,,Reduced metastatic progression rates in patients with early intervention using combination therapy
text,27a4ad41-e601-4220-9daf-b30714752806,insights_interaction,latest,,,2022-12-09,MSL Interactions,Oncology,Vibranium,,WB-EU-00447,Gregory Chacon,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Sweden,,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,3dfed764-2c59-4ae6-86e2-46d0014d4bf4,insights_interaction,latest,,,2023-04-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00500,Marcella Burgess,,onco-eu-0001,Sofia Andersson,Phone,X-Men,Denmark,,The need for frequent imaging and blood tests increases the overall treatment burden.
text,f507847e-e246-4d82-8e13-cabc2e8c8a8a,insights_interaction,latest,,,2023-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00351,Rodney Murphree,,onco-eu-0001,Sofia Andersson,Phone,Deadpool,Finland,,No significant changes in quality of life reported in one patient with stable disease after 2 cycles.
text,8b7314e1-307d-4a5c-9646-cf646d66ad96,insights_interaction,latest,,,2023-07-14,MSL Interactions,Oncology,Vibranium,,WB-EU-00794,Roy Kapper,,onco-eu-0001,Sofia Andersson,Phone,Wolverine,Norway,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,59f45f81-2e85-47f6-bafb-7bcc453f28a5,insights_interaction,latest,,,2023-08-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00606,George Rzeczycki,,onco-eu-0001,Sofia Andersson,Phone,X-Men,Finland,,Median progression-free survival of 8.7 months in advanced solid tumors with complex molecular profiles
text,855226b0-831d-4cb6-b3fb-da0361f159f6,insights_interaction,latest,,,2023-09-20,MSL Interactions,Oncology,Vibranium,,WB-EU-00254,Dianna Alvarado,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Sweden,,"Median progression-free survival of 5.7 months observed across multiple solid tumor subtypes, with heterogeneous response patterns noted."
text,98fe891e-8bfd-48fc-a259-c08027c97ef1,insights_interaction,latest,,,2023-10-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00660,Steven Rodriguez,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Sweden,,"Partial response observed in a patient with advanced lung cancer after 4 cycles of Vibranium/Wakanda, with a 30% reduction in tumor burden."
text,7a73e633-6691-40c1-9a29-84e5884ebc62,insights_interaction,latest,,,2023-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00130,Stephen Perez,,onco-eu-0001,Sofia Andersson,Iron Man,X-Men,Norway,,"Treatment response appears to be heterogenous, with some patients exhibiting complete responses while others show minimal or no response."
text,dbdf3d3a-6c6d-4591-9e52-d715987620de,insights_interaction,latest,,,2023-10-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00322,James Decena,,onco-eu-0001,Sofia Andersson,Iron Man,Deadpool,Finland,,No significant drug interactions detected with common co-medications in geriatric patient populations
text,22dfec32-925b-4067-ad80-f1c5aa55144e,insights_interaction,latest,,,2024-04-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00551,Juanita Givens,,onco-eu-0001,Sofia Andersson,Phone,X-Men,Denmark,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,3d54c0ef-5890-4f99-9303-32ce63c941a7,insights_interaction,latest,,,2024-05-01,MSL Interactions,Oncology,Vibranium,,WB-EU-00609,Kevin Rosario,,onco-eu-0001,Sofia Andersson,Ulton,X-Men,Finland,,"Significant correlation detected between PD-L1 expression and treatment response, predictive marker identified"
text,5122613f-bbf7-46c1-8815-5f7f8bb4ab98,insights_interaction,latest,,,2024-09-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00339,Laurence Mccall,,onco-eu-0001,Sofia Andersson,Ulton,Avenger,Sweden,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,f1b4af1f-4917-4c2f-ac09-3b766f82ed5a,insights_interaction,latest,,,2024-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00660,Steven Rodriguez,,onco-eu-0001,Sofia Andersson,Ulton,Avenger,Sweden,,"Increased expression of PD-L1 was noted in tumor biopsies post-treatment, suggesting a potential synergy with immune checkpoint inhibitors."
text,2742b41b-ff46-4ed3-ae16-8bf543fa02e3,insights_interaction,latest,,,2024-11-29,MSL Interactions,Oncology,Vibranium,,WB-EU-00673,Nicole Charles,,onco-eu-0001,Sofia Andersson,Iron Man,Avenger,Denmark,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,64f56164-8e2a-4640-bfc5-a0705e812916,insights_interaction,latest,,,2024-12-28,MSL Interactions,Oncology,Vibranium,,WB-EU-00158,Jeffrey Williams,,onco-eu-0001,Sofia Andersson,Phone,Avenger,Norway,,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,8720deb4-d022-477f-8987-3a16232baba7,insights_interaction,latest,,,2021-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01783,Joel Foster,,onco-eu-0034,Sophia Costa,Phone,Avenger,Austria,,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,b32f36fe-dac0-4de5-a72f-7f80485328f9,insights_interaction,latest,,,2021-03-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01719,Patricia Gammon,,onco-eu-0034,Sophia Costa,Iron Man,X-Men,Austria,,Strong correlation between PD-L1 expression >50% and enhanced treatment response
text,455948f6-31d6-4dc4-8d03-12da2f2c80ff,insights_interaction,latest,,,2021-04-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01860,Hannah Ramos,,onco-eu-0034,Sophia Costa,Iron Man,Avenger,Switzerland,,Reduction in pain levels reported by patients with bone metastases.
text,605b4ca2-1201-4d6c-ad13-6099670d7a81,insights_interaction,latest,,,2021-04-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01389,John Smith,,onco-eu-0034,Sophia Costa,Ulton,X-Men,Netherlands,,"Patient reported significant improvement in quality of life after initiating Vibranium/Wakanda.  She experienced decreased pain, improved appetite, and increased energy levels, allowing her to resume some of her daily activities."
text,b34f170f-12a5-4185-b033-8f1ed2737d2a,insights_interaction,latest,,,2021-05-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01746,Jill Martin,,onco-eu-0034,Sophia Costa,Iron Man,Deadpool,Germany,,PD-L1 expression did not appear to be a reliable predictor of response to Vibranium/Wakanda.
text,d3e0ad70-204f-4ef5-92d8-6bc8a530c5c2,insights_interaction,latest,,,2021-10-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01498,David Matthews,,onco-eu-0034,Sophia Costa,Phone,Avenger,Switzerland,,Development of novel companion diagnostic algorithm to improve patient stratification and personalized treatment approaches
text,a2ea6723-cb8e-4128-9283-8811af792666,insights_interaction,latest,,,2022-03-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01677,Larry Reyes,,onco-eu-0034,Sophia Costa,Phone,Avenger,Austria,,Strong correlation between PD-L1 expression and treatment response observed
text,2d75f4e4-e45d-46f6-a9d2-141bdfce6306,insights_interaction,latest,,,2022-03-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01449,Stanley Mercado,,onco-eu-0034,Sophia Costa,Ulton,Avenger,Switzerland,,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,dbd37a50-e1d3-463e-9f6d-88bbb1d58a68,insights_interaction,latest,,,2022-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01930,Joel Lara,,onco-eu-0034,Sophia Costa,Iron Man,Avenger,Austria,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,c01f00a3-1eaf-4c8e-bac1-014622faaa4f,insights_interaction,latest,,,2023-02-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01719,Patricia Gammon,,onco-eu-0034,Sophia Costa,Iron Man,X-Men,Austria,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,c6f461c9-2df0-4ec9-a34c-b89bf113110b,insights_interaction,latest,,,2023-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-00961,Bobby Defazio,,onco-eu-0034,Sophia Costa,Ulton,Avenger,Germany,,Variable patient-reported outcomes suggest individualized response experiences requiring personalized supportive care approaches.
text,b2160c28-7b0c-423e-8f54-01d225b327ea,insights_interaction,latest,,,2023-05-26,MSL Interactions,Oncology,Vibranium,,WB-EU-00960,Roger Bartkowiak,,onco-eu-0034,Sophia Costa,Phone,Deadpool,Austria,,Improved appetite and reduced pain reported by several patients.
text,edc05d27-02f0-4bb8-bb98-e02ad916c689,insights_interaction,latest,,,2023-06-22,MSL Interactions,Oncology,Vibranium,,WB-EU-00960,Roger Bartkowiak,,onco-eu-0034,Sophia Costa,Phone,Deadpool,Austria,,Strong correlation between PD-L1 expression and treatment response observed
text,7ce23f7b-790e-4c55-b91e-8581b0d659c2,insights_interaction,latest,,,2023-07-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01679,Jean Soloman,,onco-eu-0034,Sophia Costa,Ulton,Clinical Pharmacist,Belgium,,Moderate effectiveness in treatment-resistant cancer subtypes with complex molecular profiles
text,8b495869-c523-4a88-991c-a3c4be3cb1f6,insights_interaction,latest,,,2023-08-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01347,Mariana Pitcher,,onco-eu-0034,Sophia Costa,Iron Man,Avenger,Switzerland,,"Reported sleep disturbances and fatigue in 35% of patients, suggesting need for comprehensive supportive care interventions."
text,b68b33a9-229e-49c3-96a1-250bcd03e12e,insights_interaction,latest,,,2023-12-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01000,Thomas Maldonado,,onco-eu-0034,Sophia Costa,Ulton,Avenger,Switzerland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,673b7d5c-c992-403c-aa28-318a4360ebd0,insights_interaction,latest,,,2023-12-10,MSL Interactions,Oncology,Vibranium,,WB-EU-00832,Robert Mielke,,onco-eu-0034,Sophia Costa,Ulton,X-Men,Netherlands,,"Administration of Vibranium/Wakanda requires specialized training and expertise, potentially limiting accessibility in some clinical settings."
text,dd2270b8-0d57-4e8b-a818-ebbf41216d42,insights_interaction,latest,,,2023-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01347,Mariana Pitcher,,onco-eu-0034,Sophia Costa,Ulton,Avenger,Switzerland,,One patient experienced Grade 3 hepatotoxicity requiring treatment discontinuation and hospitalization.  Further investigation into potential contributing factors is ongoing.
text,fde56e59-928c-40dc-8bba-dbe4cd0e8111,insights_interaction,latest,,,2024-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01920,Angela Zenon,,onco-eu-0034,Sophia Costa,Ulton,Deadpool,Switzerland,,Variability in treatment response across different cancer stages
text,8471a4df-5658-477b-908e-3205ccf2416e,insights_interaction,latest,,,2024-07-03,MSL Interactions,Oncology,Vibranium,,WB-EU-00835,Diana Blow,,onco-eu-0034,Sophia Costa,Phone,Wolverine,Switzerland,,"Observed a wide range of response times to Vibranium/Wakanda, suggesting potential for personalized treatment approaches."
text,ae5ba421-5802-4a9a-9b30-6a9c3bc2da10,insights_interaction,latest,,,2024-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01952,Jennifer Johnson,,onco-eu-0034,Sophia Costa,Phone,Avenger,Austria,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,94bcde60-1403-4bd1-8e9d-431107676b12,insights_interaction,latest,,,2024-12-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01860,Hannah Ramos,,onco-eu-0034,Sophia Costa,Iron Man,Avenger,Switzerland,,Patient developed grade 3 thrombocytopenia requiring treatment interruption and platelet transfusion.
text,6c8a60d8-1a1b-414f-bc83-1d633b3e302c,insights_interaction,latest,,,2021-02-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02222,Sharon Cook,,onco-eu-0050,Sophie Martin,Phone,Avenger,Greece,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,e68e0850-be4c-43f7-8df4-d2efdf7cef36,insights_interaction,latest,,,2021-03-31,MSL Interactions,Oncology,Vibranium,,WB-EU-02764,Robert Paddock,,onco-eu-0050,Sophie Martin,Iron Man,Avenger,Spain,,Stable disease observed for over 6 months in several patients with previously refractory disease.
text,ab25bb22-bf82-442b-8659-f4d2fa89575e,insights_interaction,latest,,,2021-05-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02567,Dennis Harper,,onco-eu-0050,Sophie Martin,Ulton,X-Men,Italy,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,4a45a313-7b34-4ad2-9159-8b992e03fbbd,insights_interaction,latest,,,2021-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02528,Leslie Paetzold,,onco-eu-0050,Sophie Martin,Iron Man,Wolverine,Italy,,Cost-effectiveness analysis suggests potential for reduced hospital readmission rates with targeted combination approach
text,8051c9e0-c293-48e4-89c7-2213ef821386,insights_interaction,latest,,,2021-07-23,MSL Interactions,Oncology,Vibranium,,WB-EU-02527,Nina Higgins,,onco-eu-0050,Sophie Martin,Ulton,X-Men,Greece,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,a7adbf2e-f8f1-4d66-8784-f906078243f8,insights_interaction,latest,,,2021-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-02849,Russell Mcswain,,onco-eu-0050,Sophie Martin,Iron Man,Avenger,Spain,,"Strong correlation identified between PD-L1 expression >50% and enhanced therapeutic response, suggesting potential predictive biomarker for patient selection."
text,261b7bd0-2656-4c63-8771-4e5945f3f10f,insights_interaction,latest,,,2022-01-03,MSL Interactions,Oncology,Vibranium,,WB-EU-02707,Richard Lee,,onco-eu-0050,Sophie Martin,Iron Man,Deadpool,Greece,,Cost-effectiveness analysis demonstrates potential healthcare system savings compared to current standard-of-care treatments
text,d61e5b95-8cb8-438e-b305-1eded803ea69,insights_interaction,latest,,,2022-01-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02260,Laura Atwell,,onco-eu-0050,Sophie Martin,Phone,Avenger,Ragnarok,,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,6e414248-9b07-4b4d-a787-826494d11e5d,insights_interaction,latest,,,2022-03-14,MSL Interactions,Oncology,Vibranium,,WB-EU-02969,Erma Bruce,,onco-eu-0050,Sophie Martin,Phone,Avenger,Italy,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,6553fd0f-22fd-41be-9d8a-686a552693ff,insights_interaction,latest,,,2022-03-27,MSL Interactions,Oncology,Vibranium,,WB-EU-02789,James Sanchez,,onco-eu-0050,Sophie Martin,Phone,Clinical Pharmacist,Ragnarok,,"Significant increase in CD8+ T-cell infiltration observed in tumor biopsies after Vibranium/Wakanda administration, suggesting an immune response."
text,f1afdd6a-6d64-4379-8b44-2cba6a28edb7,insights_interaction,latest,,,2022-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02967,Kayla Sharp,,onco-eu-0050,Sophie Martin,Phone,X-Men,Greece,,"Improved quality of life reported by most patients receiving Vibranium/Wakanda, as measured by FACT-G."
text,cd3c5b4b-8e64-4475-8ca7-f2e50ed53d28,insights_interaction,latest,,,2022-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-02527,Nina Higgins,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Greece,,Significant tumor reduction in hard-to-treat cancer subtypes
text,fef25079-19af-4e6f-8007-f6a85b9b45be,insights_interaction,latest,,,2022-11-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02567,Dennis Harper,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Italy,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 2 cycles of Vibranium/Wakanda therapy, with a 30% reduction in tumor size confirmed by CT scan.  Significant reduction in CA 19-9 levels also observed."
text,497d6483-071a-4d9e-b379-3c3046e57839,insights_interaction,latest,,,2022-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-02260,Laura Atwell,,onco-eu-0050,Sophie Martin,Ulton,Avenger,Ragnarok,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,5d4e49bc-78a5-4c12-bbb5-813ca4b88d73,insights_interaction,latest,,,2023-02-07,MSL Interactions,Oncology,Vibranium,,WB-EU-02334,Charles Hensley,,onco-eu-0050,Sophie Martin,Phone,Avenger,Spain,,Progression-free survival (PFS) significantly improved in patients with recurrent glioblastoma treated with Vibranium in combination with standard radiation therapy compared to radiation therapy alone.
text,612a8c71-5877-43d6-a044-6efbb409c8e5,insights_interaction,latest,,,2023-03-17,MSL Interactions,Oncology,Vibranium,,WB-EU-02033,Minnie Mcauliffe,,onco-eu-0050,Sophie Martin,Phone,X-Men,Ragnarok,,Grade 2 immune-related adverse events reported in 18% of patients during initial treatment phase
text,a150dfa2-d1a8-4b18-800e-7791cea049e1,insights_interaction,latest,,,2023-05-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02434,Ronald Hartman,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Spain,,Some patients reported increased anxiety related to treatment side effects.
text,be787d8e-579b-49c0-a1c2-032a28ea1a2d,insights_interaction,latest,,,2023-07-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02967,Kayla Sharp,,onco-eu-0050,Sophie Martin,Ulton,X-Men,Greece,,"Partial response observed in a patient with advanced pancreatic cancer after 12 weeks of treatment, evidenced by decreased CA 19-9 levels and improved imaging findings."
text,113fe5a1-2938-4df3-840b-82390ec396e7,insights_interaction,latest,,,2023-09-19,MSL Interactions,Oncology,Vibranium,,WB-EU-02078,John Rivera,,onco-eu-0050,Sophie Martin,Phone,Avenger,Italy,,Most adverse events associated with Vibranium/Wakanda were manageable and resolved without long-term sequelae.
text,8873f772-91a3-4a4a-ba8f-e9fc48e6d7bb,insights_interaction,latest,,,2023-09-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02135,Roger Shackelford,,onco-eu-0050,Sophie Martin,Ulton,X-Men,Ragnarok,,Grade 2 immune-related adverse events reported in 18% of patients during initial treatment phase
text,ca671c6a-7a79-4dd2-befc-936a4c4d761e,insights_interaction,latest,,,2024-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-02967,Kayla Sharp,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Greece,,Observed variability in response to Vibranium/Wakanda combination therapy across different patient populations.
text,6d0ed4b1-a677-4d0e-aa2e-958aa516a5c2,insights_interaction,latest,,,2024-02-29,MSL Interactions,Oncology,Vibranium,,WB-EU-02135,Roger Shackelford,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Ragnarok,,Significant reduction in treatment-related fatigue reported by 72% of patients
text,4039af8d-2a77-497c-af43-d04a97fa2780,insights_interaction,latest,,,2024-03-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02769,David Johnson,,onco-eu-0050,Sophie Martin,Iron Man,X-Men,Greece,,Mild injection site reactions reported in some patients.
text,cf928221-f685-47d1-bcba-67b5e4e8b9fd,insights_interaction,latest,,,2024-10-04,MSL Interactions,Oncology,Vibranium,,WB-EU-02386,Michael Baltimore,,onco-eu-0050,Sophie Martin,Ulton,Avenger,Italy,,Correlation observed between serum interferon-gamma levels and response to Vibranium/Wakanda therapy.
text,a6f6a0c4-8b9c-4283-b062-6b885e155409,insights_interaction,latest,,,2024-10-18,MSL Interactions,Oncology,Vibranium,,WB-EU-02643,Irene Abernathy,,onco-eu-0050,Sophie Martin,Ulton,Avenger,Italy,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,bde57858-1932-476f-a701-ccf9cc54e4e5,insights_interaction,latest,,,2024-11-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02260,Laura Atwell,,onco-eu-0050,Sophie Martin,Phone,Avenger,Ragnarok,,"Increased incidence of hepatic toxicity observed in a subset of patients receiving Vibranium/Wakanda, necessitating close monitoring of liver function."
text,8f387a22-11c1-4fab-8e7b-8f120d429690,insights_interaction,latest,,,2021-01-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01563,Elizabeth Alaniz,,onco-eu-0018,Stefan Schmidt,Ulton,X-Men,Germany,,Complete response rates in metastatic melanoma patients reached 31%
text,fd45661a-f6e5-4c48-bf20-7fa134f94aab,insights_interaction,latest,,,2021-04-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01102,Tanya Summa,,onco-eu-0018,Stefan Schmidt,Ulton,X-Men,Germany,,Improved patient reported outcomes (PROs) regarding pain and fatigue were noted in several patients after three cycles of treatment.
text,12d2c399-7f6a-42ef-a16a-e469eb7328cc,insights_interaction,latest,,,2021-05-22,MSL Interactions,Oncology,Vibranium,,WB-EU-01549,Dawn Hale,,onco-eu-0018,Stefan Schmidt,Phone,Deadpool,Switzerland,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,0d2f11d2-fa97-483d-a693-4bb50eb81704,insights_interaction,latest,,,2021-07-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01086,Stephaine Boone,,onco-eu-0018,Stefan Schmidt,Ulton,Avenger,Austria,,Improved sleep quality reported by several patients on the therapy.
text,076e70d7-bb07-48c8-955e-c989e0500e7c,insights_interaction,latest,,,2021-11-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01063,Edward Garcia,,onco-eu-0018,Stefan Schmidt,Iron Man,Avenger,Austria,,Significant tumor size reduction in 35% of advanced stage cancer patients
text,5722530f-210e-428e-8424-5fcbac2ea82e,insights_interaction,latest,,,2022-03-02,MSL Interactions,Oncology,Vibranium,,WB-EU-00889,Louise Wilson,,onco-eu-0018,Stefan Schmidt,Ulton,X-Men,Austria,,Improved sleep quality reported by several patients on the therapy.
text,bd86c554-a42d-4a05-9c13-ba10e6971e22,insights_interaction,latest,,,2022-03-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01102,Tanya Summa,,onco-eu-0018,Stefan Schmidt,Ulton,X-Men,Germany,,Simplified bi-weekly administration protocol improves patient treatment adherence
text,2a20cdbf-605d-47f0-a432-a2e35f3dc57a,insights_interaction,latest,,,2022-04-04,MSL Interactions,Oncology,Vibranium,,WB-EU-01145,Roger Stone,,onco-eu-0018,Stefan Schmidt,Iron Man,X-Men,Belgium,,Strong predictive value of circulating tumor DNA for treatment response
text,00c5915f-2b7a-4fdd-b227-35b037fc19d0,insights_interaction,latest,,,2022-04-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01239,Mabel Sloan,,onco-eu-0018,Stefan Schmidt,Iron Man,Avenger,Netherlands,,Significant tumor regression observed in multiple patients with advanced melanoma.
text,8965de1e-84ae-4c82-89d6-c596a0786588,insights_interaction,latest,,,2022-05-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01750,Dustin Davis,,onco-eu-0018,Stefan Schmidt,Phone,Deadpool,Switzerland,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,3f6be125-1759-4edf-a17c-9bf1a6141cd1,insights_interaction,latest,,,2022-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00812,Brian Mondell,,onco-eu-0018,Stefan Schmidt,Ulton,Avenger,Netherlands,,Cost-effectiveness analysis demonstrates potential for significant healthcare resource optimization
text,5bee00f8-ff58-4a08-855e-722d70a99889,insights_interaction,latest,,,2022-08-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01103,Stanley Sullivan,,onco-eu-0018,Stefan Schmidt,Phone,X-Men,Netherlands,,We observed a correlation between early viral replication kinetics as measured by PCR and subsequent tumor response in patients receiving Vibranium/Wakanda. This may serve as a potential predictive biomarker for treatment efficacy.
text,bc7d8954-be19-4017-8f98-367a6e18331f,insights_interaction,latest,,,2024-05-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01997,Maria Wood,,onco-eu-0018,Stefan Schmidt,Ulton,Avenger,Switzerland,,"Identified potential cardiotoxicity risk in patients with pre-existing cardiac conditions, recommending comprehensive cardiac screening"
text,48b9055c-e330-4c2a-a57e-24bcb41f6713,insights_interaction,latest,,,2024-05-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01913,Michelle Taylor,,onco-eu-0018,Stefan Schmidt,Phone,Wolverine,Germany,,The optimal dosing schedule for Vibranium/Wakanda is still under investigation.
text,01ac847f-8868-419b-a514-235d5cd5f7c1,insights_interaction,latest,,,2024-12-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01342,Hector Oconor,,onco-eu-0018,Stefan Schmidt,Phone,Deadpool,Austria,,"Mild flu-like symptoms (fatigue, myalgia) observed in a patient receiving Vibranium/Wakanda, resolving spontaneously within 48 hours with supportive care."
text,298ea4f8-df35-44d2-b76f-38bcb966e7b2,insights_interaction,latest,,,2021-04-03,MSL Interactions,Oncology,Vibranium,,WB-US-06940,Douglas Johnston,,onco-us-0026,Steven Wright,Ulton,Deadpool,United States,WI,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,657a2b89-a712-4c1c-9c24-e39e0d4c1bbd,insights_interaction,latest,,,2021-07-20,MSL Interactions,Oncology,Vibranium,,WB-US-07798,Michael Sipe,,onco-us-0026,Steven Wright,Iron Man,X-Men,United States,MI,No unexpected or severe adverse events were reported in the majority of patients.
text,32075055-6417-47f6-9c36-47f1650e52ba,insights_interaction,latest,,,2021-10-20,MSL Interactions,Oncology,Vibranium,,WB-US-07487,Brenda Rizzio,,onco-us-0026,Steven Wright,Ulton,Avenger,United States,MN,"Significant survival advantage demonstrated in patients with historically challenging metastatic carcinomas, extending median overall survival."
text,da7b325e-6658-41da-8f9b-1c2524ce2456,insights_interaction,latest,,,2021-11-05,MSL Interactions,Oncology,Vibranium,,WB-US-07530,Linda Roach,,onco-us-0026,Steven Wright,Phone,Deadpool,United States,MI,Improved management of potential immune-related adverse events through proactive monitoring
text,f9f8ba31-a475-477b-8571-2f43e755ed82,insights_interaction,latest,,,2021-11-10,MSL Interactions,Oncology,Vibranium,,WB-US-07732,Vincent Husbands,,onco-us-0026,Steven Wright,Iron Man,X-Men,United States,OH,Streamlined treatment protocol reducing overall hospital intervention time
text,1a3dd35e-9351-4f75-951f-bb302dbb9992,insights_interaction,latest,,,2021-11-22,MSL Interactions,Oncology,Vibranium,,WB-US-08093,James Mayfield,,onco-us-0026,Steven Wright,Ulton,Avenger,United States,MI,Sustained complete response observed in 23% of advanced melanoma patients after 12-month follow-up
text,421d3a8f-bfb7-4da7-a5f0-4e114ff0a430,insights_interaction,latest,,,2021-12-09,MSL Interactions,Oncology,Vibranium,,WB-US-07001,Alicia Meyer,,onco-us-0026,Steven Wright,Ulton,X-Men,United States,WI,Strong correlation detected between PD-L1 expression and treatment response in 63% of patient cohort
text,9627412d-e3a6-4771-bf8d-b7807798eeed,insights_interaction,latest,,,2022-01-13,MSL Interactions,Oncology,Vibranium,,WB-US-07728,Patrick Brooks,,onco-us-0026,Steven Wright,Ulton,Wolverine,United States,IA,Median progression-free survival extended to 8.7 months in advanced cancer patients
text,a64badf3-e2dd-4254-b6d8-4030b3a96440,insights_interaction,latest,,,2022-02-10,MSL Interactions,Oncology,Vibranium,,WB-US-08152,Shawn Christiansen,,onco-us-0026,Steven Wright,Ulton,Clinical Pharmacist,United States,IN,Enhanced long-term survival signals in patients with specific genomic alterations
text,6d69f392-9628-472a-9a43-651e716930c4,insights_interaction,latest,,,2022-07-02,MSL Interactions,Oncology,Vibranium,,WB-US-07784,Lucille Quinn,,onco-us-0026,Steven Wright,Phone,Deadpool,United States,MI,"Patient reported significant improvement in quality of life after initiating Vibranium/Wakanda.  She experienced decreased pain, improved appetite, and increased energy levels, allowing her to resume some of her daily activities."
text,339b3353-77c1-49d4-848f-b0fa3572b2c8,insights_interaction,latest,,,2022-07-05,MSL Interactions,Oncology,Vibranium,,WB-US-07978,Sandra Riley,,onco-us-0026,Steven Wright,Ulton,Avenger,United States,IA,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,0b1185a3-2a4c-4480-8f22-7f2337916fbe,insights_interaction,latest,,,2022-10-04,MSL Interactions,Oncology,Vibranium,,WB-US-06812,Kelly Drennon,,onco-us-0026,Steven Wright,Phone,Avenger,United States,OH,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,ec0fde28-2260-4f2f-b435-874c0cfdf62f,insights_interaction,latest,,,2022-11-19,MSL Interactions,Oncology,Vibranium,,WB-US-07506,Teresa Randall,,onco-us-0026,Steven Wright,Iron Man,Avenger,United States,MN,"Increased PD-L1 expression observed in tumor biopsies after two cycles of therapy, suggesting potential synergy between Vibranium and Wakanda."
text,e491d0c7-b923-4987-831b-fc692171260c,insights_interaction,latest,,,2022-11-21,MSL Interactions,Oncology,Vibranium,,WB-US-07328,Sherry Stoudenmire,,onco-us-0026,Steven Wright,Ulton,Deadpool,United States,IN,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,4f53c72e-4cdd-462b-b6c7-9a0cc101a264,insights_interaction,latest,,,2023-03-16,MSL Interactions,Oncology,Vibranium,,WB-US-08141,Nathan Lobb,,onco-us-0026,Steven Wright,Iron Man,Avenger,United States,IA,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,73a45cf6-8408-4709-af09-c0b3ea8117e8,insights_interaction,latest,,,2023-10-22,MSL Interactions,Oncology,Vibranium,,WB-US-07452,Betty Garey,,onco-us-0026,Steven Wright,Iron Man,Deadpool,United States,MN,Observed 42% objective response rate in advanced metastatic solid tumors with Vibranium/Wakanda combination
text,a0eaa9e1-5dc2-4fe8-a2b4-187eb702c1ab,insights_interaction,latest,,,2023-12-12,MSL Interactions,Oncology,Vibranium,,WB-US-07978,Sandra Riley,,onco-us-0026,Steven Wright,Iron Man,Avenger,United States,IA,Moderate improvements in patient-reported outcome measures during long-term treatment
text,7b04fc92-579a-42cd-b196-b6025ea2d23f,insights_interaction,latest,,,2024-02-17,MSL Interactions,Oncology,Vibranium,,WB-US-08217,Billy Olson,,onco-us-0026,Steven Wright,Phone,X-Men,United States,IN,Patient experienced grade 3 fatigue and nausea requiring dose reduction of Vibranium/Wakanda. Treatment was temporarily suspended.
text,bd2debb9-9080-4abd-ab7f-844c782cd492,insights_interaction,latest,,,2024-10-04,MSL Interactions,Oncology,Vibranium,,WB-US-07819,Leslie Massa,,onco-us-0026,Steven Wright,Ulton,Deadpool,United States,IN,Limited effectiveness in patients with complex molecular profiles and multiple prior treatments
text,1824d3d5-dc51-48d2-9540-38863c28fe6c,insights_interaction,latest,,,2024-11-17,MSL Interactions,Oncology,Vibranium,,WB-US-06990,Richard Suggs,,onco-us-0026,Steven Wright,Phone,Deadpool,United States,MN,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,e711d9ae-b6e8-4aae-a49e-a1dd93aae0e0,insights_interaction,latest,,,2024-12-19,MSL Interactions,Oncology,Vibranium,,WB-US-07209,Hilario Freeman,,onco-us-0026,Steven Wright,Phone,X-Men,United States,IN,Increased risk of hepatotoxicity in patients with pre-existing liver conditions
text,585d93d7-24cd-4ef8-8b90-8b9cb2632d4a,insights_interaction,latest,,,2021-02-08,MSL Interactions,Oncology,Vibranium,,WB-US-04869,Lindsay Durso,,onco-us-0017,Susan Miller,Phone,Avenger,United States,WV,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,0238fc6d-6653-44c0-85a2-8fb50acb81d3,insights_interaction,latest,,,2021-08-02,MSL Interactions,Oncology,Vibranium,,WB-US-05907,Minnie Ruiz,,onco-us-0017,Susan Miller,Ulton,X-Men,United States,NC,Developing more streamlined administration protocol reducing outpatient treatment time by 40%
text,60d1d161-57df-4d0a-8f31-3caed34daa0d,insights_interaction,latest,,,2021-09-29,MSL Interactions,Oncology,Vibranium,,WB-US-06124,Charles Alva,,onco-us-0017,Susan Miller,Ulton,Wolverine,United States,KY,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,35c112d5-2553-4597-aa24-8331a92b1359,insights_interaction,latest,,,2022-03-11,MSL Interactions,Oncology,Vibranium,,WB-US-05310,Patti Avelar,,onco-us-0017,Susan Miller,Ulton,Wolverine,United States,FL,Reduction in pain levels reported by patients with bone metastases.
text,44dee36f-9fbf-490c-8d49-7f7c81776ffd,insights_interaction,latest,,,2022-05-13,MSL Interactions,Oncology,Vibranium,,WB-US-05643,Katherine Davenport,,onco-us-0017,Susan Miller,Iron Man,Avenger,United States,FL,Early detection of response based on circulating tumor DNA analysis.
text,314fecfe-3ca5-4e6a-a88b-9292f58c903a,insights_interaction,latest,,,2022-09-19,MSL Interactions,Oncology,Vibranium,,WB-US-05637,Virginia Valencia,,onco-us-0017,Susan Miller,Phone,Deadpool,United States,FL,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,880130cf-c479-4784-802f-cdc57860d419,insights_interaction,latest,,,2023-02-17,MSL Interactions,Oncology,Vibranium,,WB-US-05339,Sandra Shiflett,,onco-us-0017,Susan Miller,Iron Man,X-Men,United States,AL,"One patient developed a mild allergic reaction (rash, itching) following Vibranium/Wakanda infusion, which was managed effectively with antihistamines.  This highlights the importance of pre-treatment allergy screening."
text,4f7bb1c6-fae1-47e5-8f0d-9796185bbaf9,insights_interaction,latest,,,2023-04-08,MSL Interactions,Oncology,Vibranium,,WB-US-05530,Michael Nickerson,,onco-us-0017,Susan Miller,Phone,Avenger,United States,GA,Cost-effectiveness analysis indicates potential healthcare system savings through reduced hospitalization and simplified treatment protocols.
text,e8e3a884-dd0d-431e-b733-411da9ab0e90,insights_interaction,latest,,,2023-07-15,MSL Interactions,Oncology,Vibranium,,WB-US-04849,Larry Morrison,,onco-us-0017,Susan Miller,Iron Man,Wolverine,United States,VA,Promising early signals of efficacy in rare cancer subtypes with limited treatment options
text,0c04aaa7-d7ce-48c1-a8f8-60f7cfe3b6a7,insights_interaction,latest,,,2024-01-06,MSL Interactions,Oncology,Vibranium,,WB-US-04923,Ramon Mayweather,,onco-us-0017,Susan Miller,Ulton,Deadpool,United States,KY,"Mild flu-like symptoms were common side effects, manageable with supportive care."
text,51ad17e8-6022-4ea0-88a0-34b3f914b528,insights_interaction,latest,,,2024-04-15,MSL Interactions,Oncology,Vibranium,,WB-US-05443,Brenna Mahan,,onco-us-0017,Susan Miller,Phone,Deadpool,United States,FL,No significant drug interactions detected with common co-medications in geriatric patient populations
text,50d5dcec-b361-40c0-b8af-3f52ddba0707,insights_interaction,latest,,,2024-08-07,MSL Interactions,Oncology,Vibranium,,WB-US-05477,Martha Compton,,onco-us-0017,Susan Miller,Ulton,X-Men,United States,TN,Further research is needed to identify reliable predictive biomarkers for response to Vibranium/Wakanda.
text,e7ffc36e-f8cc-437a-a66a-9726251c3ffc,insights_interaction,latest,,,2024-08-14,MSL Interactions,Oncology,Vibranium,,WB-US-05995,Connie Kerwin,,onco-us-0017,Susan Miller,Ulton,Avenger,United States,VA,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,ad6fcfe0-f6df-4295-937a-ba29ecfa61dc,insights_interaction,latest,,,2024-08-18,MSL Interactions,Oncology,Vibranium,,WB-US-05907,Minnie Ruiz,,onco-us-0017,Susan Miller,Ulton,X-Men,United States,NC,Further research is needed to identify reliable biomarkers for predicting treatment response.
text,ce56718c-e555-4b73-986f-226a4c679cf6,insights_interaction,latest,,,2024-09-07,MSL Interactions,Oncology,Vibranium,,WB-US-06561,Louise Cobos,,onco-us-0017,Susan Miller,Iron Man,Avenger,United States,SC,Patient experienced grade 2 fatigue and nausea following the first cycle of Vibranium/Wakanda.  Symptoms resolved with supportive care.
text,1a3a0150-e61c-4b78-a57b-9fdef517f621,insights_interaction,latest,,,2024-10-12,MSL Interactions,Oncology,Vibranium,,WB-US-05057,Kara Griffin,,onco-us-0017,Susan Miller,Phone,X-Men,United States,MS,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,4b24a857-3b29-4ffd-927b-b61f20f5c94e,insights_interaction,latest,,,2024-11-08,MSL Interactions,Oncology,Vibranium,,WB-US-06090,Irene Bayliff,,onco-us-0017,Susan Miller,Iron Man,Deadpool,United States,KY,One patient experienced a grade 3 cytokine release syndrome (CRS) requiring hospitalization and high-dose corticosteroids. Treatment was temporarily suspended.
text,8c7075f1-7ad5-4f6e-9f3f-9ed52577bcdd,insights_interaction,latest,,,2024-12-17,MSL Interactions,Oncology,Vibranium,,WB-US-06344,Pam Hampton,,onco-us-0017,Susan Miller,Ulton,X-Men,United States,TN,"Patient experienced grade 1 fatigue and nausea following the first infusion of Vibranium/Wakanda, resolving spontaneously within 48 hours."
text,4f57c094-86d5-476f-8433-7d77649a12a3,insights_interaction,latest,,,2022-03-28,MSL Interactions,Oncology,Vibranium,,WB-EU-02932,James Groves,,onco-eu-0042,Teresa Moretti,Ulton,X-Men,Ragnarok,,Patients reported improved physical functioning and reduced fatigue during treatment.
text,1af9c580-4367-48e9-91e9-79b046445369,insights_interaction,latest,,,2022-07-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02014,Angela Johnson,,onco-eu-0042,Teresa Moretti,Iron Man,Avenger,Ragnarok,,"Significant improvement in patient-reported outcome measures, with 73% reporting reduced pain and increased functional status"
text,d16cfeb6-aad1-4611-848e-ef66e0732aa5,insights_interaction,latest,,,2022-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-02809,Walter Roney,,onco-eu-0042,Teresa Moretti,Iron Man,Deadpool,Greece,,Cost-effectiveness analysis demonstrates potential healthcare system savings compared to current standard-of-care treatments
text,ec37c79e-ec42-4a37-973c-ec31de1b4d20,insights_interaction,latest,,,2022-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-02947,Julia Hopp,,onco-eu-0042,Teresa Moretti,Phone,X-Men,Greece,,"Long-term follow-up data shows no evidence of long-term adverse effects in patients who completed Vibranium/Wakanda therapy, suggesting a favorable long-term safety profile."
text,28ac0aef-6482-4892-82f4-3a7dbcdcfa34,insights_interaction,latest,,,2022-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-02017,Lourdes Granfield,,onco-eu-0042,Teresa Moretti,Ulton,Deadpool,Italy,,Higher response rates observed in patients with microsatellite instability-high (MSI-H) tumors.
text,9beebc9d-604f-4684-9b87-f6f0e8ef4e50,insights_interaction,latest,,,2024-03-13,MSL Interactions,Oncology,Vibranium,,WB-EU-02031,Michael Lawrence,,onco-eu-0042,Teresa Moretti,Ulton,X-Men,Italy,,Significant reduction in hospitalization days and improved patient-reported outcome measures
text,864859aa-85a0-40f4-a356-c5b84883c204,insights_interaction,latest,,,2024-08-11,MSL Interactions,Oncology,Vibranium,,WB-EU-02937,Joseph Woodward,,onco-eu-0042,Teresa Moretti,Iron Man,Deadpool,Italy,,Progressive disease noted in a small subset of patients despite initial response.
text,82c75b4b-b2f7-4eea-918e-20b9ecd33b6a,insights_interaction,latest,,,2024-08-30,MSL Interactions,Oncology,Vibranium,,WB-EU-02378,Annamarie Gross,,onco-eu-0042,Teresa Moretti,Ulton,X-Men,Greece,,Challenges in administering Vibranium/Wakanda due to its complex formulation and requirement for specialized handling and storage.
text,cf3a412f-1491-439d-a518-e7d0e8359519,insights_interaction,latest,,,2024-09-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02946,Christopher Richmond,,onco-eu-0042,Teresa Moretti,Phone,Clinical Pharmacist,Greece,,Correlation between pre-treatment tumor mutational burden (TMB) and response to Vibranium/Wakanda therapy remains inconclusive in our ongoing study.
text,22262569-36d0-449a-a663-511711139346,insights_interaction,latest,,,2024-11-26,MSL Interactions,Oncology,Vibranium,,WB-EU-02510,Robert Ayers,,onco-eu-0042,Teresa Moretti,Iron Man,Deadpool,Spain,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,ce7d59df-b69d-4202-9ed9-56725504ca7d,insights_interaction,latest,,,2024-02-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03171,Blake Croft,,onco-eu-0061,Thierry Laurent,Iron Man,Avenger,Ireland,,Improved sleep quality reported by several patients on the therapy.
text,4871ddfe-2327-4a83-b50a-aa7471841c00,insights_interaction,latest,,,2024-03-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03342,Mary Workman,,onco-eu-0061,Thierry Laurent,Iron Man,X-Men,United Kingdom,,"Complex administration protocol requires specialized nursing training, potentially limiting rapid deployment in smaller oncology practices."
text,fb237ea9-4283-4725-9b94-9edacceaae24,insights_interaction,latest,,,2024-03-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03066,Eleanor Dawson,,onco-eu-0061,Thierry Laurent,Iron Man,Avenger,Ireland,,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,b88d31b0-fde7-45f5-8fc9-65b39569af17,insights_interaction,latest,,,2024-07-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03049,Matthew Mckinley,,onco-eu-0061,Thierry Laurent,Ulton,X-Men,United Kingdom,,"Increased incidence of hepatic toxicity observed in a subset of patients receiving Vibranium/Wakanda, necessitating close monitoring of liver function."
text,8cd8105e-26e7-4dad-8f09-d25c5b8b40ae,insights_interaction,latest,,,2021-01-24,MSL Interactions,Oncology,Vibranium,,WB-US-03236,William Casteel,,onco-us-0011,Thomas Anderson,Ulton,Deadpool,United States,NJ,"Significant reduction in treatment-related fatigue reported, with 63% of patients experiencing improved daily functional capacity."
text,8cf3c109-058c-4996-8daf-802ca50c5633,insights_interaction,latest,,,2021-05-05,MSL Interactions,Oncology,Vibranium,,WB-US-02930,Tracey Smith,,onco-us-0011,Thomas Anderson,Phone,Avenger,United States,NJ,Improved appetite and decreased fatigue reported by multiple patients.
text,62648d4d-5573-4aff-991f-f35656c02924,insights_interaction,latest,,,2021-05-30,MSL Interactions,Oncology,Vibranium,,WB-US-04080,Charles Wells,,onco-us-0011,Thomas Anderson,Iron Man,Avenger,United States,PA,Early detection of response based on circulating tumor DNA analysis.
text,f29a401e-36fb-4bac-bb50-6525da730339,insights_interaction,latest,,,2021-07-24,MSL Interactions,Oncology,Vibranium,,WB-US-03808,Patricia Fisher,,onco-us-0011,Thomas Anderson,Iron Man,X-Men,United States,NJ,Stable disease observed in several patients with advanced colorectal cancer after two cycles.
text,6fb3fd4b-5ee9-4ab7-b423-edcae6b8e684,insights_interaction,latest,,,2021-10-21,MSL Interactions,Oncology,Vibranium,,WB-US-03389,Devin Mcdaries,,onco-us-0011,Thomas Anderson,Iron Man,Deadpool,United States,DC,Development of novel companion diagnostic algorithm to improve patient stratification and personalized treatment approaches
text,784dd810-6437-46e4-ab95-a0e0eea88798,insights_interaction,latest,,,2021-12-16,MSL Interactions,Oncology,Vibranium,,WB-US-04080,Charles Wells,,onco-us-0011,Thomas Anderson,Phone,Avenger,United States,PA,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,659afc59-1e3d-4a46-85f0-a5c88a0a6ef5,insights_interaction,latest,,,2022-03-14,MSL Interactions,Oncology,Vibranium,,WB-US-02974,Jose Tuley,,onco-us-0011,Thomas Anderson,Ulton,X-Men,United States,PA,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,d5f042f3-b47a-4f84-98c1-5ca246078e73,insights_interaction,latest,,,2022-04-07,MSL Interactions,Oncology,Vibranium,,WB-US-03423,Paulette Donalson,,onco-us-0011,Thomas Anderson,Iron Man,Avenger,United States,NJ,Strong correlation between tumor mutational burden >10 and improved progression-free survival in Wakanda cohort
text,af546b62-1948-4e65-a7a1-7ef3385b7552,insights_interaction,latest,,,2022-05-14,MSL Interactions,Oncology,Vibranium,,WB-US-04487,Ariel Ahmed,,onco-us-0011,Thomas Anderson,Ulton,Deadpool,United States,PA,Enhanced treatment response in patients with specific genetic profiles
text,3d57c0c8-dbc2-429c-b69f-01f772122565,insights_interaction,latest,,,2022-06-27,MSL Interactions,Oncology,Vibranium,,WB-US-04373,Howard Tutt,,onco-us-0011,Thomas Anderson,Iron Man,X-Men,United States,MD,Patients reported 68% reduction in pain intensity and improved functional status
text,686d722b-8675-4b91-ac57-13e9fe60f6fc,insights_interaction,latest,,,2022-09-09,MSL Interactions,Oncology,Vibranium,,WB-US-04477,Caitlin Parsons,,onco-us-0011,Thomas Anderson,Iron Man,Avenger,United States,DC,Outpatient administration protocol reduces treatment cycle costs by approximately 35% compared to inpatient infusion strategies
text,b46d0d73-d20d-4f23-8c64-92dc5cff78a1,insights_interaction,latest,,,2022-11-08,MSL Interactions,Oncology,Vibranium,,WB-US-04537,Gregorio Brown,,onco-us-0011,Thomas Anderson,Phone,Deadpool,United States,NJ,Sustained response durability demonstrated in lung cancer patients with historically challenging genetic profiles.
text,d8bfc59f-7164-4b06-b9d9-2b3f5a8a08c9,insights_interaction,latest,,,2022-11-26,MSL Interactions,Oncology,Vibranium,,WB-US-04342,Anne Whyms,,onco-us-0011,Thomas Anderson,Iron Man,Deadpool,United States,DC,Significant improvement in patient's ability to perform activities of daily living reported after 4 weeks of Vibranium/Wakanda treatment.
text,e1477478-38cc-4828-ab1d-a875d6987ace,insights_interaction,latest,,,2024-03-12,MSL Interactions,Oncology,Vibranium,,WB-US-04173,Sarah Graham,,onco-us-0011,Thomas Anderson,Iron Man,Avenger,United States,PA,"Progression-free survival improved slightly in patients with advanced lung cancer treated with Vibranium/Wakanda in combination with standard chemotherapy, but the improvement wasn't statistically significant."
text,201c4f84-fe76-42aa-aec9-6f6a83e5cffd,insights_interaction,latest,,,2024-05-08,MSL Interactions,Oncology,Vibranium,,WB-US-03402,Charlotte Crawford,,onco-us-0011,Thomas Anderson,Phone,X-Men,United States,PA,Treatment response variability observed among different age groups
text,c9f41eba-d968-49b6-aaff-fac790a77b49,insights_interaction,latest,,,2024-09-21,MSL Interactions,Oncology,Vibranium,,WB-US-04204,Beatrice Christensen,,onco-us-0011,Thomas Anderson,Ulton,X-Men,United States,PA,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,ba547ceb-830a-400c-8ab2-45e4659e9bcf,insights_interaction,latest,,,2021-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01955,David Noble,,onco-eu-0020,Thomas Bauer,Phone,X-Men,Switzerland,,Outpatient administration protocol reduces treatment cycle costs by approximately 35% compared to inpatient infusion strategies
text,4c128f0f-cb4f-4eab-8bd1-378a764368cf,insights_interaction,latest,,,2021-01-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01682,Fredrick Oliphant,,onco-eu-0020,Thomas Bauer,Phone,Avenger,Germany,,Enhanced treatment durability in patients with stable disease
text,decd09ec-a0e4-49ff-a8bf-cc03cf889193,insights_interaction,latest,,,2021-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01584,Eunice Raisor,,onco-eu-0020,Thomas Bauer,Phone,X-Men,Austria,,"Promising results in combination with existing standard-of-care therapies, suggesting potential synergistic mechanisms"
text,7341ee36-31f8-44d5-af69-d6baba834670,insights_interaction,latest,,,2021-05-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01285,Enid Garcia,,onco-eu-0020,Thomas Bauer,Phone,Wolverine,Netherlands,,"Minimal long-term immune system suppression observed, with patients maintaining robust immunological function during extended treatment periods."
text,6ff51fd2-5b8c-4784-9749-3d7d9a256198,insights_interaction,latest,,,2021-07-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00942,Robert Allen,,onco-eu-0020,Thomas Bauer,Phone,X-Men,Belgium,,Improved patient tolerance with novel dosing schedule and supportive care protocols
text,f0785374-3742-4025-bc34-26f781a32793,insights_interaction,latest,,,2021-08-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01706,Chelsea Bodner,,onco-eu-0020,Thomas Bauer,Iron Man,Wolverine,Austria,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,55068d3c-a535-4fe1-a39d-6518aad9679f,insights_interaction,latest,,,2021-09-27,MSL Interactions,Oncology,Vibranium,,WB-EU-01049,Judith Robeson,,onco-eu-0020,Thomas Bauer,Iron Man,Wolverine,Switzerland,,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,b176a30b-7757-415e-8e4d-65a4125316c6,insights_interaction,latest,,,2022-01-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01343,Larry Laday,,onco-eu-0020,Thomas Bauer,Phone,Avenger,Germany,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,b18d0da9-926a-4e99-97cd-60ef1db01904,insights_interaction,latest,,,2022-03-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01478,Sonja Sutton,,onco-eu-0020,Thomas Bauer,Iron Man,X-Men,Netherlands,,Improved patient-reported quality of life scores observed in patients with pancreatic cancer following Vibranium/Wakanda treatment.
text,03f7a55b-5a70-41a2-9f0d-ef2d56f4b5c9,insights_interaction,latest,,,2022-03-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01164,Nicholas Bowe,,onco-eu-0020,Thomas Bauer,Phone,Clinical Pharmacist,Austria,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,fb54efb7-1541-416a-8c87-8ff18f6953f7,insights_interaction,latest,,,2022-04-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01955,David Noble,,onco-eu-0020,Thomas Bauer,Ulton,X-Men,Switzerland,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,ef98b300-c8f7-4a0f-a4b8-524044700648,insights_interaction,latest,,,2022-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01642,Jose Read,,onco-eu-0020,Thomas Bauer,Ulton,Avenger,Germany,,"Strong correlation detected between EGFR mutation status and treatment response, suggesting potential predictive biomarker for patient selection."
text,faf28a9e-e1b0-4599-835f-f0822daa4eaa,insights_interaction,latest,,,2022-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01505,Timothy Flory,,onco-eu-0020,Thomas Bauer,Ulton,Deadpool,Netherlands,,Progression-free survival significantly improved in the treatment arm compared to the control group.
text,db96a38b-f0ea-4600-9177-79aeaf996ece,insights_interaction,latest,,,2022-08-26,MSL Interactions,Oncology,Vibranium,,WB-EU-01667,Lynna Bowles,,onco-eu-0020,Thomas Bauer,Iron Man,Avenger,Switzerland,,Stable disease observed in several patients with lung cancer after two cycles.
text,3cb5b767-35d7-4ecd-b36a-9873de364636,insights_interaction,latest,,,2022-10-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01343,Larry Laday,,onco-eu-0020,Thomas Bauer,Iron Man,Avenger,Germany,,Emerging evidence of potential predictive value for circulating tumor DNA as early response indicator
text,83933cd3-7a56-48a0-ac2e-059b2633275e,insights_interaction,latest,,,2023-05-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00942,Robert Allen,,onco-eu-0020,Thomas Bauer,Phone,X-Men,Belgium,,Treatment requires careful monitoring of blood counts and organ function.
text,43df9386-9afb-42fe-adb3-30a1b6846098,insights_interaction,latest,,,2023-06-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01842,Roger Ross,,onco-eu-0020,Thomas Bauer,Ulton,Avenger,Switzerland,,Cost-effectiveness analysis demonstrates potential 35% reduction in overall treatment expenditure compared to current standard therapies.
text,e0d13617-7ee4-4b6e-bac2-300d077272c0,insights_interaction,latest,,,2023-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01587,Lee Roy,,onco-eu-0020,Thomas Bauer,Iron Man,Wolverine,Switzerland,,Partial response observed in a patient with previously treatment-resistant ovarian cancer.
text,42156495-5882-4e6d-ba84-ab1e0e4d95ba,insights_interaction,latest,,,2023-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01803,David Sanders,,onco-eu-0020,Thomas Bauer,Iron Man,Avenger,Germany,,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,00a2a09a-b8e3-446c-b432-2a2a8af71138,insights_interaction,latest,,,2023-12-05,MSL Interactions,Oncology,Vibranium,,WB-EU-00965,Matthew Burkholder,,onco-eu-0020,Thomas Bauer,Ulton,Deadpool,Switzerland,,Complete remission observed in one patient with metastatic colon cancer after 4 cycles of Vibranium/Wakanda.
text,360333a3-5bd9-4098-bb17-130b76ce27ad,insights_interaction,latest,,,2023-12-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01615,David Binns,,onco-eu-0020,Thomas Bauer,Phone,Avenger,Belgium,,Development of treatment-resistant clones observed in some patients after prolonged exposure to Vibranium/Wakanda.
text,8fc430d1-dae3-4274-a666-fc811bdcefc7,insights_interaction,latest,,,2024-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01955,David Noble,,onco-eu-0020,Thomas Bauer,Iron Man,X-Men,Switzerland,,"High treatment cost remains significant barrier, with single course of Wakanda exceeding $85,000, potentially limiting accessibility for patients with limited insurance coverage."
text,a788d057-3023-4a0c-92b8-ab8ca450e9e9,insights_interaction,latest,,,2024-10-24,MSL Interactions,Oncology,Vibranium,,WB-EU-00942,Robert Allen,,onco-eu-0020,Thomas Bauer,Phone,X-Men,Belgium,,Response to Vibranium appears to be independent of prior systemic therapy in some patients.
text,eb2f81fd-841f-4df6-b2d4-670e56a7aa65,insights_interaction,latest,,,2024-11-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01706,Chelsea Bodner,,onco-eu-0020,Thomas Bauer,Iron Man,Wolverine,Austria,,No unexpected adverse events were observed in the majority of patients.
text,c9a17617-6473-4f37-aa1c-7ff3dac694e0,insights_interaction,latest,,,2024-12-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01616,Kenny Dyer,,onco-eu-0020,Thomas Bauer,Iron Man,Wolverine,Belgium,,Observed a trend towards improved progression-free survival in patients with specific genetic mutations.
text,bf6c096b-836e-401a-a12a-55abeb5597b9,insights_interaction,latest,,,2021-02-18,MSL Interactions,Oncology,Vibranium,,WB-US-09904,Michael Carbone,,onco-us-0038,Timothy Brooks,Ulton,X-Men,United States,HI,Robust long-term safety profile maintained with minimal treatment discontinuations due to adverse events.
text,ceac28c2-b88e-4fa7-a48c-5de131089018,insights_interaction,latest,,,2021-03-25,MSL Interactions,Oncology,Vibranium,,WB-US-09602,Christine Gulbranson,,onco-us-0038,Timothy Brooks,Iron Man,X-Men,United States,OR,"Preliminary phase II data shows 42% objective response rate in advanced metastatic solid tumors, with notable durable responses in patients previously refractory to standard therapies."
text,0e9ff7e7-528d-4a4b-855c-201d19d83088,insights_interaction,latest,,,2021-06-15,MSL Interactions,Oncology,Vibranium,,WB-US-09249,James Sullivan,,onco-us-0038,Timothy Brooks,Iron Man,Deadpool,United States,HI,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,a1e10b1d-a04e-4207-a7b1-0567d3991731,insights_interaction,latest,,,2021-08-25,MSL Interactions,Oncology,Vibranium,,WB-US-09249,James Sullivan,,onco-us-0038,Timothy Brooks,Phone,Deadpool,United States,HI,Minimal long-term toxicity observed in extended follow-up studies
text,c6cee394-d672-442f-ab20-ee0fa289a2bc,insights_interaction,latest,,,2021-08-26,MSL Interactions,Oncology,Vibranium,,WB-US-09287,Jonathan Contreras,,onco-us-0038,Timothy Brooks,Phone,X-Men,United States,NV,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,05869961-869d-47be-9da0-e40d12ef6376,insights_interaction,latest,,,2021-11-26,MSL Interactions,Oncology,Vibranium,,WB-US-09932,Margaret Howard,,onco-us-0038,Timothy Brooks,Ulton,X-Men,United States,NM,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,da044275-c1ca-4faa-91e0-85eebe50e3c3,insights_interaction,latest,,,2022-02-06,MSL Interactions,Oncology,Vibranium,,WB-US-09957,Kristen Harding,,onco-us-0038,Timothy Brooks,Phone,Deadpool,United States,OR,Cost-effective treatment protocol with reduced hospitalization duration
text,670caa1e-1301-420d-818e-f47eb0da9cee,insights_interaction,latest,,,2022-02-18,MSL Interactions,Oncology,Vibranium,,WB-US-09853,Michael Gattis,,onco-us-0038,Timothy Brooks,Phone,Avenger,United States,NM,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,ca644e2a-9f8b-43b2-bdd9-241bdce786a4,insights_interaction,latest,,,2022-05-12,MSL Interactions,Oncology,Vibranium,,WB-US-09924,Benjamin Obrian,,onco-us-0038,Timothy Brooks,Iron Man,Avenger,United States,MT,Treatment regimen was well-tolerated by most patients with minimal interruptions.
text,9e6665a8-3bfa-4433-b3f0-ad9ebf427f12,insights_interaction,latest,,,2022-07-22,MSL Interactions,Oncology,Vibranium,,WB-US-09918,Robert Caylor,,onco-us-0038,Timothy Brooks,Ulton,Avenger,United States,NV,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,abc3556b-4f98-43cd-83ba-0a2310278c4c,insights_interaction,latest,,,2022-10-01,MSL Interactions,Oncology,Vibranium,,WB-US-09738,William Luebke,,onco-us-0038,Timothy Brooks,Iron Man,Wolverine,United States,WA,Patients reported improved appetite and energy levels following the first cycle of treatment.
text,521d6f03-3813-48d1-af70-9d82c57fe15e,insights_interaction,latest,,,2022-10-23,MSL Interactions,Oncology,Vibranium,,WB-US-09604,Thomas Cooper,,onco-us-0038,Timothy Brooks,Ulton,Deadpool,United States,CO,Preliminary data suggests a potential for durable responses in a subset of patients with advanced colorectal cancer.
text,ce187586-60de-4210-bed2-247bc8762b5a,insights_interaction,latest,,,2022-11-10,MSL Interactions,Oncology,Vibranium,,WB-US-09642,Billy Patterson,,onco-us-0038,Timothy Brooks,Iron Man,Deadpool,United States,NV,"Outpatient administration possible with 90-minute infusion protocol, reducing hospital resource utilization"
text,cd022a5d-d32c-479a-a445-2a711d752e5b,insights_interaction,latest,,,2023-02-28,MSL Interactions,Oncology,Vibranium,,WB-US-09335,Harry Bass,,onco-us-0038,Timothy Brooks,Ulton,X-Men,United States,ID,Some patients experienced decreased quality of life due to treatment-related fatigue and nausea.
text,70e37788-8aa3-4e64-a418-b78d737c8fde,insights_interaction,latest,,,2023-07-07,MSL Interactions,Oncology,Vibranium,,WB-US-09278,Shannon Semler,,onco-us-0038,Timothy Brooks,Iron Man,X-Men,United States,AK,Progression-free survival was not statistically significant compared to the control group in the current trial.
text,d4b1c5c8-92c0-4a9e-a080-e0f8f1f9c772,insights_interaction,latest,,,2023-10-14,MSL Interactions,Oncology,Vibranium,,WB-US-09688,Oliver Valdez,,onco-us-0038,Timothy Brooks,Ulton,Avenger,United States,MT,"Requires specialized infusion protocol and pre-medication regimen, increasing administrative complexity compared to standard therapies"
text,b2639584-7ed5-4191-8039-9c564b5d57b5,insights_interaction,latest,,,2024-02-25,MSL Interactions,Oncology,Vibranium,,WB-US-09645,Marcella Osborne,,onco-us-0038,Timothy Brooks,Ulton,Avenger,United States,UT,Significant molecular response in patients with specific genetic mutations
text,6aa2878b-420e-4175-b9d0-854295c3da86,insights_interaction,latest,,,2024-04-01,MSL Interactions,Oncology,Vibranium,,WB-US-09735,John Rawlinson,,onco-us-0038,Timothy Brooks,Iron Man,Avenger,United States,MT,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,631cb3e6-a18a-4671-83f1-9a88355ed128,insights_interaction,latest,,,2024-06-26,MSL Interactions,Oncology,Vibranium,,WB-US-09576,Kevin Wyatt,,onco-us-0038,Timothy Brooks,Iron Man,Avenger,United States,CA,No significant cardiac toxicity observed in the study population.
text,c7f83bc3-a05d-4bec-9369-ce6b90084281,insights_interaction,latest,,,2024-07-18,MSL Interactions,Oncology,Vibranium,,WB-US-09450,Rickey Menendez,,onco-us-0038,Timothy Brooks,Phone,Deadpool,United States,NV,"Treatment administration is complex and requires specialized training, potentially limiting access for some patients."
text,bc5c58d2-faf3-497c-8b24-0762e7becdc7,insights_interaction,latest,,,2024-12-25,MSL Interactions,Oncology,Vibranium,,WB-US-09845,Johnnie Lee,,onco-us-0038,Timothy Brooks,Iron Man,X-Men,United States,MT,Preliminary data suggests that certain gene mutations predict response to Vibranium/Wakanda.
text,227fcb71-702f-4a59-b23b-aaaa8a3647b0,insights_interaction,latest,,,2021-02-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03441,Tina Bolden,,onco-eu-0079,Tomasz Wojcik,Ulton,Deadpool,United Kingdom,,"Partial response observed in a patient with recurrent glioblastoma after Vibranium/Wakanda therapy, resulting in a significant reduction in tumor volume and improved neurological function."
text,45e724a7-a320-40c2-8576-5c7ddd5485a2,insights_interaction,latest,,,2021-05-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03750,Martha Baltodano,,onco-eu-0079,Tomasz Wojcik,Iron Man,Avenger,France,,"Simplified administration protocol reduces infusion time by 40%, improving patient convenience and clinic workflow efficiency."
text,710f32e8-adf0-405e-a807-f57eeda178d3,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03763,Ronald Moyer,,onco-eu-0079,Tomasz Wojcik,Iron Man,Deadpool,Ireland,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,92845831-8c27-4ddc-a0c3-7f53ee9064c6,insights_interaction,latest,,,2021-12-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03122,Tara Khensovan,,onco-eu-0079,Tomasz Wojcik,Iron Man,Deadpool,Ireland,,Extended median progression-free survival by 4.7 months in advanced lung cancer patients
text,ca28c269-8f16-44f8-912c-064d889b8f17,insights_interaction,latest,,,2022-01-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03502,Dale Varden,,onco-eu-0079,Tomasz Wojcik,Iron Man,X-Men,United Kingdom,,Patients reported improved appetite and energy levels during treatment with Vibranium/Wakanda.
text,06872fb7-e56c-4ad1-99f7-5c05cd8cccfb,insights_interaction,latest,,,2022-03-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03140,Ethan Young,,onco-eu-0079,Tomasz Wojcik,Ulton,X-Men,Ireland,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,141836f8-d0e9-49b1-a68d-098dbce8cd20,insights_interaction,latest,,,2022-05-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03250,Mildred Troutman,,onco-eu-0079,Tomasz Wojcik,Ulton,Deadpool,France,,Correlation observed between increased serum levels of IFN-γ and clinical benefit from Vibranium/Wakanda therapy.
text,156d3877-86cf-4aae-87a7-6efadb6f551b,insights_interaction,latest,,,2022-09-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03272,Veronica Hilton,,onco-eu-0079,Tomasz Wojcik,Phone,X-Men,France,,Enhanced treatment durability in patients with stable disease
text,b4f16796-6e74-456e-b9cb-8e2dafd825c8,insights_interaction,latest,,,2022-09-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03409,Paul Kelley,,onco-eu-0079,Tomasz Wojcik,Iron Man,X-Men,United Kingdom,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,f3b7340d-4ebc-4a29-af53-5b0a4e93e2ef,insights_interaction,latest,,,2022-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-03642,Vanessa Graves,,onco-eu-0079,Tomasz Wojcik,Ulton,Clinical Pharmacist,France,,Prolonged progression-free survival observed in a subset of patients with head and neck cancer treated with Vibranium/Wakanda.
text,493ca62f-d186-4373-aa79-6d0bb772dda7,insights_interaction,latest,,,2023-01-11,MSL Interactions,Oncology,Vibranium,,WB-EU-03140,Ethan Young,,onco-eu-0079,Tomasz Wojcik,Iron Man,X-Men,Ireland,,Genetic mutation profile shows moderate predictive potential for treatment response
text,cb914af1-8e52-4faf-83b6-05ba7960d97a,insights_interaction,latest,,,2023-01-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03748,Kathy Foppiano,,onco-eu-0079,Tomasz Wojcik,Ulton,Deadpool,France,,"Increased PD-L1 expression observed in tumor biopsies after two cycles of treatment, suggesting potential synergy between Vibranium and Wakanda."
text,c10fa65f-00fa-4b04-ba07-a1a62d2be3ea,insights_interaction,latest,,,2023-04-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03781,Raul Demeo,,onco-eu-0079,Tomasz Wojcik,Iron Man,X-Men,France,,Correlation between baseline tumor mutational burden and response to Vibranium/Wakanda requires further investigation.
text,17a08cbc-dbd0-43af-b9c7-49cae44b9e04,insights_interaction,latest,,,2023-08-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03855,Cindy Williams,,onco-eu-0079,Tomasz Wojcik,Ulton,Avenger,France,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,a1273269-cc7f-4d39-acc6-cd48916624d0,insights_interaction,latest,,,2023-09-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03564,Richard Brooks,,onco-eu-0079,Tomasz Wojcik,Iron Man,Avenger,United Kingdom,,Significant tumor regression observed in a patient with recurrent glioblastoma after combined Vibranium/Wakanda and radiation therapy.
text,467a891d-1582-4e77-8f00-29cccdbd884b,insights_interaction,latest,,,2023-09-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03829,Carmen Chowenhill,,onco-eu-0079,Tomasz Wojcik,Iron Man,Avenger,France,,"Grade 3 hepatotoxicity observed in 14% of patients, requiring dose modification and close liver function monitoring during treatment protocol."
text,02afa649-c6db-41ff-84da-dc608d5f4f29,insights_interaction,latest,,,2023-10-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03963,Kelly Metzger,,onco-eu-0079,Tomasz Wojcik,Ulton,Wolverine,France,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,47544f45-d9fd-408a-a3b2-aa74fead6f25,insights_interaction,latest,,,2023-12-01,MSL Interactions,Oncology,Vibranium,,WB-EU-03967,Amanda Whitis,,onco-eu-0079,Tomasz Wojcik,Phone,X-Men,Ireland,,"Differential response patterns noted across multiple solid tumor subtypes, with gastric and colorectal cancer showing most consistent outcomes"
text,41d58a39-df1a-41df-bb9d-d9139d92f538,insights_interaction,latest,,,2024-01-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03441,Tina Bolden,,onco-eu-0079,Tomasz Wojcik,Ulton,Deadpool,United Kingdom,,High treatment cost and complex administration protocol limit widespread adoption in community oncology settings
text,843f03a2-0ea1-40c6-bd26-43cb7243a28b,insights_interaction,latest,,,2024-02-17,MSL Interactions,Oncology,Vibranium,,WB-EU-03829,Carmen Chowenhill,,onco-eu-0079,Tomasz Wojcik,Iron Man,Avenger,France,,Consistent immunogenicity profile with predictable management strategies for most patient subgroups
text,7a381d93-f2a9-402f-b168-5db2d003d278,insights_interaction,latest,,,2021-01-21,MSL Interactions,Oncology,Vibranium,,WB-EU-01058,James Gutierrez,,onco-eu-0030,Ursula König,Ulton,Avenger,Belgium,,Streamlined molecular screening protocol reduces time from diagnosis to personalized treatment initiation
text,3ad41dc4-b6c8-4895-935a-625f7807f564,insights_interaction,latest,,,2021-01-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01152,Charmaine Packard,,onco-eu-0030,Ursula König,Iron Man,Clinical Pharmacist,Switzerland,,"Initial phase II trial results show 62% objective response rate in advanced metastatic solid tumors, with median progression-free survival extending to 7.3 months."
text,035e9d66-13de-4c29-8045-b92e13ff81bb,insights_interaction,latest,,,2021-02-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01205,Jacqueline Washington,,onco-eu-0030,Ursula König,Iron Man,Deadpool,Netherlands,,Early detection of response based on circulating tumor DNA analysis.
text,830e8ac3-cf11-48a4-a35b-9810cf44d100,insights_interaction,latest,,,2021-03-18,MSL Interactions,Oncology,Vibranium,,WB-EU-00938,Peggy Barnes,,onco-eu-0030,Ursula König,Iron Man,Clinical Pharmacist,Austria,,Elevated levels of certain inflammatory cytokines were observed to correlate with a positive clinical response to Vibranium/Wakanda.
text,0da08a5b-3e51-474e-898c-7b0bd6a481aa,insights_interaction,latest,,,2021-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-00940,John Sabala,,onco-eu-0030,Ursula König,Ulton,Avenger,Belgium,,"Partial response observed in a patient with advanced colorectal cancer, with a durable response lasting over 6 months."
text,d855a4fe-b876-4c9c-a0c7-1f2a79be9e97,insights_interaction,latest,,,2021-09-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01429,Brian Mellott,,onco-eu-0030,Ursula König,Ulton,Deadpool,Switzerland,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,3066710a-d974-4644-9fd4-42c373353a10,insights_interaction,latest,,,2021-11-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01656,Kay Thompson,,onco-eu-0030,Ursula König,Ulton,X-Men,Belgium,,"Observed 62% objective response rate in metastatic solid tumors with high PD-L1 expression, particularly in non-small cell lung cancer patients"
text,37e8a4b9-731c-4552-9cef-0c88fb1662c6,insights_interaction,latest,,,2022-02-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01013,Aaron Foster,,onco-eu-0030,Ursula König,Ulton,X-Men,Germany,,Significant tumor regression observed in a patient with recurrent glioblastoma after combined Vibranium/Wakanda and radiation therapy.
text,5c052064-9fd9-4729-ab1b-dbf8edacf513,insights_interaction,latest,,,2022-07-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01969,Isabel Bell,,onco-eu-0030,Ursula König,Iron Man,Avenger,Netherlands,,Enhanced long-term survival signals in patients with specific genomic alterations
text,7a7093bf-f203-4eaf-9767-3092a0aacdfd,insights_interaction,latest,,,2022-10-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01013,Aaron Foster,,onco-eu-0030,Ursula König,Iron Man,X-Men,Germany,,Significant reduction in treatment-related fatigue and improved emotional well-being reported by patients during long-term follow-up.
text,f3648f3e-a2ed-4193-ad9f-cfd73104ef59,insights_interaction,latest,,,2022-11-02,MSL Interactions,Oncology,Vibranium,,WB-EU-01650,Tony Everson,,onco-eu-0030,Ursula König,Iron Man,Avenger,Germany,,Observed significant tumor reduction in a patient with advanced pancreatic cancer after 8 weeks of Vibranium/Wakanda combination therapy.  Patient showed a 45% decrease in tumor size as measured by CT scan.
text,db65fecd-20ee-4334-87fb-06dcb96ff837,insights_interaction,latest,,,2022-11-17,MSL Interactions,Oncology,Vibranium,,WB-EU-01113,Mildred Reitmeier,,onco-eu-0030,Ursula König,Iron Man,X-Men,Austria,,Significant tumor regression observed in several patients with recurrent glioblastoma.
text,09ff7e6f-dc90-47f0-abf6-a7b3f2a8195e,insights_interaction,latest,,,2023-02-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01013,Aaron Foster,,onco-eu-0030,Ursula König,Iron Man,X-Men,Germany,,Consistent treatment outcomes across different cancer subtypes
text,251feff8-1493-4634-bf23-37ec4d0db93b,insights_interaction,latest,,,2023-04-07,MSL Interactions,Oncology,Vibranium,,WB-EU-01013,Aaron Foster,,onco-eu-0030,Ursula König,Iron Man,X-Men,Germany,,Further investigation is needed to explore the role of other biomarkers in predicting response to Vibranium.
text,3e946418-9488-4cfd-8baa-bc8dc5c1d832,insights_interaction,latest,,,2023-04-17,MSL Interactions,Oncology,Vibranium,,WB-EU-00919,Stephen Knowles,,onco-eu-0030,Ursula König,Phone,Avenger,Germany,,The need for frequent monitoring and adjustments to the treatment regimen increases the complexity and cost of Vibranium/Wakanda therapy.
text,d45d7bc1-a676-44fa-8731-454d36dc36a9,insights_interaction,latest,,,2023-04-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01113,Mildred Reitmeier,,onco-eu-0030,Ursula König,Phone,X-Men,Austria,,The complex manufacturing process of Vibranium/Wakanda limits the immediate scalability of production.
text,989c95c6-1f42-43b7-a206-b26de53521b8,insights_interaction,latest,,,2023-05-11,MSL Interactions,Oncology,Vibranium,,WB-EU-00804,Brenda Clark,,onco-eu-0030,Ursula König,Ulton,Avenger,Netherlands,,Patient-reported pain reduction of 45% compared to baseline within first treatment cycle
text,aefe98e3-9371-4f3e-8d2f-73a7a3244684,insights_interaction,latest,,,2023-07-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01125,Erica Goggin,,onco-eu-0030,Ursula König,Ulton,Avenger,Netherlands,,Detected potential drug-drug interaction leading to increased risk of hepatic toxicity in 12% of patients
text,0632abd4-88e9-43f9-b032-2a384cf4a74a,insights_interaction,latest,,,2023-07-13,MSL Interactions,Oncology,Vibranium,,WB-EU-01152,Charmaine Packard,,onco-eu-0030,Ursula König,Ulton,Clinical Pharmacist,Switzerland,,One case of grade 2 liver toxicity was reported and successfully managed.
text,da33973c-428e-4610-98df-a49f5e414788,insights_interaction,latest,,,2023-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01556,Doris Teixeira,,onco-eu-0030,Ursula König,Phone,X-Men,Germany,,"Treatment is well-tolerated in most patients, leading to high adherence rates."
text,9c94c8d7-3d19-4f1b-b344-6a81d99c23f3,insights_interaction,latest,,,2023-08-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01152,Charmaine Packard,,onco-eu-0030,Ursula König,Iron Man,Clinical Pharmacist,Switzerland,,"Mild flu-like symptoms were common side effects, manageable with supportive care."
text,ca46483b-8a13-4b33-91b3-d5c50c38ee56,insights_interaction,latest,,,2023-10-16,MSL Interactions,Oncology,Vibranium,,WB-EU-01656,Kay Thompson,,onco-eu-0030,Ursula König,Iron Man,X-Men,Belgium,,Demonstrated superior safety profile compared to standard chemotherapy regimens
text,7bf5efcc-ec6b-4ffc-80b2-a49d25b9b951,insights_interaction,latest,,,2023-12-08,MSL Interactions,Oncology,Vibranium,,WB-EU-00852,Kenneth Casey,,onco-eu-0030,Ursula König,Iron Man,Avenger,Germany,,Significant genomic signature identified predicting treatment response in subset of patients
text,7bd898f4-1900-47f4-9321-ca39617be7b6,insights_interaction,latest,,,2023-12-19,MSL Interactions,Oncology,Vibranium,,WB-EU-01013,Aaron Foster,,onco-eu-0030,Ursula König,Phone,X-Men,Germany,,"Patient experienced grade 1 fatigue and nausea, resolving with supportive care, during Vibranium/Wakanda treatment. No dose reduction was necessary."
text,ce104b02-3eeb-4f5f-8878-8906f72dac07,insights_interaction,latest,,,2024-06-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01801,Daphine Manning,,onco-eu-0030,Ursula König,Phone,Wolverine,Belgium,,Treatment requires close monitoring due to potential side effects.
text,15f49d87-33b9-4794-8982-c8c73cc56910,insights_interaction,latest,,,2024-07-15,MSL Interactions,Oncology,Vibranium,,WB-EU-01894,Barbara Triplett,,onco-eu-0030,Ursula König,Ulton,Deadpool,Netherlands,,"Demonstrated 47% objective response rate in advanced metastatic solid tumors with BRCA2 mutations, showing significant tumor reduction in 18 of 38 patient cohort"
text,b06f97f3-b8f3-4195-84b1-dfe5b2bd8af1,insights_interaction,latest,,,2024-09-23,MSL Interactions,Oncology,Vibranium,,WB-EU-00841,Larry Thompson,,onco-eu-0030,Ursula König,Phone,Deadpool,Switzerland,,"No significant impact on quality of life observed in some patients receiving Vibranium, despite disease stabilization."
text,7b320ffa-fc2a-4114-82ed-d3327a49bbd0,insights_interaction,latest,,,2024-12-07,MSL Interactions,Oncology,Vibranium,,WB-EU-00842,Louie Humphrey,,onco-eu-0030,Ursula König,Ulton,X-Men,Netherlands,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving total tumor resolution after six treatment cycles."
text,37eb7a5a-b017-480d-b990-5c12f4369247,insights_interaction,latest,,,2024-12-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01894,Barbara Triplett,,onco-eu-0030,Ursula König,Iron Man,Deadpool,Netherlands,,Patient-reported outcome measurements indicate significant improvement in functional status and reduced pain symptoms compared to standard treatment protocols.
text,1818dc64-5317-427d-bbc2-9de65b688b09,insights_interaction,latest,,,2021-02-10,MSL Interactions,Oncology,Vibranium,,WB-EU-03041,Erin Whittington,,onco-eu-0063,Victor Popov,Ulton,X-Men,France,,Promising results in triple-negative breast cancer subtype with 35% response rate
text,50085bce-b83b-45bc-889b-4c80f8eb4721,insights_interaction,latest,,,2021-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-03826,Mark Roman,,onco-eu-0063,Victor Popov,Ulton,Avenger,Ireland,,Preliminary data suggests correlation between T-cell infiltration and response to therapy.
text,17342c5e-e586-4168-8736-75231f908e81,insights_interaction,latest,,,2021-09-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03902,Desmond Singh,,onco-eu-0063,Victor Popov,Phone,Wolverine,United Kingdom,,Observed stable disease in a patient with metastatic melanoma after 6 months of Vibranium/Wakanda treatment.
text,7f34ebc7-dd24-4a3a-b06b-4d41804ae224,insights_interaction,latest,,,2021-09-24,MSL Interactions,Oncology,Vibranium,,WB-EU-03354,Christopher Cochran,,onco-eu-0063,Victor Popov,Phone,Avenger,Ireland,,No serious adverse events reported in 50% of the patients enrolled in the ongoing phase II trial.
text,bebc846e-ae76-4e4a-b63a-ebdf09ac44cd,insights_interaction,latest,,,2021-10-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03304,Charles Collett,,onco-eu-0063,Victor Popov,Iron Man,Avenger,Ireland,,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,916aefff-fd30-459b-9d42-42599b0eb01c,insights_interaction,latest,,,2021-11-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03517,Rhonda Edwards,,onco-eu-0063,Victor Popov,Phone,X-Men,France,,"Increased levels of IFN-γ and other inflammatory cytokines were observed in serum samples of patients responding to Vibranium, suggesting an immunomodulatory effect."
text,9f74d281-4932-453d-bb57-18b9df081877,insights_interaction,latest,,,2021-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03629,Tina Strate,,onco-eu-0063,Victor Popov,Ulton,Wolverine,United Kingdom,,"Patients with advanced metastatic lung cancer showed a 42% objective response rate after 12 weeks of Vibranium/Wakanda, with median progression-free survival extending to 7.3 months."
text,2464749e-d762-432c-a559-11b445587be6,insights_interaction,latest,,,2021-12-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03003,Gretchen Garcia,,onco-eu-0063,Victor Popov,Phone,Deadpool,Ireland,,Significant reduction in pain scores and improved emotional well-being reported by patients undergoing combination Vibranium/Wakanda therapy.
text,b696e84f-e147-4d38-a408-a018653a3684,insights_interaction,latest,,,2022-02-18,MSL Interactions,Oncology,Vibranium,,WB-EU-03604,Phyllis White,,onco-eu-0063,Victor Popov,Ulton,X-Men,Ireland,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,ccea9b8c-f58d-4182-9412-13613e608d37,insights_interaction,latest,,,2022-05-15,MSL Interactions,Oncology,Vibranium,,WB-EU-03925,Margaret Brown,,onco-eu-0063,Victor Popov,Ulton,X-Men,France,,Machine learning algorithms successfully developed to predict individualized treatment response with unprecedented accuracy.
text,5c4bde32-00d5-4eec-ba50-776121091852,insights_interaction,latest,,,2022-11-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03836,Joshua Wall,,onco-eu-0063,Victor Popov,Phone,X-Men,Ireland,,Significant reduction in treatment-related fatigue and improved patient mobility
text,275f5e80-0b57-486b-bd4d-7167a136793e,insights_interaction,latest,,,2023-03-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03354,Christopher Cochran,,onco-eu-0063,Victor Popov,Ulton,Avenger,Ireland,,"Patients reported improved quality of life scores on the EORTC QLQ-C30 questionnaire following Vibranium/Wakanda treatment, particularly in terms of fatigue and pain reduction."
text,0c1be378-08dd-4a53-99ca-2220913a2ee7,insights_interaction,latest,,,2023-07-22,MSL Interactions,Oncology,Vibranium,,WB-EU-03003,Gretchen Garcia,,onco-eu-0063,Victor Popov,Phone,Deadpool,Ireland,,"Observed differential response patterns across age groups, with patients under 55 demonstrating more robust tumor reduction compared to older patient cohorts."
text,13f9ee27-bd62-4455-bfda-42475a0b5a7a,insights_interaction,latest,,,2023-07-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03022,Barbara Johnson,,onco-eu-0063,Victor Popov,Ulton,X-Men,France,,"Mild to moderate immune-related adverse events detected in 27% of patients, predominantly low-grade dermatitis and transient hepatic enzyme elevations"
text,775e1afd-e3d2-4251-a218-4dfd9942e68b,insights_interaction,latest,,,2023-12-03,MSL Interactions,Oncology,Vibranium,,WB-EU-03200,Mary Johnson,,onco-eu-0063,Victor Popov,Iron Man,Deadpool,United Kingdom,,"Observed 62% objective response rate in metastatic solid tumors with high PD-L1 expression, particularly in non-small cell lung cancer patients"
text,1218e7d8-c92a-4304-bdb8-ed634a83db02,insights_interaction,latest,,,2021-01-11,MSL Interactions,Oncology,Vibranium,,WB-US-06582,Simon Allen,,onco-us-0013,William Taylor,Phone,X-Men,United States,TN,"Enhanced synergistic effects when combined with targeted immunotherapeutic interventions, expanding potential treatment strategies."
text,e3652028-d0c1-4b6a-a4ba-e4d64a0c1c64,insights_interaction,latest,,,2021-01-11,MSL Interactions,Oncology,Vibranium,,WB-US-06522,Edwin Brow,,onco-us-0013,William Taylor,Ulton,Wolverine,United States,GA,Patients reported improved appetite and energy levels following the initiation of Vibranium/Wakanda.
text,f28cb708-6c06-43ed-acf9-8f50be4b3fdf,insights_interaction,latest,,,2021-02-09,MSL Interactions,Oncology,Vibranium,,WB-US-06223,Joni Uchida,,onco-us-0013,William Taylor,Phone,Avenger,United States,GA,"Elevated levels of PD-L1 expression were correlated with a better response to Vibranium/Wakanda therapy, suggesting a potential predictive biomarker for improved outcomes."
text,611ed992-581b-4f48-a289-15b5959bf10d,insights_interaction,latest,,,2021-02-13,MSL Interactions,Oncology,Vibranium,,WB-US-04879,Scott Mckinley,,onco-us-0013,William Taylor,Phone,X-Men,United States,WV,Patients reported significant improvements in pain management and daily functionality. Quality of life score increased by 47% using standardized EORTC questionnaires during 12-week treatment protocol.
text,a1b0b563-2e0d-4070-8c2d-0b2d8adaf99c,insights_interaction,latest,,,2021-02-22,MSL Interactions,Oncology,Vibranium,,WB-US-04836,John Jones,,onco-us-0013,William Taylor,Ulton,X-Men,United States,TN,Strong correlation between PD-L1 expression and treatment response observed
text,f95f82c2-6530-45ee-ae64-e692c7008b12,insights_interaction,latest,,,2021-02-24,MSL Interactions,Oncology,Vibranium,,WB-US-05142,Evelyn Finch,,onco-us-0013,William Taylor,Ulton,Avenger,United States,GA,Significant tumor shrinkage observed in several patients with head and neck cancer.
text,d275c4d8-147c-4e8e-8cf2-c29e58e7b03f,insights_interaction,latest,,,2021-04-18,MSL Interactions,Oncology,Vibranium,,WB-US-05096,Jo Stevens,,onco-us-0013,William Taylor,Phone,Wolverine,United States,AL,"Improved patient-reported quality of life scores (using EORTC QLQ-C30) observed in patients with advanced lung cancer receiving Vibranium/Wakanda, particularly in fatigue and dyspnea domains."
text,7dcf7ab1-67a7-4999-be3d-68d1716b3c59,insights_interaction,latest,,,2021-04-29,MSL Interactions,Oncology,Vibranium,,WB-US-04822,Lynn Gower,,onco-us-0013,William Taylor,Phone,Avenger,United States,WV,"Patients reported significantly reduced pain scores and improved performance status compared to standard chemotherapy, indicating enhanced symptomatic management."
text,cef8e5a6-99a9-4d57-8e22-0cb82b282d08,insights_interaction,latest,,,2021-06-04,MSL Interactions,Oncology,Vibranium,,WB-US-05709,Carl Leventhal,,onco-us-0013,William Taylor,Iron Man,X-Men,United States,VA,Patient with stage IV metastatic lung cancer exhibited complete tumor regression after 8 weeks of Vibranium treatment. PET-CT scans showed 92% reduction in tumor mass and significant improvement in overall metabolic activity.
text,07f828d2-0cc1-4616-821c-1e500769e468,insights_interaction,latest,,,2021-10-15,MSL Interactions,Oncology,Vibranium,,WB-US-04872,Mike Losinski,,onco-us-0013,William Taylor,Ulton,X-Men,United States,GA,"Enhanced synergistic effects demonstrated when combined with targeted molecular therapies, expanding potential treatment combinations."
text,316d234c-e89d-45dc-bff1-b2e065147179,insights_interaction,latest,,,2022-01-14,MSL Interactions,Oncology,Vibranium,,WB-US-04877,Isabel Leak,,onco-us-0013,William Taylor,Ulton,Avenger,United States,VA,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,fbbeafc2-ca4f-4e96-adcf-75965041bbec,insights_interaction,latest,,,2022-08-03,MSL Interactions,Oncology,Vibranium,,WB-US-06281,Fred Brazier,,onco-us-0013,William Taylor,Ulton,X-Men,United States,VA,Reduced treatment-related fatigue reported by 65% of patients compared to traditional chemotherapy protocols
text,3b1f0785-7232-4b7d-81ec-f239ae39bb99,insights_interaction,latest,,,2022-09-26,MSL Interactions,Oncology,Vibranium,,WB-US-05614,Daniel Grace,,onco-us-0013,William Taylor,Phone,X-Men,United States,FL,Outpatient administration protocol demonstrates high patient compliance and reduced healthcare resource utilization compared to traditional chemotherapy regimens.
text,6d7d0b95-8983-4332-97ba-29dc5ecd6b45,insights_interaction,latest,,,2022-11-27,MSL Interactions,Oncology,Vibranium,,WB-US-06363,Joshua Apo,,onco-us-0013,William Taylor,Phone,Avenger,United States,VA,Streamlined patient monitoring protocol reduces overall clinical management complexity
text,8bc1b59a-baf0-4e99-a535-45c0d5f80b21,insights_interaction,latest,,,2023-01-04,MSL Interactions,Oncology,Vibranium,,WB-US-06347,Edward Meis,,onco-us-0013,William Taylor,Ulton,Deadpool,United States,TN,"Median progression-free survival of 7.2 months in patients with triple-negative breast cancer, consistent with initial phase II trial projections"
text,d6279dd3-66e8-442f-a471-ea26e68f4204,insights_interaction,latest,,,2023-01-10,MSL Interactions,Oncology,Vibranium,,WB-US-05164,Russell Aguilar,,onco-us-0013,William Taylor,Ulton,Avenger,United States,FL,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,810ef0f9-5196-4633-99a1-fcc791b48663,insights_interaction,latest,,,2023-03-04,MSL Interactions,Oncology,Vibranium,,WB-US-05940,Howard Smith,,onco-us-0013,William Taylor,Iron Man,Avenger,United States,VA,"Patients reported improved appetite and reduced fatigue, leading to increased overall activity levels during treatment."
text,dd7d9d00-9409-447c-a426-6b0afea38e86,insights_interaction,latest,,,2023-03-06,MSL Interactions,Oncology,Vibranium,,WB-US-06264,Michael Thomas,,onco-us-0013,William Taylor,Phone,Avenger,United States,MS,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,e728fa98-6eb8-4ab0-b12a-87a7d468a044,insights_interaction,latest,,,2023-05-24,MSL Interactions,Oncology,Vibranium,,WB-US-05456,Ernest Cahoon,,onco-us-0013,William Taylor,Ulton,Wolverine,United States,TN,Increased levels of interferon-gamma correlated with positive clinical response in patients treated with Vibranium/Wakanda.
text,6dfa36ed-b7f2-46bd-addd-4531977d7609,insights_interaction,latest,,,2023-06-03,MSL Interactions,Oncology,Vibranium,,WB-US-05976,Ricky Kerr,,onco-us-0013,William Taylor,Phone,X-Men,United States,WV,"Patient with advanced pancreatic cancer showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, exceeding initial expectations."
text,b7ab0969-b8ba-48aa-bb4c-fe806fc2628e,insights_interaction,latest,,,2023-11-14,MSL Interactions,Oncology,Vibranium,,WB-US-05621,Ryan Carroll,,onco-us-0013,William Taylor,Phone,X-Men,United States,AL,Strong correlation between PD-L1 expression >50% and enhanced treatment response
text,8a6c3e12-c0c4-468e-8baf-65335dc7d83d,insights_interaction,latest,,,2023-12-04,MSL Interactions,Oncology,Vibranium,,WB-US-05351,Craig Strickland,,onco-us-0013,William Taylor,Iron Man,Deadpool,United States,KY,Demonstrated 37% objective response rate in advanced metastatic solid tumors with minimal prior treatment resistance
text,3afe5428-d658-4a5d-9b28-7f9aeb179881,insights_interaction,latest,,,2024-03-14,MSL Interactions,Oncology,Vibranium,,WB-US-05996,Glenn Blankenship,,onco-us-0013,William Taylor,Phone,Avenger,United States,KY,Early detection of response based on circulating tumor DNA analysis.
text,b7a5a0ff-f767-4972-8640-e077329dda41,insights_interaction,latest,,,2024-10-12,MSL Interactions,Oncology,Vibranium,,WB-US-05226,Amanda Pritchett,,onco-us-0013,William Taylor,Ulton,Wolverine,United States,GA,Moderate complexity of administration requires specialized oncology nursing support
text,ebcce68e-5f16-411c-8662-158e7307e660,insights_interaction,latest,,,2021-02-05,MSL Interactions,Oncology,Vibranium,,WB-EU-01320,Maria Maul,,onco-eu-0025,Wolfgang Meyer,Ulton,Deadpool,Germany,,Promising early indicators of treatment efficacy in rare cancer subtypes
text,f9dddd93-fc75-4632-96ab-18534efa576f,insights_interaction,latest,,,2021-03-28,MSL Interactions,Oncology,Vibranium,,WB-EU-01869,Mark Abreu,,onco-eu-0025,Wolfgang Meyer,Iron Man,Avenger,Germany,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,55d5d9a0-880a-4608-80da-c8113b30b315,insights_interaction,latest,,,2021-06-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01036,Ronald Chappell,,onco-eu-0025,Wolfgang Meyer,Ulton,Avenger,Austria,,"Promising results in combination with immunotherapy, showing synergistic effects in treatment-resistant malignancies"
text,7cfa53f6-a82d-496c-ab26-29a2316044a5,insights_interaction,latest,,,2021-08-12,MSL Interactions,Oncology,Vibranium,,WB-EU-01036,Ronald Chappell,,onco-eu-0025,Wolfgang Meyer,Ulton,Avenger,Austria,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,03064092-107d-4b6e-991c-4d62d0e900e8,insights_interaction,latest,,,2021-11-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01464,Lois Romine,,onco-eu-0025,Wolfgang Meyer,Phone,Clinical Pharmacist,Germany,,"Improved patient reported quality of life scores noted in several patients, particularly regarding fatigue and pain."
text,69a0f4df-3e87-4d09-a0e2-075589fca9ce,insights_interaction,latest,,,2022-01-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01330,Victoria Swackhammer,,onco-eu-0025,Wolfgang Meyer,Iron Man,Avenger,Netherlands,,Circulating tumor DNA analysis demonstrates early treatment response prediction with high molecular specificity.
text,9c5f8fe5-b64e-4be8-ab1d-15108ff24f34,insights_interaction,latest,,,2022-02-14,MSL Interactions,Oncology,Vibranium,,WB-EU-01108,Calvin Greer,,onco-eu-0025,Wolfgang Meyer,Phone,Deadpool,Netherlands,,Improved pain management observed in some patients with bone metastases after Vibranium treatment.
text,a2a555a3-815e-4a03-9cff-61f10cc52a8f,insights_interaction,latest,,,2022-04-10,MSL Interactions,Oncology,Vibranium,,WB-EU-01619,James Diaz,,onco-eu-0025,Wolfgang Meyer,Ulton,Deadpool,Netherlands,,Reduction in pain levels reported by patients with bone metastases.
text,aea3cd4f-d6a3-47b3-b7c3-443fa3abf16d,insights_interaction,latest,,,2022-05-30,MSL Interactions,Oncology,Vibranium,,WB-EU-01869,Mark Abreu,,onco-eu-0025,Wolfgang Meyer,Phone,Avenger,Germany,,Significant improvement in patient-reported emotional well-being scores
text,6342e18e-239e-48ff-b5e6-1ef8793b615a,insights_interaction,latest,,,2022-10-23,MSL Interactions,Oncology,Vibranium,,WB-EU-01641,Kim Daum,,onco-eu-0025,Wolfgang Meyer,Phone,Wolverine,Belgium,,Enhanced hepatic tolerance profile with only 6% experiencing transient liver enzyme elevations
text,98996c96-9f1c-430d-8bd4-ae3288704bf5,insights_interaction,latest,,,2023-01-06,MSL Interactions,Oncology,Vibranium,,WB-EU-01833,Cynthia Hernandez,,onco-eu-0025,Wolfgang Meyer,Phone,X-Men,Germany,,Grade 3 fatigue reported in a patient receiving Vibranium/Wakanda; treatment was temporarily suspended.
text,9f96ac35-4d10-4b9f-bc82-0880d8454281,insights_interaction,latest,,,2023-02-25,MSL Interactions,Oncology,Vibranium,,WB-EU-01330,Victoria Swackhammer,,onco-eu-0025,Wolfgang Meyer,Iron Man,Avenger,Netherlands,,Grade 3 fatigue reported in a patient receiving Vibranium/Wakanda; treatment was temporarily suspended.
text,ae9e3b2b-0685-49e1-bf81-02bc6ce93429,insights_interaction,latest,,,2023-07-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01243,Robert Reed,,onco-eu-0025,Wolfgang Meyer,Ulton,Deadpool,Germany,,Streamlined patient monitoring protocol reduces clinical assessment time and improves overall treatment management efficiency.
text,09cbe609-d375-44d5-a774-c171f7052559,insights_interaction,latest,,,2023-08-08,MSL Interactions,Oncology,Vibranium,,WB-EU-01313,James Hicks,,onco-eu-0025,Wolfgang Meyer,Phone,Avenger,Netherlands,,Most adverse events associated with Vibranium/Wakanda were manageable and mild in severity.
text,b79aee04-67c0-4152-b7d1-0102372dcf96,insights_interaction,latest,,,2023-09-09,MSL Interactions,Oncology,Vibranium,,WB-EU-01047,Esther Tipton,,onco-eu-0025,Wolfgang Meyer,Ulton,X-Men,Germany,,"Improved emotional well-being was reported by many patients receiving Vibranium/Wakanda, potentially due to the hope and optimism associated with a novel treatment."
text,6622474a-263f-497a-bf81-ba0d3988353f,insights_interaction,latest,,,2023-10-31,MSL Interactions,Oncology,Vibranium,,WB-EU-01758,Christopher Carlton,,onco-eu-0025,Wolfgang Meyer,Ulton,Clinical Pharmacist,Netherlands,,Combination therapy requires careful dosage titration and frequent monitoring of liver function tests
text,20cfc400-6f80-4f4f-a219-fffd47662ac0,insights_interaction,latest,,,2023-11-11,MSL Interactions,Oncology,Vibranium,,WB-EU-01691,Theresa Young,,onco-eu-0025,Wolfgang Meyer,Iron Man,Avenger,Netherlands,,"Patient with advanced pancreatic cancer (PDAC) demonstrated a partial response after 2 cycles of Vibranium/Wakanda therapy, with a 30% reduction in tumor size confirmed by CT scan.  Significant reduction in CA 19-9 levels also observed."
text,918232e5-1e84-4150-ba92-791f54a062f8,insights_interaction,latest,,,2023-11-18,MSL Interactions,Oncology,Vibranium,,WB-EU-01464,Lois Romine,,onco-eu-0025,Wolfgang Meyer,Phone,Clinical Pharmacist,Germany,,"Significant improvements in patient-reported quality of life metrics, particularly in pain management and functional capacity."
text,18effc80-23e0-4f18-be7d-d8d38aa4e9e9,insights_interaction,latest,,,2024-01-03,MSL Interactions,Oncology,Vibranium,,WB-EU-01752,Jon Antonelli,,onco-eu-0025,Wolfgang Meyer,Iron Man,Avenger,Austria,,Grade 1 fatigue and nausea reported in a patient receiving Vibranium; symptoms resolved with supportive care.
text,f6e4fef3-f712-4ef2-bf66-32052b3f9a96,insights_interaction,latest,,,2024-06-20,MSL Interactions,Oncology,Vibranium,,WB-EU-01243,Robert Reed,,onco-eu-0025,Wolfgang Meyer,Iron Man,Deadpool,Germany,,Elevated CA-19-9 levels decreased significantly in some patients with pancreatic cancer.
text,3a0575c4-c777-4692-930c-c7c5dc02e824,insights_interaction,latest,,,2024-07-24,MSL Interactions,Oncology,Vibranium,,WB-EU-01681,Christina Rierson,,onco-eu-0025,Wolfgang Meyer,Phone,Deadpool,Switzerland,,Combination therapy requires careful monitoring of hepatic function and potential drug interactions
text,5c5c009a-6f92-46dc-86ca-791863dbb831,insights_interaction,latest,,,2024-10-29,MSL Interactions,Oncology,Vibranium,,WB-EU-01244,Evelyn Meyer,,onco-eu-0025,Wolfgang Meyer,Phone,X-Men,Germany,,"Observed mild to moderate immune-related adverse events in 23% of patients, primarily low-grade fatigue and transient hepatic enzyme elevations requiring routine monitoring."
text,c0c5440c-6535-4c4f-93f3-d3929c87f391,insights_interaction,latest,,,2021-04-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03090,Josephine Smiechowski,,onco-eu-0077,Zuzana Horvat,Phone,X-Men,Ireland,,Observed significant tumor reduction in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.  Partial responses noted in the other two patients.
text,29eddbbe-6f41-46b0-b9b8-ac2ab6c09848,insights_interaction,latest,,,2021-05-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03241,Albert Duran,,onco-eu-0077,Zuzana Horvat,Ulton,X-Men,France,,"Remarkable complete response rates in triple-negative breast cancer patients, with 27% achieving complete tumor resolution after six treatment cycles."
text,a250c51d-1419-4e94-9429-0a8873fe9666,insights_interaction,latest,,,2021-05-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03241,Albert Duran,,onco-eu-0077,Zuzana Horvat,Phone,X-Men,France,,Complete remission observed in one patient with a rare form of sarcoma after three cycles of treatment.
text,1a9935a7-32fa-45c7-96f9-cf155761f653,insights_interaction,latest,,,2022-01-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03353,Richard Herndon,,onco-eu-0077,Zuzana Horvat,Phone,X-Men,United Kingdom,,Strong positive correlation between Ki-67 expression and treatment response rate
text,bc2a87a1-6205-4df7-bc91-53904b88e479,insights_interaction,latest,,,2022-02-27,MSL Interactions,Oncology,Vibranium,,WB-EU-03922,Darnell Cisneros,,onco-eu-0077,Zuzana Horvat,Ulton,Deadpool,United Kingdom,,"Significant improvements in patient-reported outcomes, including reduced treatment-related anxiety and enhanced functional status."
text,844eb553-9166-4c1f-af23-9d326712b872,insights_interaction,latest,,,2022-03-26,MSL Interactions,Oncology,Vibranium,,WB-EU-03915,Donald Ridgeway,,onco-eu-0077,Zuzana Horvat,Iron Man,X-Men,Ireland,,Observed significant tumor reduction in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.  Further follow-up required.
text,6304a89e-9e98-403e-8bc6-a295a5214e90,insights_interaction,latest,,,2022-04-30,MSL Interactions,Oncology,Vibranium,,WB-EU-03574,David Ramirez,,onco-eu-0077,Zuzana Horvat,Ulton,Deadpool,United Kingdom,,"Patient reported improved appetite and energy levels after commencing Vibranium/Wakanda therapy, as measured by EORTC QLQ-C30."
text,dd91bdd5-11c4-4588-9bb0-a855040b04f3,insights_interaction,latest,,,2022-06-05,MSL Interactions,Oncology,Vibranium,,WB-EU-03574,David Ramirez,,onco-eu-0077,Zuzana Horvat,Iron Man,Deadpool,United Kingdom,,"Patient with advanced melanoma showed a significant reduction in tumor size after two cycles of Vibranium/Wakanda therapy, confirmed by imaging."
text,b3e5aa38-3224-4055-992b-ba3009e1e650,insights_interaction,latest,,,2022-08-07,MSL Interactions,Oncology,Vibranium,,WB-EU-03547,Barbara Dailey,,onco-eu-0077,Zuzana Horvat,Phone,X-Men,United Kingdom,,Observed significant tumor regression in 3 out of 5 patients with advanced pancreatic cancer after 2 cycles of Vibranium/Wakanda combination therapy.
text,45ff1d13-d803-4ea3-ae4f-42e57d9f0560,insights_interaction,latest,,,2022-09-13,MSL Interactions,Oncology,Vibranium,,WB-EU-03025,Douglas Whitaker,,onco-eu-0077,Zuzana Horvat,Ulton,Deadpool,France,,"Significant tumor shrinkage observed in pancreatic cancer patients with limited conventional treatment options, offering promising alternative approach."
text,42747775-4075-47db-a518-26cd4d0f34ca,insights_interaction,latest,,,2023-10-25,MSL Interactions,Oncology,Vibranium,,WB-EU-03437,James Adcox,,onco-eu-0077,Zuzana Horvat,Phone,Clinical Pharmacist,France,,Response rates varied significantly across different patient subgroups based on initial tumor size.
text,130710d7-59c9-4ae0-974b-0828e798bf86,insights_interaction,latest,,,2023-11-21,MSL Interactions,Oncology,Vibranium,,WB-EU-03997,Lucy Dixon,,onco-eu-0077,Zuzana Horvat,Phone,Avenger,France,,Emerging evidence suggests potential genomic predictors of treatment response require further investigation
text,5727abdb-e856-4f8a-a127-ac34cd398ef4,insights_interaction,latest,,,2024-02-08,MSL Interactions,Oncology,Vibranium,,WB-EU-03496,Wanda Hicks,,onco-eu-0077,Zuzana Horvat,Phone,Avenger,France,,"Remarkable complete response rates in triple-negative breast cancer patients, with 35% achieving long-term remission after targeted therapy."
text,9f99f0ec-4a90-4972-9b28-8cf3b1da4625,insights_interaction,latest,,,2024-03-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03300,Gregory Williams,,onco-eu-0077,Zuzana Horvat,Ulton,Avenger,France,,Preliminary investigation of circulating tumor DNA reveals potential early response predictors requiring further validation.
text,0c201092-2744-4e86-89a3-8e38afeadd35,insights_interaction,latest,,,2024-04-09,MSL Interactions,Oncology,Vibranium,,WB-EU-03090,Josephine Smiechowski,,onco-eu-0077,Zuzana Horvat,Iron Man,X-Men,Ireland,,Complex genomic screening requirements may create significant logistical challenges in implementing widespread therapeutic approach.
text,6e13d869-8692-4991-a862-2ce64cee842e,insights_interaction,latest,,,2024-04-28,MSL Interactions,Oncology,Vibranium,,WB-EU-03110,Debbie Spence,,onco-eu-0077,Zuzana Horvat,Iron Man,X-Men,Ireland,,Mild to moderate injection site reactions were frequently observed in patients receiving Vibranium/Wakanda.
text,5c3b6ac9-0836-4557-94cc-6341de7a9822,insights_interaction,latest,,,2024-07-20,MSL Interactions,Oncology,Vibranium,,WB-EU-03303,Wendy Campbell,,onco-eu-0077,Zuzana Horvat,Ulton,Avenger,Ireland,,Cost-effectiveness analysis suggests potential for reduced hospital readmission rates with targeted combination approach
text,589582fd-5809-48a7-acee-f5da1a5be493,insights_interaction,latest,,,2024-09-04,MSL Interactions,Oncology,Vibranium,,WB-EU-03100,Mildred Christie,,onco-eu-0077,Zuzana Horvat,Iron Man,Deadpool,United Kingdom,,Reduced metastatic progression rates in patients with early intervention using combination therapy
